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ABSTRACT 
Although available evidence suggests that NTS 1 receptors play a key role in the 
transduction of many of the central effects of neurotensin (NT), recent data indicate 
that the NTS2 subtype may be responsible for mediating NT -induced analgesia. 
However, little is known about the cellular and molecular mechanisms underlying 
NTS2 function. It is also unc1ear whether endogenous NT is an agonist at the NTS2 
site and to which second messenger systemes) this receptor is coupled since 
conflicting data has emerged from studies carried out in systems heterologously 
expressing the NTS2 receptor. In this context, the overall objective of the present 
study was to characterize the distribution of the NTS2 protein in rat brain, to further 
document the role played by NTS2 receptors in antinociception, and to unravel the 
cellular mechanisms underlying NTS2-mediated transduction of NT' s effects. Our 
immunohistochemical studies revealed that NTS2 receptors are widely expressed 
within the rat CNS with high densities of labeled neurons and/or processes in 
descending antinociceptive pathways inc1uding the periaqueductal gray (P AG), and 
the rostroventral medial medulla. Both the full-Iength and alternatively-spliced 
isoforms induced a rapid and sustained activation of the mitogen-activated protein 
kinase (ERK1I2) pathway in both transfected CHû and CÛS-7 cells upon stimulation 
with NT. Combined biochemical and confocal microscopie studies revealed that 
NTS2 receptors were maintained at the ceU surface following long-term agoni st 
exposure despite efficient intemalization mechanisms. This preservation was neither 
due to NTS2 neosynthesis nor recyc1ing but rather appeared to involve translocation 
of spare receptors from intracellular stores as observed in both transfected cells and 
rat spinal cord neurons. NTS2 was demonstrated to heterodimerize with NTS 1 in 
cells co-transfected with the two receptors. This heterodimerization was found to 
affect cell surface recruitment of NTS 1, making it more similar to that of NTS2. 
AIso, upon prolonged NT stimulation, cell surface NTS 1 were more resistant to 
down-regulation in cells co-expressing NTS 1 and NTS2 than in ceUs expressing 
NTS 1 alone. Such maintenance of NT receptors bioavailability might prove of great 
importance for the use ofNTS2-selective agonists for the treatment of chronic pain. 
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RÉSUMÉ 
Bien que la plupart des effets de la neurotensine (NT) soient reliés à la stimulation 
des récepteurs de sous-type NTS 1, certains restent intouchés par l'administration 
d'antagonistes sélectifs, suggérant qu'ils sont induits par d'autres sous-types de 
récepteur. Afin d'évaluer l'implication éventuelle des récepteurs NTS2 dans l'effet 
analgésique de la NT, nous avons étudié la distribution régionale et cellulaire de ce 
récepteur dans le système nerveux central (SNC) du rat. Nos analyses 
immunohistochimiques ont révélé que le récepteur NTS2 est exclusivement neuronal, 
et qu'il est exprimé de façon ubiquitaire dans le SNC avec des concentrations 
particulièrement importantes dans les régions impliquées dans l'antinoception telles 
que la substance grise periaqueductale et le bulbe rachidien rostro-ventral. Nos 
travaux ont par ailleurs démontré l'existence de deux isoformes de NTS2 dans le 
SNC du rat: une forme complète à sept domaines transmembranaires et une forme 
variante tronquée à cinq domaines transmembranaires (vNTS2). La liaison de la NT 
à ces deux sous-types de récepteurs induit une internalisation du complexe 
ligand/récepteur de même qu'une activation rapide et soutenue de la voie de la 
famille des MAP kinases dans les cellules CÛS-7 et CHû transfectées. Des études 
de radioliaison ont d'autre part révélé que, contrairement au NTS l, les récepteurs 
NTS2 sont maintenus à la membrane cellulaire suite à une stimulation prolongée par 
la NT. Cette préservation des récepteurs NTS2 à la membrane est indépendante de 
leur recyclage ou de la synthèse de nouveaux récepteurs mais semble impliquer un 
adressage de récepteurs de réserve à partir du complexe Golgi/TGN, selon nos 
observations en microscopie confocale et électronique dans les cellules CÛS-7 et 
neurones de la moelle épinière de rat, respectivement. Finalement, nous avons 
démontré que dans des cellules co-exprimant le NTS 1 et le NTS2, les deux récepteurs 
forment des complexes hétérodimériques. Cette hétérodimérisation réduit l'adressage 
membranaire du NTS 1 et amoindrit la perte de sa densité de surface suite à une 
exposition prolongée à la neurotensine. L'utilisation d'agonistes spécifiques du 
récepteur NTS2 pourrait par conséquent s'avérer une stratégie intéressante pour le 
traitement de la douleur chronique par des agonistes de la neurotensine. 
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ORIGINALITY 
This thesis furthers our knowledge of the molecular and cellular characterization of 
NTS2 receptors. It demonstrates that NTS2 receptors are expressed as two different 
isoforms, which are wide1y distributed throughout the rat central nervous system. 
Additionally, this thesis provides functional evidence that these receptors behave as 
bona fide NT receptors but are not down-regulated following persistent agoni st 
exposure, providing physiological relevance for the use ofNTS2-selective agoni st for 
the treatment of chronic pain. Finally, it reveals that NTS2 receptor expression 
influences the intracellular trafficking of other NT receptor subtypes through 
heterodimerization. 
CHAPTER3: 
Immunohistochemical Distribution of NTS2 Neurotensin Receptors in the Rat 
Central Nervous System. This chapter provides the first comprehensive description 
of the immunohistochemical distribution of NTS2 receptors in the rat CNS at the 
light microscopic level. For this purpose, we have designed and sub-contracted the 
production of a NTS2 antibody directed toward a 15-amino acid synthetic sequence 
derived from the N-terminal portion of the rat NTS2 receptor, common to both short 
and long receptor isoforms. Our study indicated that NTS2 receptors are broadly 
distributed within the rat CNS with high levels of NTS2 receptor proteins detected in 
regions involved in the descending control of nociceptive inputs, in keeping with its 
postulated role in antinociception. It also showed that NTS2 receptors are essentially 
neuronal and that they are mostly, although not solely targeted to dendrites. 
CHAPTER4: 
Low-affmity Neurotensin Receptor (NTS2) Signaling: Internalization-
Dependent Activation of Extracellular Signal-Regulated Kinases 1/2. In this 
study, we investigated NTS2 signaling pathways in heterologously expressing cell 
systems. In contrast to what has previously been reported in the literature, our data 
revealed that NT, as well as many of the known NTS2 receptor ligands, act as 
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agonists at the rat NTS2 receptor site, in that all induced a NTS2-mediated activation 
of the MAP Kinase cascade. Furthermore, this agonist-induced phosphorylation of 
ERK1I2 was completely abolished by both overexpression of a dominant-negative 
mutant of dynamin-l (DynK44A) and preincubation with endocytosis inhibitors (i.e. 
phenylarsine oxide and monodansylcadaverine), indicating that internalization was 
required for this activation to occur. Contrary to previous studies in which NT was 
shown to act as an antagonist at the human NTS2 site, we observed the same NT-
triggered ERK1I2 phosphorylation in human and rat NTS2 receptor expressing CHû 
cells. This finding is important in that it lends further support to the premise that NT 
is an endogenous ligand at this receptor. 
CHAPTER5: 
Identification and Functional CharacterÏZation of the 5-Transmembrane 
Domain Variant Isoform in the Rat Central Nervous System. We presented here 
a novel spliced variant isoform of the NTS2 receptor that we have isolated from rat 
brain RNA (GenBank accession number A Y946024; see Appendix D). Most 
importantly, we showed that this 5-transmembrane domain receptor is functional, in 
that is specifica1ly binds and internalizes NT and is coupled to the activation of the 
ERKll2 pathway. To our knowledge, this truncated NTS2 isoform is the first 
transmembrane spliced GPCR variant c10ned to date that was found to maintain its 
signaling properties. Furthermore, we have demonstrated that the variant NTS2 
isoform is expressed in conjunction with the full-Iength NTS2 isoform throughout the 
CNS. Our data also indicate that this truncated NTS2 receptor associates both with 
itself and with the full-Iength NTS2 receptor to form large molecular weight homo-
and heterodimer species in the rat CNS. 
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CHAPTER6: 
Sustained Agonist Exposure Promotes Cell Surface Recruitment of NTS2 
Neurotensin Receptors. In this chapter, we demonstrated that in contrast to what is 
observed in cells transfected with NTS l, NTS2-expressing cells retain the same 
surface receptor density during persistent NT exposure despite efficient 
intemalization mechanisms. This preservation of cell surface NTS2 receptors is 
neither due to receptor recycling nor neosynthesis but rather involves translocation of 
spare receptors from intracellular stores to the plasma membrane. Additionally, our 
confocal immunolocalization studies revealed that as opposed to NTS 1, intemalized 
NTS2 receptors are not targeted to lysosomes for degradation. The physiological 
relevance of these observations was provided by immunogold electron microscopie 
studies on neurons of the superficial laminae of the rat spinal cord in which agoni st 
stimulation was found to trigger an extensive relocalization of intracellular receptors 
from intracellular stores to the plasma membrane. This report also represents the 
first account of the subcellular localization ofNTS2 by electron microscopy. 
CHAPTER 7: 
NTS2 Modulates the Intracellular Distribution and Trafficking of NTSI via 
Heterodimerization. This section demonstrates that NTS 1 and NTS2 receptors 
form heterodimeric complexes in a transfected cell system. This report also shows 
that the formation of NTS 1/NTS2 heterodimers markedly inhibits cell surface 
recruitment of NTS 1 binding sites, which remain accumulated in the perinuclear 
region (i.e. in the same compartment that harbours the bulk of NTS2 receptors when 
they are expressed alone). Additionally, radioligand binding studies have 
demonstrated that NTS 1 cell surface binding sites are more resistant to down-
regulation when the two NT receptor subtypes are expressed together, suggesting that 
NTSI/NTS2 heterodimerization might represent an additional mechanism in the 
regulation of NT -induced responses mediated by NTS 1 and NTS2 receptors. 
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CBAPTER 1: INTRODUCTION 
1. NEUROTENSIN AS A NEUROTRANSMITTER 
The tridecapeptide neurotensin (NT) (Glu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-
Tyr-Ile-Leu) origina1ly isolated from bovine hypothalamus (Carrawayand Leeman, 
1973), is broadly distributed throughout the central nervous system (CNS) and 
peripheral tissues. NT acts as a neuromodulator/neurotransmitter in the CNS, while 
it fulfills a function oflocal hormone in the periphery (Vincent et al., 1999). 
1.1 Physiologie al and Pathologieal Effeets 
1.1.1 Neurotensin-dopamine Interactions 
NT has been shown to modulate dopaminergic (DA) transmission in the nigrostriatal 
and mesocorticolimbic pathways (Nemeroff, 1986; Kitabgi et al., 1989), thereby 
implicating this neuropeptide in the pathophysiology of several CNS disorders 
including Parkinson's disease and schizophrenia (Garver et al., 1991; Rostène et al., 
1992; Binder et al., 2001a). Indeed, NT was formally proposed to be a potential 
endogenous neuroleptic 25 years ago based on the fact that central NT elicited a 
range of effects similar to those of antipsychotics drugs (APD) (reviewed in Binder et 
al., 2001a; Kinkead and Nemeroff, 2002). For instance, both intracerebroventricular 
NT injections and peripherally administrated APD blocked stimulant-induced 
hyperlocomotion (Kalivas et al., 1984; Skoog et al., 1986; Sarhan et al., 1997) and 
decreased spontaneous locomotor activity (Jolicoeur et al., 1983; Dubuc et al., 1994; 
Gully et al., 1995). However, NT was reported to mediate contrary effects on DA 
transmission, depending on the injection site in the brain. Accordingly, 
microinjection of NT into the nucleus accumbens, a projection area of mesolimbic 
DA neurons, was shown to pro duce neuroleptic-like effects, while NT injections into 
the ventral tegmental area (VTA), which contains DA neurons that project to the 
nucleus accumbens, triggered psychostimulant-like effects (e.g. hyperlocomotion and 
turning behavior) (Kalivas and Steketee, 1992; Kalivas et al., 1993; Steinberg et al., 
1994; Kitabgi, 2002; Dobner et al., 2003). Finally, intrastriatal administration of NT 
was shown to trigger vacuous chewing movements, suggesting that increased levels 
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of endogenous NT within the ventrolateral striatum may play a critical role in the 
development of tardive dyskinesia (Stoessl, 1995). 
1.1.2 Neurotensin and Neuroendocrine Systems 
Several studies have shown that NT participates in the regulation of mammalian 
neuroendocrine systems (reviewed in Rostène and Alexander, 1997). At the 
hypothalamic level, NT was reported to modulate the release of gonadotropin-
releasing hormone (GnRH) (Alexander et al., 1989a), somatostatin (Sheppard et al., 
1979), corticotropin-releasing hormone (CRH) (Nussdorfer et al., 1992), and growth 
hormone releasing hormone (GHRH) (Niimi et al., 1991). NT was also shown to 
have a variety of effects on the release ofpituitary hormones (Rowe et al., 1992). For 
instance, NT injection in the preoptic area was shown to regulate the preovulatory 
surge of luiteinizing hormone (LH) in female rats (Ferris et al., 1984). AdditionaIly, 
NT was reported to modulate the secretion of prolactin (McCann et al., 1982) and 
growth hormone (GH) (McCann and Vijayan, 1992). FinaIly, NT was shown to have 
a regulatory effect on corticotropin-releasing factor (CRF) and adrenocorticotropic 
hormone (ACTH) release from adrenal medulla (Mazzocchi et al, 1997). 
1.1.3 Neurotensin and Hypothermia 
Various studies support the proposition that NT may act endogenously to mediate 
heat-loss mechanisms in mammals (Nemeroff et al., 1977; Kalivas et al., 1985; 
Benmoussa et al., 1996; Yamada et al. 1995). For instance, intracistemal or 
intraventricular administration of NT is followed by a drop in core temperature in 
mouse, rat, gerbil and monkey (Bissette et al., 1976; Loosen et al., 1978; Prange et 
al., 1979). In particular, microinjection studies in rodents have demonstrated that NT 
produced a rapid onset of hypothermia ranging in the magnitude of 0.8-2.3°C below 
the baseline rectal temperature following administration in the medial preoptic region 
of the hypothalamus as weIl as in the periaqueductal area (Martin et al., 1980). This 
thermal response was shown to result from a significant dose and time-dependent 
increase in heat loss, while oxygen consumption was not affected (Handler et al., 
1994). However, the fact that the core temperature is more sensitive to 
intracistemally-injected NT than a dose given intraventricularly (Martin et al., 1980) 
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suggest that the main site of action of NT in inducing hypothennia may be distant 
from the forebrain hypothalamic structures which have been classically implicated in 
temperature homeostasis (Prange et al., 1979). Interestingly, recent studies have 
demonstrated that NT -induced hypothermia provided marked neuroprotection in both 
models of global and focal cerebral ischemia (Babcock et al., 1993; Torup et al., 
2003; Gordon et al., 2003; Katz et al., 2004a and 2004b). However, the mechanisms 
of NT -induced hypothermic protection are not entirelY understood. 
1.1.4 Neurotensin and Pain Modulation 
Pharmacological studies in rodents have revealed that centrally administrated NT 
exerts analgesic actions both spinally and supraspinally (reviewed in Yaksh et al., 
1982; Clineschmidt et al., 1982; Behbehani, 1992). Of great interest is the finding 
that these effects are not antagonized by naloxone, implying an opioid-independent 
mechanism (Clineschmidt et al., 1979; Osbahr et al., 1981; Martin and Naruse, 1982; 
Coquerel et al., 1986). At the spinal level, intrathecal NT injection produced a 
nociceptive threshold increase in the hotplate test and altered the tail-flick and acid-
induced writhing response latency (Yaksh et al., 1982; Martin and Naruse, 1982; 
Spampinato et al., 1988). Moreover, NT has been shown to be effective in another 
model of chemically induced-nociception, the hypertonic saline assay, following 
intrathecal injection in mice (Hylden and Wilcox, 1983). At supraspinal levels, 
microinjection of NT into the preoptic area, the central nucleus of the amygdala, the 
hypothalamic medial nucleus, the rostrovendral medulla (RVM), and the 
periaqueductal gray (P AG) triggered antinociceptive responses in both tonic and 
acute pain models (Kalivas et al., 1982a; Kalivas et al., 1982b; Behbehani and Pert, 
1984; Fang et al, 1987; Urban and Smith, 1993; Benmoussa et al., 1996). 
Interestingly, lesions of the stria tenninalis and the nucleus raphe magnus both totally 
aboli shed the antinociceptive effects of NT following injections into the amygdala 
(Kalivas et al., 1982a) and the PAG (Behbehani and Pert, 1984), respectively. PAG 
neurons are known to be innervated by NT -immunoreactive nerve terminaIs, which 
originate from the bed nucleus of the stria terminalis, the central nucleus of the 
amygdala, and the lateral hypothalamus (Behbehani et al., 1988; Gray and 
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Magnuson, 1992; Rizvi et al., 1991). Conversely, current and voltage clamp 
recording studies have shown that NT depolarized retrogradely PAG-RVM neurons 
and evoked action potentials by opening voltage-insensitive and nonse1ective cation 
channels (Behbehani et al., 1988; Li et al., 2001). It is thus very likely that NT 
produces its analgesic effect by directly exciting P AG neurons that project to the 
RVM. However, NT was also shown to have bipolar effects on pain modulation 
foIlowing administration in the PAG, RVM, and brain regions that project to these 
structures (reviewed in Dobner, 2005). For instance, microinjection of NT into the 
RVM elicited analgesia at higher doses (nanomolar), whereas lower doses 
(picomolar) faciHtated both somatic and visceral pain (Urban and Smith, 1993; 
Urban et al., 1999; Gui et al., 2004). Conversely, intense stress (i.e. forced 
swimming in cold water) was shown to trigger both inhibitory and facilitatory 
pathways that modulate visceral nociception (Gui et al., 2004). Finally, NT was also 
implicated in the development of secondary hyperalgesia foIlowing topical 
application of the skin irritant, mustard oil (Urban et al., 1996a). However, the pain 
facilitatory effects of exogenous NT are re1ative1y smaIl and have not been observed 
in aIl studies (Urban et al., 1996b; Smith et al., 1997). These nociceptive responses 
are thought to rely on spinal cholecystokinin signaling (Urban et al., 1996b). The 
mechanisms underlying NT -mediated pain modulation remain unclear. However, 
there is limited evidence that NT produces analgesia through the activation of 
descending noradrenergic and serotonergic neurons that project to the dorsal horn of 
the spinal columns (Naranjo et al., 1989). 
1.1.5 Neurotensin and Blood Pressure 
In vitro studies have revealed that NT elicited the contraction of isolated blood 
vessels including the rat portal vein (Rioux et al., 1980) and the coronary vasculature 
of guinea pigs (Ni sato et al., 1994). When given intravenously, NT was shown to 
dilate the cutaneous vesse1s and to increase vascular permeability in rodents (Chahl et 
and Walker, 1981). Administrated at low doses, NT evoked hypotension in 
anesthetized rats (Carraway and Leeman, 1973; Quirion et al., 1980; Rioux et al., 
1980), rabbits (Kataoka et al., 1978), and dogs (RoseIl et al., 1976). Atropine, 
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phenoxybenzamine or propanolol did not alter the vasodepressor effect of NT in vivo, 
suggesting the lack of involvement of the muscarinic or p and a adrenoreceptors 
(Carraway and Leeman, 1973). In contrast, higher doses of NT induced a slight 
increase in rat blood pressure (Carraway and Leeman, 1973; Quirion et al., 1979; Di 
Paola and Richelson, 1990; Gully et al., 1996). This hypertensinve effect is thought 
to be mediated by an activation of the sympathetic nervous system (Di Paola and 
Richelson, 1990). Additionally, the sensitivity of species to histamine was proposed 
to play a role in the NT vasopressor response, rats being the most sensitive (Gullyet 
al., 1996). 
1.1.6 Neurotensin and Food Intake 
Several reports have indicated that NT also plays a key role in the regulation of food 
consumption in rodents (Luttinger et al., 1982; Sahu et al., 2001; Wilding, 2002). 
Accordingly, early microinjection experiments have demonstrated that NT produced 
anorexigenic effects following administration in the nucleus of the solitary tract (de 
Beaurepaire and Suaudeau, 1988), the paraventricular hypothalamic nucleus (Stanley 
et al., 1983), the VTA (Cador et al., 1986), and the substantia nigra (Vaughn et al., 
1990). Moreover, hypothalamic NT expression levels were shown to be reduced in 
genetic models of obese rats (i.e. Zucker Jaifa) and mice (i.e. ob/ob), further 
supporting a role of NT in food intake (Beek et al. 1989; Wilding et al., 1993). This 
action most likely involves a co-inhibitory effect ofleptin and NT, which reciprocally 
stimulate each other (Beck et al., 1998). 
1.1.7 Neurotensin and the Gastrointestinal Tract 
NT is known to function as a hormone in the gastrointestinal tract (Andersson et al., 
1976; Polak and Bloom, 1978; Bloom and Polak, 1980; Blackburn et al., 1980; 
Rosell, 1980). Indeed, NT was found in endocrine cells of the distal jejunum and 
terminal ileum (Polak et al., 1977), which were shown to release NT upon fat 
ingestion (Rosell, 1982). However, NT was shown to exert opposite actions in the 
intestine (reviewed in Kitabgi, 1982). For instance, it has inhibitory and excitatory 
effects on the peristaltic activity (Ohashi et al., 1996), while it produces contractile 
and relaxant responses in intestinal smooth muscle (Kitabgi and Freychet 1979; 
29 
Chapter 1: Introduction 
Huidobro-Toro and Zhu, 1984; Ohashi et al., 1994). In particular, studies with rat 
proximal colon have shown that NT exerts its contractile effects acting both directly 
on smooth muscle cells and indirectly on nerves through acetylcholine release 
(Ohashi et al., 1994; Mulè et al., 1995). Conversely, NT was shown to induce a 
direct myogenic relaxation (Allescher et al., 1992) and to block the spontaneous 
phasic mechanical activity in rat proximal colon (Mulè and Serio, 1997). 
Nevertheless, these data are in contrast with studies using isolated smooth muscle 
preparations from human colon, which have indicated only direct, contractile actions 
of NT (Bennett et al., 1992; Maselli et al., 1998; Croci et al., 1999). 
1.1.8 Neurotensin and Cancer 
Increasing evidence suggests that NT plays an important role in growth regulation of 
carcinomas from diverse organs (reviewed in Kitabgi, 2002). Indeed, NT has been 
detected in a number of colon cell lines (Evers et al., 1992; Rovère et al., 1998) as 
well as in human pancreatic (Go et al., 1984; Townsend et al., 1994), prostate (Gu et 
al., 1983), and lung (Goedert et al., 1984a; Moody et al., 1985) cancer tissues in 
which NT is thought to act as an autocrine/paracrine trophic factor. In particular, the 
androgen-sensitive prostate cancer ceIl line LNCaP was shown to produce and 
secrete NT during androgen deprivation as a result of both neuropeptide 
synthesis/secretion and decreased neuropeptide-directed proteolytic activity (Sehgal 
et al., 1994). Additionally, recent studies have demonstrated that NT triggers a rapid 
Ca2+ mobilization from intracellular stores (Ryder et al., 2001) and PKC activation 
(Guha et al., 2002), leading to c-Raf-1-dependent phosphorylation of ERK1/2 in 
human ductal pancreatic cancer celllines (Guha et al., 2003). Interestingly, treatment 
with the MEK-l/2 inhibitors prevented NT-induced DNA synthesis and colony 
formation, indicating that activation of MAPK cascade plays a central role in 
mediating NT-induced mitogenesis (Guha et al., 2003). NT-induced ceIl growth has 
also been reported in small-celliung cancers (Davis et al., 1989; Sethi and Rozengurt, 
1991). This proliferative effect was shown to rely on the activation of focal adhesion 
kinases (F AK), which are invoived in cell adhesion, spreading, migration, and 
survivai mechanisms (Leyton et al., 2002). 
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1.2 Biosynthesis, Processing, and Inactivation of NT and its Related Peptides 
1.2.1 Structure of the Neurotensin/neuromedin N Gene 
NT and its structurally related analogue neuromedin-N (NN) (Lys-Ile-Pro-Tyr-Ile-
Leu) are synthesized as part of a common precursor protein in mammalian brain 
(Kislauskis et al., 1988) and intestine (Dobner et al., 1987). This gene consists of a 
10.2-kb segment containing four exons and three introns (Kislauskis et al., 1988). 
The transcription of the rat NTINN gene generates two mRNA species (1.0 and 1.5 
kb), arising from different consensus polyadenylation signaIs (Kislauskis et al., 
1988). Elements involved in the regulation ofNTINN mRNA expression are located 
in the upstream 200-bp flanking region of the rat gene in which several cis-regulatory 
elements function cooperatively to integrate multiple environmental stimuli into a 
concerted transcriptional response (Kislauskis and Dobner, 1990). ln the rat NTINN 
gene, these sites include one consensus AP-1 site that binds c-Jun and Jun D, two 
nearby cyclic AMP response elements (CRE), and a glucocorticoid response element 
(GRE), which is not expressed in the human (Kislauskis and Dobner, 1990; Bean et 
al., 1992; Evers et aI., 1995). ln particular, analysis of NTINN gene expression in 
PC12 cells revealed that combined treatment with NGF, dexamethasone, and the 
adenylate cyclase activator forskolin triggered a large increase in NTINN mRNA 
(Dobner et al., 1988; Kislauskis and Dobner, 1990; Tischler et al., 1991). 
1.2.2 Processing of the Neurotensin/neuromedin N Precursor 
Neurotensin and neuromedin N are both located in the C-terminal region ofthe 169-
amino acid prohormone (pro-NT) where they are flanked and separated by four Lys-
Arg sequences (Fig. 1.1), which represent putative sites for proteolytic maturation 
enzymes. Of these sites, the three that are closest to the C-terminus flank and 
separate NT and NN, whereas the fourth precedes a NN-like sequence. However, 
previous biochemical and immunological studies have shown that this most-terminal 
site is less extensively maturated than the remaining three (Nadai et al., 1994; Woulfe 
et al., 1994). Finally, the active NT and NN peptides have been shown to be released 
from their precursor in a tissue-specifie manner. For instance, processing of the 
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NTINN precursor was shown to essentially lead to the fonnation of NT and NN in 
the mammalian brain (Carraway and Mitra, 1990; Kitabgi et al., 1992), whereas NT 
and predominantly extended fonns of NN were found in the intestine following food 
ingestion (Carraway et al., 1992; Vincent et al., 1999). 
Previous immunohistochemical studies have shown a high degree of overlap 
between the Ca2+ -dependent prohonnone convertases (PC) PCAS and PCA2 in most 
NT -rich areas throughout the rat brain, suggesting that these two convertases may act 
jointly to process pro-NTINN (Villeneuve et al., 2000a). According to this scheme, 
the C-tenninal most dibasic sites, which are preferentially cleaved by PCAS (Barbero 
et al., 1998) are processed first to re1ease NT, whereas the third dibasic site, which is 
specifically cleaved by PC2, is then processed to release NN (Villeneuve et al., 
2000a). However, in certain regions such as the nucleus accumbens and 
periventricular nucleus of the hypothalamus, there were only a few cells in which NT 
co-Iocalized with either PCSA or PC2, suggesting that NTINN can also be processed 
in the absence of either PCSA or PC2. Indeed, PC1 was shown to be se1ective1y 
expressed in NT -positive neuronal and endocrine cells throughout the rat brain 
neuraxis (Schafer et al. 1993; Winsky-Sommerer et al., 2000; Villeneuve et al., 
2000b). Additionally, PC1 has also been shown to cleave pro-NTINN with a pattern 
similar to that observed in the gut (Rovère et al., 1996). 
KRKLPL VLDD ... KRKIPYILKRQL YENKPRRPYILKR 
Figure 1.1: Schematic Representation of the Rat NTINN Precursor Protein. The 
position of the four Lys-Arg doublets is illustrated. The amino acid sequence of NT 
and its re1ated peptides are shown. Numbers indicate the length of the precursor 
amino acid sequence. 
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1.2.3 Neurotensin as a Peptide 
The carboxyl-terminal hexapeptide portion of NT is preserved among vertebrate 
species, whereas the amino tenninus exhibits considerably more phylogenic 
variability as shown in Table 1.1 (Rostène and Alexander, 1997). For instance, 
human and bovine NT gave rise to the same fragments when treated with papain, 
which were indistinguishable in radioimmunoassays and in their hypotensive effect 
on anesthetized rats (Hammer et al., 1980). However, chicken NT purified from 
extracts of intestine displayed 3 amino acid substitutions located in its NH2-terminal 
(Carraway and Bhatnagar, 1980). Structure-activity relationship studies have 
established that the 8-13 C-tenninal hexapeptide portion of NT contains all the 
structural elements responsible for its biological activity. 
TABLE 1.1 
Phylogenic Variations in NT Primary Structure Among Vertebrates 
Species Sequence (position) Reference 
1 2 3 4 5 6 7 8 9 10 11 12 13 
Human Glu Leu Tyr Glu Asn Lys Pro Arg Arg Pro Tyr Ile Leu Hammer et al., 1980 
Cow Glu Leu Tyr Glu Asn Lys Pro Arg Arg Pro Tyr Ile Leu Carrawayet al, 1975 
Dog Glu Leu Tyr Glu Asn Lys Pro Arg Arg Pro Tyr Ile Leu Dobner et al., 1987 
Rat Glu Leu Tyr Glu Asn Lys Pro Arg Arg Pro Tyr Ile Leu Kislauskis et al., 1988 
Guinea Glu Leu Tyr Glu Asn Lys Ser Arg Arg Pro Tyr Ile Leu Shaw et al., 1986 pig 
Chicken Glu Leu His Val Asn Lys Ala Arg Arg Pro Tyr Ile Leu Carrawayet al., 1980 
Frog Glu Ser His Re Ser Lls Ala A~ ArK, Pro Tlr Ile Leu Shaw et al., 1992 
1.2.4 Proteolytic Degradation ofNeurotensin and Neuromedin N 
Since NT and NN appear to be co-Iocalized within the same vesic1es (Carraway and 
Mitra, 1987; Kitabgi et al., 1990) and hence are most likely co-released, their 
differential degradation presides over the relative concentration at which they will 
reach and activate their receptors on target cells. Indeed, these two peptides were 
shown to be degraded via proteolytic c1eavage by a distinct set of peptidases with 
characteristic kinetic properties (Kitabgi et al., 1992). In the rat brain, NT is mainly 
inactivated by a combination of three zinc-containing metallo-endopeptidases, 
referred to as 24.11, 24.15, and 24.16, c1eaving the peptide in its C-tenninal domain 
(Chec1er et al., 1986a; 1986b). In particular, endopeptidase 24.16 was shown to 
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ubiquitously participate in the catabolism of NT in various tissues and cell cultures 
from central and peripheral origin, giving rise to the biologically inert catabolites 
neurotensin 1-10 and 11-13 (Checler et al., 1988). Rowever, this endopeptidase was 
shown to be both secreted and expressed at the plasma membrane in neurons, 
whereas the membrane associate form of the enzyme was absent in astrocytes 
(Vincent et al., 1996). It was thus suggested that the secreted form would act in the 
extracellular space, thereby restricting diffusion of released NT, while the neuronal 
membrane-associated activity would be responsible for the physiological inactivation 
of the peptide in the synaptic cleft (Vincent et al., 1996). On the other hand, NN is 
primarily inactivated by bestatin-sensitive aminopeptidases, which are directed 
towards its N-terminal Lys residue (Barelli et al., 1995). Since aminopeptidases are 
quite abundant in tissues, NN is usually degraded more rapidly than NT (Vincent et 
al., 1999). Indeed, the half-life of NT is in the order of 15 min, which is about 2.5 
times longer than that ofNN in mammalian CNS (Kitabgi et al., 1992). 
1.3 Expression of Neurotensin in Mammalian CNS 
1.3.1 Ontogenie Patterns ofNeurotensin in the Developing Brain 
In the rat, expression ofNTINN mRNA and immunoreactive-NT is known to change 
during brain deve10pment in a region-specific manner (Rara et al., 1982; Bissetle et 
al., 1984; Sato et al., 1991a). Accordingly, NTINN mRNA was detected in most 
brain regions (e.g. hypothalamus) in the perinatal period, reaching maximalleve1s by 
adulthood. On the contrary, a second deve10pment profile was reported in different 
regions including the subiculum and CAl region of the hippocampus in which 
mRNA appeared early in the perinatal period and reached maximal levels within the 
first postnatal week, decreasing thereafter (Nicot et al., 1992). Finally, in regions 
such as the olfactory bulb and hypoglossal nucleus, NTINN mRNA was first detected 
during embryonic deve10pment (day 14), reached maximal leve1s perinataIly, and 
decreased to very low or undetectable leve1s within several weeks (K.iyama et al., 
1991a and 1991b). The transient expression of NTINN mRNA during the 
synaptogenesis peek (first postnatal week) suggests that NT and/or NN released from 
these cells might subserve a trophic function (Vincent et al, 1999). 
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1.3.2 Neurotensin Distribution in Adu/t CNS 
Radioimmunoassays and immunohistochemical studies concerning the distribution of 
NT in adult brain have revealed that NT is most abundant in areas in which 
dopaminergic systems are present (Fig. 1.2). In particular, dense networks of NT-
positive cell bodies and/or axonal fibers were observed in the substantia nigra and the 
VTA, and in projections areas of both nigrostriatal and mesolimbic dopaminergic 
pathways, such as the striatum, the nucleus accumbens, the bed nucleus of the stria 
terminalis, the amygdala, and the frontal cortex (Jennes et al., 1982; Emson et al., 
1985a and 1985b; Woulfe and Beaudet, 1989; Binder et al., 2001b). AIso, electron 
microscopic studies have shown direct synaptic connections between NT -
immunoreactive axon terminaIs and tyrosine hydroxylase-immunopositive perikarya 
and dendrites within the substantia nigra and VTA, suggesting a predominantly 
parasynaptic mechanism of action for NT (Woulfe and Beaudet, 1992). In the rat 
hypothalamus, neurosecretory cells capable of NT synthesis were found in the 
arcuate nucleus, parvocellular division of the paraventricular nucleus (PVN), and 
periventricular nucleus (Kiss et al., 1987; Merchenthaler and Lennard, 1991). 
Although most research on the role of NT in the CNS has focused on its 
interaction with dopaminergic systems (reviewed in Binder et al., 2001 b; Kinkead 
and Nemeroff, 2004), the interaction of NT with serotoninergic neurons has recently 
become a target of investigation due to the presence of abundant NT -immunoreactive 
neurons, fibers and terminals within the raphe complex (reviewed in Jolas and 
Aghajanian, 1997). Moreover, immunohistochemical studies of the basal forebrain 
have documented the presence NT -immunoreactive fibers in cholinergie systems 
extending from the medial septum and the diagonal band of Broca through the 
magnocellular preoptic area and the substantia innominata into the the globus 
pallidus (Uhl and Snyder, 1976; Jennes et al., 1982; Uhl, 1982; Zahm and Reimer, 
1988; Woulfe et al., 1994). At high magnification, neurotensinergic fibers were 
shown to form a dense plexus of varicose axons in close proximity to cholinergic 
neurons within the posterior substantia innominata and the globus pallidus (i.e. 
caudal basal forebrain), suggesting that NT effects could be exerted synaptically upon 
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distal dendrites of basal forebrain neurons (Morin et al., 1996). AIso, retro grade NT 
labeling studies have identified projections from the lateral hypothalamus and 
pontomesencephalic tegmentum to the magnocellular preoptic nucleus and posterior 
substantia innominata, which project to the cerebral cortex and amygdala, suggesting 
that NT neurons might be part of the ascending reticular formation involved in the 
regulation of sleep and wakefulness (Morin and Beaudet, 1998). 
It is worth noting that NT was also found in nonneuronal cells such as those in 
the anterior pituitary, which indicates that it may also play a role in cell-to-cell 
signaling on autocrine, paracrine, and endocrine levels (Vincent et al., 1999). 
Figure 1.2: Topographie Distribution of NT-containing Neurons in Rat CNS. 
Schematic midsagittal section through the rat brain provides an overview of the 
distribution ofNT-immunoreactivity throughout the neuraxis (according to Jennes et 
al., 1982). 
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However, sorne discrepancies exist between the NTINN rnRNA distribution and 
NT immunoreactivity within the rat CNS (Alexander et al., 1989b; Smits et al., 
2004). For instance, NTINN mRNA was abundant in the CAl region of the . 
hippocampus, a region devoid of NT -immunoreactive neurons (Alexander et al., 
1989b). These data suggest that in specifie regions of the forebrain, NTINN 
precursor is processed to yield other products than NT. Interestingly, comparative 
studies using an NH2-terminally directed anti-NN antiserum in rat brain revealed that 
distributions of NT and NN were generally parallel, with NT being usually more 
abundant than NN (e.g. dopaminergic areas) (Kitabgi et al., 1991). Indeed, high 
immunonoreactive-NT over NN ratio values (>3) were found in the globus pallidus, 
the posterior hypothalamus, the substantia nigra pars compacta, and the VT A. On the 
other hand, values close to one were observed in most cortical areas in addition to the 
striatum and the hippocampus. 
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2. NEUROTENSIN RECEPTORS 
Early autoradiographic studies using radiolabe1ed NT tirst suggested the existence of 
two binding sites in both rodent (Goedert et al., 1984b; Kitabgi et al., 1987) and 
human (Sadoul et al., 1984; Zsurger et al., 1992) CNS. These sites were 
distinguished by their binding affinity for NT, displaying high (Kt = 0.15-0.5 nM) 
and 10w (Kt = 5-7 nM) affinity (Mazella et al., 1983; Kitabgi et al., 1985). NT is 
now known to mediate its central and peripheral effects through interaction with three 
different receptor subtypes, referred to as NTS 1, NTS2, and NTS3 (reviewed in 
Vincent et al., 1999; Kitabgi, 2002; Dobner, 2005). NTS 1 and NTS2 (both illustrated 
in Fig. 1.3) belong to the G protein-coupled receptor (GPCR) family of receptors, 
whereas NTS3 is a single transmembrane domain receptor. The pharmacological 
properties of NTS 1 and NTS2 are reviewed in Table 1.2 and 2.3, respectively, and a 
summary of their binding properties is provided in Table 1.4. 
Figure 1.3: Schematic Representation of Rat NTS 1 and NTS2 Receptors. Amino 
acids exclusive to NTS 1 are represented in blue, while those that strongly differ from 
NTSI are indicated in yellow. Invariants residues between NTS1 and NTS2 are 
shown in green. Glycosylation sites (Y) and regions corresponding to extracellular 
(E) and intracellular (I) domains are illustrated (Adaptedfrom Vincent et 1999). 
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2.1 Cloning and Structural Features 
2.1.1 NTS1 Receptor 
NTSI was first cloned from rat brain by Nakanishi and colleagues using the oocyte 
expression technique (Tanaka et al., 1990). This gene occurs as a single copy in the 
rat haploid genome and contains three introns in its coding region (Maeno et al., 
1996). In addition, the upstream putative promoter region was shown to contain a 
consensus sequence for the transcription factor Sp-l (Maeno et al., 1996). The open 
reading frame of rat NTS 1 cDNA encodes a 424 amino acids protein with seven 
putative transmembrane (TM) domains, sharing 84% homology with its human 
counterpart isolated from the colon carcinoma HT-29 cell line (Vita et al., 1993). 
Western blotting analysis using an anti-peptide raised against a fragment of the third 
intracellular loop of the receptor, revealed the presence of immunoreactive bands 
between 62 and 72 kDa, while only a faint labeling was observed at 47 kDa, 
corresponding to the molecular mass deduced from the rat NTS 1 cDNA sequence 
(Boudin et al., 1995). The bands of higher molecular mass were no longer present 
after deglycosylation of membrane proteins by peptide N-glycosidase F, indicating 
that they represented glycosylated forms of the receptor. Interestingly, the receptor 
was only observed as the 47 kDa band in membrane extracts prepared from 
recombinant sf9 cells (Boudin et al., 1995), which are unable to process N-linked 
oligosaccharides (Luckow and Summers, 1988). A second translation initiation site 
(Met 27) was also reported in the cDNA sequence encoding the NTS 1 receptor, 
generating a truncated form of the receptor (i.e. 44 kDa) by using a reticulocytes 
lysate-based in vitro transcription-translation system (Botto et al., 1997a). 
2.1.2 NTS2 Receptor 
A second type of NT receptor (i.e. NTS2) was cloned form murine (Mazella et al., 
1996), rat (Chalon et al., 1996), and human (Vita et al., 1998) brain. The cDNA 
sequence of the mouse NTS2 is composed of four exons separated by three introns 
(Sun et al., 2001). The first exon encodes the region containing TM domains 1-4, 
whereas exons 2-4 encode the region containing TM 5-6, TM 6 and TM 7, 
correspondingly. The existence of a C-terminally truncated form of NTS2 mRNA 
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lacking a 181-bp internaI sequence has also been reported in the mouse (Botto et al., 
1 997b). Both mouse NTS2 mRNA isoforms are derived from a single NTS2 gene, 
the short form resulting from alternative splicing of the primary transcript at intron 2a 
(Sun et al., 2001). The promoter region ofNTS2 includes putative binding sites for 
neuronal transcriptional factors, GATA-2, CREB (cAMP-responsive element binding 
protein), Oct-2, and Ikarous 2 (Sun et al., 2001). Whether or not these sites are true 
regulatory elements remains to be determined. 
The full-Iength rat NTS2 cDNA contains a large open-reading frame encoding a 
416 amino acid protein, sharing extensive similarity with that of the mouse (96% 
identity and 98% homology) and human (79% identity and 87% homology) receptors 
(Vita et al., 1998). Nonetheless, the rat and mouse NTS2 (416 amino acids) are also 
slightly longer than their human counterpart (410 amino acids) and differ the most in 
their C-terminal domain. However, most theronine and serine residues within this 
region are conserved. Other features of the NTS2 receptor include the presence of a 
cysteine residue in each of the extracellular loops, which might enable the formation 
of intra- or intermolecular disulfide bonds as weIl as a putative palmytoylation site in 
the C-terminal region (Vita et al., 1998). Photoaffinity labeling experiments carried 
out on HEK 293 cells expressing the mouse NTS2 using a photoreactive NT 
analogue revealed the presence of a labeled protein with an apparent molecular 
weight of 45 kDa (Botto et al., 1998). 
The rat NTS2 receptor protein shares 43% identity and 64% homology with the 
NTS 1 amino acid sequence as shown in Fig. 1.4 (Chalon et al., 1996; Vincent et al., 
1999). Although the lengths ofboth proteins are very similar, the NTS2 receptor has 
a shorter N-terminal extracellular region devoid of potential N-glycosylation sites. 
NTS 1 and NTS2 differ most in their third cytoplasmic loops and C-terminal domains, 
two regions bearing specificity to G-protein coupling and receptor regulation 
(Yamada 1994; Vincent et al., 1999). In particular, the third intracellular loop is 
much longer in the NTS2 (~50 residues) than in the NTS1 (~30 residues) and shares 
only five identical residues between the two receptor subtypes (Richard et al., 2001a). 
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Figure 1.4: Alignment of Rat (r), Mouse (m), and Human (h) NTS 1 and NTS2 
Amino Acid Sequences. Invariant residues found in NT receptors are shown in 
green, whereas those that are common in either NTS 1 or NTS2 sequences are 
illustrated in blue and yellow, respectively. The solid line above the sequences 
indicates the putative transmembrane (TM) segments. Gaps for alignments are 
represented by dots (Adaptedfrom Vincent et al., 1999). 
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2.1.3 NTS3 Receptor 
NTS3 was first cloned from a human brain cDNA library (MazeIla et al., 1998; 
reviewed in MazeIla, 2001) and found to be 100% identical to sortilin, which was 
previously isolated from human brain homogenates based on its interacting properties 
with RAP, an endoplasmic reticulum-resident protein (Petersen et al., 1997). In 
addition to the brain, NTS3/sortilin has been localized to several peripheral ceIl types 
including 3T3-L1 adipocytes (Lin et al., 1997; Morris et al, 1998), as weIl as 
prostatic, colonie, and pancreatic cancer ceIllines (DaI Farra et al., 2001; Martin et 
al., 2002a). NTS3/sortilin is a non-G protein coupled receptor that is 833 amino acid 
residues long and encodes a single TM domain protein (MazeIla et al., 1998). 
Interestingly, insulin was shown to trigger the translocation of NTS3/sortilin from 
glucose transporter GLUT4 vesicles to the plasma membrane, suggesting that this 
receptor is also involved in the sorting of lumenal proteins from the trans-Golgi in 
addition to its role as a NT receptor (Lin et al., 1997; Morris et al., 1998). 
NTS3/sortilin belongs to the type-I receptor family including the receptors SorLA 
and Sorcs (Jacobsen et al., 1996; Yamazaki et al., 1996; Hermey et al., 1999). This 
family is characterized by the presence of aluminai extraceIlular region containing a 
cysteine-rich domain homologous to the yeast sorting protein Vps10p (Marcusson et 
al., 1994), as shown in Fig. 1.5. The NTS3/sortilin C-terminus is also homologous to 
the mannose-6-phosphate receptor MPR300 (Johnson and Kornfeld, 1992) . 
• Signal peptide 
tri Propeptide 
FS Furinsle 
li Vps10p cys-rich domain 
< "Transmembrane segment 
Figure 1.5: Schematic diagram of NTS3/sortilin receptor. NTS3/sortilin is 
composed of an N-terminal signal peptide, a propeptide released by furin cleavage 
(FS), a cysteine-rich domain, a transmembrane domain, and a cytoplasmic tail 
(Adaptedfrom Mazel/a, 2001). 
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NTS3/sortilin is synthesized as a precursor protein that is converted to its 
mature form through proteolytic cleavage by furin (see Fig. 1.5) in late Golgi 
compartments (Mazella, 2001). This step was shown to be crucial for both ligand 
recognition and functional activity of the receptor (Mazella et al., 1998). 
Accordingly, binding experiments showed that the NTS3/sortilin was processed into 
a higher affinity protein receptor upon co-transfection with furin (Mazella et al., 
1998). In line with these results, photoaffinity labeling experiments revealed the 
presence of a 100 and 110 kDa-band in the presence or absence of furin, respective1y 
(Mazella et al., 1998). 
2.2 Binding Properties and Transduction Mechanisms 
2.2.1 NTS1 Receptor 
Experiments on mammalian cells transfected with recombinant NTS 1 revealed that 
this receptor is insensitive to levocabastine ((-)-trans-1-[cis-4-cyano-4-(p-fluoro-
phenyl)-cyclohexyl]-3-methyl-4-phenylisonipecotic acid monohydrochloride) and 
binds NT with high affinity (~in the subnanomo1ar range; see Table 1.4) (Mazella et 
al., 1989; Tanaka et al., 1990). This interaction is known to be sensitive to Na+ and 
GTP, which decrease the affinity of the receptor for NT (Vincent et al., 1999). The 
NT binding pocket encompasses aromatic residues located in the third extracellular 
loop in addition to hydrophobic residues in TM 6 and 7 of rat NTS 1 (Barroso et al., 
2000; Richard et al., 2001a). Additionally, nuclear magnetic resonance studies have 
revealed that residues 8-13 in NT peptide are essential for its interaction with the 
agonist-binding site (Williamson et al., 2002). 
Pharmacological and biochemical studies have indicated that NTS 1 is involved 
in the modulation of intracellular second messengers levels, including cGMP (Gilbert 
et al., 1988; Amar et al., 1985; Slusher et al., 1994), cAMP (Bozou et al., 1989a; 
Yamada et al., 1993; Richard et al., 2001a; Barroso et al., 2002), and inositol 
phosphates (Snider et al., 1986; Amar et al., 1986; Amar et al., 1987; Hermans et al., 
1992; Watson et al., 1992; Choi et al., 1999). Previous studies have suggested that 
the third intracellular loop and carboxy terminal portion of NTS 1 play a critical role 
in its coupling to Gq/ll and Gi/o, respectively (Yamada et al., 1994; Najimi et al., 
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2002). Functional properties of NTS 1 receptors also include the activation of 
extracellular signal-regulated kinases 1/2 (ERK1/2) through coupling with both 
pertussis toxin-sensitive and insensitive G-proteins in transfected CHO cells (Poinot-
Chazel et al., 1996). This MAPK phosphorylation leads in turn to the expression of 
proliferative genes, such as c-fos, Krox-24, and c-jun (Poinot-Chazel et al., 1996; 
Portier et al., 1998). NT was shown to trigger the phosphorylation of ERKl/2 
through a PKC-dependent mechanism in human pancreatic carcinoma PANC-1 cells 
(Guha et al., 2003), as weIl as in human androgen-insensitive prostate cancer PC3 
cells (Hassan et al., 2004), which are both known to endogenously express the NTS1 
receptor. 
TABLE 1.2 
NT-induced Signaling Cascades Modu/ated by NTSI Receptors 
Model Response measured Reference 
CellUnes 
NIE-115 1- [IP3] Snider et al., 1986; Amar et al., 1987 
1- [Ca2+] Snider et al., 1986 
1- [cGMP] Gilbert et al., 1988; Amar et al., 1985 
NG108-15 1- [IP3] Imaizumi et al., 1989 
1- [Ca2+] Imaizumi et al., 1989 
HT-29 1- [IP3] Amar et al., 1986 
1- [Ca2+] Bozou et al., 1989b; Turner et al., 1990 
HL-60 1- [IP3] Choi et al., 1999 
1- [Ca2+] Choi et al., 1999 
PANC-l MAPK Guha et al., 2003 
PC3 MAPK Hassan et al., 2004 
Transfected cells 
CHO 1- [IP3] Hennans et al., 1992; Watson et al., 1992 
1- [Ca2+] Hennans et al., 1995 
1- [cAMP] Yamada et al., 1993 
PC12 1- [Ca2+] Hennans et al., 1994 
HEK293 l' [cGMP] Slusher et al., 1994 
LTK 1- [IP3] Chabry et al., 1994 
1- [Ca2+] Chabry et al., 1994 
COS 1- [IP3] Richard et al., 2001a; Barroso et al., 2002 
1- [cAMP] Richard et al., 2001a; Barroso et al., 2002 
CHO MAPK Poinot-Chazel et al., 1996; Portier et al., 1998 
(Adaptedfrom Hermans et al, 1998) 
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A significant advance in the understanding of NT interactions with its receptors 
came with the development of the non-peptide NT antagonist SR48692 (2-[1-(7-
chloroquinoline-4-yl)-5-(2,6-dimethoxyphenyl)-IH-pyrasol-3-carbonyl]-amino-ada-
mantane-2-carboxylic acid; illustrated in Fig. 1.6), which displays a much higher 
affinity for NTS 1 (lCso = 5.6 JlM) than for NTS2 (lCso = 300 nM) (Guny et al., 
1993). This antagonist was shown to competitively inhibit [l25I]-NT binding in rat, 
guinea pig, and human brain homogenates (Guny et al., 1993; Azzi et al., 1994; 
Brouard et al., 1994a). It was also reported to antagonize the inositol production 
evoked by NT in NTSI expressing sf9 cells (Boudin et al., 1996a). Recent 
mutagenesis studies have demonstrated that contact with hydrophobic residues in TM 
6 and 7 of NTS 1 are crucial for SR48692 binding. These residues include Tyr 342, 
Phe 331, and Tyr 359, which also appeared to interact with NT, suggesting a basis for 
the ability of SR48692 to compete for NT binding to the receptor (Labbé-Jullié et al., 
1998; Barroso et al., 2000). 
Figure 1.6: Chemical Structure of Non-peptide Ligands for NT Receptors. 
SR48692 and SR124948A were developed by Sanofi-Synthélabo Inc. through 
random screening and chemical optimization (see Guny et al., 1993 and Guny et al., 
1997). Levocabastine is an original product of Janssen Pharmaceuticals, Inc. 
45 
Chapter 1: Introduction 
A follow-up compound, SR142948A (2-[5-(2,6-dimethoxylphenyl)-I-(4-(N-(3-
dimethylaminopropyl)-N-methyl-carbamoyl]-amino-adamantane-2-carboxylic acid) 
was also introduced (illustrated in Fig. 1.6), displaying a better solubility and an 
increased affinity in the rat brain as compared with SR48692 (GuIly et al., 1997). 
This nonpeptide antagonist was shown to recognize both NTS 1 and NTS2 receptors 
with high affinity (ICso = 6.8 J.1M and 4.8 J.1M, respectively) (Bétancur et al., 1998). 
SR142948A was also shown to antagonize the c1assical NT's in vitro effects (i.e. the 
inositol phosphate production in HT-29 cells or intracellular calcium mobilization in 
NTSI expressing CHû cells (Gullyet al., 1997». 
2.2.2 NTS2 Receptor 
Binding studies on transfected cells showed that NTS2 binds NT with a lower affinity 
(~ = 2 nM) than NTS 1 (Mazella et al., 1996). Conversely, the NT analogue JMV 
431 (Boc-Arg-Arg-Pro-Tyr-<p(CH2-NH)-Ile-Leu-ûH) has a higher affinity for the 
mouse NTS2 (~ = 38 nM) than for the rat NTSI (~ = 3315 nM) (Dubuc et al., 
1999b). As opposed to NTS1, binding of NT to NTS2 is insensitive to Na+ and GTP 
analogs (Martin et al., 1999). NTS2 is also recognized by the histamine Ht-
antagonist drug levocabastine, which is known to selectively inhibits NT binding to 
NTS2 without affecting its binding to NTS 1 (Schotte et al., 1986). Finally, NTS2 
was shown to specifically bind p-Iactotensin (His-Ile-Arg-Leu), an ileum-contracting 
peptide derived from the chymotrypsin digestion of p-Iactoglobulin (Yamauchi et al., 
2003b). Interestingly, this peptide was found to be about 47 times more selective for 
NTS2 (~= 7.7 !lM) than NTSI (~= 363 !lM). The binding properties ofNTS2 are 
reviewed in Table 1.4. 
However, the signaling properties of NTS2 are still controversial. In particular, 
there is inconsistency between reported agonistic and antagonistic properties of NT in 
systems heterologously expressing NTS2. For instance, in mammalian cells 
transfected with human NTS2, the NT antagonist SR48692, but neither NT nor 
levocabastine was reported to activate c1assical second messenger systems such as 
phosphoinositide hydrolysis, Ca2+ mobilization, arachidonic acid (AA) release or 
MAPK phosphorylation (Vita et al., 1998). In addition, these SR48692-induced 
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activities were blocked by NT, NN and levocabastine, suggesting that the 
endogenous peptide was acting as a competitive antagonist at NTS2 sites. Similarly, 
NT was reported to reverse the SR48692-induced inositol phosphate production in 
COS-M6 cells transfected with the human NTS2 receptor cDNA (Richard et al., 
200Ib). In contrast, in Xenopus oocytes expressing the mouse NTS2 receptor, NT, 
NN, and levocabastine were all found to activate Ca2+-dependent chloride currents 
(Mazella et al., 1996; Botlo et al., 1997c). Additionally, studies on rat cerebellar 
granule cells in culture showed that both NT and levocabastine, but not SR48692, 
induced a sustained MAPK p42/p44 activation, indicating that these ligands act as 
agonists on endogenously expressed rat NTS2 receptors (Sarret et al., 2002). 
Surprisingly, the human NTS2 was shown to exhibit a robust constitutive activity on 
inositol phosphate production when transiently expressed in COS-M6 cells (Richard 
et al., 200Ib). However, this spontaneous phospholipase C activity was reported for 
neither rat NTS2, mouse NTS2 nor human NTS 1, suggesting that this constitutive 
activation might result from the divergent structure of the third intracellular loop 
among different species or receptor subtypes. 
TABLE 1.3 
NTS2-Mediated Signaling Pathways in Different Expression Systems 
Species Expression Transduction Agonist Antagonist Reference 
system pathway 
Human CHO ..,.. [IP3, Ca2] SR48692 NT Vita et al., 1998 
AA,MAPK SR142948A Levocabastine 
COS ..,.. [IP3] SR48692 NT Richard et al., 2000a 
Mouse Xenopus ..,.. [Ca2+] NT,NN Mazella et al., 1996 
oocyte Levocabastine Botto et al., 1997c 
SR48692 
Rat CHO ..,.. [Ca2+] NT Yamada et al., 1998 
Levocabastine 
SR48692 
Cerebellar cells MAPK NT 
Sarret et al., 2002 
Levocabastine 
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2.2.3 NTS3 Receptor 
Binding experiments on COS-7 cells transfected with the human NTS3 cDNA have 
revealed that CHAPS solubilized extracts bind to NT with a Kt of 10 nM (Mazella et 
al., 1998). However, no NT binding was detected either on whole cells or crude 
homogenates, indicating that the receptor is not expressed at the cell surface (Mazella 
et al., 1998). This observation is in agreement with several studies that have revealed 
a predominant association of NTS3/sortilin with intracellular organelles such as the 
endoplasmic reticulum, the Golgi apparatus and GLUT4 glucose transporter-positive 
vesic1es (Petersen et al., 1997; Nie1sen et al., 2001; Li et al., 1997). The 
NTS3/sortilin was also shown to bind severalligands inc1uding RAP (Petersen et al., 
1997), lipoprotein lipase (Nielsen et al., 1999), and the precursor of nerve growth 
factor (Nykjaer et al., 2004), suggesting that its role probably exceeds that of a NT 
signaling receptor. 
Recent RT-PCR studies have revealed that NTS3/sortilin is co-expressed with 
the NTS 1 receptor in most of human colonic and pancreatic cancer cell lines (DaI 
Farra et al., 2001). Of interest is the finding that NTS3 forms endogenous 
heterodimers with NTS1 in HT-29 cells (Martin et al., 2002a). This interaction was 
shown to modulate both NTS 1-mediated ERKl/2 MAPK signaling and 
phosphoinositide turnover (Martin et al., 2002a). However, NTS3 was also found to 
be expressed without other NT receptor subtypes in different cancer cell lines (e.g. 
LnCaP and Lo Vo), suggesting that it might also be specifically involved in the NT-
induced growth response (DaI Farra et al., 2001). In addition, the stimulation of 
NTS3/sortilin with NT was shown to lead to the activation of both ERKl/2 and Akt 
phosphorylation in the human micro glial C13NJ cellline (Martin et al., 2003). This 
activation was found to promote a phosphatidylinositol 3-kinase-dependent formation 
of filopodia, which was then followed by a marked activation of cell migration 
(Martin et al., 2003). 
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TABLE 1.4 
Binding Properties of NT Receptor Subtypes for NT and Different Compounds 
Kc. 
Compound NTSI NTS2 NTS3 Reference 
Neurotensin 0.1-0.3 nM 2-4nM 10nM Tanaka et al., 1990 
Chalon et al., 1996 
Mazella et al., 1998 
JMV 431 3315 nM 38nM N.A Dubuc et al., 1999b 
JMV 449 0.04nM 0.56nM N.A Labbé-Jullié et al., 1994 
Yamada et al., 1998 
Neuromedin N 2.6 1.5-2.5 N.A Tanaka et al., 1990 
Vita et al., 1993 
Mazella et al., 1996 
Levocabastine N.A 1-9nM N.A Yamada et al., 1998 
Mazella et al., 1996 
f3-Lactotensin 363 JlM 77 JlM N.A Yamauchi et al., 2003b 
SR48692 5-6nM 300nM N.A Gully et al., 1993 
SR142948A 1-7nM 4.8nM N.A Gully et al., 1997 
Bétancur et al., 1998 
2.3 Desensitization of Responses to Neurotensin 
2.3.1 NTS1 Receptor 
Carraway tirst reported that NT's systemic hypotensive effects exhibited acute 
tachyphylaxis following subsequent applications of the peptide, suggesting that 
responses to NT were susceptible to rapid desensitization (Carraway and Leeman, 
1973). Likewise, Richelson's group found that NT-induced cGMP reduction 
declined within the tirst minutes of agoni st stimulation and that the concentration-
response curve shifted to higher doses for ensuing applications (Gilbert et al., 1988). 
Desensitization of NTS I-mediated second messenger systems response has also been 
reported in cultures ofneurons (Sato et al., 1991b) as weIl as in HT-29 (Turner et al., 
1990) and NIE-lIS (Yamada and Richelson, 1993a and 1993b) cells. However, few 
reports have shown NT responses in which desensitization was not observed 
(reviewed in Hermans and Maloteaux, 1998). For instance, electrophysiological 
studies on cholinergic neurons of the basal forebrain have reported that NT 
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application produced a slow and long-lasting membrane potential depolarization 
associated with a decrease in apparent input conductance (Alonso et al., 1994). In 
addition, persistent activation of p42/p44 mitogen-activated protein kinases was 
detected in non-differentiated NTSI expressing NIE-115 cells following a 24 h 
exposure to JMV 449 (Toy-Miou-Leong et al., 2004a). 
Nonethe1ess, there is orny limited information on the molecular and cellular 
mechanisms underlying NTS 1 desensitization. Several studies on GPCRs have 
shown that the phosphorylation of serine and threonine residues in the carboxy 
terminus and/or the third intracellular loop plays an important role in the 
desensitization of receptor responsiveness (Bouvier et al., 1988; Ferguson, 2001). 
Likewise, the NT -induced dopamine release observed in mesencephalic cell cultures 
was suppressed by both short- and long-term treatment with phorbol esters, 
suggestive of a PKC-dependent desensitization pro cess (Brouard et al., 1994b). 
Accordingly, the NTS 1 third intracellular loop and carboxy-terminal tail contain 13 
and 6 serine/threonine residues, respective1y (Tanaka et al., 1990). It is thus like1y 
that these residues participate in NTS 1 desensitization as a result of phosphorylation. 
However, agonist-induced phosphorylation of NTS 1 has never been directly 
demonstrated so far. 
Receptor intemalization has also been proposed to play a critical role in the 
control of cell responsiveness to NT (reviewed in Hermans and Maloteaux, 1998; 
Vincent et al., 1999; Kitabgi, 2002). For instance, incubation of rat cultured neurons 
with NT was shown to be followed by a dramatic decrease in the number of receptors 
from the cell surface (Vanisberg et al., 1991). Autoradiographic and/or biochemical 
studies have then shown radioactive NT to be rapidly taken up by mouse and rat 
neurons in culture in a receptor-dependent manner (Mazella et al., 1991; Vanisberg et 
al., 1991; Beaudet et al., 1994). Accordingly, photoaffinity labe1ing experiments 
indicated that the intracellular NT was associated with a protein of a molecular 
weight similar to that ofNTSI receptor (Chabry et al., 1993). To gain insight into 
the mechanisms underlying the intemalization process of NTS 1, the intracellular 
migration of NTS 1 was monitored by confocal microscopic studies using a 
fluorescent analogue of NT (Faure et al., 1994; Alonso et al., 1994; Faure et al., 
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1995a; Faure et al., 1995b; Nouel et al., 1997; Vandenbulcke et al., 2000; Cape et al., 
2000). Indeed, results show that Fluo-NT was internalized at the somatodendritic 
level both in DA (Noue1 et al., 1997) and cholinergic neurons (Faure et al., 1995a; 
Faure et al., 1995b). However, light microscopic evidence for retro grade transport of 
intrastriatal neurotensin within nigrostriatal dopaminergic neurons was provided, 
suggesting that the peptide may also be internalized presynaptically and transported 
back to nigrostriatal nerve cell bodies (Castel et al., 1990). 
NTS 1 endocytosis was shown to be prevented by hypertonic sucrose, potassium 
depletion and cytosol acidification, suggesting that the internalization process was 
mediated via c1athrin-coated vesic1es (Faure et al., 1995a: Faure et al., 1995b; Noue1 
et al., 1997: Vandenbulcke et al., 2000; Nguyen et al., 2002). In particular, confocal 
microscopic studies demonstrated that J3-arrestin 1 and 2 were both translocated to 
NTSI following NT exposure (Oakleyet al., 2000). As opposed to c1ass A receptors 
(i.e. J32_adrenergic (AR), ~ opioid receptor, endothelin type A receptor), both J3-
arrestin isoforms remained associated with NTS 1 and intemalized with the receptor 
into endocytic vesic1es. These vesic1es concentrated the transferrin receptor and 
displayed colocalization with the low pH indicator Acridine orange, and rab 5, 
indicating that they corresponded to early endosomes (see Fig. 1.7; Vandenbulcke et 
al., 2000). The NTS 1 intemalization process was also shown to depend on dynamin 
(Savdie et al., 2006), which is known for its role in the scission of newly formed 
vesic1es from the plasma membrane (for reviews, see Schmid et al., 1998; Sever, 
2002). However, the molecular pathways involved in NTS 1 endocytosis were shown 
to differ among cell types. In particular, it required the participation of the endocytic 
scaffolding protein intersectin in COS-7 cells but not in HEK-293 cells (Savdie et al., 
2006). Mutagenesis studies have revealed that the C-terminal tail of NTS 1 is 
involved in receptor intemalization and desensitization (Chabry et al., 1993; Hermans 
et al., 1996). More precisely, the substitution of Thr-422 and Tyr-424 virtually 
abolished ligand-induced receptor intemalization in transfected COS-7 cells (Chabry 
et al., 1995). 
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CUITent biochemical and immunocytochemical data suggest that intemalized 
NTS 1 receptors are not recycled back to the plasma membrane, but rather targeted to 
lamp-I-immunopositive lysosomes via rab 7-immunopositive late endosomes 
(Hermans et Maloteaux, 1998; Vandenbulcke et al., 2000). Accordingly, the 
lysosomotropic drugs chloroquine and methylamine were reported to partially reduce 
the progressive loss of cell surface binding sites observed in rat primary cultured 
neurons following persistent agoni st exposure, indicating that lysosomal degradation 
may be involved in the down-regulation of NTS 1 receptors (Hermans et al., 1997). 
Interestingly, chronic exposure to JMV 449 ([Lys8-(CH2NH)-Lys9]Pro-Tyr-Ile-Leu) 
was shown to induce the degradation of NTS 1 rnRNA in cultures of rat embryonic 
cerebral cortex neurons, suggesting that post-transcriptional events may also be 
directly implicated in the down-regulation process (Lépée-Lorgeoux et al., 2000). 
This phenomenon is in agreement with the destabilization of NTS 1 mRNA that was 
previously reported in NIE-lIS cells after long-term agoni st exposure (Najimi et al., 
1998). Finally, it has been established that de nova synthesis is required for the 
recovery of NTS 1 receptor-binding sites and function (Donato di Paola et al., 1993; 
Hermans et al., 1997). Specific autoradiographic NT labeling was also detected in 
the nucleus of DA neurons and human lung cancer cells, suggesting that NT alone, or 
complexed to its receptor, might be involved in the regulation of gene expression 
through direct or indirect interactions with nuclear DNA (Castel et al., 1990; Toy-
Miou Leong, 2004b). 
However, radio ligand binding on synaptosomes from rat neostriatum revea1ed 
that NT intemalizes in nerve terminaIs via an endocytic pathway that is related to, but 
is mechanistically distinct from that responsible for NT intemalization in nerve cell 
bodies (Nguyen et al., 2002). Contrary to what was reported at the somatodendritic 
level, NTS l-mediated intemalization of NT was insentitive to the endocytosis 
inhibitor phenylarsine oxide (Nguyen et al., 2002). Additionally, treatment of 
synaptosomes with monensin reduced NT binding and intemalization, suggesting that 
presynaptic NTSI receptors are recycled back to the plasma membrane (Nguyen et 
al., 2002). In line with these data, a study in NTSI expressing NIE-lIS cells has 
demonstrated that intemalized NTS 1 receptors are recycled back to the cell surface 
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under prolonged treatment with saturating concentrations of NT agoni st (Toy-Miou 
Leong et al., 2004a). Indeed, confocal microscopie studies revealed that these 
receptors accumulated slowly (> 6 h) in the perinuc1ear recyc1ing compartment upon 
retuming to the cell surface, restoring NT binding capacity to half of baseline values 
after 24 h of agoni st exposure (Toy-Miou Leong et al., 2004a) . 
. .. ... .. 
Coated pit 
Early endosome ~ __ 
rabS+,AO+ 
trolrerrin+ 1 
~. Late endosome A rab 7+, AO+ Lysosome . ./ 
" .. pH .-
~ 
Figure 1.7: Model for the NTSI-mediated Endocytosis of Neurotensin. Fluo-NT 
and human NTS 1 receptors are intemalized together into rab 5-immunopositive 
acidic endosomes via a c1athrin-dependent mechanism. The receptors are then 
translocated to late endosomes and targeted to lamp l-immunopositive lysosomes for 
intracellular degradation (Adapted from Vandenbu1cke et al., 2000). 
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2.3.2 NTS2 Receptor 
Little is known about the regulation of the NTS2 receptor, except that its stimulation 
with NT induces long-term metabolic effects due to prolonged and sustained 
activation of ERK1I2 in rat cerebellar granules cells (Sarret et al., 2002). 
Furthermore, biochemical and cell imaging evidence suggested that NTS2 receptors 
are sequestered rapidly upon NT exposure either in cells expressing the recombinant 
mouse NTS2 (Botto et al., 1998) or in rat cultured neurons (Sarret et al., 2002). This 
process was proposed to occur via a clathrin-coated pit dependent mechanism since it 
was abolished by either hypertonic sucrose or phenylarsine oxide (Sarret et al., 2002). 
On the other hand, ligand-receptor complexes were found to form clusters at the cell 
surface but not to internalize in cultured astrocytes following stimulation with NT at 
37°C, suggesting that NTS2 internalization capacities might be cell type-dependent 
(Nouel et al., 1997). Nevertheless, RT-PCR studies have demonstrated that cortical 
glial cells in culture expressed a combine population of NTS2 and NTS3 receptor 
subtypes, which might influence NTS2 behavior (Nouel et al., 1999). 
Several lines of evidence suggest that mouse NTS2 receptors are recycled back 
to the cell surface through a monensin-sensitive mechanism following their 
sequestration, as observed in HEK 293 and COS-7 cells (Botto et al., 1998; Debaigt 
et al., 2004). Recycling of NTS2 receptors was shown to involve both 
phosphatidylinositol 3-kinase (wortmannin-sensitive) and endosome (Brefeldin A-
sensitive) pathways (Debaigt et al., 2004). In addition, the suppression of the neuron-
enriched endosomal protein of 21 kDa (NEEP21) was shown to strongly inhibited 
NTS2 recycling in transfected COS-7 cells, indicating that NEEP21 is essential for 
the correct recycling of internalized receptors (Debaigt et al., 2004). Site-directed 
mutagenesis studies have revealed that phosphorylation of Tyr 237 is a critical step in 
the recycling process of NTS2 receptors (Martin et al., 2002b). Indeed, the human 
NTS2 in which a cysteine residue naturally replaces the tyrosine in position 237 do es 
not undergo recycling following internalization. Interestingly, the single substitution 
of this cysteine for a tyrosine gives rise to a human NTS2 receptor mutant that is able 
to recycle as efficiently as the mouse NTS2 (Martin et al., 2002b). 
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2.3.3 NTS3 Receptor 
A striking feature of NTS3/sortilin is its low cell surface expression (10% of total 
receptors) (Mazella et al., 2001; Morinville et al., 2004). Indeed, a major pool of 
NTS3/sortilin was found in association with Golgi vesic1es in adipocytes (Morris et 
al., 1998). However, NT was shown to intemalize efficiently after binding to 
NTS3/sortilin receptors on the surface of transfected COS-7 cells (Navarro et al., 
2001). Intriguingly, this sequestration process involved no detectable loss of cell 
surface receptors, suggesting compensation through either recyc1ing or intracellular 
receptor recruitment mechanisms (Morinville et al., 2004). Indeed, NTS3 was shown 
to be recruited to the cell surface following stimulation of neuronal cell cultures with 
NT (Chabry et al., 1993). 
2.4 Ontogeny and Localization of NT Receptors Subtypes 
One general feature in the deve10pment profile of NT receptors is the very low levels 
of NTS2 mRNA observed in the perinatal period, which is in sharp contrast with the 
presence of high amounts of NTSI mRNA (Lépée-Lorgeoux et al. 1999). Indeed, 
NTS2 mRNA was shown to tirst appear in mouse brain tissues around postnatal day 
7 and to increase progressive1y thereafter, reaching a plateau between 30 and 60 days 
oflife (Schotte and Laduron, 1987; Mazella et al., 1996; Sarret et al., 1998). 
Quite the opposite, NTS 1 is known to appear in rat embryo on day 18 and to 
peak within the tirst postnatal week as demonstrated by in situ hybridization (Sato et 
al., 1992) and autoradiographic (Palacios et al., 1988; Hermans et al., 1993) studies. 
Afterward, NTS 1 mRNA was found to decrease dramatically reaching adult levels at 
the end of the third postnatal week (Sato et al., 1992). Interestingly, previous studies 
have demonstrated that NTS 1 exists as two differentially glycosylated forms in 
deve10ping rat brain: a heavily glycosylated form corresponding to that found in adult 
brain, which is largely associated with neuronal processes, and a incomplete1y 
glycosylated form transiently expressed between postnatal days 10 and 15, which is 
concentrated within nerve cell bodies (Boudin et al., 1995; Boudin et al. 2000). This 
selective expression of the short form at early development stages suggests that it 
might play a role in the establishment of neuronal circuitry (Boudin et al., 2000). 
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Less is known about the ontogeny of NTS3/sortilin, expect that its mRNA was 
detected during embryonic development (from day 7.5 to 16.5), suggesting that it 
might be involved in proliferation of neuronal precursors (Hermans-Borgmeyer et al., 
1999). 
2.4.1 NTS1 Receptor 
Autoradiographie ligand binding (Quirion et al., 1982; Schotle et al., 1986; Kitabgi et 
al., 1987; Kessler et al., 1987), in situ hybridization (Elde et al., 1990; Nicot et al., 
1995; Alexander and Leeman, 1998) and immunohistochemical (Boudin et al., 
1996b; Fassio et al., 2000) studies have yielded extensive information on the 
distribution ofNTS 1 receptors in mammalian brain (see Table 1.5). 
Briefly, prominent NTS 1 expression levels were found in association with 
selective neuronal populations throughout the basal forebrain, hypothalamus, 
thalamus, limbic system, and brainstem (Boudin et al., 1996b; Alexander and 
Leeman, 1998). More precisely, high concentrations of NTS 1 rnRNA 
immunoreactive proteins and radiolabeled binding sites were observed in the 
substantia nigra and VT A in association with dopaminergic neurons (Palacios et al., 
1981; Quirion et al., 1985; Szigethy and Beaudet, 1987; Szigethyand Beaudet, 1989; 
Dana et al., 1989; Fassio et al., 2000) as well as in the diagonal band of Broca and 
magnocellular preoptic nucleus where they were shown to be selectively associated 
with cholinergie cells (Szigethy et al., 1988; Szigethy et al., 1990; Faure et al., 
1995b; Morin et al., 1996; Morin and Beaudet, 1998). AdditionalIy, dual labeling 
immunohistochemistry demonstrated precise overlap between e25I]-NT binding sites 
and both vasoactive intestinal peptide (VIP)-containing nerve cell bodies and 
serotonin (5-HT)-containing axons throughout the suprachiasmatic nucleus (SCN) of 
the rat hypothalamus (François-Bellan et al., 1992). Both VIP and 5-HT innervations 
of the SCN have been implicated in the control of phasic gonadotropin release (Hery 
et al., 1978; Hery and Faudon, 1984). Conversely, NTSI binding sites were shown to 
be down-regulated by gonadal steroids (Moyse et al., 1987). Taken together these 
data suggest evidence for an integrated involvement of NT, 5-HT, and VIP 
innervations of the SCN in the regulation of gonadotropin secretion (François-Bellan 
et al., 1992). 
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Within the pons, high affinity NT labeling was detected in the periventricular 
region, particularly within the dorsal tegmental nucleus and the laterodorsal 
tegmental nucleus (Kessler et al., 1987). More dorsally, NTSI-labeled neurons were 
detected within the ventral tegmental nucleus as weIl as the median raphe nucleus 
(Boudin et al., 1996b). Intense NTS 1 immunolabeling was also found throughout the 
pontine nuclei, where it pervaded both perikarya and neutropil (Boudin et al., 1996b). 
In the medulla, high affinity NT binding sites and NTS 1 immunolabeling were 
mainly concentrated within the nucleus of the solitary tract, the medial vestibular 
nucleus, inferior olive, and the cuneate nucleus (Young and Kuhar, 1981; Kessler et 
al., 1987; Boudin et al., 1996b). NTSI receptors were also found in vagal 
projections, providing an anatomical correlate for the NT -induced hypotensive and 
gastrointestinal functions since vagus nerve components are involved in the control 
of both cardiovascular and gastrointestinal functions (Roman and Gonella, 1981; 
Hellstrom, 1986). 
In the rat spinal cord, NTSI-immunoreactivity was found exclusively within the 
substantia gelatinosa (laminae II) of the dorsal horn, suggesting that this receptor 
might play a role in the spinal NT antinociceptive action (Fassio et al., 2000). 
Finally, quantitative RT-PCR studies in rat peripheral tissues revealed that NTSI 
mRNA is also found in the colon, liver, duodenum and pancreas (Mendez et al., 
1997). 
Mapping of NTS 1 at the cellular level by a antipeptide antibody approach using 
photonic and electon microscopy demonstrated that this receptor is broadly 
distributed both post and presynaptically in rat CNS (Boudin et al. 1996b; Boudin et 
aL, 1998; Pickel et aL, 2001). This cellular distribution is consistent with 
electrophysiological and pharmacological evidence for postsynaptic effects of NT in 
mammalian brain. Indeed, NT was shown to directly activate mesencephalic 
dopaminergic (Pinnock, 1985) and basal forebrain cholinergic (Alonso et al., 1994) 
neurons, which both exhibit widespread dendritic and somatic NTS 1-like 
immunoreactivity (Boudin et aL, 1996b). Additionally, the NTSI-like labeling 
associated with axonal arborizations within the cerebral cortex (Boudin et aL, 1996b) 
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is in agreement with the NT-induced increase in acetylcholine release reported in 
slices from rat frontal cortex (Lapchak et al., 1993). However, a few structures (e.g. 
the amygdala, the PAO, and the superior colliculus) that are known to be innervated 
by NT fibers were devoid of NTS 1 immunohistochemical signal (Boudin et al., 
1996b; Fassio et al., 2000), suggesting the existence of another NT receptor subtype 
that would be detectable by autoradiography but not by immunohistochemistry. 
TABLE 1.S 
Regional Distribution of NTSI Receptors in the Adult Rat Brain 
Structure [12sI]_NT mRNA NTSI immunoreactivityc 
binding3 levelsb 
Cell bodies Axons and 
and dendrites nerve terminaIs 
Telencephalon 
Cerebral cortex 
Frontal cortex + +/++ ++ + 
Parietal cortex + + ++ 
Cingulate cortex +++ ++ ++ 
Perihinal cortex +++ +/++ ++ ++ 
Entorhinal cortex +++ ++/+++ ++ + 
Retrosplenial cortex +++ + ++ ++/+++ 
Basal ganglia 
Caudate putamen ++ 
-/+ ++ 
Nucleus accumbens ++ + + + 
Olfactory tuberc/e 
Islands of Calleja ++++ + ++++ 
Basal forebrain 
Medium septum ++ ++++ ++ 
Diagonal band of Broca ++/+++ ++++ ++++ + 
Magnocellular preoptic area +++ ++++ ++++ 
Substantia innominata ++ ++++ ++ 
Lateral septum ++ ++/+++ 
-/+ +++ 
Bed nucleus of the stria ++ ++/+++ 
-/+ +++ 
terminalis 
Amygdala 
Posterior cortical nucleus ++++ ++ ++ ++ 
Basomedial nucleus ++ + + 
Central nucleus ++ ++/+++ -/+ 
Lateral nucleus ++ + + 
Hippocampal formation 
Pre, parasubiculum ++++ +/++ +++ ++ 
CAl, CA2, CA3 + ++ + 
Dentate gyrus ++ + 
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Diencephalon 
Thalamus 
Anterior dorsal nucleus 
Paraventrucular nucleus 
Hypothalamus 
Suprachiasmatic nucleus 
Periventricular nucleus 
Paraventricular nucleus 
Lateral hypothalamic area 
Mesencephalon 
Substantia nigra 
Ventral tegmental area 
Periaqueductal gray 
Dorsal raphe nue/eus 
Superior col/iculus 
Pons 
Pontine nue/ei 
Reticulotegmental nue/eus 
Ventral tegmenta! nue/eus 
Median raphe nue/eus 
Medulla 
Media! vestibu!ar nue/eus 
Dorsal cochlear nue/eus 
Retrofacia! nue/eus 
Inferior olive 
Nue/eus of the vagus 
Nue/eus of the solitary tract 
Cuneate nue/eus 
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+++ 
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+ 
++ 
+++/++++ 
+++ 
-/+ 
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+++ 
+++ 
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+++ 
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+ 
++ 
++ 
++ 
+ 
+++ 
+++ 
"Density of [125I]_NT binding sites as described in Moyse et al., 1987; "NrS1 rnRNA leve1s as stated 
by Alexander et al., 1998; "NTS1 immunoreactivity as per Boudin et al., 1996b. - = no labeling; +/- = 
limit of detection, + = low signal; ++ = moderate signal; +++ = high signal; ++++ = very high signal. 
2.4.2 NTS2 Receptor 
Expression ofNTS2 rnRNA was tirst investigated by Northern blot analysis (Chalon 
et al., 1996; Mazella et al., 1996; Vita et al., 1998). These studies revealed that the 
NTS2 rnRNA is rnainly expressed in the brain, cerebellum, and to a lesser extent in 
the heart, kidney, lung and uterus (Vita et al., 1998). Northern blot studies also 
disclosed the presence of two altematively spliced transcripts of 1.6 and 1.4 kb in 
rnouse brain (Botto et al., 1997b). Using NTS2-specitic oligonucleotides, these two 
isoforms were then detected by RT-PCR analysis in the rat olfactory bulb, neocortex, 
cerebellum, striaturn and hypothalamus (Botto et al., 1997b). Interestingly, only the 
long form of the receptor was detected in cortical glial cells, whereas both forms 
were observed in rat cerebellar granule cells in culture, suggesting that the shorter 
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variant NTS2 (vNTS2) isofonn may be exclusive1y neuronal (Nouel et al., 1999; 
Sarret et al., 2002). 
As opposed to NTS1, much less is known about the distribution ofNTS2 within 
the mammalian CNS (reviewed in Table 1.6). Early autoradiographic studies based 
on displacement of e25I]-NT, eH]-NT, or eH]-SRI42948A binding by levocabastine 
reported a widespread distribution ofNTS2 in the adult rat brain (Schotte et al., 1986; 
Kitabgi et al., 1987; Bétancur et al., 1998), which was subsequently confinned by 
direct labe1ing carried out with eH]-levocabastine (Asselin et al., 2001). 
Accordingly, these studies demonstrated that specific NTS2 binding sites are 
particularly abundant in cerebral cortex, limbic areas (e.g. the amygdala and the 
hippocampal fonnation) and regions involved in pain perception (e.g. the P AG and 
the superior colliculus). 
In confonnity with these results, in situ hybridization studies using probes that 
did not discriminate between the two spliced isofonns have shown that NTS2 
rnRNAs are diffuse1y distributed throughout the rodent CNS (Sarret et al., 1998; 
Walker et al., 1998; Lépée-Lorgeoux et al., 1999). In particular, moderate to dense 
hybridization signal was observed in the cerebral and cerebellar cortices, P AG, 
superior colliculus, amygdaloid complex, and hippocampal fonnation (Sarret et al 
1998). Expression ofNTS2 mRNA was also found in association with a collection of 
auditory, visual, olfactory, and somatosensory nuclei, suggesting that this receptor 
might be implicated in virtually aIl primary afferent pathways (Sarret et al., 1998). A 
high degree of correspondence exists between NTS2 biding sites distribution with 
that of NTS2 rnRNA within the rat CNS (Asselin et al., 2001). These studies also 
revealed that the distribution ofNTS2 mRNA overlapped to sorne extent with that of 
NTS 1 (e.g. the enthorhinal and retrosplenial cortices, the medial septum, and the 
hypothalamic suprachiasmatic nucleus), implying that certain neurons might jointly 
express NTS 1 and NTS2. 
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FinaIly, in situ hybridization studies have shown that central NTS2 receptors are 
predominantly expressed by neurons in homeostatic conditions (Sarret et al., 1998). 
However, NTS2 receptor expression was also detected in aStrocytes and found to be 
up-regulated during astrocytic reaction, suggesting that NTS2 may play a role in 
regulating glial response to injury (Nouel et al., 1999). At the subcellular level, 
labeling with eH]-levocabastine revealed that NTS2 receptors are mainly 
intracellular, signifying that they might correspond to newly synthesized receptors or 
receptors recyc1ed to the cell surface (Asselin et al., 2001). AdditionaIly, eH]-NT 
binding studies on synaptosomal preparations have proposed that a proportion of 
NTS2 receptors located to the molecular layer of the rat cerebellar cortex are 
expressed presynaptically on parallel fibers (Sarret et al., 2002). 
TABLE 1.6 
Regional Distribution of NTS2 Binding Sites and mRNA in Mammalian CNS 
Brain region 
Telencephalon 
Cerebral cortex 
Piriform cortex 
Cingulate cortex 
Perihinal cortex 
Entorhinal cortex 
Retrosplenial cortex 
Basal ganglia 
Caudate/Putamen 
Nucleus accumbens 
Basal forebrain 
Olfactory tubercle 
Medium septum 
Diagonal band of Broca 
Magnocellular preoptic nucleus 
Lateral septal nucleus 
Bed nucleus of the stria terminalis 
Amygdala 
Cortical nucleus 
Basolateral nucleus 
Basomedial nucleus 
Medial nucleus 
Hippocampal formation 
Pre, parasubiculum 
CAl, CA2, CA3 
Dentate gyrus 
eH]-levocabastine labelinga 
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++++ 
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TABLE 1.6 (continued) 
Diencephalon 
Thalamus 
Reticular nucleus 
Parafascicular nucleus 
Medial geniculate nucleus 
Lateral geniculate nucleus 
Hypothalamus 
Suprachiasmatic nucleus 
Paraventricular nucleus 
Lateral hypothalamic area 
Arcuate nucleus 
Ventromedial nucleus 
Dorsomedial nucleus 
Mesencephalon 
Substantia nigra 
Ventral tegmental area 
Periaqueductal gray 
Superior col/iculus 
Dorsal raphe nucleus 
Pons 
Pontine nuclei 
Superior olivary nucleus 
Motor trigeminal nucleus 
Medulla 
Vestibu/ar comp/ex 
Ventral cochlear nucleus 
Gigantocellular reticular nucleus, pars alpha 
Inferior olivary nucleus 
Dorsal motor nucleus of the vagus 
Nucleus of the solitary tract 
++++ 
+++ 
+ 
+ 
++ 
+++ 
+/++ 
N/A 
+/++ 
N.A 
N.A 
N.A 
N.A 
N.A 
++ 
+++ 
++ 
+/++ 
+++ 
++++ 
+ 
++++ 
++++ 
++++ 
+/++ 
-/+ 
+++ 
+++ 
+/++ 
+++ 
+++ 
++ 
++ 
++ 
++ 
+ 
-/+ 
+ 
3Density of eH]-levocabastine binding sites in rat brain as described by Asselin et al., 2001. +/- = 
limit of detection (1-10 fmol/mg/tissue equivalent), + = low signal (10-20 fmol/mg/tissue equivalent); 
+/++ = low to moderate signal (20-30 fmol/mg/tissue equivalent); ++ = moderate signal (30-40 
fmol/mg/tissue equivalent); +++ = high si~al (40-50 fmol/mg/tissue equivalent); ++++ = very high 
signal (50-60 fmol/mg/tissue equivalent). "NTS2 mRNA levels in mouse CNS as stated by Sarret et 
al., 1998. +/- = limit of detection (0-25 arbitrary optical density units (OD», += low signal (25-40 
OD); +/++ = low to moderate signal (40-55 OD); ++ = moderate signal (55-70 OD); +++ = high signal 
(70-85 OD); ++++ = very high signal (85-100 OD). 
2.4.3 NTS3 Receptor 
NTS3/sortilin expression was tirst detected in vanous tissues by Northern and 
Western blotting analysis (Petersen et al., 1997; Lin et al., 1997). Indeed, the NTS3 
mRNA appeared particularly abundant in brain, spinal cord, ske1etal muscle, heart, 
thyroid, placenta, and testis (Petersen at al., 1997). More recently, in situ 
hybridization and immunohistochemical studies displayed a widespread distribution 
of NTS3/sortilin throughout the rat brain (see Table 1.7) including neuronal cell 
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bodies and dendrites of the olfactory bulb, piriform cortex, amygdaloid nuclei, 
substantia nigra, lateral septum, diagonal band of Broca, and thalamic nuclei (Sarret 
et al., 2003b). The distribution and labeling intensity of NTS3-immunoreactive cell 
bodies basically matched with the localization and levels of NTS3/sortilin mRNA, 
except in the nucleus accumbens, medial geniculate nucleus, dorsal raphe nucleus, 
and cerebellar granule cell layer, in which there were neurons displaying a weak 
NTS3/sortilin mRNA signal without receptor immunolabeling (Sarret et al., 2003b). 
This divergence may be due to variations in the messenger stability among brain 
regions or to differential translation regulatory mechanisms (Sarret et al., 2003b). 
NTS3/sortilin expression was also found within neurons and oligodendrocytes 
III major fiber tracks (Sarret et al., 2003b). In particular, electron microscopy 
revealed that NTS3/sortilin immunoreactivity was mainly associated with the Golgi 
apparatus, saccules of the endoplasmic reticulum, and vesicular organelles, whereas 
only a small proportion of NTS3/sortilin was found in association with neuronal 
plasma membranes (Sarret et al., 2003b). 
TABLE 1.7 
Distribution of NTS3/sortilin mRNA and Immunoreactivity in the Adult Rat Brain 
Structure 
Telencephalon 
Cerebral cortex 
Frontal cortex 
Parietal cortex 
Temporal cortex 
Cingulate cortex 
Piriform cortex 
Entorhinal cortex 
Retrosplenial cortex 
Basal ganglia 
Caudate/Putamen 
Nucleus accumbens 
Basal forebrain 
Olfactory tubercle 
Islands of Calleja 
Lateral septum 
Medium septum 
Diagonal band of Broca 
Magnocellular preoptic area 
Bed nucleus of the stria terminalis 
mRNA levels3 
++ 
++ 
++ 
+++ 
+++ 
++/+++ 
++/+++ 
+/++ 
+/++ 
+/++ 
++ 
++/+++ 
++ 
+ 
+/++ 
+/++ 
63 
NTSI immunoreactivitl 
Cell bodies Axons and 
and dendrites nerve terminaIs 
+/++ 
++ 
++ 
+/++ 
++/+++ 
++ 
+/++ 
++ 
++ 
++ 
+++ 
++/+++ 
++/+++ 
+++ 
++ 
+ 
+ 
+/++ 
+ 
+ 
+ 
++ 
++ 
-/+ 
++ 
++/+++ 
+++ 
TABLE 1.7 (continued) 
Amygdala 
Central nucleus 
Basomedial nucleus 
Basolateral nucleus 
Cortical nucleus 
Hippocampal formation 
Pre, parasubiculum 
CAl, CA2, CA3 
Dentate gyrus 
Diencephalon 
Thalamus 
Anterior dorsal nucleus 
Paraventricular nucleus 
Reticular nucleus 
Medial nucleus 
Medial geniculate nucleus 
Lateral geniculate nucleus 
Hypothalamus 
Anterior hypothalamic area 
Suprachiasmatic nucleus 
Supraoptic nucleus 
Paraventricular nucleus 
Arcuate nucleus 
Mesencephalon 
Substantia nigra pars compacta 
Substantia nigra pars reticulata 
Ventral tegmental area 
Periaqueductal gray 
Superior colliculus 
Dorsal raphe nucleus 
Red nue/eus 
Pons 
Pontine nuclei 
Superior olivary nucleus 
Median raphe nue/eus 
Medulla 
Vestibular complex 
Cochlear nue/ei 
Inferior olivary nucleus 
Nucleus of the solitary tract 
Cuneate nucleus 
Gracile nue/eus 
Abducens nue/eus 
Facial nucleus 
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Dorsal motor nucleus orthe vagus + ++ -/+ 
"NTS3/sortilin mRNA levels as stated by Sarret et al., 2003b; ~S3/sortilin immunoreactivity as per 
Sarret et al., 2003b. - = no labeling; +/- = limit of detection, + = low signal; +/++ = low to moderate 
signal; ++ = moderate signal; ++/+++ = moderate to high signal; +++ = high signal; ++++ = very high 
signal (referring to both labeling intensity and the number oflabeled elements). 
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2.5 Physiologie al Roles of NT Reeeptor Subtypes 
2.5.1 Nonpeptide Antagonists and NT Analogues 
A better understanding of the central effects of endogenous NT was provided by 
phannacological studies using the NTS1-specific antagonist SR48692. Indeed, this 
compound was shown to reverse both the turning behavior induced by intrastriatal 
NT injections in mice (Gully et al., 1993) and the hypolocomotor response elicited by 
intracerebroventricular NT administration (Dubuc et al., 1994; Pugsley et al., 1995). 
It also antagonized the locomotor activity evoked by NT injection into the VTA 
(Steinberg et al., 1994). On the other hand, it did not antagonize the hypothermic and 
analgesic response to NT in rodents, suggesting that these central effects are not 
mediated through NTS1 (Dubuc et al., 1994). Likewise, SR48692 failed to inhibit 
NT-mediated excitation ofPAG-RVM neurons (Li et al., 2000). However, SR48692 
was used over a narrow dose range in these studies and other investigations have 
shown that this antagonist has a triphasic effect on the increase in tail-flick response 
latencies triggered by an antinociceptive dose of NT (Smith et al., 1997). For 
instance, NT-induced analgesia following administration into the RVM was 
attenuated, overtumed, or partially blocked by femtomolar, picomolar, or higher 
doses of SR48692, respectively. 
Unlike SR48692, SR142948 recognizes both NTS1 and NTS2 receptors with 
high affinity (ICso = 1-4 nM) (Gullyet al., 1997). SR142948A inhibited the NT-
mediated tuming behavior in mice and had no effect on DA release elicited by NT 
injection into the VTA (Gully et al., 1997). Interestingly, it also blocked both the 
analgesic and hypothermic responses induced by central injection of NT, as well as 
the depolarization induced by exogenously applied NT on P AG neurons, suggesting 
that the NTS2 receptor subtype may mediate these effects (Gullyet al., 1997; Kreitel 
et al., 2002). In line with these results, structure-activity studies have suggested that 
the hypothermic and analgesic actions of NT in the mouse brain appear to be 
mediated through a receptor, whose phannacological properties are distinct from 
those of the high affinity NT receptor (Al Rhodan et al., 1991; Labbé-Jullié et al., 
1994; Tyler et al., 1998a). However, only the NT-induced analgesia was reversed by 
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the NTS2-specific ligand levocabastine, suggesting that NT receptors involved in 
hypothermia differ from those involved in analgesia (Tyler et al., 1998b; Dubuc et 
al., 1999a). A similar effect on NT -mediated antinociception was observed following 
pretreatment with another specific Hl antagonist (i.e. diphenhydramine) (Tyler et al., 
1998b). This antagonist also blocked the responses of P AG neurons to stimulation of 
the medial preoptic (MPO) nucleus in anesthetized rats, suggesting that the MPO-
P AG interaction is, in part, mediated by activation of NTS2 receptors (Kreitel et al., 
2002). 
2.5.2 Knock-down Strategies 
Experiments in knock-out mice have shown that NTS 1 gene deletion resulted in the 
loss of NT -induced hypothermia and contractile effects in both isolated distal colon 
and stomach fundus (Pettibone et al., 2002; Remaury et al., 2002). Additionally, 
NTS 1 deficient mice did not respond to intracerebroventricular NT -mediated 
hypolocomotion and feeding regulation, indicating that NTS 1 mediates several of the 
central and peripheral effects of NT (Pettibone et al., 2002; Remaury et al., 2002). 
However, several lines of evidence suggest that NTS2 may play a particularly 
important role in mediating the antinociceptive effects of NT (GuIly et al., 1997; 
Dubuc et al., 1999b). For instance, injection of antisense oligonucleotides designed 
to knock-down NTS2 receptors markedly inhibited NT -induced analgesia (Dubuc et 
al., 1999b). This response was specific for the NTS2 receptor subtype since 
treatment with oligonucleotides raised against NTS 1 did not induce any effects. 
Similarly, the antinociceptive activity of ~-lactotensin, a NTS2 specific agonist, was 
blocked by treatment with NTS2 antisense oligonucleotides while treatment with 
NTS 1 antisense oligonucleotides had no effect (Yamauchi et al., 2003a). Structure-
activity studies also revealed a close correlation between the analgesic potencies of 
NT analogues and their affinity for the levocabastine-sensitive NT receptor (Labbé-
Jullié et al., 1994; Dubuc et al., 1999b). In line with these observations, 
levocabastine was shown to behave as a partial agonist in the writhing test following 
intracerebroventricular administration in mice (Dubuc et al., 1 999b). Nonetheless, 
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this analgesic effect was not additive to that of NT, but rather decreased its effect to a 
level not significantly different from that observed with levocabastine alone. 
On the other hand, these results are in contrast with those of Tyler et al (l998c) 
who demonstrated that the inhibition of NTS 1 receptor synthesis after gene blockade 
by complementary peptide nucleic acids resulted in a loss of analgesic response to 
NT. Nonetheless, recent demonstration that NTS 1 knockout mice displayed defects 
in NT -induced analgesia in the hot plate (Pettibone et al., 2002), but not in the 
writhing test (Remaury et al., 2002) suggested that the NT receptor subtype required 
for NT -mediated antinociception might depend on the stimulus. However, it is 
hazardous to compare these analgesic effects with one another since they implicate 
different signaling pathways (i.e. thermal vs. visceral pain). Finally, NTS2, but not 
NTS 1 knockout mice have been reported to exhibit increased jump latency in the hot 
plate test, suggesting that NT facilitates pain transmission via NTS2, which might 
play a different role under physiological conditions (Maeno et al., 2004). Taken 
together, these results indicate that multiple NT receptors with distinct antagonist 
binding affinities seem to be involved in NT -induced modulation of inhibitory and 
facilitatory nociceptive systems. 
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CHAPTER 2: RATIONALE OF THE THESIS 
NOTE: This section corresponds to the connecting texts that provide the logical 
bridges between each chapter. 
CHAPTER3: 
Immunohistochemical Distribution of NTS2 Neurotensin Receptors in the Rat 
Central N ervous System 
Little is known concerning the distribution of the NTS2 receptors in the mammalian 
brain except that in situ hybridization and radioligand binding studies have shown 
that NTS2 is diffuse1y expressed throughout the rodent CNS (refer to Section 2.4.2 
for details and references). However, no data are currently available on the 
distribution of NTS2 receptor proteins, nor of their putative colocalization with other 
NT receptor subtypes in the brain. A precise knowledge of neuronal networks 
harbouring NTS2 receptors was thus crucial to our understanding of their function in 
mammalian CNS. 
In order to address these questions, the subcellular distribution ofNTS2 receptor 
proteins was tirst investigated by confocal microscopy in NTS2-expressing COS-7 
cells using a custom-synthesized antibody raised against a synthetic peptide 
corresponding to the 7-21 amino acid sequence in the N-terminal segment of the rat 
receptor. These studies revealed the presence of a prominent pool of intracellular 
receptors in the perinuclear region, suggesting that NTS2 receptors are poorly 
expressed at the cell surface. Additionnally, immunohistochemical studies on rat 
brain sections showed that NTS2 immunoreactivity was selectively associated with 
neurons and for the most part, although not exclusively, with their dendritic arbors. 
Of particular interest from a functional perspective was the intense labelling of brain 
structures involved in pain control (e.g. PAO and dorsal raphe). Interestingly, many 
of the regions which displayed NTS2-like immunoreactivity had previously been 
shown to contain high leve1s of NTS 1 immunostaining (e.g. anterodorsal thalamic 
nucleus, substantia nigra, VTA), suggesting that NTS2 is in a position to interact with 
NTS 1 in mediating NT' s central effects. 
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CHAPTER4: 
Low-Affmity Neurotensin Receptor (NTS2) Signaling: Internalization-
Dependent Activation of Extracellular Signal-Regulated Kinases 1/2. 
The role and signaling properties of NTS2 are still controversial. In particular, it is 
unc1ear whether NT acts as an agonist, inverse agonist, or antagonist at this site (refer 
to Section 2.2.2 for details and references). However, our immunohistochemical 
studies (refer to Chapter 3) have shown that NTS2 receptors are expressed in 
structures implicated in the descending control of nociceptive inputs, suggesting that 
NTS2 may mediate certain analgesic effects of NT. 
In order to elucidate the functional role of NTS2, we have investigated the 
pharmacological and signaling properties of this receptor in NTS2-expressing CHO 
cens. We found that NT activates the mitogen-activated protein kinase cascade 
through its interaction with either rat or human NTS2 receptors. The present NT-
induced effects on ERKll2 phosphorylation are unlikely to be caused by neutral 
antagonistic or inverse agonistic properties of the drug since there was no evidence of 
constitutive NTS2 receptor activity in our system. The similarity of this NT-
mediated ERK1I2 phosphorylation with that obtained in cultured neurons (refer to 
Section 2.2.2 for details and references) suggests that this activation is physiological 
and not caused by artifactual coupling of the receptor subsequent to its aberrant 
expression in CHO cens. In addition, the fact that NT was found to induce NTS2 
intemalization further argues in favour of its putative role as an agoni st at the NTS2 
receptor. Fina1ly, we found that blocking internalization with phenylarsine oxide or 
monodansy1cadaverine complete1y impaired the ability of NT to activate ERKll2 in 
NTS2-expressing CHO cens, suggesting that the NTS2-mediated activation of the 
MAP kinase pathway is predicated on the intemalization of receptor-ligand 
complexes. 
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CHAPTER5: 
Identification and Functional Characterization of the 5-Transmembrane 
Domain Variant Isoform in the Rat Central Nervous System. 
The mouse NTS2 receptor exists in two different isoforms referred to as NTS2 (full-
length receptor) and vNTS2, an alternative1y spliced form in which the last two 
transmembrane domains have been de1eted (see Section 2.1.2 for more information). 
However, the latter protein failed to bind NT after transient expression in COS-7 
cells, suggesting that the variant NTS2 isoform was non-functional protein (Botto et 
al., 1997b). Interestingly, our previous Western blotting analysis of NTS2 receptors 
in rat brain membrane preparations (refer to Chapter 3) had revealed the presence of 
high molecular weight immunoreactive species that could correspond to either NTS2 
homodimers or putative heterodimers of NTS2 and vNTS2, suggesting that this 
truncated isoform might also be found in the rat CNS. 
Hence, to clarify whether vNTS2 is a true NT receptor, we first investigated the 
binding and internalization properties of this truncated receptor in COS-7 cells stably 
transfected with the HA-tagged vNTS2 cDNA that we isolated from rat brain tissue 
(refer to Appendix D for GenBank accession number). As opposed to what had been 
reported for the mouse vNTS2, our results demonstrated that the rat vNTS2 bound 
NT, albeit with a considerably lower affinity than the full-Iength receptor (as 
demonstrated in Chapter 4). Immunocytochemical analysis using the NTS2 N-
terminally directed antiserum (refer to Chapter 3 for characterization) revealed that 
the bulk of immunoreactive receptors was intracellular and concentrated in a Golgi-
like structure surrounding the nucleus. This subcellular localization is in agreement 
with what was observed for NTS2 in cells expressing the full-Iength receptor (as 
demonstrated in Chapter 3), suggesting that the greater part of NTS2 receptors (Le. 
full-Iength and variant isoforms) is concentrated intracellularly. Despite its poor 
trafficking to the cell surface, confocal microscopie experiments demonstrated 
specific vNTS2 receptor-mediated internalization of fluorescent NT following 
incubation at 37°C with a pattern consistent with former report on intemalization via 
the full-Iength NTS2 receptor (see Chapter 4). We then investigated whether the 
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truncated NTS2 receptor retained the MAP Kinase activation properties exhibited by 
the long NTS2 isofonn (as described in Chapter 4). Our results indicated that 
stimulation with NT induced a rapid and sustained increase in ERK1I2 
phosphorylation in CHO cells transfected with vNTS2, suggesting that the two NTS2 
isofonns are functionally responsive to NT. 
In order to detennine if it was possible that the high molecular weight species of 
NTS2 receptors detected in rat brain membrane preparations corresponded to 
vNTS2/NTS2 heterodimers as hypothesised earlier (see Chapter 3), we co-expressed 
HA-tagged vNTS2 together with untagged NTS2 receptors in COS-7 cells and 
subjected cell lysates to immunoprecipitation with the anti-HA antibody. 
Immunoblotting with our custom-synthesized C-tenninally directed NTS2 antiserum 
revealed the presence of immunoreactive bands corresponding to NTS2, indicating 
that it has been co-immunoprecipitated with the variant NTS2 via heterodimerization. 
CHAPTER6: 
Sustained Agonist Exposure Promotes Cell Surface Recruitment of NTS2 
Neurotensin Receptors 
Receptor intemalization has been shown to play a critical role in the control of cell 
responsiveness to NT (see Section 2.3 for more details). AIso, CUITent biochemical 
and immunocytochemical data suggest that intemalized NTS 1 are not recycled back 
to the plasma membrane but rather targeted to lysosomes for degradation. However, 
little is known about the regulation of NTS2 except that its stimulation with NT 
induces long-tenn metabolic effects as demonstrated in our ERK1I2 activation 
experiments (see Chapter 4). 
The next study was thus initiated in order to detennine whether extended 
stimulation of NTS2 leads to down-regulation of cell surface receptor densities as in 
the case of NTS 1. We have found that, contrary to NTS 1, cell surface NTS2 
receptors are resistant to down-regulation despite efficient intemalization 
mechanisms. By tracking the intracellular routing of NTS2 receptors using confocal 
microscopy, we established that cell surface NTS2 receptors are maintained through 
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recruitment of spare receptors from internaI stores. This intracellular pool of NTS2 
receptors is congruent with what was observed in our earlier studies (refer to Chapter 
1). The cell surface binding sites maintained during persistent NT exposure 
corresponded to functional NTS2 receptors since NT-induced ERKI/2 
phosphorylation levels in cells exposed to NT for 24 h were comparable to those 
previously reported in transfected CHO cells (see Chapter 4). To ascertain the 
physiological relevance of these observations, we monitored by electron microseopy 
the effect of intrathecal NT injection on the subcellular distribution of NTS2 in 
neurons of the superficial laminae of the rat spinal cord by using our NTS2 peptide 
antiserum (previously characterized in Chapter 3). Twenty minutes after NT 
injection, we found an enhanced NTS2 receptor density on neuronal plasma 
membranes without any change in NTS2 total density suggesting that in vivo, as in 
vitro, exposure to NT triggers a relocalization of intracellular receptors to the plasma 
membrane. 
CHAPTER 7: 
NTS2 Modulates NTSI Expression and Internalization via Heterodimerization. 
Our . previous immunohistoehemical studies have shown that NTS2 receptor 
distribution shares similarities with that ofNTSl within the rat CNS (see Chapter 3), 
supporting the hypothesis that NTS2 might co-Ioealize within the same neurons as 
NTS 1 and that, within these neurons, NTS2 and NTS 1 might either interact together 
or be found in the same protein complex. 
We thus combined biochemical, pharmacologieal, and immunoeytochemical 
approaches to determine whether NTS2 can physically interact with NTS 1 and to 
investigate the effect of NTS2 expression on NTS 1 regulation. Our results indieated 
that NTS2 is able to form heterodimers with NTS 1 in vitro via hydrophobie 
interactions. They also showed that coexpression of NTS2 markedly inhibited cell 
surface expression of NTS 1 by causing its accumulation in the perinuc1ear region, 
where it colocalized with NTS2 immunoreactivity (as described in Chapter 6). 
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Chronic exposure of NTS 1 to its ligand was previously shown to result in time-
dependent decline in cell surface receptors (see Section 2.3.1 for more details and 
references). By contrast, we have shown that NTS2 cell surface binding sites are 
resistant to down-regulation (see Chapter 6). We thus hypothesized that NTS2 
expression might affect the regulation of NTS 1 cell surface densities upon extended 
NT stimulation. Indeed, we found that NTS 1 binding sites were more resistant to 
down-regulation when the two NT receptor subtypes were expressed together than 
when expressed alone. These data suggest that NTS2 influences intracellular 
trafficking of NTS 1, likely mediated through heterodimerization of these two 
receptor subtypes. 
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CHAPTER3 
IMMUNOHISTOCHEMICAL DISTRIBUTION OF NTS2 NEUROTENSIN 
RECEPTORS IN THE RAT CENTRAL NERVOUS SYSTEM 
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3.1 ABSTRACT 
In the present study, we localized the levocabastine-sensitive neurotensin receptor 
(NTS2) protein in adult rat brain by using an N-tenninally directed antibody. NTS2-
like immunoreactivity was broadly distributed throughout the rat brain. At the 
cellular level, the reaction product was exclusively associated with neurons and 
predominantly, although not exclusively, with their dendritic arbors. No NTS2 signal 
was observed in astrocytes, as confinned by dual confocal microscopic 
immunofluorescence studies using the astrocytic marker SI 00/3. High densities of 
NTS2-like immunoreactive nerve cell bodies and/or processes were detected in many 
regions documented to receive a dense neurotensinergic innervation, such as the 
olfactory bulb, bed nucleus of the stria tenninalis, magnocellular preoptic nucleus, 
amygdaloid complex, anterodorsal thalamic nucleus, substantia nigra, ventral 
tegmental area, and several brainstem nuclei. Most conspicuous among the latter 
were structures implicated in the descending control of nociceptive inputs (e.g., the 
periaqueductal gray, dorsal raphe, gigantocellular reticular nucleus, pars alpha, lateral 
paragigantocellular and raphe magnus), in keeping with the postulated role ofNTS2 
receptors in the mediation of neurotensin's supraspinal antinociceptive actions. 
However, the distribution of NTS2-like immunoreactivity largely exceeded that of 
neurotensin terminal fields, and sorne of the highest concentrations of the receptor 
were found in areas devoid of neurotensinergic inputs such as the cerebral cortex, the 
hippocampus, and the cerebellum, suggesting that neurotensin may not be the 
exclusive endogenous ligand for this receptor subtype. 
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3.2 INTRODUCTION 
The tridecapeptide neurotensin (NT), originally isolated from bovine hypothalamus 
(Carraway and Leeman, 1973), was subsequently localized throughout the central 
nervous system (CNS) of several mammalian species (for review, see Uhl, 1982 and 
Emson, 1985a) and shown to be involved in a variety of central functions inc1uding 
thermoregulation, nociception, food consumption, regulation of dopaminergic and 
cholinergie neurotransmission, and neuroendocrine control (for reviews, see Kitabgi 
et al., 1985; Kitabgi and Nemeroff, 1992; Rostène and Alexander, 1997; Sarret and 
Beaudet, 2002). 
Neurotensin effects are exerted through a variety of receptor subtypes, two of 
which have been distinguished pharmacologically on the basis of their affinities for 
NT and sensitivity to the histamine antagonist levocabastine: a NT high-affinity site, 
which does not bind levocabastine (NTS 1; l<tI = 0.3 nM) and a NT low-affinity site, 
which recognizes levocabastine (NTS2; l<tI = 2-4 nM) (Mazella et al., 1983; Schotte 
et al., 1986; Kitabgi et al., 1987). These two receptors have been molecularly 
identified in recent years and shown to belong to the seven transmembrane domain, G 
protein-coupled receptor family (GPCR, for review, see Hermans and Maloteaux, 
1998; Vincent et al., 1999; Sarret and Beaudet, 2002). A third NT receptor (NTS3) 
was recently c10ned from human brain (Mazella et al., 1998). This receptor is a type 1 
amino-acid receptor with a single transmembrane-spanning region corresponding to 
the previously c10ned gp95/sortilin (Petersen et al., 1997). 
Autoradiographie ligand binding, in situ hybridization, and immunohisto-
chemical studies have yielded abundant information on the distribution of the NTS 1 
receptors in mammalian brain. In brief, high concentrations of NTS 1 were found in 
association with selective neuronal populations throughout the hypothalamus, basal 
forebrain and limbic system (Sarrieau et al., 1985; Schotte et al., 1986; Moyse et al., 
1987; Kitabgi et al., 1987; Palacios et al., 1988; Dana et al., 1989; Elde et al., 1990; 
Sato et al., 1992; Nicot et al., 1994a,b, 1995; Boudin et al., 1996b; Alexander and 
Leeman, 1998; Fassio et al., 2000). They were markedly enriched over dopaminergic 
neurons of the ventral midbrain (Palacios and Kuhar, 1981; Quirion et al., 1985; 
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Hervé et al., 1986; Szigethy and Beaudet, 1989, Schotte and Leysen, 1989; Goulet et 
al., 1999), cholinergie neurons of the basal forebrain (Szigethy and Beaudet, 1987; 
Szigethy et al., 1988; Faure et al., 1995; Cape et al 2000), and VIPergic neurons of 
the suprachiasmatic nucleus of the hypothalamus (François-BeHan et al., 1992). This 
distribution is consistent with reported NTS I-mediated NT effects on locomotion and 
cognition, as well as on the sleep-wake cycle, memory, and regulation of 
hypothalamo-pituitary functions (Cape et al., 2000; for review, see Rostène and 
Alexander, 1997; Binder et al., 2001a; Sarret and Beaudet, 2002). 
Much less is known concerning the distribution, particularly at the cellular level, 
of the levocabastine-sensitive NTS2 receptors. Early autoradiographic binding 
studies, based on the displacement of specific 12sl-labeled NT, eH]-NT, or eH]-
SR142948A binding by levocabastine, reported a widespread distribution of 
levocabastine-sensitive NTS2 receptor sites in adult rat brain (Kitabgi et al., 1987; 
Schotte et al., 1986, 1988; Schotte and Laduron, 1987; Bétancur et al., 1998). This 
widespread distribution ofNTS2 binding sites was confirmed recently by using direct 
autoradiographic localization of eH]-levocabastine (Asse1in et al., 2001). Based on 
their ubiquitous distribution, as weIl as on their pattern of ontogenetic development 
(Schotte and Laduron, 1987) and recovery after local destruction of neurons with 
kainic acid (Schotte et al., 1988), low-affinity NT binding sites were originally 
surmised to be mainly associated with glial cells. Accordingly, NTS2 binding and/or 
mRNA were detected in association with astrocytes both in vivo and in vitro (Nouel 
et al., 1997; Walker et al., 1998; Lépée-Lorgeoux et al., 1999) and NTS2 expression 
was found to be markedly up-regulated in reactive astrocytes surrounding a cortical 
stab wound (Nouel et al., 1999). However, in situ hybridization studies also 
demonstrated that, in homeostatic conditions, NTS2 was predominantly expressed by 
neurons within the CNS (Sarret et al., 1998). Further evidence for the expression of 
functional NTS2 receptors in neurons was provided recently by studies in rat 
cerebeHar granule ceHs in culture, which demonstrated cell surface NTS2 binding, 
ligand-induced receptor intemalization, and NT -induced MAP kinase activation in 
these cells (Sarret et al., 2002). 
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The contribution of NTS2 to the mediation of central NT functions is not as 
c1early established as that of NTSl. Nonethe1ess, pharmacologie data based on the 
use of selective NTS2 agonists (Labbé-Jullié et al., 1994) and antisense 
oligonuc1eotides (Dubuc et al., 1999b) have suggested that NTS2 may play a role in 
the mediation of NT antinociceptive effects. Further insight into the functional role of 
NTS2 requires precise knowledge of the distribution of this receptor at both regional 
and cellular levels. To this aim, we have investigated here the localization of NTS2 
receptor proteins in rat brain by immunohistochemistry, using an antibody raised 
against the N-terminal segment of the c10ned rat NTS2 receptor. 
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3.3 MATE RIAL AND METHODS 
AlI animal-related procedures were approved by the McGill University Animal Care 
Committee and carried out according to the regulations of the Canadian Council on 
animal care. 
3.3.1 Primary Antibody for NTS2 Immunodetection 
Rabbit anti-NTS2 peptide antiserum was generated by using a synthetic peptide 
(WPPRPSPSAGLSLEA), corresponding to the 7-21 predicted amino acid sequence 
in the N-terminal segment of the rat receptor (Chalon et al., 1996), and showing no 
homology with other known neurotensin receptor subtypes. The peptide was 
conjugated via maleimide to ovalbumin. The conjugate was used to immunize two 
rabbits (Affinity BioReagents, ABR, Golden, CO). The initial immunization was 
folIowed by five additional booster injections. Serum samples were analyzed 
separately for reactivity by Western blotting and immunohistochemistry. One of the 
sera proved more sensitive than the other for immunohistochemistry and, therefore, 
was used throughout the present study. 
3.3.2 Preparation of Rat NTS2 Construct 
The HA-tagged NTS2 cDNA was obtained through reverse transcription of rat brain 
rnRNA isolated by polymerase chain reaction (PCR) using nucleotide sequences 35-
61 bp (5'-ACAGAGATGGCATACCCATACGACGTCCCAGACTACGC TGAGA-
CCAGCAGTCCGTGG-3') and 1268-1291 bp (5'-TCATACTTGTATTTCTCCC-
AGGCT-3') of the open reading frame of NTS2 rnRNA (Chalon et al., 1996) as 
sense and antisense oligonucleotides, respectively. The PCR product was purified 
from a 1 % low melting temperature agarose gel and subcloned into the pT ARGET 
expression vector (Promega, Madison, WI). That the proper rat NTS2 sequence had 
been cloned was confirmed by base pair sequencing. 
3.3.3 Culture and Transfection ofCOS-7 Cells 
COS-7 celIs were maintained in Dulbecco's modified Eagle's medium with high 
glucose supplemented with 5% fetal bovine serum in the presence of 100 U/ml 
penicillinlstreptomycin (GibcoBRL, Life Technologies, Burlington, Ontario, CAN). 
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Cells were grown at 37°C in a humidified atmosphere with 5% C02 and plated in 
lOO-mm Petri dishes at a density of 106 cells/dish. On the following day, 
semiconfluent cells were transiently transfected with the rat HA-tagged NTS2 
receptor cDNA by the diethylaminoethanol-dextran/chloroquine method, as described 
previously (Innamorati et al., 2001). Cells were collected 48-72 hours after the 
beginning of the transfection and processed for immunoprecipitation or 
immunocytochemistry as described below. 
3.3.4 Preparation of Brain Membranes 
Adult Sprague-Dawley rats (200-250g; Charles River, St-Constant, Québec, Canada) 
were killed by decapitation. Their brains were removed quickly and placed on ice. 
Cerebellum and brain were dissected, homogenized separately with a Polytron in 
buffer A containing 50 mM Tris-HCI (pH 7.0) and 4 mM ethylenediaminetetraacetic 
acid (EDTA) with protease inhibitors (Complete Protease inhibitors tablets, Roche 
Molecular Biochemicals, Laval, Québec, Canada), and centrifuged at 1,000 rpm for 
10 minutes at 4°C. The supematant was collected and the pellet resuspended in buffer 
A and centrifuged again for 10 minutes at 4°C. The supematant from the second spin 
was combined with that of the first for each sample and centrifuged at 4°C for 10 
minutes at 46,000 rpm. The pellets were then resuspended in buffer B, consisting of 
50 mM Tris-HCI (pH 7.0) and 0.2 mM EDTA with protease inhibitors, by vortexing 
and brief sonication. Protein concentration was determined by the Bio-Rad procedure 
with bovine serum albumin (BSA) as standard (Bradford, 1976). 
3.3.5 Immunoblotting Analysis 
Membranes from rat brain and cerebellum were denatured by using Laemmli sample 
buffer (Laemmli, 1970) containing 5% j3-mercaptoethanol, resolved by using 8% 
Tris-glycine precast gels (Invitrogen, Burlington, Ontario, CAN), and transferred to 
nitrocellulose membranes (Bio-Rad laboratories, Mississauga, Ontario, Canada). 
Nonspecific sites were blocked by 0.1 % Tween 20 and 10% milk powder (Carnation, 
Don Mills, Ontario, Canada) in phosphate-buffered saline (PBS; pH 7.4) ovemight at 
4°C. Nitrocellulose membranes were then incubated ovemight at 4°C with the N-
terminal specific anti-NTS2 rabbit antibody (1110,000) in PBS with 1 % BSA and 1 % 
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ovalbumin. After washing with PBS-Tween, blots were incubated for 1 hour at room 
temperature (RT) with an horseradish peroxidase (HRP)-conjugated goat anti-rabbit 
secondary antibody (1/4000; Amersham Pharmacia Biotech, Baie d'Urfé, Québec, 
Canada) in PBS with 5% milk powder and proteins were visualized by using an 
enhanced chemiluminescent detection system (Perkin Elmer, Life Sciences, Boston, 
MA). Specificity of antiserum was confirmed by preadsorption of the NTS2 antibody 
ovemight with an excess of immunizing peptide (2 Jlglml of adsorbing peptide at a 
final antibody dilution of 1/10,000). 
3.3.6 Immunoprecipitation 
COS-7 cells were rinsed with PBS 72 hour after transfection, detached from the 
dishes, and centrifuged. The cell pellet was disrupted in RIPA buffer (150 mM NaCI, 
50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1%, IGEPAL, 0.5% deoxycholic acid, 0.1% 
sodium dodecyl sulfate) containing protease inhibitors and incubated for 30 minutes 
on ice. Lysates were then precleared with 25 Jlg of protein A-Sepharose (Sigma, St-
Louis, MO) for 45 minutes at 4°C and incubated overnight at 4°C with the NTS2 
rabbit antibody (1/800) or with a rat monoclonal antibody (clone 3FlO) directed 
toward the HA-epitope (1/400; Roche Molecular Biochemicals, Indianapolis, IN). 
The protein A-sepharose was gently shaken in lysis buffer containing 1 % BSA for 30 
minutes at room temperature before use. HA epitope-tagged NTS2 receptors were 
precipitated by incubation with 100 Jlg of protein A-sepharose for 2 hours at 4°C. 
After washing three times in lysis buffer, complexes were dissolved in Laemmli 
sample buffer and resolved as described above. Nitrocellulose membranes were then 
incubated overnight at 4°C in PBS with a solution containing 1 % BSA and 1 % 
ovalbumin and a 1/2,500 dilution of a mouse monoclonal antibody (clone 12CA5) 
directed toward the HA-epitope (samples precipitated with NTS2 antibody) or with a 
1/10,000 dilution of the NTS2 antibody (samples precipitated with anti-HA 
antibody). After washing with PBS-Tween, blots were incubated for 1 hour at RT 
with HRP-conjugated goat anti-rabbit or anti-mouse secondary antibodies in PBS 
with 5% milk powder (1/4,000; Amersham Pharmacia Biotech, Baie d'Urfé, Québec, 
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CAN) and proteins were visualized using an enhanced chemiluminescent detection 
system. 
3.3.7 Immunocytochemistry on COS-7 Cells 
Transfected COS-7 cens, plated on poly-L-Iysine-coated glass coverslips, were fixed 
for 20 minutes with 4% paraformaldehyde (PFA; Polysciences, Warington, PA) in 
0.1 M phosphate buffer (PB), pH 7.4, rinsed with 0.1 M Trisma base-buffered saline 
(TBS), pH 7.4, and preincubated for 30 minutes at RT with a blocking solution 
consisting of 5% normal goat serum (NOS), 2% BSA and 0.1 % Triton X-I00 (BDH, 
Inc., Toronto, Ontario, Canada) in 0.1 M TBS. Double immunostaining was 
performed by incubating cens overnight at 4°C with the anti-NTS2 peptide antiserum 
(1/15,000) or with the anti-NTS2 peptide antiserum preadsorbed with the antigenic 
peptide, together with the mouse monoclonal antibody (clone 12CA5) directed 
toward the HA epitope, diluted 1/500 in 0.1 M TBS, pH 7.4, containing 1 % NOS and 
0.05% Triton X-lOO. After washing with TBS, cens were incubated for 1 hour at RT 
with a mixture of Alexa 488-conjugated goat anti-mouse and Alexa 594-conjugated 
goat anti-rabbit (1/750; Molecular Probes, Eugene, OR), washed twice in TBS and 
mounted on glass slides with Aquamount. 
Double-Iabeled cens were analyzed by confocal microscopy using a Zeiss 510 
laser scanning microscope equipped with a Zeiss inverted microscope and Argon2 
(488 nm) and HelNel (543 nm) lasers (Carl Zeiss Micro Imaging Inc. Thomwood, 
NY). Images were acquired simultaneously for both fluorophores (Alexa-488 and 
Alexa-594) by using the multitrack configuration mode and processed using the Zeiss 
510 laser scanning microscope software. Identical parameters were used to acquire 
the images for cens immunolabeled in the presence or absence of NTS2 blocking 
peptide. 
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3.3.8 Light Microscopie Immunolabeling of Rat Brain Sections 
3.3.8.1 Tissue Fixation 
Adult male Sprague-Dawley rats (200-250 g; n = 10) were anesthetized with sodium 
pentobarbital (Somnotol; 1.2 ml/kg) and perfused transaortically with a freshly 
prepared solution of 4% PFA in 0.1 M PB, pH 7.4. Brains were rapidly removed, 
cryoprotected overnight in 0.1 M PB containing 30% sucrose at 4°C, and frozen for 1 
minute in isopentane at -40°C. 
3.3.8.2 Single-Labeling Immunohistochemistry 
Coronal sections (30 ~m thick) were cut on a freezing microtome along the whole 
rostrocaudal extent of the brain from bregma 6.70 to -14.60 and collected in 0.1 M 
PB. Immunohistochemistry was performed according to the avidin biotinylated-HRP 
complex (ABC) method by using a Elite ABC kit (Vector Laboratories, Burlingame, 
CAN). Briefly, free-floating sections were washed twice with 0.1 M TBS, pH 7.4, 
pretreated for 30 minutes with 3% hydrogen peroxide in 0.1 M TBS to quench 
endogenous peroxidase. SeriaI sections were then washed twice with TBS (2 x 10 
minutes), preincubated for 1 hour at RT in a blocking solution containing 3% NOS 
and 0.2% Triton X-I00 in TBS, and incubated overnight at 4°C with the primary 
NTS2 antibody (1/10,000) diluted in TBS containing 0.05% Triton X-100 and 0.5% 
NOS. After two rinses in TBS containing 1 % NOS (2 x 10 minutes), sections were 
incubated for 1 hour at RT in biotinylated goat anti-rabbit immunoglobulin diluted 
1/400 in TBS (Vector laboratories), and then 1 hour in Elite ABC solution (Vector; 
prepared according to the manufacturer's instructions). Visualization of bound 
peroxidase was achieved by reaction in a solution of 0.1 M Tris-HCl (TB; pH 7.4) 
containing 0.05% 3-3' -diaminobenzidine (DAB, Sigma-Aldrich), 0.04% nickel 
chloride, and 0.001 % H2Û2. The DAB reaction was monitored under a microscope to 
determine the optimal duration of incubation (5 minutes maximum) for yielding 
intense immunolabeling with minimal background staining. This reaction was 
stopped by several washes with 0.1 M TB. 
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The same procedure was used for control experiments except that sections were 
processed either with antibodies preabsorbed overnight with an excess of immunizing 
peptide (as for Western blotting procedures) or in the absence of primary antibody. 
Sections were mounted on chrome alum/gelatin-coated slides, dehydrated in graded 
ethanols, defatted in xylene, and mounted with Permount (Fisher Scientific, 
Montreal, Québec, Canada). Labeled structures were examined under bright-field 
illumination with a Leitz Aristoplan miscroscope (Lei ca, Dollard Desormeaux, 
Québec, Canada) and labeling densities were assessed for each region and visually 
scored on a scale of - /+ to +++ according to both the number of labeled elements 
and the intensity of immunoreactive signal. 
3.3.8.3 Double-Labeling Immunohistochemistry 
Frozen sections, prepared as above (n = 4 rats), were treated for 30 minutes in 3% 
NOS in TBS and incubated ovemight at 4°C in a mixture of rabbit NTS2 antibody 
(1110,000) and monoclonal mouse anti-S 1 00 J3-subunit (11500; Sigma) diluted in TBS 
containing 0.05% Triton X-100 and 0.5% NOS. The following day, sections were 
rinsed twice in TBS containing 1 % NOS and incubated for 1 hour in the same buffer 
containing a mixture ofbiotinylated goat anti-rabbit immunoglobulin (11400; Vector) 
and Alexa 488-tagged goat anti-mouse (11500; Molecular Probes). Sections were then 
rinsed in TBS, incubated for 1 hour in ABC complex solution, rinsed again in TBS, 
and incubated as above for 10 minutes in a biotinylated tyramine solution (Adam, 
1992; NEN-Dupont, Wilmington, DE). After several buffer washes, sections were 
incubated for 1 hour in a solution of Texas-Red-conjugated streptavidin (1/250; 
Jackson, West Orove, PA). Sections were then rinsed and mounted with Aquamount. 
The absence of cross-reactivity of the secondary antibodies was verified by omitting 
one or both primary antibodies during the ovemight incubation. Double-Iabeled 
sections were analyzed by confocal microscopy by using a Zeiss 510 laser scanning 
microscope equipped with a Zeiss inverted microscope and Argon2 (488 nm) and 
HeINe1 (543 nm) lasers. Images were acquired simultaneously for both fluorophores 
(Alexa-488 and Texas Red) by using the multitrack configuration mode and 
processed by using the Zeiss 510 laser scanning microscope software. 
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3.3.9 Data Analysis 
Light microscopie photomicrographs and color images from double-Iabeling 
experiments were adjusted for contrast and brightness by using Adobe Photoshop 6.0 
software (Adobe, San Jose, CA). The final composites were processed by using 
Deneba's Canvas 7.0 imaging software (Deneba Software, Miami, FL) on an Apple 
PowerBook G3. Brain structures were identified according to the nomenclature of 
Paxinos and Watson's atlas (Paxinos and Watson, 1986). 
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3.4 RESULTS 
3.4.1 Characterization of NTS2 Antiserum 
To demonstrate the specificity of the NTS2 antiserum, Western blotting was 
performed on membranes prepared from rat brain and cerebellum (Fig. 3.1A). In 
both structures, anti-NTS2 specifically detected a band at 46 kDa, consistent with the 
molecular weight of the monomeric form of the receptor as deduced from its cDNA 
sequence (Fig. 3.1A, lanes 1 and 2). Specific immunoreactive bands, which might 
reflect multimeric species of NTS2 receptors, were also detected at approximately 
80-85 kDa and 124-206 kDa in both whole brain (Fig. 3.1A, lane 1) and cerebellar 
membranes (Fig. 3.1A, lane 2). All of these bands were absent when the antibody 
was presaturated with the immunizing peptide (Fig. 3.1A, lanes 3 and 4). 
To confirm that these immunoreactive bands corresponded to the NTS2 
receptor, crude membrane preparations from COS-7 cells expressing HA-tagged rat 
NTS2 receptors were immunoprecipitated with the NTS2 antiserum (Fig. 3.1B, lane 
2) or with the 3FlO antibody specific for the HA-epitope tag (Fig. 3.1B, lane 4), and 
respectively, immunoblotted with the 12CA5 HA antibody (Fig. 3.1B, lane 2) or with 
the NTS2 antiserum (Fig. 3.1B, lane 4). These experiments revealed the presence of 
46- and 83-kDa protein bands, as observed in rat brain and cerebellum, in both 
immunoprecipitates (Fig. 3.1B, lanes 2 and 4). In addition, immunoreactive bands 
were detected at approximately 124-206 kDa in both preparations (Fig. 3.1B, lane 2 
and 4), which presumably correspond to multimeric complexes of the receptor. No 
specific bands were detected in membranes prepared from nontransfected cells (Fig. 
3.1B, lanes 1 and 3). 
3.4.2 Specificity of Immunolabeling 
To demonstrate the applicability of the NTS2 antiserum to immunohistochemical 
detection of the receptor in PFA-fixed material, double immunofluorescent staining 
was carried out on COS-7 cells expressing the HA-tagged NTS2 receptor. Confocal 
microscopy revealed that HA (Fig. 3.1C) and NTS2 (Fig. 3.1D) antibodies produced 
very similar patterns of immunostaining. No signal was detected in untransfected 
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ceUs or in the absence of primary antibodies (data not shown). Preincubation of the 
anti-NTS2 antiserum with the N-terminal immunogenic peptide completely aboli shed 
NTS2-like (NTS2-l) immunolabeling (Fig. 3.lF). However, the same ceUs were still 
positively stained for the HA-epitope, indicating that they did express the receptor 
(Fig.3.lE). 
Immunolabeling of rat brain sections with a 1/10,000 dilution of NTS2 
antiserum gave rise to selective immunostaining patterns throughout the neuraxis 
(e.g. Figs. 3.2A, 3.4-11). By contrast, sections incubated with antiserum pre-
adsorbed with the immunogenic peptide were completely devoid of immunolabeling 
(Figs. 3.2B, 3.6e). 
3.4.3 Cellular Distribution of NTS2-1 Immunoreactivity 
NTS2-1 immunoreactivity was selectively concentrated over neurons, and most 
prominently within neuronal processes (Table 3.1). Thus, in many regions such as 
the piriform cortex (Fig. 3.3A) and other cortical areas, NTS2-1 immunolabeling was 
highly concentrated over pyramidal ceU dendrites, whereas the vast majority of the 
corresponding perikarya were only moderately labeled. However, in other regions, 
such as the central amygdaloid nucleus (Fig. 3.3B), the bed nucleus of the stria 
terminalis (Fig. 3.3D, 3.5A), or CAl of Ammon's horn (Fig. 3.6A and B), both 
perikarya and dendrites showed moderate to intense NTS2-1 immunolabeling. NTS2-1 
immunoreactivity was also detected in axons and axon terminaIs throughout the 
neuraxis, e.g. in the diagonal band of Broca (Fig. 3.3e) and in the anterior 
hypothalamus (Fig. 3.3G). Labeling of the ependyma was observed in sorne of our 
sections (e.g. Fig. 3.5A, 3.8A and E), but this labeling was non-specific as it was still 
present in sections incubated with preadsorbed antiserum. 
No obvious NTS2-1 immunolabeling was evident over glial ceUs in our single-
labeling experiments. To formally exclude astrocytic involvement, dual 
immunolabeling experiments were performed by using our NTS2 antiserum and the 
astrocytic marker SlOOp in regions exhibiting either prominent somatic (Fig. 3.3D-F) 
or process labeling (Fig. 3.3G-l). In the bed nucleus of the stria terminalis, strongly 
NTS2-1-positive perikarya as weU as smaU fluorescent puncta resembling cross-
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sectioned processes were evident by confocal microscopy (Fig. 3.3D). None ofthese 
structures exhibited SlOOp immunolabeling within the same sections (Fig. 3.3E and 
F). In the anterior hypothalamus, NTS2-1 immunoreactivity was localized to punctate 
structures reminiscent oftransected dendrites and/or glial elements (Fig. 3.3G). Here 
again, none of these structures were dually labeled with the SlOOp antibody, which 
revealed a number of astrocytic cell bodies as weIl as the entire ependyma (Fig. 3.3H 
and!). 
3.4.4 Regional Distribution of NTS2-1 Immunoreactivity 
3.4.4.1 Telencephalon 
Within the telencephalon, strong and selective NTS2-1 immunolabeling was apparent 
in the olfactory bulb and tubercle, the basal forebrain, the basal ganglia, the 
amygdaloid complex, the hippocampal formation, and the cerebral cortex (Table 3.1; 
for topographical overview, see Fig. 3.4). 
ln the main olfactory bulb, NTS2-1 immunoreactivity was distributed throughout 
the granule ceIl, mitral ceIl, external plexiform, and glomerular layers (Fig. 3.2A; 
Table 3.1). Immunopositive perikarya were most intensely labeled in the mitral cell 
layer (Table 3.1). Moderately labeled mitral cell dendrites also extended through the 
external plexiform layer into the glomerular layer. In the glomerular layer, a 
moderate meshwork of NTS2-I-positive neuronal processes surrounded the glomeruli. 
Periglomerular cells were occasionally labeled (Table 3.1). Labeling in the granule 
cell layer was abundant although quite diffuse, making it difficult to identify 
individual immunoreactive cells. The accessory olfactory bulb displayed very strong 
immunolabeling ofneuronal processes (Fig. 3.2A; Table 3.1). In the olfactory cortex, 
only the olfactory tubercle displayed substantial numbers of immunolabeled nerve 
cell bodies. A few NTS2-I-positive perikarya were also present in the taenia tecta, the 
islands of Calleja, the piriform and prepiriform cortex (Fig. 3.3A), and the lateral 
olfactory nucleus (Table 3.1). AlI ofthese structures, as weIl as the anterior olfactory 
nucleus (Fig. 3.4) and the dorsal and ventral endopiriform nuclei displayed at least 
low levels of fiber labeling. In contrast, the piriform and prepiriform cortex stood out 
by exhibiting a dense network of strongly immunostained dendrites (Fig. 3.3A). 
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In the basal forebrain, NTS2-I-immunoreactive neuronal cell bodies were 
observed in the ventral pallidum, the substriatal area, the medial and lateral septum 
(Fig. 3.4A), the diagonal band of Broca (Fig. 3.4A), the magnocellular preoptic 
nucleus, and most prominently the bed nucleus of the stria terminalis (Fig. 3.5A). 
With the exception of the latter two nuclei, labeling of processes and terminaIs in all 
of these structures was more prominent than that of neuronal perikarya (Fig. 3.3C; 
Table 3.1). In addition, immunoreactive processes and terminals were encountered in 
the septohippocampal nucleus and the substantia innominata (Table 3.1). 
With the exception of the caudate-putamen, which displayed low to moderate 
numbers ofrelatively small, NTS2-I-positive neurons (Fig. 3.5C; Table 3.1), the basal 
ganglia exhibited only low numbers of immunolabeled nerve cells or none at all 
(Table 3.1). The nucleus accumbens (core and shell), the caudate-putamen, and the 
fundus striati also contained sparse NTS2-I-immunoreactive processes and terminaIs. 
By contrast, the globus pallidus (Fig. 3.5B) and the entopeduncular nucleus exhibited 
a dense network of immunolabe1ed fibers (Table 3.1). The central amygdaloid 
nucleus (Fig. 3.3B) and the sub-nuclei of the cortical amygdala (cf posteromedial 
amygdaloid nucleus in Fig. 3.4B) both exhibited a moderate number of strongly 
NTS2-I-immunoreactive multipolar neurons (Table 3.1). In addition, sparse 
immunolabeled cells were found in the medial nucleus of the amygdala. AlI of these 
nuclei, as well as the basomedial nucleus, exhibited low to moderate densities of 
labeled processes and terminaIs (Table 3.1). 
The hippocampal formation was among the most heavily labeled regions of the 
brain (Fig. 3.4B; Table 3.1). The most striking pattern of staining was found in the 
CA fields of the hippocampus proper. CAl exhibited extremely strong 
immunostaining of pyramidal cell bodies and apical dendrites (Figs. 3.4 and 3.6A 
and B). These processes coursed through the stratum radiatum and ramified into the 
stratum lacunosum moleculare, forming a mesh of transected dendritic profiles (Fig. 
3.6A and B). In CA2, the labe1ing diminished in intensity (Fig. 3.6A; Table 1) and in 
CA3, no labe1ing was apparent at low magnification except for a light staining of the 
stratum lacunosum moleculare (Fig. 3.6A). At high magnification, however, it 
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became obvious that the apical dendrites of CA3 pyramidal cells were in fact 
labeled, although less intensely so than in CAl or CA2. CA3 nerve cell bodies were 
not labeled (Table 3.1). In the dentate gyms, granule cells were immunonegative 
(Fig. 3.6A; Table 3.1) but a few faintly labeled cell bodies, as weIl as sparse fibers, 
showed NTS2-1 immunolabeling (Table 3.1). No immunolabeling was apparent in 
the hippocampus in sections incubated with antiserum pre-adsorbed with 2 Ilglml 
antigenic peptide (Fig. 3.6C). The entorhinal cortex, as weIl as the pre- and 
parasubiculum, exhibited moderately to intensely labeled nerve cell bodies in layer II 
(Fig. 3.6D and E). The enthorinal cortex also exhibited moderate staining of 
neuronal processes (Fig. 3.6E, Table 3.1). 
In aIl neocortical areas, apical dendrites of layer V pyramidal neurons were the 
most strongly immunoreactive structures (Fig. 3.7A, Table 3.1). These could be 
traced aIl the way to layer 1 in which they ramified (Fig. 3.7A). Allocorticai areas, 
represented by the retrosplenial cortex, also displayed strongly labeled pyramidal 
cells (Fig. 3.7B, insert). Moderate numbers of NTS2-1-positive neuronal somata were 
observed in the frontal, parietal (Fig. 3.7A, insert), occipital, temporal, retrospenial, 
and insular cortex. Cingulate and perirhinal cortices exhibited only low numbers of 
immunoreactive somata (Table 3.1). 
3.4.4.2 Diencephalon 
In the thalamus, the paraventricular (Fig. 3.8A), anterior dorsal and anterior ventral 
(Fig. 8B), ventromedial, mediodorsal, lateral and medial geniculate (Fig. 3.8e, insert) 
nuclei displayed low to moderate numbers of NTS2-1-immunoreactive somata (Table 
3.1). Most of these nuclei also exhibited intensely labeled neuronal processes except 
for the anterior ventral and medial geniculate nuclei or the dorsal tier of the lateral 
geniculate body, which were completely devoid of NTS2-1-positive processes (Table 
3.1). The reuniens, reticular, central medial, rhomboid, parafascicular (Fig. 3.4B), 
and subparafascicular nuclei aIl exhibited moderate to dense networks of NTS2-1-
positive fibers but no immunopositive nerve cell bodies (Table 3.1). Within the 
hypothalamus, low to moderate numbers of immunoreactive nerve cell bodies were 
evident in the supraoptic, arcuate (Fig. 3.8E and F), and ventromedial nucleus (Fig. 
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3.4), as weIl as in the retrochiasmatic area (Fig. 3.4), the Iaterai hypothalamic area, 
and the laterai mammillary nucleus (Fig. 3.8F). AIl of these nuclei aiso displayed 
moderate to high Ieve1s ofimmunolabeled neuronal processes (Table 3.1). As in the 
thalamus, light to moderate labeling of processes was detected in a number of 
additional nuclei, namely the anterior hypothalamus (Fig. 3.3G), suprachiasmatic 
nucleus, para- (Fig. 3.8D) and periventricular nuclei (Fig. 3.3G), tuber cinereum (Fig. 
3.3G), medial mammillary nucleus (Figs. 3.4 and 3.8F), and lateral and medial 
preoptic area (Fig. 3.4; Table 3.1). The outer zone of the median eminence (Fig. 
3.8E) as well as the supramammillary nucleus (Fig. 3.8F) exhibited strong NTS2-1 
fiber labeling (Table 3.1). 
In the zona incerta, sparse, lightly stained nerve cell bodies were detected 
amidst intense1y labe1ed neuronal processes (Fig. 3.8C; Table 3.1). The subthalamic 
nucleus exhibited moderate levels of NTS2-I-positive processes, but no 
immunoreactive nerve cell bodies (Table 3.1). Both subdivisions of the habenula 
displayed sparse, lightly labeled nerve cell bodies (Fig. 3.8A; Table 3.1). The lateral 
habenula also exhibited a moderate1y dense plexus of NTS2-I-positive processes (Fig. 
3.8A; Table 3.1). The subfomical organ, while devoid of immunopositive cell 
bodies, harbored a moderate1y dense network of immunoreactive processes (Table 
3.1). 
3.4.4.3 Mesencephalon 
In the midbrain, the oculomotor (Figs. 3.4 and 3.9A) and magnocellular part of the 
red nucleus (Fig. 3.9C) contained medium numbers of intense1y stained NTS2-
positive nerve cell bodies. Lightly labe1ed and/or less numerous neurons were also 
observed in the substantia nigra, pars reticulata (Fig. 3.9D and E), ventral tegmental 
area (Figs. 3.4 and 3.9D), interpeduncular (Figs. 3.4 and 3.9D) and interfascicular 
nuclei, periaqueductal gray (Figs. 3.4 and 3.9A,B), dorsal raphe nucleus (Figs. 3.4 
and 3.9A), and superior and inferior colliculi (Fig. 3.4, Table 3.1). In most of these 
structures, and most prominently in the periaqueductal gray, dorsal raphe nucleus, 
and substantia nigra pars reticulata, these labe1ed perikarya were embedded in a 
dense meshwork of immunolabe1ed pro cesses (Figs. 3.4 and 3.9). In the superior 
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colliculus, labeled perikarya were exclusively observed in the inner gray layer, 
immediately adjacent to the optic nerve layer, and in the deep gray, where they were 
concentrated lateraIly. The substantia nigra, pars compacta (Fig. 3.9D), 
peripeduncular nucleus, deep mesencephalic nucleus (Fig. 3.9D), and 
precommissural nucleus were devoid of immunopositive perikarya but displayed low 
to moderate to labeling of neuronal processes (Table 3.1). The caudallinear raphe 
nucleus (Fig. 3.40, while devoid of perikaryal immunolabeling displayed intensely 
labeled processes (Table 3.1). 
3.4.4.4 Pons 
The pontine nuclei (Fig. 3.40 and nucleus of the trapezoid body (Figs. 3.4D and 
3.9H) displayed a moderate number of strongly immunostained neuronal perikarya. 
Less numerous and/or more lightly stained ceIl bodies were also evident in the 
superior olivary complex and superior paraolivary nucleus (Figs. 3.4D and 3.9F) as 
weIl as in the principal sensory (Fig. 3.4D) and motor trigeminal nuclei (Table 3.1). 
Except for the nucleus of the trapezoid body, these structures were also pervaded by 
moderately abundant immunoreactive neuronal processes (Fig. 3.9F,G; Table 3.1). 
The paramedian raphe nucleus displayed no NTS2-I-positive nerve ceIl bodies, but a 
moderately dense network of immunolabeled processes (Fig. 3.9G; Table 3.1). 
3.4.4.5 Medul/a Oblongata 
In the meduIla oblongata, variable numbers of moderately to intensely labeled NTS2-1 
immunoreactive ceIl bodies and processes were observed in aIl sensory and most of 
the motor cranial nerve nuclei (Table 3.1), including the vestibular complex (Fig. 
3.10A,B), the cochlear nuclei (Figs. 3.4D, 3.10A), the subnuclei of the spinal 
trigeminal nucleus (Fig. 3.l0A-C), the nucleus of the solitary tract (Figs. 3.4D and 
3.10B,C) as weIl as the trochlear, abducens (Fig. 3.l0D), facial (Fig. 3.lOA), vagal 
(Fig. 3.1 OB) and hypoglossal (Fig. 3.1 OB and C) nuclei. In addition, the inferior olive 
(Fig. 3.10B and C), the gigantoceIlular reticular nucleus, pars alpha (rostroventral 
medial meduIla; Fig. 3.lOA and F), the lateral paragigantoceIlular (Fig. 3.l0A) and 
lateral reticular nuclei, the parvoceIlular reticular nucleus (Fig. 3.10A, B, and G), the 
external cuneate and cuneate nuclei (Fig. 3.10B, C, and E), the linear nucleus of the 
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raphe (Fig. 3.10B), and the nuclei raphe magnus and pallidus (Fig. 3.lOA and F) 
displayed low to moderate perikaryal NTS2 -1 immunolabeling as weIl as moderate to 
dense labeling ofneuronal processes (Table 3.1). Structures in which immunolabeled 
processes but no cell bodies were observed include the gigantocellular and 
intermediate reticular nuclei (Fig. 3.10A and B), the medullary reticular field (Fig. 
3.10C), the paratrigeminal (Fig. 3.10H) and gracile (Fig. 3.10C) nuclei, nucleus X 
(Fig. 3.10B), and the nucleus raphe obscurus (Fig. 3. lOB) (Table 3.1). 
3.4.4.6 Cerebel/um 
The deep cerebellar nuclei displayed a moderate number of strongly immunoreactive 
nerve cell bodies interspersed among a plexus of immunopositive processes (Fig. 
3.11A; Table 3.1). The lateral nucleus was slightly more intensely stained than 
intermediate and medial nuclei (Figs. 3.4D and 3.11A). In the cerebellar cortex, 
NTS2-1 immunoreactivity was present in aIl three layers. Purkinje cell perikarya and 
dendritic pro cesses ascending in the molecular layer were the most strongly labeled 
elements (Figs. 3.11B and C; Table 3.1). Labeling in the granule ceIllayer was less 
pronounced and essentially accounted for by the immunolabeling of a subpopulation 
of granule cells (Fig. 3.11D; Table 3.1). In the molecular layer, sparse, strongly 
labeled neuronal perikarya (not shown) were evident among the pervasive Purkinje 
cell dendrites (Fig. 3.11 C and D). 
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3.5 DISCUSSION 
The present study provides the first description of the distribution of NTS2 receptor 
proteins in mammalian brain. The NTS2 antiserum used here was raised against a 
sequence from the N-terminus of the rat receptor unique among known NT receptor 
sequences. The specificity of the antiserum was initially established by Western 
blotting of membranes prepared from whole brain and cerebellum (which previously 
had been shown to express among the highest levels of NTS2 rnRNA and binding 
sites in rodent brain; cf. Sarret et al., 1998, 2002; Walker et al., 1998). The NTS2 
antiserum specifically recognized a band at 46 kDa, which corresponds to the 
molecular weight of the monomeric receptor deduced from its cDNA sequence. In 
addition, other specific bands were detected at molecular weights corresponding to 
multiples of the monomeric receptor's size, thus possibly representing multimeric 
complexes of NTS2. None of these bands were present when the blots were 
incubated with antiserum preadsorbed with the antigenic peptide, indicating that the 
NTS2 antiserum selectively recognized the native receptor protein. To further 
support the notion that the immunoreactive bands detected in brain homogenates 
indeed corresponded to the NTS2 receptor, immunoprecipitation experiments were 
carried out on membranes from COS-7 cells transfected or not with cDNA encoding 
the N-terminally HA-tagged NTS2 receptor. Both immunoprecipitation with an anti-
HA epitope antibody and detection with anti-NTS2 and the reverse experiment gave 
rise to the same major bands pattern as detected in rat brain and cerebellum 
homogenates. These findings confirm that our antiserum selectively cross-reacts 
with the rat NTS2 receptor. 
To establish the applicability of the antiserum to the immunohistochemical 
detection of NTS2 receptors, double-labeling studies were performed on COS-7 cells 
transiently expressing the N-terminally HA-tagged NTS2 receptor. The NTS2 
antiserum exc1usively labeled cells that also exhibited HA-immunoreactivity, 
indicating that it selectively recognized cells expressing the NTS2 receptor. 
Preadsorption of the NTS2 antiserum with immunogenic peptide completely 
abolished immunostaining, confirming that it was attributable to the NTS2 antibody. 
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Similarly, sections of rat brain incubated with preadsorbed antiserum were virtually 
devoid of immunostaining, suggesting that as in transfected cells, the antibody 
selectively recognized the NTS2 receptor. 
Within the brain, NTS2-1 immunoreactivity was exc1usively found in neurons. 
However, its subcellular compartmentalization varied markedly between brain 
regions. Thus, whereas in sorne areas, such as the hippocampus, the immunolabeling 
was associated with both perikarya and dendrites, in others, such as the cerebral 
cortex or the globus pallidus, it c1early predominated over dendrites. In yet others, 
such as the diagonal band of Broca and the anterior hypothalamus, it was mainly 
associated with axons and axon terminaIs. These data suggest that unlike NTS 1 
receptors, which are reportedly more or less uniformly distributed over perikarya, 
dendrites, and axons of neurons in which they are expressed (Boudin et al., 1996b; 
Fassio et al., 2000), NTS2 receptors may be selectively targeted to specific neuronal 
elements, and most prominentIy to dendritic processes. 
Previous in situ hybridization studies have reported the presence of NTS2 
mRNA expression in glial and ependymal cells in intact adult rat brain (Walker et al., 
1998; Lépée-Lorgeoux et al., 1999). Furthermore, double-Iabeling experiments have 
demonstrated NTS2 mRNA expression in glial fibrillary acidic protein-
immunolabeled reactive astrocytes, both in vitro and in vivo (Nouel et al., 1999). No 
glial and/or ependymallabeling was readily apparent here in NTS2-immunoreacted 
sections. To confirm the lack of association of NTS2-1 immunoreactivity with 
astrocytes, we performed dual-labeling experiments using the astroglial marker 
S 100J3. In none of the regions examined did SI 00J3 immunoreactivity co-Iocalize 
with NTS2-1 immunostaining, suggesting that under basal conditions, NTS2 receptor 
proteins are not present in astrocytes. This is not to say, however, that they would 
not be detectable under conditions of reactive gliosis. 
The topographic distribution of the NTS2-1 immunoreactivity was extensive, as 
expeeted from earlier subtraetive autoradiographie binding studies based on the 
displaeement of specific 125I-Iabeled NT, eH]-NT, or eH]-SRI42948A binding by 
levoeabastine (Kitabgi et al., 1987; Sehotte et al., 1986, 1988; Schotte and Laduron, 
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1987; Bétancur et al., 1998) or on direct binding of [3H]-levocabastine (Asselin et al., 
2001). Thus, NTS2-1 immunolabeling was detected in all regions previouslyreported 
to exhibit high levels of NTS2 binding sites including olfactory bulb, all olfactory 
relay nuclei, septum, bed nucleus of the stria terminalis, amygdaloid nuclei, CAl of 
the hippocampus, pre- and parasubiculum, cerebral cortex, several thalamic nuclei, 
arcuate nucleus, mammillary bodies, interpeduncular nucleus, superior colliculus, 
periaqueductal gray, dorsal raphe nucleus, red nucleus, substantia nigra, ventral 
tegmental area, nucleus raphe magnus, vestibular complex, and cerebellum. 
However, the present study also demonstrated that if widespread, the distribution of 
NTS2 receptor proteins was also more selective than previously surmised from the 
diffuse distributional patterns yielded by autoradiographie binding studies (Kitabgi et 
aL, 1987; Schotte et aL, 1986, 1988; Schotte and Laduron, 1987; Bétancur et aL, 
1998; Asselin et aL, 2001). 
The distribution of NTS2-1-immunoreactive nerve cell bodies was also in good 
agreement with that of NTS2-expressing cells as determined by in situ hybridization 
in both rat (Walker et al., 1998; Lépée-Lorgeoux et aL, 1999) and mouse (Sarret et 
aL, 1998) brain. By and large, all regions reported to exhibit medium to strong NTS2 
mRNA levels, such as the olfactory bulb, cerebral cortex, hippocampal formation, 
periaqueductal gray, and cerebellar cortex to name but a few, were immunolabeled 
here. There were several regions, however, in which NTS2-1 immunolabeling 
appeared more restricted than expected from in situ hybridization data. For instance, 
the medial habenula, which was reported to contain high levels of NTS2 mRNA 
(Sarret et aL, 1998; Lépée-Lorgeoux et aL, 1999), was barely immunoreactive in the 
present study. Similarly, the hippocampus, which was shown to express very high 
levels of NTS2 rnRNA throughout all subfields of Ammon's horn and the dentate 
gyrus (Sarret et aL, 1998; Walker et al., 1998; Lépée-Lorgeoux et aL, 1999), 
exhibited NTS2-immunoreactive cell bodies only in CAl and CA2 subfields. These 
discrepancies could reflect poor translation of the NTS2 message in certain sub-
population of neurons or could be due to selective targeting of NTS2 proteins to 
neuronal processes. Thus, NTS2 rnRNA-positive/NTS2-immunonegative neurons in 
the medial habenula could account for the terminal immunolabeling observed in their 
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projection field within the interpeduncular nucleus (Butcher, 1995). Alternatively, 
the lack of apparent cellular immunoreactivity in areas containing high levels of 
NTS2 mRNA could reflect selective targeting of NTS2 receptor proteins to plasma 
membranes. Indeed, the diffuse NTS2-1 immunolabeling observed here over the CA3 
subfield and dentate gyrus was reminiscent of the pattern of labeling described for the 
SShA somatostatin receptor in brain areas in which this receptor was found by 
electron microscopy to be selectively addressed to plasma membranes (Doumaud et 
al., 1996). 
In contrast to NTSI rnRNA (Elde et al., 1990; Sato et al., 1992; Nicot et al., 
1994a,b; Alexander and Leeman, 1998) or immunoreactivity (Boudin at al., 1996b; 
Fassio et al., 2000), which are more or less restricted to regions innervated by 
neurotensinergic axons, NTS2-1 immunoreactivity considerably exceeded that of NT 
terminal fields. Thus, sorne of the most heavily labeled regions in the brain, such as 
the hippocampus, the cerebral and cerebellar cortices, and medullary cranial nerve 
nuclei had been described as being innervated only sparsely if at aIl by NT fibers 
(Jennes et al., 1982, Emson et al., 1985a and 1985b). These findings provide further 
support to the hypothesis that NT may not be the exclusive endogenous ligand for 
this receptor subtype (Sarret et al., 1998). There were, however, regions in which 
NTS2-1 immunoreactivity showed considerable overlap with NT terminal fields, 
including the olfactory bulb, bed nucleus of the stria terminalis, magnocellular 
preoptic nucleus, anterior dorsal thalamic nucleus, substantia nigra, ventral tegmental 
area, periaqueductal gray, nucleus raphe dorsalis and magnus, and lateral 
paragigantocellular nucleus (Jennes et al., 1982; Emson et al., 1985b). AlI of these 
regions (except for nuclei raphe magnus and lateral paragigantocellular nucleus), as 
weIl as several others in which NT axons are less prominent, such as the entorhinal, 
frontal, and retrosplenial cortices, the pre-and parasubiculum, the cortical amygdala, 
the pontine nuclei, and various medullary nuclei, also display high levels of NTS 1 
(Boudin et al., 1996b; Fassio et al., 2000), indicating that in many brain structures, 
NTS2 is in a position to interact with NTS 1 in mediating NT' s central effects. 
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The distribution of NTS2-1 immunoreactivity also overlapped extensively with 
that of the single-transmembrane domain receptor NTS3/sortilin (except in the 
granule cell layer of the cerebellar cortex and medullary reticular formation which 
were enriched in NTS2-, but not in NTS3-immunoreactive neurons; Sarret et al., 
submitted). This widespread co-distribution of NTS2 with NTS3/sortilin raises the 
possibility of interactions between these two receptors for the mediation of the NT 
signal, particularly in light of recent studies showing that NTS3 can interact with 
NTSI to enhance the NT-induced phosphorylation of mitogen-activated protein 
kinases and turnover of phosphoinositides in the HT29 human cancer cell line 
(Martin et al., 2002a). 
A striking feature of NTS2 distribution was its association with every single 
sensory system in the brain. Thus, all olfactory relay nuclei, including the olfactory 
bulb, exhibited NTS2-1 immunoreactivity. The auditory system was also labeled from 
the cochlear nuclei, through the superior olive, the inferior colliculus, and the medial 
geniculate nucleus, all the way to the temporal cortex. Likewise, the visual system 
exhibited NTS2-1 immunolabeling throughout the lateral geniculate body, 
suprachiasmatic nucleus, superior colliculus, and occipital cortex. The nucleus of the 
solitary tract, a major relay for visceral and gustatory input, exhibited moderate 
immunolabeling. Finally, NTS2-1 immunoreactivity was associated with relay nuclei 
of ascending somatosensory information, including the gracile and cuneate nuclei, 
spinal and principal sensory trigeminal nuclei, and parietal cortex. 
Of particular interest from a functional perspective was the intense labeling of 
brainstem structures involved in pain control. Indeed, recent pharmacological studies 
have demonstrated that the NT antagonist SR142948A, which does not distinguish 
between NTSI and NTS2, blocks NT-induced antinociception (GuIly et al., 1997), 
whereas the NTSI-specific antagonist SR48692 does not (GuIly et al., 1993; Dubuc 
et al., 1994; Labbé-Jullié, 1994). Furthermore, the NTS2-selective ligand, 
levocabastine (Tyler et al., 1998; Dubuc et al., 1999a) and NTS2 antisense 
oligonucleotides (Dubuc et al., 1999b) both inhibit the antinociceptive effects of 
intracerebroventricularly administered NT, whereas knocking down the NTSI gene 
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in mice is without effect (Remaury et al., 2002; but also see Pettibone et al., 2002). 
Microinjection studies have long identified regions involved in the descending 
control of nociceptive inputs as sites of NT -induced antinociception (Kalivas et al., 
1982b; Mayer and Price 1989; McHaffie et al., 1989). The strong NTS2-1 
immunolabeling found here in regions such as the periaqueductal gray, dorsal raphe 
nucleus, raphe magnus and pallidus, gigantocellular nucleus, pars alpha, and lateral 
paragigantocellular nucleus suggests that NTS2 receptors are ideally poised to 
regulate NT's supraspinal antinociceptive actions. 
Strong NTS2-1 immunoreactivity was associated with cerebellum-related 
brainstem nuclei such as the external cuneate nucleus, pontine nuclei, inferior olive, 
and vestibular complex, suggesting that NTS2 is associated with both mossy and 
climbing fiber afferent cerebellar systems. NTS2 immunolabeling was also observed 
over Purkinje cells, deep cerebellar nuclei, vestibular complex, and red nucleus 
suggesting that NTS2 receptors are equally involved in the regulation of the 
cerebellar output. In cerebellar cortex, NTS2-1 immunoreactivity was evident over a 
sub-population of granule cells, in conformity with the recent demonstration of 
functionally coupled NTS2 receptors in these cells in primary culture (Sarret et al., 
2002). Taken together, the present results suggest a prominent involvement ofNTS2 
in the regulation of cerebellar function. However, because the cerebellum is 
essentially devoid of NT innervation, the stimulus responsible for NTS2 activation in 
this structure remains to be established. 
In conclusion, the present study demonstrates that NTS2 receptors are widely 
distributed in the rat CNS. It also indicates that this receptor is essentially neuronal 
and that it is predominantly, although not exclusively, targeted to dendrites. High 
levels of NTS2 receptor proteins were detected in regions documented to receive a 
dense neurotensinergic innervation (namely the hypothalamus, the basal forebrain 
and ventral midbrain, and severallimbic and brainstem structures), in keeping with 
the postulated role ofthis receptor in transducing NT's actions, and most specifically 
its antinociceptive effects. However, the distribution of NTS2 largely exceeded that 
of NT' s terminal fields, suggesting that it may also serve as receptor for other 
endogenous ligand(s). 
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3.7 ABBREVIATIONS 
V Layer of the cerebral cortex 
3V 3
rd ventricle 
4V 4
th ventricle 
3n Oculomotor nucleus 
6n Abducens nucleus 
7n Facial nucleus 
12n Hypoglossal nucleus 
Acb Accumbens nucleus 
AD Anterodorsal thalamic nucleus 
ABC Anterior hypothalamic area, central part 
AOB Accessory olfactory bulb 
AON Anterior olfactory nucleus 
Aq Aqueduct (Sylvius) 
Arc Arcuate hypothalamic nucleus 
AV Anteroventral thalamic nucleus 
CAl-3 Fields CAl-3 of Ammon's horn 
CLi Caudallinear nucleus of the raphe 
cp Cerebral peduncle, ventral part 
Cpu Caudate putamen (striatum) 
Cu Cuneate nucleus 
DC Dorsal cochlear nucleus 
DG Dentate gyms 
DLG Dorsallateral geniculate nucleus 
DMSp5 Dorsomedial spinal trigeminal nucleus 
DR Dorsal raphe nucleus 
Ecu External cuneate nucleus 
Ent Entorhinal cortex 
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Epi 
f 
Frl 
Gel 
Gi 
GiA 
GI 
Gr 
GrA 
ic 
icp 
Igr 
Int 
10 
IP 
Ipl 
Lat 
LHb 
Li 
LM 
LPGi 
LRt 
LSD 
LSO 
LSV 
LVe 
mS 
MD 
MdD 
MdV 
ME 
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External plexiform layer of the olfactory bulb 
Fornix 
Frontal cortex, area 1 
Granule celllayer of the cerebellum 
Gigantocellular reticular nucleus 
Gigantocellular reticular nucleus, alpha part 
Glomerular layer of the olfactory bulb 
Gracile nucleus 
Granular celllayer of the accessory olfactory bulb 
InternaI capsule 
Inferior cerebellar peduncle (restiform body) 
InternaI granular layer of the olfactory bulb 
Interposed cerebellar nucleus 
Inferior olive 
Interpeduncular nucleus 
InternaI plexifom layer of the olfactory bulb 
Lateral (dentate) cerebellar nucleus 
Lateral habenular nucleus 
Linear nucleus of the medulla 
Lateral mammillary nucleus 
Lateral paragigantocellular nucleus 
Lateral reticular nucleus 
Lateral septal nucleus, dorsal part 
Lateral superior olive 
Lateral septal nucleus, ventral part 
Lateral vestibular nucleus 
Motor root of the trigeminal nerve 
Mediodorsal thalamic nucleus 
Medullary reticular nucleus, dorsal part 
Medullary reticular nucleus, ventral part 
Median eminence 
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Med 
MG 
MHb 
Mi 
ml 
Ml 
MnR 
mol 
MSO 
mt 
MVe 
OB 
or 
Pa 
PaS 
PaS 
PAG 
Pel 
Pe 
PF 
PFL 
Pir 
PMCo 
PMR 
PMV 
Pn 
PrS 
PrS 
PV 
py 
pyr 
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Medial (fastigial) cerebellar nucleus 
Medial geniculate nucleus 
Medial habenular nucleus 
Mitral celllayer of the olfactory bulb 
Mediallenrrniscus 
Molecular layer of the cerebellum 
Median raphe nucleus 
Lacunosum molecular stratum of Ammon's hom 
Medial superior olive 
Mammillothalamic tract 
Medial vestibular nucleus 
Olfactory bulb 
Stratum oriens of Ammon's hom 
Paraventricular hypothalamic nucleus 
Paratrigeminal nucleus 
Parasubiculum 
Periaqueductal gray 
Purkinje celllayer of the cerebellum 
Periventricular hypothalamic nucleus 
Parafascicular thalamic nucleus 
Paratlocculus 
Piriform cortex 
Posteromedial cortical amygdaloid nucleus 
Paramedian raphe nucleus 
Premammillary nucleus, ventral part 
Pontine nuclei 
Principal sensory trigeminal nucleus 
Presubiculum 
Paraventricular thalamic nucleus 
Pyramidal tract 
Stratum pyramidale of Ammon's hom 
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pyx 
rad 
RCh 
RMg 
ROb 
RPa 
Rt 
s5 
SC 
sm 
SNe 
SNr 
Sol 
Sp5C 
Sp51 
Sp50 
SPO 
SuM 
SuVe 
TC 
Tu 
Tz 
VCA 
VCP 
VDB 
VLG 
VMH 
VTA 
X 
ZI 
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Pyramidal decussation 
Stratum radiatum of Ammon's horn 
Retrochiasmatic area 
Raphe magnus nucleus 
Raphe obscurus nucleus 
Raphe pallidus nucleus 
Reticular thalamic nucleus 
Sensory root of the trigeminal nerve 
Superior colliculus 
Stria medullaris of the thalamus 
Substantia nigra, pars compacta 
Substantia nigra, pars reticulata 
Nucleus of the solitary tract 
Spinal trigeminal nucleus, caudal part 
Spinal trigeminal nucleus, interpolar part 
Spinal trigeminal nucleus, oral part 
Superior paraolivary nucleus 
Supramammillary nucleus 
Superior vestibular nucleus 
Tuber cinereum area 
Olfactory tubercle 
Trapezoid nucleus 
Ventral cochlear nucleus, anterior part 
Ventral cochlear nucleus, posterior part 
Nucleus verticallimb diagonal band 
V entrailaterai geniculate nucleus 
Ventromedial hypothalamic nucleus 
Ventral tegmental area 
Nucleus X 
Zona incerta 
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3.8 FIGURES 
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Figure 3.1 
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A 
Figure 3.2 
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Figure 3.3 
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Figure 3.4 
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Figure 3.5 
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Figure 3.6 
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Figure 3.7 
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Figure 3.8 
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Figure 3.9 
113 
Chapter 3: NTS2 Localization in Rat Brain 
Figure 3.10 
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Figure 3.11 
115 
Chapter 3: NTS2 Localization in Rat Brain 
3.9 FIGURE LEGENDS 
Fig. 3.1: CharacterÏzation of Levocabastine-sensitive NTS2 Antiserum. A and B: 
Identification by Western blotting of endogenously vs. heterologously expressed 
NTS2 receptors. A: Blot from whole brain (lanes 1, 3) and cerebellar (lanes 2, 4) 
membranes incubated with the NTS2 antiserum. As a control, the antiserum was 
preadsorbed with 2 J.1g1ml of antigenic peptide (lanes 3, 4). Specifie immunoreactive 
bands are apparent at estimated molecular weights of 46, 80-85 and 124-206 kDa. 
Each lane represents the transfer of 60 J.1g of membrane protein. Data are 
representative of four independent experiments. B: Immunoprecipitation with NTS2 
antiserum and blotting with anti-HA antibody (lane 2) or immunoprecipitation with 
anti-HA antibody and blotting with anti-NTS2 antiserum (lane 4) of homogenates 
from COS-7 cells expressing (lanes 2, 4) or not (lane 1, 3) HA-NTS2. Both 
approaches reveal translation products of approximately 46, 83 and 125-206 kDa in 
transfected, but not in untransfected cells. Data are representative of three 
independent experiments. Migration of molecular weight markers is indicated on the 
left. C-F: Dual immunofluorescence labeling of COS-7 cells transfected with cDNA 
encoding HA-epitope-tagged NTS2 receptor. Labeling of the HA-epitope (C) 
overlaps with staining produced by the NTS2 antiserum. (D). Preadsorption of 
NTS2 antiserum with antigenic peptide completely abolishes NTS2-1 immunostaining 
(F) in cells expressing the epitope-tagged receptor (H). Trans-nuclear confocal 
microscopie images representative of three separate experiments. Scale bar = 5 J.1m in 
F (applies to C-F). 
Fig. 3.2.: Specificity of Levocabastine-sensitive Neurotensin Receptor-like 
(NTS2-l) Immunolabeling in Rat Brain Sections. A: Section from the olfactory 
bulb, immunostained with anti-NTS2 serum diluted 1: 1 0,000. Alllayers of the main 
olfactory bulb are strongly immunopositive. Most intensely stained are the external 
plexiform layer (EpI) and the accessory olfactory bulb (AOB). B: Section from the 
same region incubated with primary antiserum preadsorbed with 2 J.1g1ml of antigen 
at the same final dilution as in A. Note the complete suppression of the 
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immunolabeling. For other abbreviations, see li st. Scale bar = 0.6 mm in B (applies 
toA andB) 
Fig. 3.3: Cellular Distribution of Levoeabastine-sensitive Neurotensin Reeeptor-
like (NTS2-l) Immunoreaetivity in Rat Brain Sections. A: In many areas such as 
the piriform cortex, NTS2-1 immunoreactivity is mainly apparent over dendrites. In 
regions such as the central amygdaloid nucleus (B) or the bed nucleus of the stria 
terminalis (D), NTS2-1 immunoreactivity is predominantly associated with nerve cell 
bodies. C: NTS2-1-immunoreactive axons and axonal varicosities (arrowheads) are 
visible in several regions such as here in the diagonal band of Broca. D-/: Dual 
immunofluorescence labeling ofNTS2 and of the astrocyte antigen S100~. D: In the 
bed nucleus of the stria terminalis, NTS2-1 immunoreactivity is apparent over somata 
and small processes. E-F: None of these structures are immunoreactive for the 
S100~ antigen within the same section. G: In the anterior hypothalamus, NTS2-1 
labeling is detected in the form of small puncta pervading the neuropil, 
predominantly in its dorso-medial aspect. H-/: Here again, none of the NTS2-1-
immunoreactive structures co-Iocalize S100~ within the same section. For 
abbreviations, see list. Scale bar in C = 60 J..lm in A-B; 40 J..lm in C; 25 J..lm in D-F; 
200 J..lm in G-I. 
Fig. 3.4: Topographie Distribution of Levoeabastine-sensitive Neurotensin 
Reeeptor-like (NTS2-l) Immunoreaetivity. A schematic midsagittal section 
through the rat brain provides an overview of the distribution of NTS2-1 
immunoreactivity throughout the neuraxis and indicates the rostrocaudallevels of the 
coronal sections illustrated below. Symbols in schematic sagittal section: dots, 
NTS2-1-positive neuronal perikarya; twisted Unes, labeled neuronal processes. A: At 
anterior levels, the neocortex (most notably layer V and supragranular layers), 
piriform cortex, olfactory tubercle, and lateral septum all display moderate to strong 
immunoreactivity. The mediodorsal aspect of the caudate-putamen is also 
moderately labeled. B: Further caudally, very strong immunolabeling is evident in 
CA 1 and CA2 hippocampal subfields. Moderate to dense immunostaining is again 
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evident in cerebral cortex. The posteromedial cortical amygdaloid nucleus also 
displays intense NTS2-1 immunoreactivity. FinaIly, moderate immunolabeling is 
evident in the parafascicular nucleus of the thalamus and throughout the 
hypothalamus. C: At caudal mesencephalic and rostral pontine levels, the strongest 
immunoreactive signal is observed in the interpeduncular nucleus, the caudal linear 
raphe, and the periaqueductal gray. The superior colliculus also displays moderate 
immunolabeling, differentialy distributed among its layers. The pontine nuclei are 
strongly labeled. D: In the caudal pons, the superior olivary complex and the nucleus 
of the trapezoid body are conspicuously labeled. In the same section, rostral 
medullary nuclei such as the principal sensory and spinal trigeminal nuclei, the 
medial vestibular nucleus, and the cochlear nuclei display medium to strong 
immunoreactivity. In the cerebeIlum, both the deep nuclei and the cerebellar cortex 
display high levels of NTS2-1 immunoreactivity. For abbreviations, see list. Scale bar 
= 2.5 mm in D (applies to A-D) 
Fig. 3.5: Distribution of Levocabastine-sensitive Neurotensin Receptor-like 
(NTS2-l) Immunoreactivity in the Basal Forebrain (A) and Basal GangIia (B,C). 
A: In the bed nucleus of the stria terminalis, numerous cell bodies are strongly 
immunoreactive. In addition, there is a moderate staining of the neuropil surrounding 
the somata. B: Within the globus pallidus, NTS2-1 immunoreactivity is associated 
with neuronal processes coursing in between fascicles of myelinated axons. C: In the 
caudate-putamen, small spiny type II-like immunopositive neuronal perikarya are 
visible between the fiber bundles of the internaI capsule. A light staining of the 
neuropil is evident as weIl. For abbreviations, see Iist. Scale bar in B = 75 /-lm in A; 
160 /-lm in B; 40 /-lm in C. 
Fig. 3.6: Distribution of Levocabastine-sensitive Neurotensin Receptor-like 
(NTS2-l) Immunoreactivity in the Hippocampal Formation. A: In Ammon's 
horn, intense NTS2-1 immunolabeling is evident in stratum pyramidale, radiatum, and 
lacunosum moleculare of CAl and CA2. CA3 displays only moderate, diffuse 
labeling except in the stratum lacunosum moleculare, where the labeling is more 
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pronounced. The dentate gyms is likewise moderately, but diffusely labeled except 
for the granule cell layer which is totally devoid of immunostaining. B: At high 
magnification, virtually all CAl pyramidal cells are seen to be immunopositive. 
Their apical dendrites pass through the stratum radiatum and ramify in the stratum 
lacunosum moleculare. C: Preadsorption of the antiserum with 2 J..lglml of antigen 
result in a complete loss of NTS2-1 immunoreactivity. D: The entorhinal cortex as 
well as the pre- and parasubiculum all display numerous, strongly labeled nerve cell 
bodies in layer II. E: At high magnification, labeling over neurons in the entorhinal 
cortex is seen to spare the nucleus and to extend for a short distance within proximal 
dendrites. For abbreviations, see list. Scale bar in D = 400 J.lm in A and C; 80 J.lm in 
B; 150 J.lffi in D; 60 J.lm in E. 
Fig. 3.7: Distribution of Levocabastine-sensitive Neurotensin Receptor-like 
(NTS2-l) Immunoreactivity in the Cerebral Cortex. A: In neocortical areas such 
as the parietal cortex illustrated here, a sub-population of layer V pyramidal cells 
(insert) exhibit intense immunolabeling of their cell bodies and apical dendrites. The 
latter may be followed up to the superficial layers, in which they ramify. B: 
Allocortical areas, represented here by the retrosplenial cortex, display a similar 
pattern oflabeling. Scale bar in B = 150 J.lm in A (60 J.lm in insert); 75 J.lm in B (45 
J.lm in insert). 
Fig. 3.8: Distribution of Levocabastine-sensitive Neurotensin receptor-like 
(NTS2-l) Immunoreactivity in the Diencephalon. A: Habenular complex. The 
lateral habenula exhibits moderate to dense fiber staining whereas the medial 
habenula is only lightly and diffusely stained. The ventromedially adjoining 
paraventricular thalamic nucleus displays strong immunolabeling. B: The anterior 
dorsal thalamic nucleus displays intense perikaryal and neuropil immunostaining, 
whereas the neighboring anterior ventral nucleus is only lightly reactive. C: Intense 
immunoreactivity is apparent over the dorsal lateral and ventral tiers of the lateral 
geniculate nucleus as well as in the adjoining zona incerta. As seen in the insert, most 
of this immunostaining is accounted for by dendritic processes. D: Within the 
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paraventricular nucleus, NTS2-1 immunoreactivity is selectively deteeted within small 
punetate proeesses. E: The areuate nucleus (Arc) displays both immunoreaetive 
nerve cell bodies (arrowheads, insert) and a dense network of strongly 
immunoreaetive proeesses. Diffuse immunolabeling is also evident over the external 
zone of the median eminenee. F: At the level of the mammillary bodies, the lateral 
mammillary (LM) and supramammillary (SuM) nuclei show moderate to strong 
neuropil immunolabeling. For other abbreviations, see list. Seale bar in F = 130 J.lm 
in A, B, and D; 500 J.lm in C (40 J.lm in insert); 80 J.lm in E (50 J.lm in insert); 200 J.lm 
inF. 
Fig. 3.9: Distribution of Levocabastine-sensitive Neurotensin Receptor-like 
(NTS2-l) Immunoreactivity in Mesencephalon (A-E) and Pons (F-H). A: The 
ventral periaqueduetal gray (P AG) and dorsal raphe nucleus both exhibit a dense 
network of immunopositive proeesses. Intensely immunoreactive nerve cell bodies 
are also evident within the oeulomotor nucleus. B: In the dorsal part of the P AG, 
labeled neuronal perikarya (arrowheads) are apparent amidst a less intensely stained 
plexus of immunoreaetive proeesses. C: Intensely immunostained nerve eell bodies 
are detected in the ventral, magnoeellular portion of the red nucleus. D: The 
substantia nigra, pars eompaeta (SNe) and retieulata (SNr), exhibit a dense network 
of immunopositive proeesses. In the ventral tegmental area, the labeling is less 
intense and eoneerns nerve eell bodies as well as proeesses. E: At high 
magnifieation, NTS2-I-positive nerve cell bodies (arrowheads) ean be identified 
amongst the dense plexus of proeesses pervading the SNr. F: In the rostral pons, the 
superior olivary eomplex exhibits a mix of labeled somata and processes. G: The 
paramedian raphe nucleus displays a high density of immunolabeled proeesses, 
whereas the median raphe nucleus is eompletely devoid of NTS2 immunoreaetivity. 
H: In the nucleus of the trapezoid body, NTS2-1 immunoreaetivity is predominantly 
associated with small neuronal perikarya. For other abbreviations, see li st. Scale bar 
in H = 280 J.lm in A; 65 J.lm in B; 120 J.lm in C; 350 J.lm in D; 50 J.lm in E; 240 J.lm in 
F; 150 J.lm in G and H. 
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Fig. 3.10: Distribution of Levocabastine-sensitive Neurotensin Receptor-like 
(NTS1-l) Immunoreactivity in the Medulla Oblongata. A-C: Low magnification 
micrographs illustrating labeling of cranial nerve sensory nuclei. Sorne of these, such 
as the medial vestibular (A-B) and dorsal cochlear nuclei (A) are more or less 
uniformly and very strongly stained. Others, such as the superior (A) and spinal 
vestibular (B) nuclei and ventral cochlear nucleus (A) exhibit lighter staining of the 
neuropil and NTS2-positive nerve cell bodies are visible even at low magnification. 
D: The abducens nucleus diplays numerous intensely stained neurons as well as a 
strong labeling of the neuropil. E: The external cuneate nucleus exhibits a moderate 
number of NTS2-1-positive perikarya in its lateral aspect. The neuropil is strongly 
stained and pervaded by a dense network of immunolabeled processes. F: The 
gigantocellular reticular nucleus, pars alpha, exhibits numerous labeled perikarya as 
well as processes. Medially, the nucleus raphe magnus is intensely stained and the 
raphe pallidus displays moderate immunoreactivity. G: Intensely NTS2-1 
immunoreactive neurons in the parvocellular reticular nucleus are surrounded by a 
moderately dense plexus of immunopositive fibers. H: The paratrigeminal nucleus is 
pervaded by a dense plexus of intensely stained processes. For abbreviations, see 
list. Scale bar in H = 700 J.lm, in A-C; 60 J.lm in D-E, H; 170 J.lm in F; 75 J.lm in G. 
Fig. 3.11: Distribution of Levocabastine-sensitive Neurotensin Receptor-like 
(NTS1-l) Immunoreactivity in the Cerebellum. A: Intensely labeled nerve cell 
bodies are detected among a network of immunoreactive processes within the lateral 
and intermediate cerebellar nuclei. To the left of the inferior cerebellar peduncle, 
light to moderate immunoreactivity is observed in the lateral vestibular nucleus. B: 
Sagittal section through the paraflocculus illustrating the presence of NTS2-1 
immunolabeling in all three layers of cerebellar cortex. C: At higher magnification, 
labeling of Purkinje cells and of their apical dendrites traversing the molecular layer 
is evident. D: At high magnification, individual immunopositive granule ceUs can be 
identified (black arrowheads). In addition, the plexus of Purkinje cell dendrites is 
resolved in the molecular layer (white arrowheads). For abbreviations, see list. 
Scale bar in D = 400 J.lm in A, 500 J.lm in B, 130 J.lm in C, 30 J.lm in D. 
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3.10 TABLE 
TABLE 3.1. Regional Distribution ofNTS2 Immunoreactivity in Adult Rat Brain' 
NTS2 immunoreactivity NTS2 immunoreaetivity 
Processe8 and Processes and 
Structure Cell bodies Terminais Structure Cell bodi .. Terminais 
Telencephalon Paraventricular nucleU8 -/+ +1++ 
Cerebral cortex Areuate nucleus +/++ ++1+++ 
Frontal +/++ +1++ RetrochialllD81ic area ++ ++ 
Parietal ++ +++ Ventromedial nucleu. -/+ +/++ 
CiDguIate + ++ Dot"BOmedial nucleus 
Oœipital +/++ +/++ Periventricular nucleus 
Temporal +1++ +++ Lateral hypotbalamie ares -/+ ++ 
Insular +/++ ++/+++ Tuber cinereum +/++ 
Perirhinol + +/++ Medial mammillary nucleus ++ 
Re_pleniaJ ++ Lateral mammillary nucleus ++ 
Olfuclory bulb Supramammîllary nucleus ++/+++ 
Aoœssory olfac:tory bulb +++ Lateral preopûc area -/+ 
Intem.al granular layer + + Medial preoptk area ++ 
Mitral ceJllayer ++ Median eminence ++/+++ 
EIt..m.1 plexiform 1._ ++ SubtlUllamus 
Glomerular layer -/+ +1++ Zona incerta -/+ ++/+++ 
OIf.c:tory system Subthalamie nucleus +/++ 
Lateral olfactory nucleus -/+ +/++ Epithalmnua 
Pirifonn cortes. + ++/+++ Medial habenula nucleus -/+ -/+ 
Prepiriform cortex + ++/+++ Lateral habenul. nucleus -/+ ++ 
ADterlor o)(adory oucleu ++ Sublomieal organ ++ 
Dorsal endopiriform nucleus -/+ MesenœphaIon 
Ventral endopiriform nucleWi +/++ Substanûa nigra pan. compacta +1++ 
Taenia lecta -/+ Substantia nigra pari retieulata -/+ ++1+++ 
Olfactory tubercle ++ +/++ Ventral tegmental ares + + 
lslandl of CaDeja + +1++ Deep m.esencephalic nucleus +/++ 
BasaI forebrain Red llUCleus ++ + 
Septohippocampal nuc\eua ++ Peripeduncular nucleU!! ++ 
Lateral septum +1++ ++ Interpeduncular nucleus -/+ ++ 
Medial septum -/+ +/++ Interfaacicular nucleus -/+ +1++ 
Diagonal band of Broca Precommissural nudeua ++ 
VerticaJ limb -/+ +/++ Periaqueducta1 gray (tentral gray) ++J+++ 
Horizontallimb -/+ ++ Oculomotor nucleus (3n) +1++ 
Magnocellular preoptic nucleus +1++ +/++ Dorsal raphe nucleua ++1+++ 
Bed nudeWl of the stria terminais ++1+++ +/++ Caudallinear nucleus raphe ++1+++ 
Ventral pallidum -/+ ++ Superior colliculus + ++ 
Substantia innominata ++ Inferior eolliculUi + +/++ 
Subetriatal area + +/++ Pons 
BasaIpnglia Pontine Duclei ++ ++ 
Nucleus accumbens Superior olivary complu +1++ ++1+++ 
Co", -/+ -/+ Superior paraolivary nudell8 + ++ 
Shen -/+ + Nucleus of the trapezoid body ++ 
Caudate putamen +/++ -/+ Paramedian raphe nucleus +/++ 
Fundus striati + -/+ Motor trigeminal nucleus +1++ +1++ 
Globus pallidwo ++/+++ Principal .senaory nucleus (Sn) -/+ +/++ 
Entopeduncular nucleus ++1+++ Medull. 
Am,vdala Medial vestibular nucleus -/+ ++1+++ 
Central DucleWl ++ ++ Lateral vestibular nucleus +/++ + 
Baaomedial nudeWl + Ventral cochlear nucleus ++/+++ +1++ 
Medial nucleus -/+ +1++ Donuù cochleor nuclell8 +1++ + 
Cortical nudeWl ++ ++ Linear nucleus of the raphe -/+ +/++ 
Hippoeampal fOrmation Inferior olive +1++ +++ 
Entorhinal cortex ++1+++ +/++ Nucleus of the solita:ry tract -/+ ++ 
Prembiculum ++ -/+ GigantoeeUular reticular nucleus, pars alpha + +1++ 
P8l"88ubiculum ++/+++ -/+ Gigantoc:ellular reticular nucleus + 
CAl +++ +++ Lateral paragigantocellular nucleus +/++ 
CM ++ ++ Lateral reticular nucleus ++/+++ 
CM -/+ Intennediate retieular nucleus -/+ 
Dentate gyrua ParvoœlluIlll' retic:u1ar nucleu. -/+ ++1+++ 
Granule cella Medullary ret.ieular field, donsal ++ 
Hil .. -/+ + Medullary retieu1ar field, ventral -/+ 
Dienœphalon Paratrigeminal nucleus +++ 
Tha\amu. Extemal cuneate nucleus +1++ ++1+++ 
Anterior d.onal nucleus -/+ ++/+++ CUDeate nucleus -/+ 
Anterior ventral nucleus + + 0raC11e nucleus ++ 
Pal'8.ventricular nucleus + ++ NudeusX ++/+++ 
ReUDiena nuc:Ieus + Raphe magnus nucleUi -/+ ++ 
Reticular thalamk nucleus ++1+++ Raphe obacurus n\l(!leus +1++ 
Central media! thalamic nucIeu8 + Rephe pal1idus nw:leu. -/+ +/++ 
VentromediaJ thalamie nucleus + + Troclùear nucleus (4n) +1++ +/++ 
Mediodorsal thalamic nucleus +/++ -/+ Spinal trigeminal nucleus COn) + ++ 
Rhomboid thalamic nucleus + Abducens nucleus (6n) + ++/+++ 
Parafascicular nucleus ++ Facial nucleus (7n) + ++/+++ 
Subparafascicu1ar nucleus +1++ Dorsal motor nucleus of the vagua (10n) -/+ ++ 
Medial geniculate nucleus + Hypoglossal nucleus (]2n) ++/+++ 
Ventrallateral geniculate nucleus ++ Cerebellum 
Dorsallateral genicu1ate nucleus Cerebellar cortes. 
Hypothalamus Granule celllayer 
Anterior hypothalamus +/++ Purkinje celllayer ++/+++ 
Suprachiaematic nucleus ++ Molecular layer -/+ ++/+++ 
Supraoptic nucleus ++ Cerebellar nuclei Gnt. lat, medial) +/++ 
l'The intensity of immunolabeling wu qualitatively scored using the CAl (+ + +) and CA3 (-) subfields of Ammon's born 88 references. Intensity of NTS2 immunoreactivity:· no 
labeling, + low signal, + + moderate signal, + + + high signal, referring to both Inbeling intensity and the number oflabeled elements. NTS2.levombastine-sensitive neurotensin 
receptor. 
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4.1 ABSTRACT 
The role and signaling properties of the low-affinity neurotensin receptor (NTS2) are 
still controversial. In particular, it is unclear whether neurotensin acts as an agonist, 
inverse agonist, or antagonist at this site. In view of the growing evidence for a role 
of NTS2 in antinociception, the elucidation of the phannacological and coupling 
properties of this receptor is particularly critical. In the present study, we demonstrate 
that in Chinese hamster ovary (CHû) cens expressing the rat NTS2 receptor, 
neurotensin (NT), levocabastine, neuromedin N, and the high-affinity NT receptor 
antagonist SR48692 [2-{[l-( -7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-lH-
pyrazole-3-carbonyl]amino }adamantane-2-carboxylic acid] an bind to and activate 
the NTS2 receptor. This activation is foUowed by ligand-induced internalization of 
receptor-ligand complexes, as evidenced by confocal microscopy using a fluorescent 
NT analog. AU compounds tested produced a rapid and sustained activation of 
extracenular signal-regulated kinases 1/2 (ERK1/2) but were without specific effect 
on Ca2+ mobilization. The agonist-induced activation of ERK1/2 was completely 
aboli shed by preincubation of the cens with the endocytosis inhibitors phenylarsine 
oxide and monodansylcadaverine as weU as overexpression of a dominant-negative 
mutant of dynamin 1 (DynK44A), indicating that receptor internalization was 
required for ERKl/2 activation. NTS2-induced activation of ERK1/2 was not 
species-specific, because the same agonistic effects of NT and analogs were observed 
in CHû cens transfected with the human NTS2 receptor. In conclusion, this study 
demonstrates that NTS2 is a bona fide NT receptor and that activation of this receptor 
by NT or NT analogs results in an internalization-dependent activation of the 
ERK1/2 signaling cascade. 
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4.2 INTRODUCTION 
Neurotensin (NT) is a tridecapeptide that exerts neuromodulatory functions in the 
central nervous system and has endocrine/paracrine actions in the periphery (Vincent, 
1995; Rostène and Alexander, 1997). NT has been shown to modulate dopaminergic 
transmission in the nigrostriatal and mesocorticolimbic pathways (Nemeroff, 1986; 
Kitabgi et al., 1989), thereby implicating this neuropeptide in the patho-physiology of 
several central nervous system disorders, induding Parkinson's disease and 
schizophrenia (for review, see Kitabgi et al., 1989; Binder et al., 2001a; Kinkead and 
Nemeroff, 2002). In addition, NT injection in the brain or ventricular system 
produces hypothermia (Martin et al., 1980), changes in blood pressure (Rioux et al., 
1981), and nonopioid-dependent analgesia (Kalivas et al., 1982a). 
NT mediates its central and peripheral effects through interaction with three 
receptor subtypes, referred to as NTS 1, NTS2, and NTS3. NTS 1 and NTS2 belong 
to the seven transmembrane domainiG protein-coupled receptor family (Tanaka et 
al., 1990; Vita et al., 1993, 1998; Chalon et al., 1996; Mazella et al., 1996), whereas 
NTS3 is a single transmembrane domain sorting receptor predominantly associated 
with vesicular organelles and the Golgi apparatus (Petersen et al., 1997; Mazella et 
al., 1998). Pharmacological and biochemical studies have indicated that the high-
affinity (subnanomolar range) NT receptor NTSI is coupled to cGMP, cAMP, and 
inositol phosphate signaling cascades (for review, see Hermans and Maloteaux, 
1998; Vincent et al., 1999). Stimulation of NTSI also induces the activation of 
extracellular signal-regulated kinases 1/2 (ERK1I2) through coupling with both 
pertussis toxin-sensitive and -insensitive G proteins. This activation leads in tum to 
the expression of proliferative genes such as c-fos, Krox-24, and elk-l (Poinot-
Chazel et al., 1996; Ehlers et al., 1998, 2000; Portier et al., 1998; Martin et al., 
2002a). These effects are selectively blocked by the nonpeptide NT antagonist 
SR48692, which displays a nanomolar affinity for NTSI (Gullyet al., 1993). 
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The low-affinity (nanomolar range) NT receptor NTS2 differs from the NTSI 
site not only by its 10-fold lower affinity for NT, but also by its selective recognition 
of levocabastine, a nonpeptide histamine Hl receptor antagonist that selectively 
inhibits NT binding to NTS2 without affecting its binding to NTS 1 (Schotte et al., 
1986; Kitabgi et al., 1987). NTS2 also displays a much lower affinity (ICso = 300 
nM) than NTSI (ICso = 5.6 nM) for the SR48692 compound (Gullyet al., 1993); 
however, the pharmacological and signaling properties of NTS2 are still extremely 
controversial. In particular, doubts have been cast regarding the agonistic properties 
of NT at this site and, hence, about whether or not this protein may be regarded as a 
true NT receptor. Indeed, in CHû cells stably transfected with human NTS2, 
SR48692, but neither NT nor levocabastine, was found to activate classic second 
messenger systems, such as phosphoinositide hydrolysis, Ca2+ mobilization, or 
ERKl/2 phosphorylation (Vita et al., 1998). Furthermore, in transfected CHû and 
CÛS-7 cells, this SR48692-induced activation of the human NTS2 was blocked by 
NT, suggesting that the endogenous peptide was acting as a competitive antagonist at 
these sites (Vita et al., 1998; Richard et al., 2001 b). 
By contrast, in Xenopus laevis oocytes expressing the mouse NTS2 receptor, 
NT, neuromedin N (NN), and levocabastine were all found to activate Ca2+_ 
dependent chloride currents (Mazella et al., 1996). In addition, application of NT or 
levocabastine on rat cerebellar granule cells, which endogenously express the NTS2 
but not the NTSI receptor, induced a sustained activation of the ERKl/2 signaling 
cascade (Sarret et al., 2002). Congruent with an agoni st role of NT at this site, 
rodent NTS2 receptors were found to efficiently internalize via clathrin-coated pits 
upon NT binding both in stably transfected human embryonic kidney 293 cells 
(Botto et al., 1998) and in rat cerebellar granule cell cultures (Sarret et al., 2002). 
It is unclear whether the reported agonistic/antagonistic effects of NT on the 
human versus rodent NTS2 receptor are caused by species differences between the 
two receptors or by variations in receptor coupling as a result of the cell type in 
which the receptor is expressed. In view of the growing evidence for a role ofNTS2 
(Dubuc et al., 1999a and 1999b; Remaury et al., 2002; Yamauchi et al., 2003a), in 
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addition to that of NTSI (Tyler et al., 1999; Pettibone et al., 2002), in 
antinociception, and therefore of the possibility that NTS2 might represent a new 
target for the development of nonopioid analgesic drugs, the need for precise 
knowledge of the phannacological and signaling properties of this receptor seerns 
particularly critical. Thus, the aim of the present study was to characterize the 
phannacological and signaling properties of the rat NTS2 receptor expressed in 
stably transfected CHû cells and to compare these properties with those of the 
human NTS2 receptor expressed in the sarne cellline as well as with our own earlier 
data on the properties of the rat NTS2 receptor endogenously expressed in rat 
cerebellar granule cells. 
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4.3 MATERIALS AND METHODS 
4.3.1 Materials 
The chemicals used in the present study were obtained from the foIlowing sources: 
Dulbecco's modified Eagle's medium (DMEM) and F-12 medium, fetal bovine serum 
(FBS), glutamine, G-418, gentamicin, and LipofectAMINE were from Invitrogen 
(Carlsbad, CA); NT, monodansylcadaverine (MDC), phenylarsine oxide (PAO), 
sodium orthovanadate (Na3 V04), pertussis toxin (PTX), and staurosporine were from 
Sigma-Aldrich (St. Louis, MO); antiphosphorylated ERKI/2 and anti-ERK1I2 
antibodies were from New England Biolabs (Beverly, MA); horseradish peroxidase-
conjugated anti-rabbit antibodies and the enhanced chemiluminescence detection 
system were from Amersham Biosciences Inc. (Piscataway, NJ); Complete protease 
inhibitor and polyvinylidene ditluoride (PVDF) membranes were from Roche 
(Montreal, QC, Canada); NN was from Bachem California (Torrance, CA). 
Levocabastine and SR48692 were kindly provided by Janssen Pharmaceuticals 
(Antwerp, Belgium) and Sanofi Synthelabo (Toulouse, France), respectively. 
4.3.2 Transfection of CHO Cells 
CHOIKI ceIls were cultured in DMEMIF-12 medium mixture (1:1) supplemented 
with 10% FBS and 50 mgll gentamicin at 37°C in 75-cm2 Falcon tlasks in a 
humidified atmosphere of 95% air and 5% C02. For transfection, CHOIKI ceIls 
were grown to subcontluence (70-80%) in 24-weIl Petri dishes and incubated for 4 h 
at 37°C in transfection medium [mixture ofpTargeT-rNTS2 (1 ~g/ml) (Sarret et al., 
2003a) or pTargeT-hNTS2 and 40 ~g/ml LipofectAMINE in serum-free DMEM. 
Transfection medium was then replaced with DMEMIF-12 medium, and the ceIls 
were transferred 36 h later to a 75-cm2 tlask containing fresh medium supplemented 
with G-418 at a concentration of 800 ~g/ml. After 2 weeks of selection with G-418, a 
total of 23 and 12 individual clones were isolated for CHO/rNTS2 and CHOIhNTS2, 
respectively. Each clone was separately grown and tested for its capacity to 
intemalize Na-BODIPY-neurotensin-(2-13) (Fluo-NT) as described below. 
CHO/rNTS2 clone no. 16 and CHO/hNTS2 clone no. 1 were used for aIl 
experiments. 
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4.3.3 Reverse Transcription-Polymerase Chain Reaction Analysis 
Total RNAs (2 Jlg) were extracted from CHO/rNTS2 and CHOIKI cells using 
QIAGEN RNeasy Mini Spin columns (QIAGEN, Mississauga, ON, Canada) and 
submitted to reverse transcription (reverse transcription system kit; Promega, 
Madison, WI) for 1 h at 42°C. First-strand cDNAs were then subjected to 35 cycles 
of PCR in a final reaction volume of 50 JlI of the reaction buffer (50 mM KCI, 10 
mM Tris, pH 9.0, 1.5 mM MgCh, 0.1% Triton X-100, 0.02% BSA, 200 JlM dNTPs, 
and 0.5 units of Taq DNA polymerase) containing 100 ng of either one of the 
following three pairs of sense and antisense primers as described previously (Sarret et 
al., 2002). The first pair (5 '-ACACCCATTGTGGACACAGCC-3 , and 5'-
TTCATCCGAGATATAGCAGAA-3') provided for the amplification of a fragment 
of rNTSl receptor cDNA with a predicted size of 335 bp. The second pair (5'-
GAA TGTGCTGGTGTCCTTCGC-3' and 5'-ACTTGTA TTTCTCCCAGGCTG-3') 
provided for the amplification of a fragment of rNTS2 receptor cDNA with a 
predicted size of 620 bp. The third pair (5'-TCCCGAGAACTCTGGAAAGGT-3' 
and 5'-CACAGAGGCGAAGAGGAAACG-3') provided for the amplification of a 
fragment of rNTS3 receptor cDNA with a predicted size of 426 bp. Amplification 
was carried out with the first cycle at 95°C for 3 min, 54°C for 2 min, noc for 45 s, 
followed by 34 cycles at 95°C for 40 s,54°C for 35 s,72°C for 45 s, and a final 
extension step at 72°C for 5 min. PCR products were then analyzed on a 1.5% 
agarose gel. 
4.3.4 Binding 01125 [-NT to CHO/rNTS2 Cells 
For binding experiments, cells were grown on 24-well plates and incubated at 37°C 
in DMEMIF-12 medium 48 h before the assay. Cells were equilibrated for 10 min at 
37°C in Earle's buffer (130 mM NaCI, 5 mM KCI, 1.8 mM CaCh, 0.8 mM MgCh, 
and 20 mM HEPES, pH 7.4) supplemented with 0.2% BSA and 0.1% glucose. Cells 
were then incubated with 2.5 nM 125I_NT (100 Cilmmol) for 30 min at 37°C in 250 JlI 
of Earle's buffer containing 0.8 mM ortho-phenanthroline in the presence of 
increasing concentrations (from 10-11 _10-5 M) of nonradio-active NT, levocabastine, 
NN, or SR48692. Cells were then washed twice with Earle's buffer and harvested in 
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1 ml of 0.1 M NaOH, and the radioactivity content was measured in a y counter. IC50 
values were determined from competition curves as the concentration of unlabe1ed 
ligand necessary to inhibit 50% of 125I-NT -specific binding. 
4.3.5 lntracellular Calcium Measurements 
For intracellular calcium ([Ca2+]i) measurements, the CHO/rNTS2 and CHOlKl cells 
were cultured on 22-mm glass coverslips and incubated in serum-free DMEM 
supplemented with 4 !lM Fluo-4/acetoxymethyl ester (Molecular Probes, Eugene, 
OR) at 37°C for 30 min. Cells were then washed three times with 0.5% BSA and 
further incubated in PBS-HEPES (140 mM NaCI, 5.4 mM KCI, 2 mM CaC}z, 1 mM 
MgC}z . 6H20, and 10 mM HEPES, pH 7.35) at 37°C for 30 min to allow the 
acetoxymethyl ester form to be hydrolyzed. The coverslips were then mounted on 
the stage of a Nikon Eclipse TE300 inverted microscope (Nikon, Melville, NY), and 
the cells were maintained at 37°C throughout the experiments with a heating Peltier 
e1ement. NT, NN, levocabastine, or SR48692, diluted in fresh PBS-HEPES 
containing, for the solubilization of the latter two drugs, 0.01 % dimethylsulfoxide 
(DMSO), were added to the cells at a final concentration of 1 !lM, and images of 
fluorescence were acquired every 5 s using a CoolSnaprx charge-coupled device 
camera (Roper Scientific, Trenton, NJ) cooled at -35°C. Additional experiments were 
carried out using 0.01 % DMSO in PBS-HEPES alone to test for possible nonspecific 
effects of the solubilizing agent. Band-pass filters were used for excitation and 
emission (450-490 and 520-560 nm, respectively). Average fluorescence intensity 
for each cell was measured using MetaFluor software package (Universal Imaging 
Corporation, Downingtown, PA). Each Ca2+ curve in Fig 4.2 represents the average 
response of n cells. 
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4.3.6 Western Blotting Analyses of ERKI/2 Activity 
CHO/rNTS2, CHO/hNTS2, and CHO/K1 cells were grown for 3 days in DMEMIF-
12 medium containing 10% FBS, starved in serum-free DMEM for 1 h, and then 
stimulated for various time intervals (1-60 min) with NT (100 nM), levocabastine 
(100 nM or 1 J.lM), NN (100 nM), or SR48692 (100 nM) at 37°C in serum-free 
medium. In sorne experiments, cells were preincubated with PAO or MDC (two 
endocytosis inhibitors) for 30 min or with PTX (Gj protein inhibitor) for 18 h (100 
ng/ml) before stimulation with NT or NT analogs. The reaction was stopped by 
aspiration of the medium and the addition of ice-cold Hanks' balanced salt solution 
containing 0.1 J.lM staurosporine and 1 mM sodium orthovanadate. Cells were then 
left for 30 min at 4°C and lysed in 50 mM HEPES, pH 7.8, containing 1 % Triton X-
100, 0.1 J.lM staurosporine, 1 mM sodium orthovanadate, and Complete protease 
inhibitor. The cell lysates were centrifuged at 8000g for 15 min at 4°C, and the 
supernatants were stored at -20°C until use. For each lysate, equal amounts of 
proteins (25 J.lg) were separated on 10% SDS-polyacrylamide gels and 
e1ectrotransferred on PVDF membranes as described previously (Gendron et al., 
2003). PVDF membranes containing proteins were incubated for 2 h at room 
temperature with anti-phosphorylated ERK.1I2 (1:1000) or anti-ERK.1I2 (1:1000) 
rabbit antibodies, followed by three washes with Tris-buffered salinelTween 20. 
Detection of immunoreactive proteins was accompli shed using horseradish 
peroxidase-conjugated anti-rabbit (1 :2000) and an enhanced chemiluminescence 
detection system. 
To quanti:fy the effect of NT and NT analogs on ERK.ll2 phosphorylation, the 
ratios of phosphorylated ERK.1I2 over total ERK.1I2 leve1s were determined by 
densitometry, using Scion Image (Scion Corporation, Frederick, MD). The statistical 
significance of the activation of ERK.1I2 in stimulated versus nonstimulated cells was 
verified using ANOV A, and the p values were obtained from Dunnett's tables. 
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4.3.7 Binding of Fluo-NT to CHO/rNTS2 Cells 
CHO/rNTS2 cens were grown for 2 days on 12-mm poly-L-Iysine-coated glass 
coverslips in DMEMIF-12 medium containing 10% FBS and stimulated for 30 min at 
37°C with 50 nM Fluo-NT in serum-free DMEM containing 0.8 mM ortho-
phenanthroline alone or in the presence of levocabastine (10 J.1M) or phenylarsine 
oxide (endocytosis inhibitor) (10 J.1M). At the end of the incubation, cens were 
washed twice with ice-cold PBS, air-dried, mounted on glass slides with Aquamount 
(Polysciences, Warrington, PA) and examined using the Zeiss LSM510 confocal 
laser-scanning microscope (Carl Zeiss Canada Ud., Toronto, ON, Canada) equipped 
with a Zeiss inverted microscope and a heliumlneon laser (543 nm). 
4.3.8 Immunofluorescence Studies 
CHO/rNTS2 cens were grown on 12-mm glass coverslips for 3 days in DMEMIF-12 
medium containing 10% FBS and then starved in serum-free DMEM for 1 h. Cells 
pretreated or not with PAO (10 J.1M, 10 min at 37°C) were then treated or not with 
SR48692 (100 nM) for 5 min at 37°C in serum-free DMEM. The reaction was 
stopped by aspiration of the medium and the addition of ice-cold Hanks' balanced salt 
solution containing 0.1 J.1M staurosporine, and 1 mM sodium orthovanadate. After 10 
min of incubation on ice, cens were fixed for 20 min with methanol at -20°C and 
rehydrated with Hanks' balanced salt solution for 30 min at room temperature. 
Phosphorylated ERK1I2 were labeled ovemight at 4°C using anti-phosphorylated 
ERK1I2 rabbit antibodies (1: 1 00) and revealed using goat anti-rabbit Alexa488- or 
Alexa594-conjugated secondary antibodies (Molecular Probes; diluted 1 :500 in 
Hanks' balanced salt solution) for 60 min at room temperature. After washing, 
coverslips were mounted on glass slides using Aquamount and examined using the 
Zeiss LSM510 confocal laser-scanning microscope equipped with a Zeiss inverted 
microscope, an argon laser (488 nm), and a heliumlneon laser (543 nm). Images were 
an taken using the same acquisition settings. 
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To determine whether ligand-induced receptor intemalization was necessary for 
NTS2-induced ERKI/2 phosphorylation, the above immunofluorescence assay was 
repeated on CHO/rNTS2 cells preincubated for 10 min with PAO (10 JlM) as well as 
on CHO/rNTS2 cells cotransfected with pcDNAI-DynK44A (kindly provided by 
Dr. Stephen S. Ferguson, Carleton University, Ontario, QC, Canada) and pEGFP-NI 
(BD Biosciences, Mississauga, ON, Canada). For this purpose, pcDNAI-DynK44A 
(1 Jlglml) and pEGFP-NI (0.1 Jlglml) plasmids were mixed with 40 Jlglml 
LipofectAMINE, and the mixture was kept at room temperature for 30 min before 
being added to the culture medium. CHO/rNTS2 cells grown to 25 to 30% 
subconfluence on 12-mm poly-L-Iysine-coated glass coverslips were then 
transfected for 4 h at 37°C with this DNA-lipid complex. At the end of the 
incubation, transfection medium was replaced with fresh medium, and cells were 
processed 36 h later for immunolabeling of the phosphorylated ERKI/2 as described 
above. 
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4.4 RESULTS 
4.4.1 Expression and Binding Properties ofrNTS2 in CHO Cells 
Reverse transcription-polymerase chain reaction (RT-PCR) analysis of rat NTS1, 
NTS2, and NTS3 expression was perfonned on nontransfected CHO cells (CHOIK1) 
and on CHO cens transfected with rat NTS2 receptor cDNA (CHO/rNTS2). As 
shown in Fig. 4.1A, a 620-bp band corresponding to the size of the NTS2 receptor 
fragment was observed in CHO/rNTS2 cens but not in CHOIKI cens. In contrast, a 
425-bp product corresponding to the NTS3 receptor was detected in both transfected 
and nontransfected cells. The PCR product for the NTSI receptor (expected at 336 
bp) was observed in neither of these cenlines but was present in CHO/rNTSI cens 
used as positive controls (not shown). As illustrated in Fig. 4.1B, NT, levocabastine, 
NN, and SR48692 an inhibited competitive1y specific 12SI_NT binding with ICso 
values of3.5, 74, 21, and 31 nM, respectively. 
4.4.2 Lack of NTS2-1nduced Intracellular Ca2+ Mobilization 
The capacity of NT, levocabastine, NN, and SR48692 to induce Ca2+ mobilization 
was tested in CHO/rNTS2 cens using Fluo-4 as a fluorescent marker of [Ca2+]j. As 
seen in Fig. 4.2, NT, Levo, and NN were ineffective at modifying [Ca2+]j, even when 
applied at concentrations as high as 1 JlM (A, B, and C, respectively). By contrast, 
SR48692 (1 JlM) markedly increased [Ca2+]j. This effect was caused by the drug 
itself, because it was not observed after the application of the DMSO containing 
vehic1e alone. The SR48692-induced increase in [Ca2+]j was neither prevented nor 
modified by concomitant (not shown) or prior stimulation with NT, levocabastine, or 
NN (Fig. 4.2, A, B, and C), suggesting that it was not mediated by NTS2. Congruent 
with this interpretation, SR48692 produced a similar increase in [Ca2+]j in 
nontransfected CHOIKI cens (Fig. 4.2D). 
4.4.3 NTS2-Mediated ERK1/2 Phosphorylation 
To detennine whether heterologously expressed rNTS2 were functionany coupled to 
the ERKl/2 pathway, CHO/rNTS2 cens were stimulated with 100 nM NT for various 
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periods of time. Western blot analysis of phosphorylated ERKl/2 revealed that NT 
rapidlyenhanced the leve1 of phosphorylation of ERKI/2 (Fig. 4.3, A and B). This 
increase in ERKI/2 phosphorylation was already apparent after 1 min of stimulation, 
peaked at 10 min (2.89 ± 0.80-fold increase over control), and was sustained for at 
least 1 h. This effect was mediated by NTS2, because it was not observed in 
nontransfected cells (Fig. 4.3, B and C). As shown in Fig. 4.3D, the NT-induced 
ERKl/2 activation measured after 5 min of stimulation was dose-dependent and 
readily detectable at concentrations as low as 10-8 M (i.e., within the range of the ~ 
value of NT for the rNTS2 receptor). 
We then tested whether other documented NTS2 ligands similarly affected 
ERK1/2 phosphorylation. As shown in Fig. 4.4, A and B, levocabastine (100 nM) and 
NN (100 nM) both activated ERKl/2 to the same extent as NT (3.2 ± 0.8- and 2.2 ± 
0.9-fold increase over control, respectively). Furthermore, the NTS1 antagonist 
SR48692, which binds the NTS2 receptor with less affinity than NT (Fig. 4.1B), 
induced a phosphorylation of ERKl/2 that was considerably more robust than that 
produced by either of the other NTS2 agonists tested (15.4 ± 4.2-fold increase over 
control). This effect of SR48692 was unaffected by the addition of 100 nM NT in the 
incubation medium (Fig. 4.4, A and B), suggesting that the two drugs interacted with 
different sites. Yet the effects ofSR48692, as well as those oflevocabastine and NN, 
were mediated by NTS2, because none ofthese ligands was able to activate ERKl/2 
in nontransfected, CHOIK1 cells (Fig. 4.4C). These effects were also independent 
from Gi, because they were unaffected by an overnight preincubation of CHO/rNTS2 
cells with PTX (not shown). 
To determine whether the NTS2-mediated effects of NT and NT analogs on 
ERKl/2 activation were species-specific, Western blot analyses of ERKl/2 
phosphorylation were repeated on CHO cells transfected with cDNA encoding the 
human NTS2 receptor (CHO/hNTS2). As shown in Fig. 4.5, A and C, stimulation of 
CHOlhNTS2 with 10-7 M NT for 3 to 60 min resulted in a significant increase in 
ERKI/2 phosphorylation. As in CHO/rNTS2 cells, this effect peaked at 10 min but 
was somewhat less sustained in that phosphorylation levels returned to base1ine by 1 
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h (Fig. 4.5A). Stimulation of CHOlhNTS2 cells for 5 min with 10-6 M levocabastine 
or 10-7 M SR48692 also induced a robust activation ofERK112 phosphorylation (Fig. 
4.5, B and C). As in CHO/rNTS2 cells, the effects of SR48692 were significantly 
greater than those of NT (3.07 ± 0.57-versus 1.79 ± 0.31-fold increase over control; 
Fig.4.5C). 
4.4.4 Internalization Dependence of the NTS2-Induced ERK1/2 Activation 
To determine whether heterologously expressed NTS2 internalized upon agoni st 
binding, CHO/rNTS2 and CHOIKI cells were incubated with 50 nM Fluo-NT for 30 
min at 37°C and examined by confocal microscopy. In CHO/rNTS2 cells, Fluo-NT 
pervaded the cytoplasm in the form of small, endosome-like fluorescent clusters (Fig. 
4.6A). By contrast, Fluo-NT labeling was confined to the cell surface after 
pretreatment with the endocytosis inhibitor PAO (10 !lM, 10 min) (Fig. 4.6B). Fluo-
NT intemalization was NTS2-specific, because nontransfected CHOIKI cells (not 
shown) and cells coincubated with Fluo-NT and an excess of levocabastine (Fig. 
4.6C) were entirely fluorescent-negative. 
To determine whether ligand-induced NTS2 receptor internalization was 
necessary for ERKl/2 activation, CHO/rNTS2 cells were pretreated or not with PAO 
(10 !lM) or MDC (400 !lM) and stimulated for 5 min with 100 nM NT, 
levocabastine, or SR48692. PAO and MDC both completely inhibited the effect of 
stimulation by either ligand on ERKl/2 phosphorylation, as measured by Western 
blotting (Fig. 4.7A). 
The effect of stimulation with SR48692 on ERK1I2 activation was also verified 
by immunofluorescence in CHO/rNTS2 cells, using antibodies against 
phosphorylated ERK1I2. As ooposed to nonstimulated cells, which were 
immunonegative (Figs. 4.6D,G, and 4.7B), cells stimulated for 5 min with SR48692 
(100 nM) exhibited intense phosphorylated ERKl/2 immunoreactivity, mainly 
within their nucleus (Fig. 4.7B, arrowheads). This induction of phosphorylated 
ERKl/2 immunoreactivity was totally prevented by preincubating the cells with 
PAO (Fig. 4.7B). 
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To further confinn that the NTS2-induced ERKI/2 activation was dependent on 
ligand-induced intemalization, CHO/rNTS2 cens were transiently transfected with a 
dominant-negative mutant of dynamin 1, DynK44A, together with the fluorescent 
protein EGFP (with a ratio of 10:1), to distinguish DynK44A-expressing from -
nonexpressing cens. Stimulation of these duany transfected cens with 100 nM 
SR48692 increased phosphorylated ERKI/2 immunofluorescence in approximately 
40% of the cens (Fig. 4.6, E and H), whereas 100% of the cens expressing only the 
rNTS2 receptor were activated after stimulation with SR48692 (Fig. 4.7B). This 
decrease was caused by the overexpression of the dynamin 1 dominant-negative 
mutant, because none of the cens confinned to overexpress DynK44A, by virtue of 
their co-expression of EGFP, showed phosphorylated ERK1I2 immunofluorescence 
(Fig. 4.6, F and l, arrows). 
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4.5 DISCUSSION 
The present study demonstrates that neurotensin activates the mitogen-activated 
protein kinase cascade through its interaction with either rat or human NTS2 
receptors in transfected CHû cells. It also suggests that ligand-induced 
intemalization of this receptor is required for NTS2-mediated signaling. 
We previously demonstrated that stimulation of rat cerebellar granule cells, 
which endogenously express the NTS2 receptor, with either NT or levocabastine 
resulted in ERKI/2 activation (Sarret et al., 2002). These results differed from those 
obtained by other groups that had reported antagonistic or inverse agonistic effects 
of these two drugs on the human NTS2 receptor heterologously expressed in CÛS 
(Richard et al., 2001b) and CHû cells (Vita et al., 1998), respective1y. A tirst 
objective of the present study was therefore to determine whether these discrepancies 
were caused by species differences or by endogenous versus heterologous expression 
of the NTS2 receptor. For this purpose, we tirst established a stable cellline ofCHû 
cells expressing the rat NTS2 receptor (CHû/rNTS2 cells). RT-PCR analysis 
contirmed that these cells did express the NTS2 receptor, to the exclusion of the 
NTSI. 125I-NT was accordingly found to bind to these cells with a pharmacology 
characteristic of that of NTS2, both in terms of aftinity for NT and of relative 
affinity for the NT analogs levocabastine, NN, and SR48692 (Chalon et al., 1996; 
Mazella et al., 1996; Botto et al., 1998; Vita et al., 1998; Sarret et al., 2002). 
We then tested the effects of NT and ofvarious NT analogs on the mobilization 
of [Ca2+]j in these transfected cells. As previously reported for cortical cerebellar 
neurons endogenously expressing the rat NTS2 receptor (Sarret et al., 2002), or for 
transfected CHû cells expressing the human NTS2 receptor (Vita et al., 1998), 
neither NT, levocabastine, nor NN affected Ca2+ mobilization in CHû/rNTS2 cells. 
By contrast, incubation with the NTSI antagonist SR48692 caused a marked 
elevation of intracellular calcium in the same cells. This increase conformed to 
earlier reports of SR48692-induced Ca2+ mobilization in CHû cells transfected with 
either human (Vita et al., 1998) or rat (Yamada et al., 1998) NTS2 receptors. 
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However, whereas in these previous studies the effects of SR48692 were antagonized 
by concomitant administration of an excess of NT, NN, or levocabastine and could 
not be elicited in nontransfected cells, in the present study, the effects of SR48692 
were not blocked by NT, NN, or levocabastine and were equally strong in 
nontransfected cells, suggesting that they were not mediated by NTS2. Likewise, in 
rat cerebellar granule cells, SR48692 induced a robust [Ca2+]j increase that was 
unaffected by concomitant application of NT or levocabastine and was therefore 
interpreted as being NTS2-independent (Sarret et al., 2002). 
We then sought to determine whether NT activated ERK1I2 in transfected 
CHO/rNTS2 cells as in rat cerebellar granule cells (Sarret et al., 2002). Application 
of 100 nM NT to CHO/rNTS2 cells induced a robust, dose-dependent increase in 
ERK1I2 phosphorylation. This activation was rapid and sustained over 60 min. It 
also was mediated by NTS2, because it could not be elicited in nontransfected cells. 
The similarity of these findings with those obtained in neurons in culture (Sarret et 
al., 2002) suggests that the observed activation is physiological and not caused by 
artifactitious coupling of the receptor subsequent to its aberrant expression in CHO 
cells. 
Levels of ERK1I2 activation comparable with those obtained after stimulation 
with NT were achieved by incubating CHO/rNTS2 cells with either NN or 
levocabastine. That these two drugs would display effects comparable with those of 
NT is congruent with results in X. laevis oocytes, which showed that NT, NN, and 
levocabastine all stimulated to the same extent an NTS2-mediated Ca2+ -activated 
inward cr CUITent (Mazella et al., 1996; Botto et al., 1997c; Dubuc et al., 1999b). 
However, the present results differ from those of Vita et al. (1998), who found no 
effect of NT, NN, or levocabastine on ERK1I2 activation in CHO cells transfected 
with the human NTS2 receptor. To determine whether this discrepancy was related 
to species differences, we repeated the experiments in CHO cells transfected with 
hNTS2 in lieu of rNTS2. Our results showed the same NTS2-mediated activation of 
ERK1I2 phosphorylation in cells transfected with the human plasmid as in cells 
transfected with the rNTS2, suggesting that the differences between the present and 
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earlier results are not the result of differences between rat and human NTS2 but 
rather of variations in the sensitivity of the methods employed for the detection of 
ERK1I2 phosphorylation. 
Stimulation with the NTS 1 antagonist SR48692 also resulted in a marked 
increase in ERK1I2 activation in both CHO/rNTS2 and CHOlhNTS2 cens. Unlike 
the effects of SR48692 on Ca2+ mobilization, these effects were mediated by NTS2, 
because they were not observed in nontransfected CHO cens. Previous studies have 
reported on the agonistic properties of SR48692 on both rodent (Botto et al., 1997c; 
Yamada et al., 1998) and human (Vita et al., 1998) NTS2. Surprising here was the 
fact that, although SR48692 displayed a much lower affinity than NT, NN, or 
levocabastine for the NTS2 receptor (present study; Guny et al., 1993; Mazena et al., 
1996; Botto et al., 1998; Vita et al., 1998; Yamada et al., 1998; Noue1 et al., 1999; 
Richard et al., 2001b; Sarret et al., 2002), it induced ERK1I2 phosphorylation much 
more efficiently (~7 -fold more efficient than NT in cens transfected with the rat 
receptor). To determine whether this discrepancy could be explained by the binding 
of SR48692 to a site distinct from the target of NT or its analogs, we repeated the 
SR48692 stimulation experiments in the presence of 100 nM NT. Despite its higher 
affinity for the receptor, NT had no competitive inhibiting effect on the SR48692-
induced ERKI/2 activation, suggesting that the two drugs interact with different 
binding pockets as they do on the NTSI receptor (Labbé-Jullié et al., 1995; Barroso 
et al., 2000). 
Immunofluorescent studies confirmed that stimulation of CHO/rNTS2 cens with 
SR48692 produced a robust increase in phosphorylated ERK1I2 levels. 
Furthermore, they demonstrated that this increase mainly occurred in the nucleus, 
suggesting that sorne of the targets of activated ERKI/2 may be transcription factors 
such as Elk-l, Ets, StatI/3, or c-Myc/N-Myc and, by extension, that the activation of 
the NTS2 receptor results in the modulation of gene expression. 
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It was recently shown that in COS-7 cells transfected with the human NTS2 
receptor, the receptor was constitutively active and that NT and levocabastine 
behave as a neutral antagonist and inverse agonist, respectively, on the production of 
inositol phosphate (Richard et al., 2001b). By contrast, the present NT- or 
levocabastine-induced effects on ERK1I2 phosphorylation are unlikely to be caused 
by neutral antagonistic or inverse agonistic properties of the drugs, because there 
was no evidence of constitutive NTS2 receptor activity in our system. Indeed, no 
difference was observed between the basal phosphorylation level of ERK1I2 in 
CHO/rNTS2 and in nontransfected CHO cells. Furthermore, had NT or 
levocabastine acted as inverse agonists, they should not, as they did, have increased 
phosphorylation of ERK1I2 to leve1s higher than those measured in nontransfected 
cells. 
As previously demonstrated for mouse and human NTS2 receptors in 
transfected cells (Botto et al., 1998; Martin et al., 2002b) and for rat NTS2 receptors 
in cerebellar granule cells (Sarret et al., 2002), stimulation of rat NTS2 receptors 
heterologously expressed in CHO cells resulted in a ligand-induced internalization of 
receptor-ligand complexes. This effect was inhibited by the endocytosis inhibitor 
phenylarsine oxide, suggesting that it was mediated by c1athrin, as documented for 
most G protein-coupled receptors (Kranenburg et al., 1999; Pierce et al., 2000; 
Miller and Lefkowitz, 2001; Claing et al., 2002). That a fluorescent analog of NT 
was able to induce NTS2 internalization is consistent with its agonistic role at the 
NTS2 receptor. 
It is now well documented that seven transmembrane domainiG protein-coupled 
receptors may activate ERK1I2 via G protein-independent mechanisms, involving 
interaction of the receptor with endocytic proteins such as dynamin (Kranenburg et 
al., 1999; Pierce et al., 2000) and -arrestins (Miller and Lefkowitz, 2001; Claing et 
al., 2002). In the present study, we found that blocking receptor intemalization with 
phenylarsine oxide or monodansylcadaverine complete1y impaired the ability of NT, 
as well as of all other NTS2 agonists tested, to activate ERK1I2 in CHO/rNTS2 cells. 
Furthennore, overexpression of DynK44A, a dominant-negative mutant fonn of 
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dynamin 1, was found to selectively inhibit SR48692-induced ERK.1I2 activation in 
cells dually expressing the NTS2 and the dominant-negative mutant. These results 
strongly suggest that the activation of the mitogen-activated protein kinase pathway 
(involving either NTS2 itself or other cell surface receptors) is predicated on the 
internalization of receptor-ligand complexes via a dynamin-dependent and Gi protein-
independent mechanism. 
In conclusion, the present results reveal that NT, as well as many of the known 
NTS2 receptor ligands, act as agonists at this site, at least as pertains to the promotion 
of ERK.1I2 phosphorylation. This finding is important in that it lends further support 
to the premise that NT is an endogenous ligand at this receptor. It also suggests that 
NTS2-acting NT analogs may constitute a promising new class of nonopioid 
analgesic drugs, provided that these drugs do not, as does SR48692, exert other 
actions (e.g., NTS 1 antagonism and NTS2-independent induction of Ca2+ 
mobilization). Indeed, recent studies have demonstrated that NT, but not SR48692 
(Dubuc et al., 1994), induces antinociceptive effects in the mouse through interaction 
with NTS2 as well as with NTS 1 receptors (Dubuc et al., 1999b; Tyler et al., 1999; 
Pettibone et al., 2002; Yamauchi et al., 2003a). An intriguing observation is that the 
sustained, NTS2-mediated activation of ERK.l/2 documented here seems to be 
exerted to the exclusion of other signaling systems. Thus, stimulation of NTS2 does 
not seem to induce Ca2+ mobilization (present study; Sarret et al., 2002) or cAMP or 
cGMP production (Chalon et al., 1996; Botto et al., 1998). Further studies will 
obviously be needed to determine how diverse NTS2-mediated signaIs truly are and 
whether sorne account, in contrast to those reported here, for short-term NT 
signaling. 
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4.8 ABBREVIATIONS 
NT, neurotensin; ERK 1/2 , extracellular signal-regulated kinases 1/2; SR48692, 2-
([ 1-( -7 -chloroquinolin-4-yl)-5-(2,6-dimethoxy-phenyl)-IH-pyrazole-3-carbonyl] ami-
no }adamantane-2-carboxylic acid; Levo, levocabastine; CHO, Chinese hamster 
ovary; COS, Cercopithecus aethiops; NN, neuromedin N; DMEM, Dulbecco's 
modified Eagle's medium; FBS, fetal bovine serum; G-418, geneticin; MDC, 
monodansylcadaverine; PAO, phenylarsine oxide; PTX, pertussis toxin; PVDF, 
polyvinylidene difluoride; Fluo-NT, Na-BODIPY-neurotensin-(2-13); PCR, 
polymerase chain reaction; BSA, bovine serum albumin; bp, base pair(s); PBS, 
phosphate-buffered saline; DMSO, dimethyl sulfoxide; ANOV A, analysis of 
variance; RT-PCR, reverse transcription-polymerase chain reaction; EGFP, enhanced 
green fluorescent protein. 
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4.10 FIGURE LEGENDS 
Fig.4.1: Expression and Binding Properties of the rNTS2 Receptor Transfected 
in CHO Cells. A, RT-PCR analysis of nontransfected CHO cens (CHOIKI) and 
CHO cens transfected with the rat NTS2 receptor cDNA (CHO/rNTS2). In CHOIKI 
cens, a single band of the size expected for the NTS3 receptor fragment (425 bp) is 
visible. By contrast, in CHO/rNTS2 cens, a band the size of the rNTS2 receptor 
fragment (620 bp) is amplified in addition to rNTS3. Neither cen type expressed the 
rNTSI receptor (expected size of the rNTSI receptor fragment is 336 bp). B, 
competition inhibition of l25I-NT (2 nM) binding to CHO/rNTS2 cens by neurotensin 
(e), levocabastine (0), neuromedin N (V), or SR48692 (T). Each point is the mean 
oftwo separate experiments performed in triplicate (mean ± S.D.). 
Fig. 4.2: Intracellular Ca2+ Mobilization in Fluo-4-1oaded CHO Cells. A-C, 
application of 1 ~M SR48692 to CHO/rNTS2 cens induces an increase, fonowed by 
a plateau, in intracenular Ca2+. By contrast, no increase in intracellular Ca2+ is 
observed after 1 ~M NT, 1 ~M Levo, or 1 ~M NN, nor are any of these drugs able to 
prevent the Ca2+ mobilization effect of SR48692. D, same type of SR48692-induced 
response observed in CHOIKI cens (nontransfected cens). The curves represent the 
means of n responding cens and five experiments. 
Fig. 4.3: NT Activation of ERKI/2 in rNTS2-transfected CHO Cells. 
CHO/rNTS2 (A, B, and D) and CHOIKI (C) cens were stimulated with various 
concentrations of NT (D) for 0 to 60 min (A-C), and ERK1I2 phosphorylation leve1s 
were determined as described under Materials and Methods. A, C, and D, top, 
phosphorylated ERK1I2; bottom, total ERK1I2. A, stimulation of CHO/rNTS2 cens 
with 100 nM NT induces a rapid and sustained activation of ERK1I2. B, 
densitometric measurements of ERKII2 activation (phosphorylated ERK1I2 over 
total ERK1I2) expressed as -fold increase over control ± S.E.M. (e, CHOIKI, n = 3; 
_, CHO/rNTS2, n = 4) (ANOVA and Dunnett's). *,p < 0.05; **,p < 0.02; and ***, 
p < 0.01 compared with control, untreated cens. C, stimulation of wild-type, 
nontransfected CHO cens with 100 nM NT has no effect on ERK1I2 
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phosphorylation. D, dose-dependent activation ofERK1I2 after application of 10-9 to 
10-6 M NT for 5 min (representative oftwo independent experiments). 
Fig. 4.4: Effect of NT, Levocabastine, Neuromedin N, and SR48692 on ERK1I2 
Phosphorylation in CHO/rNTS2. CHO/rNTS2 (A and B) and CHOIK1 (C) ce11s 
were treated or not for 5 min with a battery of NTS2 agonists and harvested for the 
detennination of ERK1I2 phosphorylation levels as described under Materials and 
Methods. NT (100 nM), Levo (100 nM), NN (100 nM), and SR48692 (100 nM) a11 
induce ERK1/2 phosphorylation in CHO/rNTS2 ce11s (A) but not in CHOIK1 ce11s 
(C). Note that ERK1I2 phosphorylation levels are markedly higher in ce11s 
stimulated with SR48692 than with other drugs, an effect that is not modified by 
coincubation with NT (100 nM). B, densitometric measurements of ERK1I2 
activation (phosphorylated ERK1/2 over total ERK1I2) expressed as -fold increase 
over control ± S.E.M. (n = 3) (ANOVA and Dunnett's). *, p < 0.1 and **, p < 0.05 
compared with control, untreated ce11s. 
Fig. 4.5: Effect of NT, Levocabastine, and SR48692 on ERKI/2 Phosphorylation 
in CHO/hNTS2 cells. CHO/hNTS2 ce11s were treated or not for 0 to 60 min with 
100 nM NT (A) or for 5 min with a battery of NTS2 agonists (B) and harvested for 
the determination of ERK1I2 phosphorylation levels as described under Materials 
and Methods. C, densitometric measurements of ERK1I2 activation expressed as -
fold increase over control ± S.E.M. (n = 5-7) (ANOV A and Dunnett's). *, p < 0.001 
compared with control, untreated ce11s. NT (100 nM), Levo (1 J.1M), and SR48692 
(100 nM) a11 induce ERK1I2 phosphorylation in CHOlhNTS2 ce11s. 
Fig. 4.6: Role of NTS2 Receptor Internalization in Ligand-induced ERKI/2 
Activation. A-C, CHO/rNTS2 ce11s incubated with 50 nM Fluo-NT for 30 min at 
37°C and examined by confocal microscopy. A, punctate Fluo-NT labeling is 
evident throughout the cytoplasm of CHO/rNTS2 ce11s; B, Fluo-NT labeling is 
confined to the periphery of the ce11s in CHO/rNTS2 ce11s preincubated with the 
endocytosis inhibitor PAO (10 J.1M); C, Fluo-NT labeling is specific and receptor-
mediated, because the labeling is completely abolished by an excess of levocabastine 
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(l0 /lM). Images were acquired using the same parameters and represent three 
different experiments. D-I, CHO/rNTS2 cens transfected with a 10: 1 ratio of 
dynamin 1 (DynK44A) and pEGFP and processed for immunofluorescence detection 
of phosphorylated ERKl/2. Because of the transfection ratio, most of the EGFP-
positive cens (green) can be assumed to express DynK44A. D and G, basalleve1 of 
phosphorylated ERKl/2 immunoreactivity in nontreated cens. E-H, phosphorylated 
ERKl/2-immunoreactive signal is evident within the nucleus of a subpopulation of 
NTS2-expressing cens after 5-min exposure to 100 nM SR48692. F and 1, in merged 
images ofphosphorylated ERKl/2- and EGFP-labe1ed fields, an EGFP-positive (e.g., 
DynK44A-expressing) cens (white arrows) are phosphorylated ERK1/2-
immunonegative, indicating that internalization blockade prevents ERKl/2 activation 
(representative ofthree different experiments). 
Fig. 4.7: Inhibitors of Internalization Block NT-Induced ERK Activation. A 
(Western Blot analysis), 30-min preincubation with PAO (10 /lM) or MDC (400 
/lM), two endocytosis inhibitors, prevents NT -, Levo-, and SR48692-induced 
ERKl/2 phosphorylation (5 min of stimulation) in CHO/rNTS2 cens. Immunoblots 
represent three different experiments. B (immunofluorescence labe1ing), 30-min 
preincubation with PAO (l0 /lM) prevents immunofluorescence labeling of 
phosphorylated ERKl/2 in rNTS2-transfected CHO cens treated (l00 nM SR48692) 
for 5 min. Note that ERKl/2 phosphorylation is evident in all cens and that 
phosphorylated ERKl/2 preferentiany accumulates into the nucleus (arrowheads). 
An images were acquired using the same parameters and represent two different 
experiments. 
153 
Chapter 5: NTS2 Receptor Splice Variant 
CHAPTER5 
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF THE 
5-TRANSMEMBRANE DOMAIN VARIANT ISOFORM OF 
THE NTS2 NEUROTENSIN RECEPTOR IN 
RAT CENTRAL NERVOUS SYSTEM 
Amélie Perron, Philippe Sarret', Louis Gendron, Thomas Stroh, 
and Alain Beaudet 
Montreal Neurological Institute, Department ofNeurology and Neurosurgery, 
McGill University, Montreal, Québec, Canada 
'Present Address: Department ofPhysiology and Biophysics, Faculty of Medicine, 
Sherbrooke, Québec, Canada 
Journal ofBiological Chemistry (2005) 280: 10219-10227. 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology. 
154 
Chapter 5: NTS2 Receptor Splice Variant 
5.1 ABSTRACT 
The present study demonstrated that alternative splicing of the rat nts2 receptor gene 
generates a 5-transmembrane domain variant isoform (vNTS2) that is co-expressed 
with the full-Iength NTS2 receptor throughout the brain and spinal cord, as evidenced 
by reverse transcription-PCR. The vNTS2 polypeptide is 281 amino acids in length, 
which is 135 amino acids shorter than the full-Iength isoform. Immunohistochemical 
and radio ligand binding studies revealed that the HA-tagged recombinant vNTS2 
receptor is poorly targeted to plasma membranes in transfected COS-7 cells. Binding 
studies also showed that the truncated receptor displayed a 5000-fold lower affinity 
for neurotensin (NT) than its full-Iength counterpart (lCso of 10 J.1M and 2 nM, 
respectively). Yet NT binding induced efficient internalization of receptor-ligand 
complexes in vNTS2-transfected cells. Furthermore, it produced a rapid «5 min) 
activation of the mitogen-activated protein kinases (ERKI/2) pathway, indicating 
functional coupling of the variant receptor. This activation is sustained (> 1 h) and is 
also produced by the NTS2 agoni st levocabastine. Western blotting experiments 
suggested that vNTS2 is not expressed in monomeric form in the rat central nervous 
system. However, it does appear to form a variety of multimeric complexes, 
including homodimers and heterodimers, with the full-Iength NTS2. Indeed, co-
immunoprecipitation studies in dually transfected cells demonstrated that the two 
receptor isoforms can form stable associations. Taken together, the present results 
indicated that the rat vNTS2 is a functional receptor that may play a role in NT 
signaling in mammalian central nervous system. 
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5.2 INTRODUCTION 
The tridecapeptide neurotensin (NT) produces a wide array of biological responses 
when administered peripherally or in the central nervous system (CNS). NT effects 
inc1ude analgesia (Nemeroff et al., 1979; Kalivas et al., 1982a), hypothermia (Martin 
et al., 1980), antipsychosis (Kinkead and Nemeroff, 1994), catalepsy (Snijders et al., 
1982), and change in blood pressure (Rioux et al., 1981). NT is also known for its 
regulatory role on midbrain dopaminergic and basal forebrain cholinergic neurons 
(St-Gelais et al., 2004; Cape et al., 2000), and cumulative evidence has implicated the 
NT system in the pathophysiology of schizophrenia (Binder et al., 2001 a). 
NT signaling is mediated by interaction of the peptide with either one of three 
different receptor subtypes, referred to as NTS1, NTS2, and NTS3. NTSI and NTS2 
belong to the family of seven transmembrane-spanning, G protein-coupled receptors 
(GPCRs) and exhibit high and low affinity for NT, respectively (Tanaka et al., 1990; 
Chalon et al., 1996). The NTS3 receptor is a single transmembrane domain sorting 
receptor with 100% homology to gp95/sortilin (Petersen et al., 1997, Mazella et al., 
1998). NTS 1 is predominantly coupled to Gq/ll (Hermans et al., 1998; Vincent et al., 
1999) and activates phospholipase C (Hermans et al., 1992; Chabry et al., 1994). 
Pharmacological and biochemical studies have indicated that NTS 1 is also involved 
in the modulation of intracellular levels of cGMP (Amar et al., 1985), cAMP (Bozou 
et al., 1989a; Yamada et al., 1993), inositol phosphates (Watson et al., 1992; Bozou 
et al., 1989b), and extracellular signal-regulated kinases (ERK1I2) (Poinot-Chazel et 
al., 1996). Much less is known about the signaling pathways of NTS2. Stimulation 
of NTS2 was found to induce Ca2+ -dependent chloride currents in Xenopus oocytes 
expressing the mouse receptor (Botto et al., 1997c). More recent studies have shown 
that stimulation of NTS2 with either NT or the selective NTS2 ligand, levocabastine, 
activates the ERK1I2 cascade both in CHû cells stably transfected with cDNA 
encoding rat or human NTS2 (Gendron et al., 2004) or in cultured rat cerebellar 
granule cells (Sarret et al., 2002). 
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The cDNA sequence of the mouse NTS2 receptor is composed of four exons 
separated by three introns (Sun et al., 2001). The first exon encodes the region 
containing TM domains 1-4, whereas exons 2-4 encode the region containing TM 5-
6, TM 6, and TM 7, respective1y. The existence of a de1etion-type NTS2 mRNA 
encoding a C-terminally truncated form of the receptor, which 1acks an internaI 181-
bp sequence, has been reported in the mouse (Botto et al., 1997b). Both mouse NTS2 
rnRNA isoforms are derived from a single nts2 gene, the short form resu1ting from 
alternative sp1icing of the primary NTS2 transcript at intron 2a (Sun et al., 2001). 
The corresponding truncated NTS2 rnRNA encodes a 282-amino acid protein (Botto 
et al., 1997b). 
Other GPCRs encoding sequences have been shown to similarly generate 
truncated receptor isoforms through alternative splicing, exon skipping, or intron 
retention (Kilpatrick et al., 1999). Many of these splice variants, such as the 
truncated forms of the prostanoid receptor EP3 and endothelin B receptor (Namba et 
al., 1993; Nambi et al., 2000), differ from their full-length counterparts in their 
intracellular C-terminal tail. Others show a disparity in the third intracellular loop 
(e.g. the D2 dopamine receptor variant (Monsma et al., 1989» or in the 
transmembrane (TM) domains (e.g. the D3nf dopamine receptor isoform (Schmauss 
et al., 1993». Yet others differ from the full-length receptor in their extracellular N-
terminal loop as exemplified by the truncated form of the angiotensin II receptor 
(Nishimatsu et al., 1994). 
Splice variations may have little or no effect on ligand binding properties 
(Minneman, 2001). However, sorne de1etions, particularly in TM domains, were 
shown to have significant impact on ligand recognition. For example, a short variant 
of the 5-hydroxytryptamine 2C receptor lacking TM domains 6 and 7 was reported to 
be totally devoid of serotonergic binding activity (Canton et al., 1996). Similar 
findings were also found for the truncated endothelin A (Zhang et al., 1998) and D3nf 
dopamine (Schmauss et al., 1993) isoforms. Shortened receptor isoforms may also 
display aberrant or impaired coupling, even in the face of normal ligand binding. For 
instance, the four alternative1y spliced isoforms of the EP3 receptor, which vary only 
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in their C-terminal tails, couple to different G proteins and activate diverse second 
mess enger systems (Namba et al., 1993). 
The generation of alternatively spliced GPCRs may also affect the function of 
their full-Iength counterparts. Thus, co-expression of the full-Iength gonadotropin-
releasing hormone receptor together with that of its C-terminally truncated isoform, 
which is incapable of ligand binding and signal transduction, was found to impair 
targeting of the full-Iength receptor to the plasma membrane (Grosse et al., 1997). 
Finally, alternative splicing of GPCRs has been associated with a number of genetic 
disorders (Grabowski and Black, 2001). For instance, splice variants of the growth 
hormone-releasing hormone receptors have been documented in primary human 
prostate carcinomas and diverse human cancer celllines (Rekasi et al., 2000). 
This study was initiated to determine whether the splice variant form of the 
NTS2 receptor originally identified in mouse brain extracts was also expressed in rat 
brain and to investigate the binding, internalization, and signaling properties of this 
receptor isoform, as compared with those of the full-Iength NTS2 receptor, in 
mammalian cells. Our results demonstrate the existence of a functional 5-TM 
domain variant form of NTS2 (vNTS2) in rat brain and suggest that this truncated 
receptor may play a role in the modulation of NT effects in the CNS. 
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5.3 EXPERIMENTAL PROCEDURES 
5.3.1 Expression of Rat vNTS2 mRNA 
In order to assess the expression of vNTS2 mRNA in rat CNS and spinal cord, adult 
male Sprague-Dawley rats (200--250 g; Charles River Breeding Laboratories, St-
Constant, Québec, Canada) were killed by decapitation. The brain and spinal cord 
were rapidly removed, and the areas of interest were dissected on ice. Samples were 
solubilized in lysis buffer (4 M guanidinium thiocyanate, 0.01 M Tris-HCI, pH 7.5, 
0.97% p-mercaptoethanol), and total RNA was extracted using the SV RNA Isolation 
System kit (Promega, Madison, WI), according to the manufacturer's instructions. 
These total rnRNAs (2 Ilg) were then reverse-transcribed at 42°C for 1 h using the 
Reverse Transcription System kit (Promega, Madison, WI). First strand cDNAs were 
subjected to 35 cycles of PCR in a final reaction volume of 50 III of reaction buffer 
(50 mM KCI, 10 mM Tris-HCl, pH 9.0, 1.5 mM MgCh, 0.1% Triton X-100, 0.02% 
bovine serum albumin (BSA), 200 IlM dNTPs, 0.5 unit of Taq DNA polymerase) 
using a set of primers (5'-GAATGTGCTGGTGTCCTTCGC-3' and 5 '-ACT-
TGTATTTCTCCCAGGCTG-3') derived from bases 667-1287 in the sequence 
reported previously (Chalon et al., 1996) for the rat NTS2 receptor. The 
oligonuc1eotides used are flanking the region where the deletion occurs in the mouse 
vNTS2 receptor (Botto et al., 1997b) and allow the amplification of fragments of 
predicted sizes of 620 and 439 bp, as demonstrated previously (Sarret et al., 2002) in 
rat cerebellar granule cell cultures. As internaI standard for semi-quantitative 
analysis, the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was concurrently amplified using primers 5'-CAAGATTGTCAG-
CAATGCAT-3' (sense, nucleotides 511-530) and 5'-CTTGATGTCATCATAC-
TTGGC-3' (antisense, nucleotides 856 to 836), which target a 346-bp sequence in the 
rat GAPDH gene. 
The ratios of NTS2 over GAPDH mRNAs and between the NTS2 receptor 
isoforms were determined by densitometry, using NIH Scion Image Software. 
Calculations and statistical analyses were performed using Exce1 2000 (Microsoft) 
and Prism 3.02 (Graph Pad Software). Statistical analyses were performed using a 
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one-way analysis of variance (Bonferroni's multiple comparison test). Total RNA 
samples were subjected to reverse transcription in the absence of the enzyme to 
control for intrinsic contamination by genomic DNA, and the reaction was performed 
without RNA to control for contamination during the experiment. 
5.3.2 Gene Constructs 
The HA-tagged cDNA encoding the rat variant NTS2 receptor was obtained through 
reverse transcription of vNTS2 mRNA isolated from rat brain by PCR using 
nucleotides (5'-ACAGAGATGGCATACCCATACGACGTCCCAGACTACGCTG-
AGACCAGCAGTCCGTGG-3') and (5'-TCATACTTGTA TTTCTCCCAGGCT -3') 
as sense and antisense primers, respectively. The former contains the HA tag 
sequence followed by the 44-61-bp sequence of the rat NTS2 receptor mRNA 
(Chalon et al., 1996), whereas the latter corresponds to the sequence 1268-1291 bp of 
the open reading frame of the rat nts2 receptor gene. The predicted sizes of the 
amplified fragments were 1.6 kb for the full-Iength NTS2 and 1.4 kb for the spliced 
variant form of the receptor. Fidelity of PCR amplification was confirmed by DNA 
sequence analysis using the ABIPRISM® 3100 Genetic Analyzer in the MOBIX 
laboratory (McMaster University, Hamilton, Ontario, Canada). The PCR product 
corresponding to vNTS2 was purified from a 1 % low melting agarose gel and 
subcloned into the pTargeT expression vector (Promega, Madison, WI). 
5.3.3 Cell Culture and Transfections 
For MAPK kinase activity and radioligand binding experiments, CHû and COS-7 
cells were stably transfected with the HA-vNTS2 construct. Briefly, cells were 
maintained at 37°C in a 5% C02 atmosphere in Dulbecco's modified Eagle's medium 
(DMEM) F-12 and DMEM with high glucose, respectively, supplemented with 5% 
fetal bovine serum in the presence of 100 units/ml penicillinlstreptomycin 
(Invitrogen). Cells were grown in lOO-mm dishes to 70-80% confluence and 
transfected with 4 ~g of the HA-vNTS2-pTargeT plasmid by using the 
Lipofectamine™ transfection reagent (Invitrogen) according to the manufacturer's 
instructions. After 72 h at 37°C, positive cells were selected with a FACSVantage 
cell sorter (BD Biosciences) following sequentiallabeling with a mouse monoclonal 
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antibody (clone 12CA5) directed toward the HA epitope (11500; Roche Applied 
Science) and Alexa 488-conjugated goat anti-mouse antibody (111000; Molecular 
Probes, Eugene, OR). Stable CHO (for MAPK kinase activity) and COS-7 (for 
radioligand binding experiments) transfectants were selected in the presence of 500 
Jlglml G418. 
For Western blotting and immunocytochemistry experiments, COS-7 cens were 
transiently transfected with 7 ml of a mixture of 100 JlM chloroquine and 0.25 
mg/ml DEAE-dextran containing 4 Jlg of plasmid DNA (HA-vNTS2, HA-NTS2 
(Sarret et al., 2003a), untagged NTS2, or a mixture of HA-vNTS2 and untagged 
NTS2) in DMEM high glucose. After 2 h at 37°C, the solution was removed, and 
the cens were treated for 1 min with 10% dimethyl sulfoxide in phosphate-buffered 
saline (PBS), rinsed twice with PBS, and retumed to the 37°C incubator in growth 
medium supplemented with 5% fetal bovine serum. 
5.3.4 Immunocytochemistry on COS-7 Cells 
To assess the subcenular distribution of vNTS2, COS-7 cens transfected with HA-
vNTS2 cDNA were plated on poly-L-Iysine-coated glass coverslips, fixed for 20 min 
with 4% paraformaldehyde (Polysciences, Warrington, PA) in PBS, pH 7.4, and 
preincubated for 30 min at room temperature (RT) with a blocking solution 
consisting of 5% normal goat serum, 2% BSA, and 0.1% Triton X-IOO (BDH, 
Toronto, Ontario, Canada) in PBS. cens were incubated overnight at 4°C with a 
polyc1onal antibody directed toward the 7-21-amino acid sequence in the N-terminal 
segment of the rat NTS2 receptor (1/25,000; made on demand by Affinity 
BioReagents, ABR, Golden, CO), which recognizes both short and long isoforms of 
the receptor (Sarret et al., 2003a), together with a mouse monoclonal antibody (clone 
12CA5, 1/500) directed toward the HA epitope in PBS containing 1 % normal goat 
serum and 0.05% Triton X-IOO. cens were then incubated for 1 h at RT with a 
mixture of Alexa 594-conjugated goat anti-rabbit and Alexa 488-conjugated goat 
anti-mouse antibodies (1/750; Molecular Probes, Eugene, OR). For specificity 
control s, cens were incubated with anti-NTS2 peptide antiserum preadsorbed with 
the antigenic peptide. 
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For cell surface immunolabeling experiments, COS-7 cells expressing the HA-
tagged vNTS2 receptor were stained using the Alexa 488-conjugated monoclonal 
anti-HA IgG (1/500; Molecular Probes, Eugene, OR) in serum-depleted medium for 
1 h at 37°C. Cells were then washed with PBS, fixed with 10% paraformaldehyde 
for 30 min at RT, and washed again with PBS prior to examination. 
For dual immunolocalization of vNTS2 and NTS2, COS-7 cells co-expressing 
HA-tagged vNTS2 and the untagged NTS2 were incubated overnight at 4°C with 
mouse monoclonal anti-HA antibody in concert with rabbit NTS2 peptide antiserum 
(1/10,000) in PBS containing 1 % NGS and 0.05% Triton X-1 00. This second NTS2 
antiserum is directed toward a synthetic peptide (YSFRL WGSPRNPSLG) 
corresponding to the 397--412 predicted amino acid sequence in the C-terminal tail 
of the rat NTS2 receptor (custom-raised by Affinity BioReagents, ABR, Golden, 
CO) that specifically recognizes the full-Iength receptor. Cells were then incubated 
for 1 h at RT with a mixture of Alexa 488-conjugated goat anti-mouse and Alexa 
594-conjugated goat anti-rabbit antibodies (1/750; Molecular Probes, Eugene, OR). 
Cells were examined with a Zeiss 510 laser-scanning confocal microscope 
equipped with argon2 (488 nm) and HelNel (543 nm) lasers (Carl Zeiss Micro 
Imaging Inc., Thomwood, NY). Images were processed using the Zeiss 510 laser-
scanning microscope software and Adobe Photoshop 6.0. 
5.3.5 Immunoprecipitation and Immunoblotting Analysis 
For immunoprecipitation studies, COS-7 cells expressing either the HA epitope-
tagged vNTS2 or the untagged full-Iength NTS2 were lysed in RIPA buffer (150 nM 
NaCI, 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 1% IGEPAL, 0.5% deoxycholic acid, 
0.1 % SDS) containing protease inhibitors (Complete™ inhibitor tablets; Roche 
Applied Science) and incubated for 30 min on ice. Lysates were then precleared with 
5 mg ofprotein A-Sepharose (Sigma) for 45 min at 4°C and incubated ovemight at 
4°C with a rat monoclonal antibody (clone 3FlO) directed toward the HA epitope 
(1/400; Roche Applied Science). The protein A-Sepharose was gently shaken in lysis 
buffer containing 1% BSA for 30 min at RT before use. Receptor proteins were 
immunoprecipitated with 3 mg of protein A-Sepharose for 2 h at 4°C. Complexes 
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were dissolved in Laemmli sample buffer (Laemmli, 1970) and resolved by using 
10% Tris-glycine precast gels (Invitrogen). Nonspecific sites were blocked by 0.1 % 
Tween 20 (EMD Chemicals Inc., Gibbstown, NJ) and 10% milk powder (Carnation, 
Don Mills, Ontario, Canada) in PBS overnight at 4°C. Nitrocellulose membranes 
were then incubated with rabbit N-terminally directed NTS2 antibody (1/10,000) 
overnight at 4°C, followed by horseradish peroxidase (HRP)-conjugated goat anti-
rabbit antibody for 1 h at RT (1/4000; Amersham Biosciences). Specificity of 
antiserum was confirmed by preadsorption of the NTS2 antibody overnight with an 
excess of immunizing peptide (2 J.lglml of adsorbing peptide at a final antibody 
dilution of 1/10,000). 
For cell surface labeling experiments, COS-7 cells expressing HA-vNTS2 or co-
expressing HA-vNTS2 and untagged full-Iength NTS2 were washed with ice-cold 
PBS and incubated with the N-terminally directed NTS2 peptide antiserum 
(1/10,000) in PBS containing 0.5% BSA for 2 h at RT. Cells were then washed three 
times with PBS and transferred into l.5-ml Eppendorf tubes. They were treated with 
100 J.lI of RIPA buffer for 1 h at 4°C, lysed, and centrifuged at 12,500 rpm at 4°C for 
30 min. The supematants were incubated with protein A-Sepharose for 2 h at 4°C to 
immunoprecipitate antibody-bound cell surface receptors. Immunoprecipitates were 
processed as described above. Membranes were probed with rabbit N-terminally 
directed NTS2 antibody (1/2000), followed by a 1-h incubation with HRP-
conjugated goat anti-rabbit antibody (1/4000; Amersham Biosciences). 
For heterodimerization experiments, COS-7 cells expressing the HA epitope-
tagged vNTS2 together with the untagged full-Iength NTS2 were treated as 
described above. Receptor proteins were immunoprecipitated using the rat anti-HA 
antibody (clone 3FlO; 1/400), and immunoblotting was then carried out with the N-
terminally or C-terminally directed NTS2 antisera (1/10,000). 
To determine which molecular forms of the vNTS2 protein are expressed in rat 
CNS, Western blotting experiments were performed on membranes from rat spinal 
cord, as this structure had been shown previously (Botto et al., 1997b) to express 
among the highest levels of vNTS2 mRNA in the mouse. Rat spinal cord membrane 
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preparations were obtained as described previously (Sarret et al., 2003a). 
Approximately 70 J.1g of protein from each sample were loaded onto 8% Tris-glycine 
gels and transferred to nitrocellulose membranes for immunoblotting. Membranes 
were incubated with the affinity-purified N-terminal specific anti-NTS2 rabbit 
antibody (1/1250) ovemight at 4°C in PBS containing 1 % ovalbumin and 1 % BSA, 
followed by HRP-conjugated anti-rabbit secondary antibody in PBS with 5% milk 
powder. Specificity of antiserum was confirmed by preadsorption with the antigenic 
peptide. 
5.3.6 Receptor Binding Experiments 
For radioactive ligand binding experiments, COS-7 cens expressing HA-vNTS2 were 
grown on 24-wen plates and incubated at 37°C in DMEM high glucose medium for 
72 h before the assay. cens were equilibrated for 10 min at 37°C in Earle's buffer 
(130 mM NaCI, 5 mM KCI, 1.8 mM CaCh, 0.8 mM MgCh, HEPES 20 mM, pH 7.4) 
supplemented with 0.2% BSA and 0.1 % glucose and incubated with 0.4 nM 1251_ 
labeled NT (1670 Ci/mmol) for 30 min at 37°C in 250 J.11 of Earle's buffer containing 
0.8 mM ortho-phenanthroline in the presence of increasing concentrations (from 10--
10 to 10--3 M) ofnonradioactive NT. The cens were then washed twice with Earle's 
buffer and harvested in 1 ml of 0.1 M NaOH, and the radioactivity content was 
measured in a gamma counter. 1Cso values were determined from competition curves 
as the concentration ofunlabeled ligand necessary to inhibit 50% of 12sl-labeled NT-
specific binding. Nonspecific binding was defined as binding in the presence of a 
10,000-fold excess of unlabeled ligand, which represented less than 1% of total 
counts. 
For fluorescent ligand labeling, COS-7 cells expressing the HA epitope-tagged 
vNTS2 were grown on poly-L-Iysine-treated glass coverslips and incubated at 37°C 
in DMEM high glucose medium for 24 h. They were then equilibrated for 10 min at 
37°C in Earle's buffer containing 0.2% BSA and 0.1 % glucose in the presence or in 
the absence of 10 J.1M phenylarsine oxide, an endocytosis inhibitor, and incubated for 
30 min in the same buffer with 50 nM of Na-BODIPY-NT-(2-13) (Fluo-NT) in the 
presence or absence of 1 mM nonfluorescent NT. cens were air-dried, mounted on 
164 
Chapter 5: NTS2 Receptor Splice Variant 
glass slides with Aquamount (Polysciences, Warrington, PA), and examined by 
confocal microscopy as described above. 
5.3.7 Measurement of MAP Kinase Activity 
CHO cells stably expressing HA-tagged vNTS2 were split into 6-well plates and 
incubated for 1-2 days in DMEM-F-12 at 37°C. Cells were then serum-starved 
overnight, pretreated or not with MEK inhibitors PD98059 (50 J.1M) (New England 
Biolabs, Beverly, MA) or U0126 (10 J.1M) (Promega, Madison, WI) for 30 min, and 
incubated with NT (0.1-10 J.1M) or levocabastine (1 J.1M) at 37°C for the indicated 
times. The reaction was stopped by aspiration of the medium and the addition of ice-
cold PBS containing 0.1 J.1M staurosporine and 1 mM sodium orthovanadate. After 
30 min of incubation on ice, cells were lysed in 50 mM HEPES, pH 7.8, containing 
1 % Triton X-100, 0.1 J.1M staurosporine, 1 mM sodium orthovanadate, and protease 
inhibitors. Celllysates were then centrifuged at 12,500 rpm for 10 min at 4°C, and 
the supematants were stored at -20°C until use. Parallel experlments were done 
using untransfected cells to determine the specificity of the assay. Protein 
concentration was determined by the Bio-Rad procedure with BSA as standard. 
Samples containing 40 J.1g of protein were denatured in Laemmli sample buffer 
(Laemmli, 1970), resolved using 10% Tris-glycine precast gels, and transferred to 
nitrocellulose membranes (Bio-Rad). Nitrocellulose membranes were incubated 
ovemight at 4°C with anti-phosphorylated ERK1I2 or anti-ERK1I2 rabbit antibodies 
(111000; New England Biolabs) in PBS containing 1% ovalbumin and 1% BSA. 
Detection of immunoreactive proteins was accompli shed by using HRP-conjugated 
anti-rabbit and an enhanced chemiluminescent detection system (PerkinElmer Life 
Sciences). To quantify the effect of NT on ERK1/2 phosphorylation, the ratios of 
phosphorylated ERK1I2 over total ERK1I2 leve1s were determined by densitometry, 
using NIH Scion Image software. Calculations and statistical analyses were 
performed using Excel 2000 (Microsoft) and Prism 3.02 (Graph Pad Software). The 
statistical significance of the activation of ERK1I2 between transfected and 
nontransfected cells was verified using the paired t test, and p values were obtained 
from Dunnett's tables. 
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5.4 RESULTS 
5.4.1 Expression of NTS2 Receptor mRNAs in the CNS 
In order to assess expression patterns of NTS2 mRNAs in rat brain and spinal cord, a 
set of oligonucleotide primers designed to selective1y recognize the region flanking 
the deletion yielding vNTS2 in the mouse (Botto et al., 1997b) was used for reverse 
transcription-PCR. As shown in Fig. 5.1, PCR amplification of total mRNAs yielded 
two bands of 620 and 439 bp, corresponding to the expected sizes of NTS2 and 
vNTS2 receptor fragments, respective1y, in aIl regions examined. No signal was 
detected when transcribed products from homogenates were amplified with either one 
of the sense or antisense primers alone (not shown). Semi-quantitative analyses 
performed using GAPDH as an internaI correction standard indicated that mRNA 
levels for either of the two isoforms, and hence the ratio of vNTS2 over NTS2, were 
not statistically different between the various regions examined (Table 5.1). 
5.4.2 Isolation and Molecular Characterization of the Rat Variant NTS2 
Rat vNTS2 receptor cDNA was isolated from brain tissue by reverse transcription-
PCR, using a pair of sense and antisense primers corresponding to the open reading 
frame of the full-iength NTS2 receptor. The specificity of the amplification was 
verified by agarose gel electrophoresis, which revealed two bands of the expected 
size (full-Iength = 1251 bp; variant isoform = 1070 bp) (not shown). The nucleic 
acid sequence of vNTS2 was identical to that of the full-iength NTS2 with the 
exception of a 181-nucleotide deletion corresponding to NTS2 base pairs 760--940. It 
is worth noting that the nucleotide sequence of the S'-part of the truncated receptor 
shares high homology with the consensus sequence of vertebrate splice donor-
acceptor sites (Horowitz and Krainer, 1994). The de1etion causes a frameshift in the 
open reading frame, leading to a premature stop codon. The short form of the rat 
NTS2 contains 281 amino acids, instead of 416 for the long form (Fig. 5.2A). It 
shows a global amino acid sequence homology of79.9 and 77.4% with its full-iength 
counterpart and the mouse spliced NTS2 isoform, respective1y. Hydrophobicity 
analysis, performed according to the method of Kyte and Doolittle (BioEdit version 
5.0.6), indicated that vNTS2 is a 5-transmembrane domain receptor with an 
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intracelIular C-tenninal tail. The resulting protein is devoid of the last two 
transmembrane domains of the full-Iength NTS2 receptor and contains 37 unique C-
tenninal amino acids (Fig. 5.2B). The C-tenninal domain of the variant isofonn is 
rich in cysteine and methionine residues. 
5.4.3 Expression ofvNTS2 in COS-7 Cells 
In order to investigate the pharmacological and functional properties of rat vNTS2, 
we established a COS-7 celI line stably expressing an HA epitope-tagged vNTS2 
receptor, using cDNA transfection. Immunohistochemical analysis revealed that 
within these celIs, the bulk of immunoreactive receptors, visualized using either HA 
(Fig. 5.3, A and C) or NTS2 N-tenninally directed antibodies (Fig. 5.3B), was 
intracellular and concentrated in a Golgi-like structure surrounding the nucleus. No 
immunofluorescence signal was detected in nontransfected cells or in cells incubated 
in the absence of primary antibodies (data not shown). Preincubation of the NTS2 
antiserum with its antigenic peptide completely abolished NTS2 immunolabeling 
(Fig. 5.3D) without affecting the HA epitope staining (Fig. 5.3C). Surface labeling 
studies on nonpenneabilized cells indicated that vNTS2 was poorly expressed on the 
cell surface (data not shown). 
To confinn that the immunoreactive protein expressed in transfected cells 
corresponded to the variant receptor, lysates from COS-7 cells expressing the HA 
epitope-tagged vNTS2 receptor were immunoprecipitated with the anti-HA antibody. 
Immunoblotting using the NTS2 peptide antiserum revealed the presence of two 
distinct translation products as folIows: one of ~32 kDa, corresponding to the 
monomeric fonn of the receptor as deduced from its cDNA sequence, and another of 
~60 kDa, i.e. of the size of putative vNTS2 homodimers (Fig. 5.3E, lane 1). By 
contrast, in control COS-7 cells expressing the full-Iength receptor, immunoreactive 
bands were detected at 46 kDa, as well as around 80-85 kDa, corresponding to the 
size of monomeric and dimeric fonns of the full-Iength receptor, respectively (Sarret 
et al., 2003a) (Fig. 5.3E, lane 2). No specific bands were evident in homogenates 
prepared from nontransfected cells (Fig. 5.3E, lane 3). 
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To detennine whether any particular molecular fonn of the receptor was 
targeted to the cell surface, COS-7 cells expressing the HA epitope-tagged vNTS2 
were incubated for 2 h with the N-terminally directed NTS2 peptide antiserum, and 
antibody-bound cell surface receptors were separated from unbound cytoplasmic 
receptors by using protein A-Sepharose beads. Immunoblotting was then perfonned 
by using the NTS2 antiserum. As seen in Fig. 5.3E, lane 4, the cell surface fraction 
contained the same two fonns (32 and 60 kDa) as fractions from whole cells. 
5.4.4 Binding and Internalization Properties ofvNTS2 
To detennine the binding properties of the short NTS2 isofonn, COS-7 cells stably 
expressing vNTS2 were incubated with 0.4 nM 125I-Iabe1ed NT for 30 min at 37°C 
with increasing concentrations of nonradioactive NT. As shown in Fig. 5.4A, 
unlabe1ed NT inhibited specific 125I-Iabeled NT binding with an IC50 value of 10 J.1M 
(Fig. 5.4A). No specific 125I_Iabe1ed NT binding was observed in nontransfected cells 
(data not shown). 
In order to visualize NT binding and intemalization, COS-7 cells expressing 
vNTS2 were incubated for various periods oftime with 50 nM Fluo-NT at 37°C and 
were examined by confocal microscopy (Fig. 5.4, B-D). Following 30 min of 
incubation with the fluorescent ligand, punctate fluorescent labe1ing was evident 
throughout the cytoplasm of transfected cells, sparing the nucleus (Fig. 5.4, B and 
C). No fluorescent labeling was visible in nontransfected cells (not shown) or in 
transfected cells incubated with an excess of NT (Fig. 5.4D). When the incubation 
was carried out in the presence of the endocytosis inhibitor phenylarsine oxide, 
bound fluorescent molecules remained clustered on the cell surface (data not shown). 
5.4.5 Signaling Properties ofvNTS2 
We then investigated whether the truncated fonn of the rat NTS2 receptor retained 
the MAPK activation (ERKI/2 pathway) properties exhibited by the long fonn of the 
receptor (Gendron et al., 2004). Stimulation with NT of CHO cells stablyexpressing 
the rat vNTS2 induced the phosphorylation of ERK1I2 (P42/44mapk) starting at 
concentrations of 1 J.1M (Fig. 5.5A). Time course studies in which the cells were 
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stimulated for 1-60 min with 1 ~M NT showed this effect to be rapid «5 min) and 
sustained (over 1 h) (Fig. 5.5B). Densitometric analysis of the ratio of 
phosphorylated ERK1I2 over total ERK1/2 levels indicated that the NT-induced 
increase in MAPK phosphorylation was 1.4 ± O.l-fold and reached a plateau after 15 
min of stimulation (Fig. 5.5C, .). This effect was vNTS2-mediated, as it was not 
observed in nontransfected ceUs (Fig. 5.5C, 0). A similar activation was observed 
foUowing 10 min of stimulation with the NTS2 agoni st levocabastine (1 ~M; Fig. 
5.5D). Pretreatment with selective MAP kinase kinase (MEK) inhibitors (PD98059 
or U0126) significantly inhibited NT-mediated ERK1I2 phosphorylation in these 
ceUs (Fig. 5.5E). 
5.4.6 Heterodimerization of NTSl Receptors 
In rat spinal cord membrane preparations immunoblotted with the N-terminaUy 
directed NTS2 antiserum (which recognizes both NTS2 isoforms; Fig. 5.6A), a 
prominent band was evident at 46 kDa, corresponding to the molecular weight of the 
monomeric form of the fuU-Iength NTS2 receptor detected in transfected COS-7 ceUs 
(compare Fig. 5.6A with Fig. 5.3E, lane 2). Surprisingly, no band was visible at 32 
kDa, i.e. at the size expected for the monomeric form of the truncated receptor (e.g. 
Fig. 5.3E, lane 1). However, as in COS-7 transfected with the HA-vNTS2 (Fig. 5.3E, 
lane 1), an immunoreactive band was detected at 60 kDa, corresponding to the size of 
putative vNTS2 homodimers (Fig. 5.6A). An additional band was also observed at 
75-85 kDa (Fig. 5.6A, asterisk), which might correspond to vNTS2/NTS2 
heterodimers. AlI of these bands were absent when the antibody was pre-saturated 
with the immunizing peptide (not shown). 
To investigate whether the species ofNTS2 receptors detected at the 75-85-kDa 
molecular weight mark could correspond to vNTS2/NTS2 heterodimers, we co-
expressed HA-tagged vNTS2 together with untagged NTS2 receptors in COS-7 ceUs 
and subjected ceUlysates to Western blotting analysis. As shown in Fig. 5.6B, both 
monomeric and putative homodimeric forms ofvariant (32 and -60 kDa, arrows) and 
fuU-Iength (46 and -85 kDa, arrowheads) NTS2 receptors were detected using the N-
terminally directed NTS2 peptide antiserum. An immunoreactive band was also 
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observed at the ~75-kDa mark (asterisk) , consistent with the theoretical molecular 
weight of a vNTS2/NTS2 heterodimer. 
Cell lysates were then subjected to immunoprecipitation with the rat anti-HA 
antibody. Immunoblotting of these immunoprecipitates with the N-terminally 
directed NTS2 antiserum showed that they contained HA-tagged vNTS2 as well as 
untagged NTS2 receptors, suggesting that long and short forms of NTS2 receptors 
might interact together (Fig. 5.6C, lane 1). Indeed, immunoreactive bands were 
detected at both 32 and 46 kDa, i.e. at the molecular weights of the monomeric forms 
of the variant and full-Iength receptors, as well as at ~60 kDa, corresponding to the 
presumptive homodimeric isoform of vNTS2 (Fig. 5.6C, lane 1). Higher molecular 
weight bands (~75 and ~110 kDa) were also evident, which may represent 
heteromultimeric forms of NTS2 receptors. Immunoreactive bands corresponding to 
monomeric and putative homodimeric forms of vNTS2 (32 and 65 kDa, respective1y) 
were also detected in COS-7 cells transfected with the HA-vNTS2 cDNA alone (Fig. 
5.6C, lane 3). However, no specific bands were observed in cells expressing the full-
length NTS2 alone (Fig. 5.6C, lane 2). Immunoprecipitates were also subjected to 
Western blotting analysis using the C-terminally directed NTS2 antiserum, which 
se1ective1y recognizes the full-Iength NTS2. This antibody revealed the presence of 
the full-Iength isoform in co-transfected cells subjected to immunoprecipitation with 
the HA antibody, confirming that NTS2 may be part of the same complex as vNTS2 
(Fig. 5.6D, lane 1). No bands were detected with the C-terminally directed NTS2 
peptide antiserum in immunoprecipitates from COS-7 cells expressing either NTS2 
(Fig. 5.6D, lane 2) or HA-vNTS2 (Fig. 5.6D, lane 3) alone, confirming the specificity 
of the interaction. 
To investigate whether vNTS2/NTS2 heterodimerization influenced trafficking 
of the truncated receptor to the cell surface, COS-7 cells co-expressing the HA 
epitope-tagged vNTS2 and the untagged full-Iength NTS2 were incubated for 2 h 
with the N-terminally directed NTS2 peptide antiserum, and antibody-bound cell 
surface receptors were separated from unbound cytoplasmic receptors by using 
protein A-Sepharose beads. Immunoblotting was then performed using the mouse 
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anti-HA antibody. As seen in Table 5.2, the density of both low (monomers) and 
high (dimers and multimers) molecular weight forms detected in the cell surface 
fraction (22 ± 2, 26 ± 3, and 52 ± 4%, respectively) was the same as in the cell 
fraction from cells transfected with vNTS2 alone (21 ± 2, 28 ± 4, and 51 ± 6%, 
correspondingly). Confocal microscopy confirmed that as in COS-7 cells transfected 
with vNTS2 alone (Fig. 5.3), the bulk of vNTS2 immunoreactivity in COS-7 co-
expressing NTS2 and HA-vNTS2 was intracellular (Fig. 5.7B). Predictably, vNTS2 
and NTS2 immunoreactive intracellular stores closely overlapped, in keeping with 
their demonstrated heterodimerization (Fig. 5.7, A-C). 
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5.5 DISCUSSION 
In this study, we have demonstrated the presence of an alternatively spliced fonn of 
the NTS2 receptor mRNA in rat brain, comparable with the one previously identified 
in the mouse (Botto et al., 1997b). Most importantly, we have shown that this 5-
transmembrane domain truncated receptor protein is functional, in that it specifically 
binds and internalizes NT and is coupled to the activation of the ERK1/2 pathway. 
Alternative splicing is a frequent occurrence in mammalian gene expression, 
contributing both to proteome diversity and to functional complexity of genomes by 
generating structurally distinct isofonns from a single gene (Furnham and al., 2004). 
Nucleic acid sequence analysis demonstrated that the vNTS2 isofonn results from a 
181-bp deletion in the full-Iength cDNA that leads to a frameshift in the reading 
frame, introducing a premature stop codon. The sequence of the cDNA fragment 
isolated showed partial sequence overlap with the previously published rat full-Iength 
NTS2 sequence (Chalon et al., 1996), indicating that vNTS2 was indeed generated by 
alternative splicing from a donor-acceptor splice site as suggested by Sun et al. (Sun 
et al., 2001). This type of processing does not appear to be regionally selective 
because mRNA levels and ratios of the two isofonns did not vary significantly 
between the different regions examined. 
Western blotting analysis of COS-7 cells transfected with cDNA encoding an 
HA-tagged rat vNTS2 revealed the presence of distinct translation products of -32 
and 60 kDa. The fonner corresponds to the molecular weight of the monomeric 
fonn of vNTS2 as deduced from its cDNA sequence, whereas the latter likely 
represents a homodimeric fonn of the receptor. Immunocytochemistry revealed that 
the bulk of these vNTS2 proteins were intracellular. This observation is in 
agreement with the results of subprograms executed by the PSORT II server (Kenta 
Nakai, Ruman Genome Center, Institute for Medical Science, University of Tokyo, 
Japan) , which predict the subcellular localization of vNTS2 from its amino acid 
sequence in the endoplasmic reticulum (44.4%), intracellular vacuoles (22.2%), 
Golgi apparatus (11.1 %), plasma membrane (11.1 %), and mitochondrial 
compartments (11.1 %). Both immunoblotting and immunocytochemical 
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experiments suggest that the vNTS2 receptor is poorly targeted to plasma 
membranes. However, this restricted targeting does not appear to be linked to the 
molecular species recruited to the membrane because both low (monomeric) and 
high (putative dimeric) molecular weight forms were detected at the cell surface. 
Despite its short transmembrane span, the rat vNTS2 still specifically binds 1251_ 
labeled NT, albeit with a considerably lower affinity than the full-Iength receptor 
(lCso of 10 /lM versus 2 nM, for the full-Iength isoform). This result differs from 
those of Botto et al. (1997b), who found no specific binding of 12SI_labe1ed NT to 
mouse vNTS2 transiently expressed in CûS-7 cells. This discrepancy may be 
explained by species differences, by variations in the sensitivity of the methods 
employed, or by the nature of the expression system. Indeed, stable transfectants 
might express higher levels and/or recruit more efficiently vNTS2 to the membrane 
than transiently transfected cells. Previous studies have shown that NT binding to rat 
NTS 1 and human NTS2 receptors involved residues located in TM 6 and in the third 
intracellular loop (Barroso et al., 2000; Richard et al., 2001a). These residues are lost 
in the variant isoform, due to the splicing of the last two TM domains of NTS2, 
which may explain the lower affinity of vNTS2 for NT as compared with the full-
length receptor. 
Confocal microscopic experiments demonstrated specific, receptor-mediated 
intemalization of fluorescent NT. The intemalized ligand was concentrated within 
small endosome-like organelles, a pattern consistent with earlier reports (Gendron et 
al., 2004; Botto et al., 1998) on intemalization via the full-Iength NTS2 receptor. 
This finding suggested to us that the NTS2 variant isoform was functionally 
responsive to NT, as confirmed by MAPK activation experiments. Indeed, 
stimulation with NT induced a rapid and sustained increase in ERK1I2 
phosphorylation in CHû cells transfected with vNTS2, indicating functional 
coupling of the truncated receptor to the MAPK signaling pathway. Stimulation of 
these cells with the NTS2-specific agonist levocabastine also resulted in ERK1I2 
activation. The time course of ERK1I2 activation corresponded to that observed 
following stimulation of the full-Iength receptor in a similar transfection system 
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(Gendron et al., 2004). Activation ofERK1I2 was already apparent at concentrations 
of NT lower than the 1C5o (1 JlM), in keeping with the detection of ligand-induced 
internalization at concentrations of Fluo-NT of 50 nM. However, phosphorylation 
levels obtained following stimulation with 1 JlM NT were lower in cells transfected 
with the vNTS2 than with the full-Iength receptor (1.4 versus 2.9-fold increase over 
control (Gendron et al., 2004». They were also lower than those produced in 
cultured rat cerebellar granule cells, which endogenously express the two NTS2 
isoforms (Sarret et al., 2002). These results suggest that the third intracellular loop 
and the C-terminal tail of the full-Iength NTS2 are not essential for but may play an 
accessory role in MAPK activation. To our knowledge, the vNTS2 is the first TM-
spliced GPCR variant cloned to date that was found to maintain signaling properties. 
Indeed, other TM splice variants of GPCRs, such as the corticotrophin-releasing 
factor receptor 2, have been reported to retain their agoni st binding properties but to 
totally lose their functional coupling (Miyata et al., 1999). 
Western blotting studies using an N-terminally directed NTS2 peptide antiserum 
revealed that the 32-kDa monomeric form of vNTS2 is not expressed in the spinal 
cord, whereas a band twice the size of vNTS2 is present, suggesting that the NTS2 
receptor variant may exist in homodimeric form in the rat CNS. By contrast, a 
specific band was detected at 46 kDa, i.e. at the molecular weight of the full-Iength 
isoform of the receptor, indicating that in contrast to its variant isoform, the full-
length receptor exists in monomeric form in rat CNS. These results are similar to 
those previously reported for membranes prepared from rat brain and cerebellum 
(Sarret et al., 2003a). In addition, specific bands were detected at molecular weight 
marks higher than the putative vNTS2 dimers. One of these was approximately twice 
the size of the monomeric form of the full-Iength receptor and was therefore 
interpreted as a putative NTS2 homodimer. Another migrated slightly lower, as 
would be expected from a vNTS2/NTS2 heterodimer. Indeed, recent biochemical, 
biophysical, and functional studies (reviewed in Bouvier, 2001; Devi, 2001) have 
shown that GPCR can assemble as hetero- as well as homodimeric complexes. To 
test whether the vNTS2 could actually associate with its full-Iength counterpart, we 
carried out immunoprecipitation experiments on COS-7 cells co-expressing HA-
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tagged vNTS2 and native NTS2. These experiments demonstrated that the two NTS2 
isoforms did associate when co-expressed in COS-7 cells, because both receptors 
were pulled down using an HA antibody. Furthermore, the presence in these dually 
transfected cells of a band at the theoretical molecular weight of vNTS2/NTS2 
heterodimers indicated that the band detected at the same level in spinal cord 
membranes might indeed have corresponded to a vNTS2-NTS2 heterodimer. This 
vNTS2/NTS2 heterodimer was stable during celllysis and reducing Tris-glycine gel 
electrophoresis, suggesting that the interaction involves a noncovalent hydrophobic 
interface between the receptor pro teins. 
To investigate whether heterodimerization of NTS2 and vNTS2 receptors 
affected targeting of the truncated receptor to the plasma membrane, we examined 
by Western blot the expression of vNTS2 on the cell surface of singly transfected 
versus dually transfected cells, and we compared the immunocytochemical 
distribution of NTS2 and vNTS2 in dua1ly transfected cells. By using either 
technique, we found that co-expression of the full-Iength NTS2 did not noticeably 
increase the cell surface density of the truncated form over that seen in cells 
expressing HA-vNTS2 alone, suggesting that the full-Iength NTS2 does not act as a 
chaperone protein for its shorter isoform. However, intracellular vNTS2 stores 
closely overlapped with those of NTS2, supporting the notion that the two receptors 
heterodimerize. 
In summary, our results indicate that the rat vNTS2 is a functional receptor that 
is expressed in conjunction with the full-Iength NTS2 receptor throughout the CNS. 
Our data also indicate that this truncated 5-TM receptor does not exist in monomeric 
form in the rat CNS. Rather, it associates both with itself and with the full-Iength 7-
TM receptor to form large molecular weight homo- and heterodimer species. 
Therefore, it is likely that these associations pro vide for subtle regulation of the NT 
signal, as demonstrated previously (Motomura et al., 1998) for the splice variant 
isoform of the growth hormone-releasing hormone receptor. 
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5.7 ABBREVIATIONS 
NT, neurotensin; GPCR(s), G protein-coupled receptor(s); TM, transmembrane 
domain; CHO cells, Chinese hamster ovary cells; COS-7 cells, green African monkey 
kidney cells; MAPK, mitogen-activated protein kinase; ERK1I2, extracellular signal-
regulated kinases 112; DMEM, Dulbecco's modified Eagle's medium; BSA, bovine 
serum albumin; HRP, horseradish peroxidase; HA, hemagglutinin; R T, room 
temperature; CNS, central nervous system; PBS, phosphate-buffered saline; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; MEK, MAPKJERK kinase; Fluo-NT, 
Na-BODIPY-neurotensin-(2-13). 
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5.9 FIGURE LEGENDS 
Fig 5.1: Reverse Transcription-PCR Analysis of NTS2 mRNAs. Amplification 
ofNTS2 and vNTS2 rnRNAs was from various brain regions. PCRs were performed 
on mRNAs reverse-transcribed using primers flanking the truncated portion ofNTS2. 
The expected sizes of the reverse transcription-PCR products were 620 and 439 bp 
for the full-Iength and spliced form of NTS2, respectively. The housekeeping gene 
GAPDH was also amplified and used as an internaI control for semi-quantitative 
analyses. 
Fig. 5.2: Comparison of Rat FuU-Length and Variant NTS2 Isoform Sequences. 
A, alignment of rat NTS2 isoform sequences. ldentical sequences found in NTS2 
receptor isoforms are shaded, and the putative transmembrane segments are boxed. 
Gaps for alignment are indicated by dots. The short form of NTS2 contains 281 
amino acids, instead of 416 for the long form. The resulting protein is devoid of the 
last two transmembrane domains and contains 37 unique C-terminal amino acids. B, 
schematic representation of the secondary structure of NTS2 receptors. Common 
amino acids are shown in black. Unique amino acid residues in the sequence of 
NTS2 and vNTS2 are represented in hatched and gray, respectively. 
Fig. 5.3: Expression of vNTS2 Receptor Protein in Transfected COS-7 CeUs. 
A-D, dual immunolabeling of COS-7 cells transfected with cDNA encoding the HA 
epitope-tagged vNTS2 receptor. Staining for the HA epitope (A) co-Iocalizes with 
NTS2 immunolabeling (B), confirming recognition of the vNTS2 by the NTS2 
antiserum. Preadsorption of NTS2 antiserum with its antigenic peptide completely 
abolishes NTS2 immunolabeling (D) in cells expressing the epitope-tagged receptor 
(C). Scaie bar, 10 ~m in A and B; 5 ~m in C and D. E, Western blotting analysis of 
NTS2 receptor isoforms. Immunoprecipitation with HA antibody and blotting with 
N-terminally directed NTS2 antiserum ofhomogenates from transfected COS-7 cells 
(lane 1, COS-7/HA-vNTS2; lane 2, COS-7/HA-NTS2; lane 3, untransfected cells). In 
cells transfected with vNTS2, specific immunoreactive bands are evident at 32 and 
60 kDa, corresponding to the molecular weights of monomeric and dimeric forms of 
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vNTS2. The same bands were detected in cell surface labeling experiments using the 
N-terminally directed NTS2 antiserum (lane 4). In cells transfected with the full-
length NTS2, immunoreactive bands are visible at 46 and 83 kDa, corresponding to 
the molecular weights of monomeric and dimeric forms of NTS2. Arrow and 
arrowhead represent the monomeric isoform of vNTS2 and NTS2, respective1y. No 
specific band is evident in nontransfected cells (lane 3). 
Fig. 5.4: Binding and Internalization of NT in COS-7 Cells Expressing vNTS2. 
A, competition inhibition of 12sI_Iabe1ed NT binding to whole CÛS-7 cells stably 
expressing vNTS2. Cells were incubated with 0.4 nM 12sI-Iabeled NT for 30 min at 
37°C with increasing concentrations of nonradioactive NT. Binding ICso = 10 J.1M. 
The results are representative of three independent experiments. B and C, confocal 
microscopic imaging of Fluo-NT internalization in CÛS-7 cells expressing vNTS2. 
Cells were incubated for 30 min at 37°C with 50 nM Fluo-NT and air-dried. 
Intemalized fluorescent ligand molecules are detected in the form of small 
endosome-like partic1es distributed throughout the cytoplasm. D, Fluo-NT labe1ing 
is prevented when the incubation is performed in the presence of an excess of 
nonfluorescent NT. Scale bar, 10 J.1min B; 5 J.1m in C and D. 
Fig. 5.5: MAPK Kinase Signaling in vNTS2 Expressing CHO Cells. A, dose-
dependent effect of NT on MAPK (ERK1/2) phosphorylation. Cells were treated for 
5 min with the indicated concentrations of NT. Phosphorylation levels of MAPK 
were detected by immunoblotting as described under "Experimental Procedures". 
Upper panels of A, B, D, and E, phosphorylated ERK1I2; lower panels, total 
ERK1I2. B, time course of NT-stimulated MAPK phosphorylation in CHû cells 
stably expressing vNTS2. C, densitometric analysis of the ratio of phosphorylated 
ERK1I2 over total ERK1I2 levels following incubation with 1 J.1M of NT. 
Untransfected (0) and vNTS2-expressing (e) CHû cells were incubated at 37°C for 
the indicated times. Values represent the means ± S.E. of five independent 
experiments. Transfected cell values are significantly different from nontransfected 
cell values at all time points as follows: *,p 0.05; **,p 0.01; and ***,p 0.001. D, 
ERK1I2 phosphorylation levels in vNTS2-expressing CHû cells stimulated with 
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levocabastine for 10 min at 37°C. E, MEK inhibitors prevent ERKl/2 activation by 
NT in CHO cells expressing vNTS2. Cells were pretreated with PD98059 (50 J.lM) 
or U0126 (10 J.lM) and treated with NT (1 J.lM) for 5-15 min at 37°C. The results are 
representative of three individual experiments, each with duplicate determinations. 
Fig. 5.6: Characterization of vNTS2/NTS2 Heterodimers by Co-immuno-
precipitation. Immunoblotting (lB) analysis of NTS2 receptors in spinal cord 
membrane preparations (A) and in COS-7 cells co-expressing NTS2 and HA-vNTS2 
(B) using a N-terminally directed NTS2 antibody. C and D, co-immunoprecipitation 
(IPP) studies on COS-7 cells heterologously expressing NTS2 (lanes 2), HA-vNTS2 
(lanes 3), or a combination of both (lanes 1). Cells were lysed and subjected to 
immunoprecipitation with rat anti-HA antibody. The co-immunoprecipitates were 
then immunoblotted using N-terminally (C) or C-terminally (D) directed NTS2 
peptide antisera as described under "Experimental Procedures". Molecular mass 
markers are shown to the left of A and B. Molecular masses for B also apply for C 
and D. Each illustrated blot is representative of three independent experiments. 
Arrows and arrowheads represent isoforms of vNTS2 and NTS2, respectively. 
Asterisks represent the putative vNTS2/NTS2 heterodimer. 
Fig. 5.7: Double Immunolabeling of COS-7 cells Co-expressing NTS2 and HA-
vNTS2. Staining with the C-terminally directed NTS2 antiserum (A), which 
exc1usively recognizes the long isoform, co-Iocalizes with immunoreactivity for the 
HA epitope (B) in co-transfected cells, as evident in the overlay (C). 
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5.10 TABLES 
TABLES.l 
Densitometric analysis of the regional expression of vNTS2 
and NTS2 mRNAs in the rot CNS 
Values representmeans ± S.E. offourindependent experiments. No 
regional difference in the expression of either isoforms is detectable 
(p > 0.051 one-way analysis of variance, Bonferroni's multiple compar-
ison test). 
Structure 
Neocortex 
Spinal cord 
Medulla 
Olfactory bulb 
Hippocampus 
Hypothalamus 
Cerebellum 
Thalamus 
Reœptor to GAPDH ratio 
vNTS2 NTS2 
arbitrary units 
0.91 ± 0.15 0.99 ± 0.07 
0.93 ± 0.10 1.06 ± 0.01 
0.93 ± 0.10 1.03 ± 0.05 
0.98 ± 0.10 1.15 ± 0.08 
0.91 ± 0.12 1.21 ± 0.13 
1.09 ± 0.14 1.28 ± 0.17 
0.73 ± 0.12 0.87 ± 0.05 
0.90 ± 0.09 1.17 ± 0.12 
TABLES.2 
vNTS2INTS2 
0.92 ± 0.15 
0.88 ± 0.11 
0.91 ± 0.13 
0.88 ± 0.14 
0.78 ± 0.16 
0.89 ± 0.14 
0.83 ± 0.15 
0.81 ± 0.14 
Dellsitometric analysis of the effect of NTS2 expression on cell sltrface 
expression of HA-vNTS2 
The relative intensity of HA-v NTS2 is expressed as percent of total 
surface receptor (monomer + dimer + multimer) immunoreactivity. 
Values represent the means ± S.E. of four independent experiments. 
HA-vNTS2 isoforms 
Monomer Dimer Multimer 
% % % 
HA-vNTS2 21 ± 2 28± 4 51 ± 6 
HA-v NTS2 + NTS2 22 ±2 26± 3 52 ± 4 
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6.1 ABSTRACT 
In this study, we investigated whether persistent agonist stimulation of NTS2 
receptors gives rise to down-regulation, in light of reports that their activation 
induced long-lasting effects. To address this issue, we incubated COS-7 cells 
expressing the rat NTS2 with neurotensin (NT) for up to 24 h and measured resultant 
cell surface [125I]_NT binding. We found that NTS2-expressing cells retained the 
same surface receptor density despite efficient internalization mechanisms. This 
preservation was neither due to NTS2 neosynthesis nor recycling since it was not 
blocked by cyc10heximide or monensin. However, it appeared to involve 
translocation of spare receptors from internaI stores, as NT induced NTS2 migration 
from trans-Golgi network to endosome-like structures. This stimulation-induced 
regulation of cell surface NTS2 receptors was even more striking in rat spinal cord 
neurons. Taken together, these results suggest that sustained NTS2 activation 
promotes recruitment of intracellular receptors to the cell surface, thereby preventing 
functional desensitization. 
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6.2 INTRODUCTION 
Neurotensin (NT) is a tridecapeptide that was shown to be involved in a variety of 
central and peripheral neuromodulatory effects inc1uding naloxone-independent 
analgesia, hypothennia, and neuroleptic-like modulation of dopaminergic pathways 
(Vincent et al., 1999). Most of these effects result from the specific interaction of the 
peptide with two cell surface G protein-coupled receptors (GPCRs) referred to as 
NTS 1 and NTS2. The former binds NT with high affinity (Ki = 0.2 nM), whereas the 
latter binds NT with lower affinity (Ki = 2 nM) and is recognized by the 
antihistamine drug levocabastine (Tanaka et al., 1990; Chalon et al., 1996). 
Biochemical studies have indicated that NTS 1 is implicated in the modulation of 
intracellular levels of inositol phosphates (Watson et al., 1992), cAMP (Yamada et 
al., 1993), and extracellular signal-regulated kinases (Poinot-Chazel et al., 1996), 
whereas NTS2 induces Ca2+ -dependent chloride currents in Xenopus oocytes (Botto 
et al., 1997b) and activates the ERlO/2 cascade, both in transfected CHû cells 
(Gendron et al., 2004) and in cerebellar granule cells in culture (Sarret et al., 2002). 
Most GPCRs are subjected to regulatory processes in order to control their 
responsiveness to persistent agoni st exposure (Tsao and von Zastrow, 2000; 
Ferguson, 2001). Agonist-induced regulation of GPCRs usually involves receptor 
desensitization, due to uncoupling from G proteins, followed by receptor 
internalization and down-regulation. The latter is characterized by a decrease in the 
total number of receptors and typically involves increased turnover or reduced 
synthesis of receptors. In the case of the NTS 1 receptor, such desensitization 
processes have been reported in N1E-115 cells as weIl as in rat cultured neurons after 
prolonged incubation in the presence of NT (Donato di Paola et al., 1993; Hermans et 
al., 1997). The disappearance of NT -binding sites was surmised to result from 
degradation of internalized receptors after fusion with lysosomes, since it was 
partially inhibited by the lysosomotropic drugs chloroquine and methylamine 
(Hermans et al., 1997; Vandenbu1cke et al., 2000). Moreover, destabilization of 
NTS1 mRNA was reported in N1E-115 and HT29 cells after long-term agoni st 
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exposure, suggesting that post-transcriptional events may be directly implicated in 
the down-regulation process (Hermans and Maloteaux, 1998). Finally, it has been 
established that de novo synthesis is required for the recovery of NTS 1 receptor-
binding sites and function (Donato di Paola et al., 1993; Hermans et al., 1997). 
Little is known about the regulation of NTS2, except that its stimulation with 
NT induces long-term metabolic effects due to prolonged and sustained activation of 
ERKI/2, either in transfected CHO cells (Gendron et al., 2004) or in neurons in 
culture (Sarret et al., 2002). Therefore, the present study was initiated in order to 
determine whether extended stimulation of NTS2 leads to a down-regulation of cell 
surface receptor density and/or of intracellular receptor protein leve1s. Our results 
demonstrate that cell surface NTS2 receptors are maintained following persistent 
exposure to NT through a recyc1ing-independent mechanism that involves 
recruitment of receptors from intracellular stores. 
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6.3 MATERIALS AND METHODS 
6.3.1 Gene Constructs 
The cDNA encoding the rat and human NTS2 receptors (rNTS2 and hNTS2, 
respectively) were obtained through reverse transcription of brain mRNA and 
subc10ned into the mammalian expression vector pTargeT (Promega, Madison, Wn 
as described in (Sarret et al., 2003aa) and (Gendron et al., 2004), respectively. The 
subc10ning of HA-tagged NTS 1 into pcDNA3 was described previously (Labbé-
Jullié et al., 1998). 
6.3.2 Cell Culture and Transfections 
COS-7 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 5% Fetal Bovine Serum (FBS) in the presence of 
penicillin/streptomycin (100 units/ml; Invitrogen Burlington, ON, Canada). Cells 
were transiently transfected by the DEAE-dextran/chloroquine method with 4 ~g of 
rNTS2, hNTS2, or HA-tagged NTSI plasmid. 
6.3.3 Receptor Binding Experiments 
COS-7 cells expressing rNTS2, hNTS2 or HA-NTS 1 were incubated with or without 
1 ~M NT for 1-24 h in DMEM with 2.5% FBS or Earle's buffer (130 mM NaCI, 5 
mM KCl, 1.8 mM CaCh, 0.8 mM MgCh, 20 mM HEPES, pH 7.4) for long (1-24 h) 
and short (0-60 min) tenn experiments, respectively. Cells were washed once with 
hypertonic acid buffer (Earle's containing 0.2 M acetic acid and 0.5 NaCI, pH 4) for 
3 min on ice, twice with Earle's, and incubated with 0.4 nM 125I-Iabeled NT (1670 
Ci/mmol; Perkin Elmer) for 60 min on ice in Earle's supplemented with 0.25% BSA, 
0.1 % glucose and 0.8 mM ortho-phenanthroline. Cells were then washed twice with 
ice-cold Earle's, harvested in 0.1 M NaOH, and radioactivity content was measured 
in a gamma counter. Non-specific binding was defined as binding in the presence of 
a 10,000-fold excess ofunlabeled ligand, which corresponded to less than 1 % of total 
counts. Statistical comparisons between groups were perfonned using a Student's t 
test. Differences were considered significant for p < 0.05. 
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For experiments with recycling inhibitors, transfected COS-7 cells were 
equilibrated for 10 min at 37°C in Earle' s supplemented with 0.25% BSA and 0.1 % 
glucose. Cells were then pre-stimulated for 30 min with 25 J..lM monensin (Sigma) in 
Earle's at 37°C and incubated with or without 1 J..lM NT in the continuous presence of 
monensin for 60 min at 37°C. Cells were then washed once with hypertonic acid 
buffer, twice with Earle's and binding with radioligand was perfonned as described 
above. 
6.3.4 Immunoblotting Analyses 
COS-7 cells expressing rNTS2 were stimulated or not with 1 J..lM NT with or without 
70 J..lM cycloheximide for 1 or 24 h at 37°C and resuspended in ice-cold buffer 
containing 10 mM Tris-HCl, pH 8.0, and 1 mM EDTA with protease inhibitors 
(Complete Protease Inhibitors tablets, Roche Molecular Biochemicals, Laval, QC, 
Canada). Cells were then disrupted by sonication and pelleted by centrifuging at 
12,000 g for 30 min at 4°C. Parallel experiments were done using untransfected cells 
as a negative control. Protein concentration was detennined using the Bio-Rad 
method (Bio-Rad Laboratories, Mississauga, ON, Canada). Samples containing 20 
J..lg of crude membrane proteins were denatured in Laemmli sample buffer, resolved 
on 10% Tris-glycine precast gels (Invitrogen) and transferred to nitrocellulose 
membranes (Bio-Rad). Membranes were then incubated with the NTS2 peptide 
antiserum (1/10,000; previously characterized in (Sarret et al., 2003a» overnight at 
4°C in PBS containing 1 % ovalbumin (Sigma, St-Louis, MO) and BSA, followed by 
HRP-conjugated anti-rabbit secondary antibody (1/3500; Amersham Pharmacia 
Biotech, Baie d'Urfé, QC, Canada) in PBS with 5% evaporated milk (Carnation, Don 
Mills, ON, Canada) for 1 h at room temperature (RT). Immunoreactive proteins were 
detected using an enhanced chemiluminescent system (Perkin Elmer Life Science, 
Boston, MA). The effects of long-tenn NT exposure on rNTS2 protein levels were 
quantified by densitometry using Scion Image. Calculation and statistical analyses 
were carried out in Excel 2000 (Microsoft). 
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6.3.5 Immunocytochemistry on COS-7 cells 
COS-7 cells expressing rNTS2 were stimulated or not with 1 J.1M NT for 1 h at 37°C, 
fixed for 20 min with 4% paraformaldehyde (PFA) (Polysciences, Warrington, PA), 
preincubated for 30 min with a blocking solution (5% Normal Goat Serum (NGS), 
2% BSA, and 0.1 % Triton (Sigma)) and incubated overnight at 4°C with the NTS2 
antiserum (1125,000) alone, or in concert with either a monoclonal antibody against 
syntaxin 6 (111000; Transduction Laboratories, Lexington, KY) or guinea pig anti-
PIST antibody (111000; gift of Dr. Hans-Jürgen Kreienkamp, Institute for Human 
Genetics, Hamburg, Germany). Cells were then incubated for 1 h at RT with a 
mixture of Alexa 488-conjugated goat anti-rabbit with either Alexa 596-conjugated 
goat anti-mouse or anti-guinea pig antibodies (1/750; Molecular Probes, Eugene, 
OR). Cells were examined with a Zeiss 510 laser scanning confocal microscope 
equipped with Argon2 (488 nm) and HeINel (543 nm) lasers (Carl Zeiss Micro 
Imaging Inc., Thomwood, NY). Images were processed using the Zeiss 510 laser-
scanning microscope software and Adobe Photoshop 6.0. 
To quantify peripheral (as an index of cell surface) versus internaI NTS2 
immunolabeling in permeabilized cells, a total of 12-15 cells per condition (i.e. 
untreated or stimulated for 60 min with NT) from 4 independent experiments were 
randomly selected and analyzed using the ImageJ software (National Institutes of 
Health, Bethesda, MD). For this purpose, peripheral and intracellular compartment 
were delineated and integrated fluorescence densities associated with either of these 
two compartments were measured. Values are expressed as a percentage of the total 
fluorescence density (peripheral + intracellular) for each condition. Statistical 
comparisons between conditions were performed using a Student's t test. 
6.3.6 Measurement of MAP Kinase Activity 
COS-7 cells expressing rNTS2 were incubated at 37°C in DMEM, 2.5% FBS with or 
without 1 J.1M NT for 24 h, serum-starved for 2 h, and then incubated with 1 J.1M NT 
for 0, 5, 15,30 or 60 min at 37°C. The reaction was stopped by addition ofice-cold 
PBS containing 0.1 /lM staurosporine (Sigma) and 1 mM sodium orthovanadate. Cells 
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were then lysed in 50 mM HEPES, pH 7.8, containing 1 % Triton, 0.1 IlM staurosporine, 
1 mM sodium orthovanadate, and protease inhibitors. Cell lysates were centrifuged at 
12,000 g for 10 min at 4°C and protein concentration was determined by the Bio-Rad 
procedure as described above. Samples containing 30 Ilg of protein were denatured in 
Laemmli buffer and resolved by using 10% Tris-glycine precast gels. Nitrocellulose 
membranes were incubated overnight at 4°C with anti-phosphorylated ERK1I2 or anti-
ERK1I2 rabbit antibodies (111000; New England Biolabs, Beverly, MA), followed by 
HRP-conjugated goat anti-rabbit antibody for 1 h at RT (1/4000; Amersham 
Pharmacia Biotech). To quantify the effect of NT on ERK1I2 phosphorylation, the 
ratios of phosphorylated ERK1I2 over total ERK1I2 levels were determined by 
densitometry using Scion Image software. Calculations and statistical analyses were 
performed using Excel 2000 and SigmaPlot 2001. Statistical significance of the 
activation of ERK1I2 between untreated and NT -prestimulated cells was determined 
using a Student's t test. 
6.3.7 NTS2 Immunogold Labeling 
Adult male Sprague Dawley rats (200-250 g; Charles River, St-Constant, QC, 
Canada) were anesthetized with halothane and intrathecally injected or not with NT 
(1200 pmol). After 20 min, rats were transaortically perfused under pentobarbital 
anesthesia with a mixture of3.75% acrolein and 2% PFA. Lumbar spinal cords were 
removed, fixed in 2% PFA and cut (50 Jlm) using a vibrating microtome. Sections 
were incubated in 1 % sodium borohydride and cryoprotectant solution (25% sucrose 
and 3% glycerol) prior to snap freezing in isopentane (-70 OC), transfer to liquid 
nitrogen, and thawing. Section were then incubated for 48 h at 4 oC with NTS2 
antiserum (111800), followed by 2 h at RT with colloidal gold-conjugated goat anti-
rabbit antibody (1150; Cedarlane Laboratories, Homby, ON, Canada). Sections were 
fixed with 2% glutaraldehyde and immunogold deposits were enhanced using the 
IntenSE kit (Amersham Pharmacia Biotech). Sections were then post-fixed with 
osmium tetroxide, dehydrated in ethanol, tlat-embedded in Epon, counterstained with 
lead citrate and uranyl acetate, and examined with a JEOL 100CX transmission 
electron microscope. Negatives were digitized on a scanner and processed using 
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Adobe Photoshop. Quantitative analysis of the ultrastructural distribution of NTS2 
immunoreactivity was perfonned on three to four grids per experimental condition 
from three independent experiments (n = 3 rats). A total of 38 and 31 randomly 
se1ected labe1ed dendritic profiles within the superficial layers (laminae 1 and II) of 
the spinal cord from respective1y non-treated and NT -injected rats were analyzed 
using the Neurolucida morphometry software. First, density of immunoreactive 
NTS2 receptor gold partic1es associated with se1ected dendrites was calculated per 
surface area and expressed as immunogold/silver partic1es per J.1m2• Second, gold 
partic1es were c1assified as being intracellular or membrane-associated. The 
proportion of membrane-associated NTS2 receptors was expressed as a percentage of 
the total number of gold partic1es. Statistical comparisons between groups were 
perfonned using a Student's t test. Differences were considered significant for p < 
0.05. 
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6.4 RESULTS 
6.4.1 Cell Surface NTS2 Receptors are Resistant to Down-regulation 
To investigate the effects of prolonged incubation with NT on NTS2 cell surface 
density, rNTS2-expressing COS-7 cells were prestimulated with 1 J.lM NT for up to 
24 h at 37°C and cell surface receptor binding was carried out using 0.4 nM e25I]-NT 
on ice. As shown in Fig. 6.IA, NT stimulation resulted in an immediate decrease in 
the density of cell surface NTS2 binding sites (50 ± 4% of baseline values after 5 
min). A similar but weaker response was obtained in NTS l-expressing cells (73 ± 
2% of baseline values at 5 min; Fig. 6.1A). Upon sustained NT exposure, NTS2 
binding progressively returned to baseline values (100 ± 4% of baseline after 24 h) 
whereas NTS 1 binding kept on decreasing (46 ± 1 % of baseline after 24 h; Fig. 
6.IB). NTS2 binding sites were also maintained at baseline levels after a 24 h-
stimulation with the metabolically-stable NT analog JMV -431 (106 ± 6%), 
suggesting that maintenance of NTS2 cell surface binding sites was not due to 
peptide degradation (not shown). Taken together, these data show that contrary to 
NTS l, cell surface NTS2 binding sites are maintained following persistent agoni st 
stimulation despite efficient internalization mechanisms (Botto et al., 1998). 
6.4.2 Effect of Prolonged NT Exposure on NTS2 Receptor Protein Levels 
In order to determine whether prolonged exposure to NT affected total NTS2 protein 
levels, rNTS2-expressing COS-7 cells were stimulated with 1 J.lM NT for different 
periods of time and crude membrane preparations were analyzed by Western blotting 
using a NTS2 peptide antiserum. As seen in Fig. 6.2, the total levels of 
immunodetected-NTS2 (45 kDa) were not significantly different after than before NT 
stimulation (103 ± 15% of control values after 24 h), suggesting that NTS2 is neither 
up- nor down-regulated following prolonged agoni st exposure. To confirm that 
prolonged NT stimulation did not induce NTS2 neosynthesis, COS-7 cells were 
incubated with NT in presence of the protein synthesis inhibitor cycloheximide for up 
to 24 h. Immunoblotting of crude membrane preparations using the NTS2 peptide 
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antiserum revealed that treatment with cyc10heximide did not affect receptor protein 
levels (not shown). 
6.4.3 Maintenance of Cell Surface NTS2 is a Recycling-independent Process 
To investigate whether receptor recycling accounted for the preservation of cell 
surface NTS2 receptors following prolonged NT exposure, rNTS2-expressing COS-7 
cells were first preincubated with monensin for 30 min and incubated with 1 /-lM NT 
together with monensin for 1 h at 37°C. Monensin is known to hinder late receptor 
recycling steps beyond the acidification of endocytic vesicles (Tycko et al., 1983). 
As shown in Fig. 6.3A monensin had little if any effect on the preservation of [1251]_ 
NT binding levels following NT exposure. Indeed, cell surface levels of NTS2 
receptors represented 92 ± 8% of pre-stimulation values, which were comparable to 
those measured in the absence of monensin following the same stimulation period 
with NT (90 ± 4%). 
Previous site-directed mutagenesis studies have revealed that Tyr 237 is a 
critical residue in the recycling process of NTS2 receptors (Martin et al., 2002b). 
Indeed, the human NTS2 in which a cysteine residue naturally replaces the tyrosine 
in position 237 does not undergo recycling following ligand-induced intemalization 
(Martin et al., 2002b). In order to study further the potential implication of receptor 
recycling in the maintenance cell surface NTS2 receptors, hNTS2-expressing COS-7 
cells were prestimulated with 1 /-lM NT for up to 24 h at 37°C and cell surface 
receptor binding was carried out by using 0.4 nM e251]-NT on ice. As shown in Fig. 
6.3B, NT stimulation resulted in rapid decrease in the density of cell surface human 
NTS2 binding sites (36 ± 8% of baseline values after 5 min), suggesting efficient 
ligand-induced intemalization. However, human NTS2 receptors also progressively 
resurfaced upon extended agoni st exposure (82 ± 5% of baseline after 24 h) despite 
their inability to undergo recycling (Martin et al., 2002b). Taken together, these 
results suggest that receptor recycling does not account by itself for the maintenance 
of cell surface NTS2 receptors, but that other mechanisms must be brought into play. 
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6.4.4 Effeet of Long-term NT Exposure on NTS2 Traffieking and Funetion 
In order to visualize the effect of NT stimulation on NTS2 intracellular trafficking, 
transfected COS-7 cells were incubated in the presence or absence of 1 JlM NT for 60 
min at 37°C and the distribution of immunolabeled receptors was examined by 
confocal mlcroscopy. Immunostaining of non stimulated, permeabilized cells 
revealed a prominent juxtanuclear pool of NTS2 receptors as well as small 
peripheral, presumably membrane-associated, receptor clusters (Fig. 6.4A). To 
ensure that the localization of the receptors was not due to an idiosyncratic feature of 
COS-7 ceIls, we repeated the experiments using CHO cells stably expressing rNTS2. 
As in COS-7 cells, NTS2 exhibited a predominantly intracellular distribution (not 
shown). Following 60 min stimulation with NT at 37°C, intracellular 
immunoreactive receptors were no longer concentrated next to the nucleus, but 
became scattered throughout the cytoplasm in the form of small vesicle-like clusters 
(Fig. 6.4A). However, there was no apparent change in the density of cell surface 
receptor clusters (Fig. 6.4A, arrowheads). Indeed, quantitative image analysis 
confirmed that there was no difference in the relative density of peripheral 
immunolabeling before and after NT stimulation (15,3 ± 1.8% versus 15.9 ± 3.6%, 
respectively; p > 0,95; Fig. 6.4B). These data suggest that receptor activation results 
in a redistribution of intracellular receptor stores without any apparent loss of cell 
surface receptors. 
To ascertain whether NTS2 receptors present at the cell surface following 
prolonged NT exposure were functional, rNTS2-expressing COS-7 cells were 
preincubated or not with 1 JlM NT for 24 h at 37°C and serum-starved for 2 h without 
the agoni st. ERK1I2 phosphorylation was then measured in response to subsequent 
pulse stimulations with NT. As shown in Fig. 6.5, NT induced a rapid « 5 min) and 
sustained phosphorylation (over 1 h) of ERK1I2, irrespective of whether cells had 
been preincubated or not with NT for 24 h. Moreover, densitometric analysis of the 
ratio of phosphorylated ERK1I2 over total ERK1I2 levels indicated that NT 
pretreatment did not significantly influence the agonist-induced ERKI/2 activation 
(5.2 ± 1.6 versus 4.6 ± 0.6-fold increase in ERKI/2 phosphorylation levels at 5 min 
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in cells pretreated or not with NT, respectively; p > 0.95). This effect was NTS2-
mediated since it was not observed in untransfected cells (not shown). Thus, these 
data indicate that NTS2 receptors maintained at the cell surface following sustained 
ligand exposure are truly functional. 
6.4.4 Golgi and TGN as Putative Sources of Newly Recruited NTS2 Receptors 
To investigate putative intracellular sources for the membrane recruitment of NTS2 
receptors, we co-Iocalized NTS2 with the molecular markers syntaxin 6 or PIST, 
using dual labeling immunocytochemistry in rNTS2-expressing COS-7 cells. 
Previous studies have shown that Syntaxin 6 is present mainly in the trans-Golgi 
network (TGN) and participates in vesicular trafficking between the TGN and 
endosomes (Bock et al., 1997), whereas PIST (PDZ domain rrotein Interacting 
~pecifically with TCI0) is known to be associated with the Golgi apparatus (Wente 
et al., 2005). In unstimulated cells (Fig. 6.6A-F), NTS2 immunoreactivity (Fig. 6.6A 
and D) was largely intracellular and concentrated in a compact juxtanuc1ear structure 
that was immunopositive for endogenous syntaxin 6 (Fig. 6.6B) and PIST (Fig. 6.6E), 
as shown in overlays (Fig. 6.6C and F). These data strongly suggest that NTS2 
localizes primarily to the TGN/Golgi complex. This observation was confirmed by 
the fact that disassembly of the Golgi complex by Brefeldin A induced a total 
dispersion of NTS2 through the cytoplasm (data not shown). Following a 1 h-
incubation with 1 ~M NT (Fig. 6.6G-L), NTS2 immunolabeling was still noticeable 
in the TGN/Golgi where it remained co-Iocalized with syntaxin 6 (Fig. 6.6H) and 
PIST (Fig. 6.6K). However, NTS2 was also apparent in vesic1e-like structures 
distributed throughout the cytoplasm of the cells. These fluorescent c1usters were 
partially immunopositive for syntaxin 6, but not for PIST, as shown in overlays (Fig 
6.61 and L). Similar experiments using the anti-Iampl antibody as a molecular 
marker revealed that NT exposure did not induce the trafficking ofNTS2 receptors to 
lysosomes for degradation (not shown). Taken together, these data suggest that 
NTS2 receptors targeted to the plasma membrane subsequent to NT stimulation could 
originate from the TGN/Golgi. 
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6.4.6 Effect of NT Stimulation on Cell Surface NTS2 Density in Rat Spinal Cord 
To determine whether the preservation of cell surface NTS2 receptors observed 
following sustained stimulation of transfected cells in vitro also occurred in neuronal 
cells in vivo, we examined by immunoelectron microscopy the fate of NT -stimulated 
NTS2 receptors in neurons of the superficial layers of the rat spinal cord, which had 
previously been reported to contain high concentrations of NTS2 receptor 
immunoreactivity (Sarret et al., 2005). In both stimulated and unstimulated 
conditions, the bulk of NTS2 immunoreactivity was associated with dendritic shafts, 
branches and branchlets (Fig. 6.7A and B). In saline-injected rats, NTS2 
immunolabeling within these dendrites was associated mostly with intracellular 
vesicles and organelles (Fig. 6.7A). Onlya small fraction of immunogold particles 
was found on the plasma membrane (4.7 ± 2.6% of total; Fig 6.7C). Following 20 
min exposure to intrathecal NT, there was a considerable increase in the proportion of 
immunogold-receptor complexes associated with the plasma membrane (35.1 ± 8.5% 
of total; Fig 6.7B and C). By contrast, the density of immunoreactive receptors 
(immunogold particles per J.lm2) was not statistically significantly different between 
NT- (4.6 ± 2.3 particles/llm2) and saline-injected (8.2 ± 4.7 particles/llm2) animaIs (p 
> 0.95; Student's t-test), indicating that the NT-induced change in plasma membrane 
receptor density was a trafficking event. 
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6.5 DISCUSSION 
In the present study, we have demonstrated a preservation of cell surface NTS2 
receptor densities following prolonged exposure to NT. This preservation did not 
depend on receptor neosynthesis or recyc1ing, but appeared to involve recruitment of 
spare receptors from intracellular stores to the plasma membrane. 
Sustained activation of most GPCRs triggers a time-dependent dec1ine of cell 
surface receptors. This process, which reverses upon agoni st removal, is of direct 
clinical relevance as it accounts in part for cellular desensitization to a variety of 
GPCR-acting drugs (Roth et al., 1998). As contirmed in the present study, agoni st 
stimulation of NTS 1 likewise resulted in a loss of cell surface receptors that is known 
to occur through internalization and lysosomal degradation degradation (reviewed in 
Hermans and Maloteaux, 1998). In the case of NTS2, stimulation with NT was 
found here to tirst induce a rapid decrease in cell surface receptor density (i.e. 50 % 
by 5 min). This decrease was previously shown by us (Sarret et al., 2002) and others 
(Botto et al., 1998) to be due to ligand-induced receptor intemalization and, 
accordingly, to be entire1y abolished in the presence of sucrose or phenylarsine oxide, 
which inhibits internalization. However, this decrease was short-lived and, in spite of 
persistent ligand exposure, NTS2 receptors rapidly resurfaced. Indeed, binding 
activity recovered to 80% of pre-stimulation leve1s by 1 h and to 100% after 24 h of 
stimulation with NT. This reinstatement of cell surface receptors cannot be ascribed 
to ligand degradation as the same phenomenon was observed when the incubation 
was carried out with the protease-resistant NT analog JMV-431, instead of NT. The 
cell surface binding sites maintained during persistent NT exposure corresponded to 
functional NTS2 receptors since NT-induced ERKII2 phosphorylation levels in cells 
exposed to NT for 24 h were comparable to those measured in control cells and were 
similar to those previously reported in rat cerebellar granule cells (Sarret et al., 2002) 
and transfected CHû cells (Gendron et al., 2004). 
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Maintenance of cell surface receptors in response to sustained activation has 
been documented for a limited number of GPCRs inc1uding the P3-adrenergic 
receptor (Thomas et al., 1992), somatostatin receptor subtype 1 (Hukovic et al., 
1999), and AT2 angiotensin II receptors (Dudley et al., 1993). It has also been shown 
for the single transmembrane domain receptor NTS3, following prolonged 
stimulation with NT (Navarro et al., 2001; Morinville et al., 2004). Cell surface 
receptor densities are known to result from the equilibrium between receptor 
intemalization, recyc1ing and recruitment from intracellular stores (Koenig et al., 
1997). In the case of NTS2, recyc1ing of intemalized receptors, demonstrated under 
different experimental conditions (Botto et al., 1998; Debaigt et al., 2004), did not 
appear to account significantly for the reinstatement of the plasma membrane 
receptor population after prolonged NT exposure. Indeed, cell surface receptor 
recovery was not affected by blockade of receptor recycling with monensin nor by 
replacing rat NTS2 with the non-recyc1ing human NTS2 (Martin et al., 2002b). 
Neither did the maintenance of cell surface NTS2 receptor densities appear to require 
receptor neosynthesis since NTS2 protein leve1s, as measured by Western blotting, 
remained unchanged following NT exposure with or without the protein synthesis 
inhibitor cyc1oheximide. 
Immunocytochemistry revealed that under baseline conditions, the bulk of 
NTS2 proteins were intracellular (i.e. 84.7 ± 1.8% of total receptors in basal 
conditions). This observation is in agreement with the results of subprograms 
executed by the PSORT II server (Kenta Nakai, Ph.D., Institute for Medical Science, 
University of Tokyo, Japan), which predicted the subcellular localization of NTS2 
from its amino acid sequence to be poorly localized to the plasma membrane (22.2%) 
and possibly confined to intracellular stores such as the endoplasmic reticulum 
(33.3%), Golgi apparatus (11.1 %), intracellular vacuoles (22.2%), and mitochondrial 
compartments (11.1%). However, confocal microscopic experiments on 
permeabilized cells demonstrated that NT induced an extensive redistribution of 
NTS2 receptors from the TGN/Golgi complex (syntaxin 6 and PIST-positive) to 
vesic1e-like structures, suggesting that the maintenance of surface NTS2 receptors 
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involved mobilization of spare receptors from internaI stores. Although syntaxin 6 
was mainly concentrated in the TGN, it was also detected in the NTS2-containing 
vesic1es that formed as a result of NT exposure. This co-Iocalization is consistent 
with previous results showing that syntaxin 6 co-Iocalizes broadly with the early 
endosomal autoantigen EEAI in BHK-2l cells and may therefore be implicated in 
TGN to endosomes trafficking (Simonsen et al., 1999). Interestingly, an earlier study 
in NTS2-expressing cerebellar granule cells had demonstrated that following 
prolonged NT stimulation, internalized fluorescently-Iabeled NT was targeted to a 
syntaxin 6-positive juxtanuc1ear compartment, corresponding to the TGN (Sarret et 
al., 2002). It is therefore possible that internalized NT is targeted to the TGN and 
serves as a triggering signal for the translocation of resident NTS2 receptors from this 
compartment to the cell surface, implying a dynamic regulation of subcellular protein 
localization. 
The physiological and pharmacological relevance of the present results was 
confirmed by immunogold electron microscopic studies of the superficiallaminae of 
the rat spinal cord. Intrathecal injection of NT resulted in a seven-fold increase in the 
proportion of immunoreactive NTS2 receptors associated with dendritic plasma 
membranes as compared with saline-injected controls. This increase in the density of 
plasma membrane-associated NTS2 was not accompanied by a statistically 
significant increase in the overall receptor population, suggesting that, as in our in 
vitro studies, the NT-induced increase ofNTS2 receptors at the plasma membrane of 
dorsal horn neurons was a trafficking event. These results are reminiscent of the 
enhanced recruitment of delta opio id receptors (DOR) to the plasma membrane of 
dendrites in the same superficial laminae of the dorsal horn following either 
prolonged morphine treatment (Cahill et al., 2003) or chronic inflammation (Cahill et 
al., 2001). However, whereas this enhanced DOR targeting was heterologously 
mediated through stimulation of jl-opioid receptors (Morinville et al., 2003), the 
present increase in NTS2 externalization likely results from stimulation of NTS2 
receptors themselves. The present results may, therefore, explain the highly potent, 
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long-lasting antinociceptive effects of the NTS2-specific agoni st JMV -431 in tests of 
spinal analgesia (Sarret et al., 2005). 
In conclusion, we have demonstrated that cell surface NTS2 receptors are 
resistant to down-regulation following persistent exposure to NT. By inference from 
the patterns of intracellular distribution of NTS2 receptors observed using confocal 
and electron microscopy, we propose that the maintenance of cell surface NTS2 
receptors is due in part to the recruitment of spare receptors from internaI stores. 
This stimulation-induced regulation of cell surface NTS2 receptors was even more 
striking in rat spinal cord neurons in vivo (7-fold increase in cell surface receptor 
density) than in transfected COS-7 cells in vitro (return to baseline). Such 
maintenance of NTS2 bioavailability upon prolonged agoni st treatment might prove 
of great importance for the use of NTS2-se1ective agonists for the treatment of 
chronic pain. 
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6.8 ABBREVIATIONS 
NT, neurotensin; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine 
serum; BSA, bovine serum albumin; PB, phosphate buffer; RT, room temperature; 
GPCR(s), G protein coupled receptor(s); TM, transmembrane domain; CûS-7 cells, 
green African monkey kidney cells; CHû, Chinese hamster ovary; MAPK, mitogen-
activated protein kinase; ERK1I2, extracellular signal-regulated kinases 112; TGN, 
trans-Golgi network. 
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6.10 FIGURE LEGENDS 
Fig. 6.1: Persistent Agonist-Induced Regulation of Cell Surface NT Receptors. 
COS-7 cens expressing rNTS2 (.) or NTS 1 (0) were exposed to 1 )..lM NT for 0-60 
min (A) and up to 24 h (B) at 37°C, acid-washed, and incubated with [1251]_NT on ice 
for monitoring cell surface receptors. The results are representative of three 
individual experiments ± S.E.M, each with triplicate determinations. Student's t tests 
were used to compare NT cen surface binding sites between rNTS2 and NTS 1 
expressing COS-7 cens. Values are significantly different at an time points with *, p 
< 0.05 and **,p < 0.01. 
Fig. 6.2: Effect of NT Stimulation on NTS2 Receptor Protein Levels in COS-7 
Cells. COS-7 cens transiently transfected with cDNA encoding the rNTS2 receptor 
were stimulated with 1 )..lM NT for different periods of time at 37°C and membranes 
were isolated as described under "Materials and Methods". Similar experiments were 
done with untransfected (UT) cens as a negative control. Western blotting analysis 
was performed using the NTS2 peptide antiserum after a 10% Tris-glycine gel 
electrophoresis under reducing conditions and NTS2 receptor protein levels were 
quantified by densitometric analysis. The data represent the mean ± S.E.M of three 
individual experiments. 
Fig. 6.3: Recycling is Not Involved in the Maintenance of Cell Surface NTS2 
Binding Sites. A, COS-7 cens expressing rNTS2 were preincubated with 25 )..lM 
monensin for 30 min and stimulated with NT with the recyc1ing inhibitor for 1 h at 
37°C. The peptide was removed by acid wash and cens were incubated with [1251]_ 
NT on ice to determine the amount of cell surface receptors. Each point is the mean 
± S.E.M from triplicate determinations of at least two different experiments. B, 
COS-7 cens expressing the non-recyc1ing human NTS2 receptor were exposed to 1 
)..lM NT for up to 24 h at 37°C, acid-washed, and incubated with [125I]_NT on ice for 
monitoring cen surface receptors. The results are representative of two individual 
experiments ± S.E.M, each with triplicate determinations. 
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Fig. 6.4: NT -Induced Intracellular Redistribution of NTS2 Receptors in COS-7 
Cells. A, rNTS2-expressing COS-7 cells were stimulated or not with 1 /lM NT for 60 
min at 37°C. Immunolabeling was then performed on permeabilized cells by using 
the NTS2 peptide antiserum. Scale bar = 5 /lm. B, Quantitative analysis ofNTS2-
like immunoreactive staining densities in COS-7 cells stimulated or not with NT. 
Data are expressed as a percentage of integrated density values associated with 
peripheral (inc1uding cell surface) versus intracellular compartments over total 
fluorescence (representative of four independent experiments). 
Fig. 6.5: Effect of Persistent Stimulation with NT on ERK1I2 Phosphorylation 
in COS-7 Cells Heterologously Expressing rNTS2. Cells were pretreated (0) or 
not (e) with 1 /lM NT for 24 h at 37°C and subsequently incubated with 1 /lM NT 
for the indicated periods of time (0-60 min). ERKl/2 activity was determined by the 
ratio of the densitometric analysis of phosphorylated ERKl/2 over total ERKl/2 
levels expressed as fold increase over control. Data represent the means ± S.E.M of 
two individual experiments, each with triplicate determinations. 
Fig. 6.6: Dual Immunolabeling of NTS2 and Trans-Golgi Network Markers in 
COS-7 Cells. Confocal microscopie images of cells transiently expressing rNTS2 
preincubated (G-L) or not (A-F) with 1 /lM NT for 1 h at 37°C. In unstimulated cells, 
NTS2 labeling with the NTS2 peptide antiserum (A, D) co-Iocalizes with 
immunoreactivity for the TGN/Golgi markers syntaxin 6 (R) and PIST (E) in the 
perinuc1ear zone as evident in the overlays (C, F). Following incubation with NT, 
NTS2 immunostaining is punctate and dispersed throughout the cell. Part of NTS2-
positive vesic1es also exhibit syntaxin 6 (H) but not PIST (K) immunoreactivity as 
shown in the merged images (1, L). All images were acquired using the same 
parameters and represent three different experiments. 
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Fig. 6.7: Electron Microscopie Detection of NTS2 Immunoreactive Receptors in 
Superficial Laminae of the Rat Lumbar Spinal Cord. A, In the absence of the 
agonist, gold partic1es (i.e. NTS2 immunolabeling) are mainly intracellular and 
poorly associated with dendritic (Den) plasma membranes. B, In the presence of NT, 
numerous immunogold partic1es are associated with dendritic plasma membranes 
(arrowheads). C, Effects of NT exposure on membrane-associatedltotal NTS2. The 
asterisk indicates a significant difference (p < 0.05) from control. 
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7.1 ABSTRACT 
G protein-coupled neurotensin (NT) receptors NTS 1 and NTS2 show considerable 
distributional overlap in mammalian central nervous system (CNS). However, 
studies on transfected cells demonstrate that while NTS 1 localizes predominantly to 
the plasma membrane, the bulk of NTS2 receptors are intracellular when either 
receptor is expressed alone. Using co-immunoprecipitation approaches, we 
demonstrate here that in transfected COS-7 cells NTS 1 forms constitutive 
heterodimers with NTS2 via hydrophobie interactions. We also show using 
radioligand-binding and confocal immunolocalization techniques, that co-expression 
of NTS2 with NTS 1 markedly decreases the cell-surface density of NTS 1 as 
compared to cells expressing NTS 1 alone. Functionally, NT -induced increase in 
ERKI/2 MAPK activity was similar in cells expressing NTS 1 alone or together with 
NTS2, indicating that NTSI/NTS2 heterodimerization did not affect this signaling 
pathway. Likewise, NT -induced NTS 1 internalization was equally efficient in both 
cell types. However, radioligand-binding studies indicated that upon prolonged NT 
stimulation, cell surface NTS 1 receptors were more resistant to down-regulation in 
cells co-expressing NTS 1 and NTS2 than in cells expressing NTS 1 alone. Taken 
together, these data suggest that NTSI/NTS2 heterodimerization affects the intra-
cellular distribution and trafficking of NTS 1 by making it more similar to that of 
NTS2 as witnessed in cells expressing NTS2 alone. NTSI/NTS2 heterodimerization 
might therefore represent an additional mechanism in the regulation of NT -triggered 
responses mediated by NTS 1 and NTS2 receptors. 
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7.2 INTRODUCTION 
There is now strong evidence that many GPCRs form homo and/or heterodimers and 
that these molecular interactions are required for their normal functioning and 
trafficking (Bouvier, 2001; Bai, 2004a and 2004b; Prinster et al., 2005). For 
instance, the heterodimerization of GABABRI and GABABR2 within the 
endoplasmic reticulum was shown to be required for the formation of functional 
GABAB receptors at the cell surface (Margeta-Mitrovic et al., 2000). Other studies 
have demonstrated that heterodimerization of taste receptors is necessary for sensing 
sweet substances or L-amino acids such as monosodium glutamate (Nelson et al., 
2001; Nelson et al., 2002). However, heterodimerization between different receptor 
subtypes can also exert a dominant-negative effect on intracellular signaling. In the 
case of ~ adrenergic receptors (AR), heterodimerization of ~IAR with ~2AR has been 
shown to inhibit both ~2AR-dependent activation of extracellular signal-regulated 
kinases (ERK1I2) and its ligand-induced intemalization (Lavoie et al., 2002). 
Likewise, the functional properties of the somatostatin receptor subtype 5 (SST5) 
were found to be modified by its heterodimerization with SSTI (Rocheville et al., 
2000). 
N eurotensin (NT) is a brain and gastrointestinal peptide that mediates a variety 
of central and peripheral functions including opioid-independent antinociception, 
neuroleptic-like modulation of dopamine neurotransmission and inhibition of food 
intake (Tyler-McMahon et al., 2000; Vincent et al., 1999). Three different NT 
receptor subtypes have been cloned to date. NTS 1 and NTS2 belong to the family of 
G protein-coupled receptors (GPCRs), whereas NTS3 is a single transmembrane 
domain sorting receptor with 100% homology to sorti lin (Tanaka et al., 1990; Chalon 
et al., 1996; Mazella et al., 1998; Petersen et al., 1997). The rat NTS 1 cDNA 
contains a large open-reading frame encoding a 424-amino acid protein, sharing 43% 
identity and 64% homology with NTS2 (Tanaka et al., 1990; Chalon et al., 1996). 
However, whereas NTS 1 binds NT with high affinity (KI = 0.2 nM), NTS2 binds NT 
with a tenfold lower affinity (KI = 2 nM). Furthermore, NTS2 recognizes the 
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antihistamine drug levocabastine, white NTS 1 does not (Vincent et al., 1999). 
Although the lengths of both receptor proteins are very similar, NTS 1 and NTS2 
differ markedly in their third intracellular domains and C-terminal tails, two regions 
bearing specificity for G-protein coupling and receptor regulation. Accordingly, 
different sets of transduction and trafficking mechanisms have been linked to each 
receptor subtype. Whereas NTS 1 was shown to modulate intracellular levels of 
cGMP (Amar et al., 1985), inositol phosphates (Watson et al., 1992), cAMP (Bozou 
et al., 1989a), and ERKl/2 (Poinot-Chazel, et al., 1996), NTS2 was found to induce 
Ca2+-dependent chloride currents in Xenopus oocytes (Botto et al., 1997c) and to 
activate ERKl/2 signaling cascades, both in CHO (Gendron et al., 2004) and rat 
cerebellar granule cells (Sarret et al., 2002). Furthermore, while both receptors 
efficiently intemalize upon ligand binding, NTS 1 down-regulates from the cell 
surface and undergoes lysosomal degradation (Hermans and Maloteaux, 1998; 
Vandenbulcke et al., 2000), whereas NTS2 recycles and does not down-regulate from 
the cell surface even after prolonged receptor stimulation (Perron et al., 2006). 
A recent study has demonstrated that NTS 1 and NTS3 formed heterodimers in 
the HT29 cell line (Martin et al., 2002b). This interaction was shown to modulate 
both NTSI-mediated ERKl/2 MAPK signaling and phosphoinositide turnover 
(Martin et al., 2002b). To date, there has been no evidence for heterodimerization 
between NTS 1 and NTS2, but both of these NT receptor subtypes possess a cysteine 
residue in each of their extracellular loops, which could enable the formation of 
disulfide bonds between them (Vincent et al., 1999). Indeed, the formation of 
disulfide bonds was shown to be essential for dimerization and proper trafficking of 
other types of receptors (Fan et al., 1998). Furthermore, there is considerable 
regional and cellular overlap between the distributions of NTS 1 and NTS2 in rodent 
brain, suggesting that these receptors are in a position to interact with one another 
physiologically (Boudin et al., 1996b; Sarret et al., 2003a). 
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In the present study, we combined biochemical and pharmacological approaches 
to investigate the ability of NTS 1 and NTS2 receptors to interact with one another in 
heterologous transfection systems. We demonstrate that NTS 1 and NTS2 receptor 
subtypes can form constitutive heterodimers. This heterodimerization does not alter 
ERKl/2 MAPK signaling but influences the subcellular distribution of NTSI and 
decreases its capacity to down-regulate following persistent agoni st exposure. 
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7.3 EXPERIMENTAL PROCEDURES 
7.3.1 Expression of NTS1 and NTS2 mRNAs 
In order to study the expression patterns of NTS 1 and NTS2 rnRNAs in the rat CNS 
and spinal cord, adult male Sprague-Dawley rats (200-250 g; Charles River, St-
Constant, Québec, Canada) were killed by decapitation. The brain and spinal cord 
were rapidly removed and areas of interest dissected on ice. Samples were processed 
as described in Perron et al., (2005). Total mRNAs (2 !-lg) were then reverse-
transcribed at 42°C for 1 h using the Reverse Transcription System kit (Promega, 
Madison, WI, USA). First strand cDNAs were subjected to 35 cycles of polymerase 
chain reaction (PCR) in a final volume of 50 !-lI reaction buffer (50 mM KCl, 10 mM 
Tris-HCl, pH 9.0,1.5 mM MgCh, 0.1% Triton X-100, 0.02% bovine serum albumin 
(BSA), 200 !-lM dNTPs, 0.5 unit of Taq DNA polymerase) containing one of the 
following pairs of sense and antisense primers. The first set (5'-
ACACCCATTGTGGACACAGCC-3' and 5'-TTCATCCGAGATATAGCAGAA-
3 ') allows the amplification of a fragment of the rat NTS 1 receptor cDNA with a 
predicted size of 335 bp as demonstrated in (Sarret et al., 2002). The second pair of 
oligonucleotides (5 '-GAATGTGCTGGTGTCCTTCGC-3 , and 5'-ACTTGTAT-
TTCTCCCAGGCTG-3') is derived from bases 667-1287 in the sequence previously 
reported for the rat NTS2 receptor (Chalon et al., 1996). These primers are bordering 
the region where the 181 bp-deletion takes place in the rat vNTS2, allowing the 
amplification of fragments of 620 and 439 bp as established before in rat cerebellar 
granule cell cultures (Sarret et al., 2002). 
7.3.2 Gene Constructs 
The molecular cloning of the cDNA sequence encoding the rat truncated (NTS2-
STOP) or full-length NTS2 receptors into the mammalian expression vector pTargeT 
(Promega, Madison, WI), and HA-tagged NTS 1 in pcDNA3 has been described 
previously (Perron et al., 2005; Sarret et al., 2003a; Labbé-Jullié et al., 1998). The 
C363A, C621A and C993A (cysteine ~ alanine) NTS2 mutants were obtained by 
site-directed mutagenesis on the NTS2 full-length cDNA with the QuickChange® II 
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Kit (Stratagene, La Jona, CA), using the respective pairs of sense and antisense 
primers (MOBIX laboratory, McMaster University, Hamilton, Ontario, Canada): (5'-
CTTCGGCGATCTGGGCGCCCGTGGCTA TT ACTTCG-3' 15' -CGAAGT AA TAG-
CCACGGGCGCCCAGATCGCCGAAG-3 '), (5' -GCCTGCCTCGCGTGTGGCCA-
CGGTGCTGGTGAGCC-3' 15' -GGCTCACCAGCACCGTGGCCACACGCGAGC-
AGGC-3 ') and (5' -CGCCGACTCATGTACGCCTACATCCCCGATGATGG-3' 1 
5' -CCATCATCGGGGATGTAGGCGTACATGAGTCGGCG-3 '). The C6211993A 
and C363/993A double mutants and the C363/621/993A triple mutant were created 
by changing cysteine at a given site to alanine throughout the next rounds of 
mutagenesis. The fidelity of PCR amplification was confirmed by DNA sequence 
analysis using the ABIPRISM® 3100 Genetic Analyzer in the MOBIX laboratory. 
7.3.3 Cell Culture and Transfections 
COS-7 cens were cultured in Dulbecco's modified Eagle's medium (DMEM) with 
high glucose supplemented with 5% fetal bovine serum (FBS) in the presence of 
penicillinlstreptomycin (100 units/ml; Invitrogen Burlington, Ontario, Canada). Cells 
were grown to 70-80% confluence in lOO-mm dishes at 37°C in a humidified 
atmosphere of 95% air and 5% C02. cens were then transiently transfected with 7 
ml of a mixture of 100 IlM chloroquine and 0.25 mg/ml DEAE-dextran containing a 
total of 4 Ilg of plasmid DNA (2 Ilg of HA-NTS 1 with 2 Ilg of either pTargeT vector 
or untagged-NTS2). 
7.3.4 lmmunoprecipitation and lmmunoblotting Analysis 
For immunoprecipitation studies, COS-7 cens expressing the HA epitope-tagged 
NTS 1 together with the untagged NTS2 receptor were lysed in RIPA buffer (150 nM 
NaCI, 50 mM Tris-Hel, pH 7.5, 5 mM EDTA, 1% IGEPAL, 0.5% deoxycholic acid, 
0.1 % sodium dodecyl sulfate) including protease inhibitors (Complete inhibitor 
tablets; Roche Laboratories, Montreal, Québec, Canada) and incubated for 30 min on 
ice. Lysates were then precleared with 25 Ilg of protein A-Sepharose (Sigma, St-
Louis, MO) for 45 min at 4°C and incubated overnight at 4°C with either a mouse 
monoclonal antibody (clone 12CA5) directed toward the HA epitope (1/500; Roche 
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Mo1ecu1ar Biochemica1s, Indianapolis, IN) or a rabbit NTS2 peptide antiserum 
(111,000; made on demand by Affinity BioReagents, ABR, Golden, CO). Receptor 
proteins were immunoprecipitated with 100 Jlg of protein A-Sepharose for 2 h at 4°C. 
Complexes were dissolved in Laemmli sample buffer (Laemmli, 1970) and resolved 
on 10% Tris-glycine precast gels (Invitrogen, Burlington, Ontario, Canada). 
Nitrocellulose membranes (Bio-Rad Laboratories, Mississauga, Ontario, Canada) were 
then incubated with either NTS2 peptide antiserum (1110,000) or anti-HA (112,500) 
overnight at 4°C, followed by a I-h incubation with horseradish peroxidase (HRP)-
conjugated goat anti-rabbit or HRP-conjugated goat anti-mouse antibodies (113,500; 
Amersham Pharmacia Biotech, Baie d'Urfé, Québec, Canada), respectively. 
Immunoreactive proteins were visualized using an enhanced chemiluminescent 
system (Perkin Elmer Life Science, Boston, MA). 
For structural heterodimerization experiments, COS-7 cells expressing HA-
NTSI together with either pTargeT vector or NTS2 mutants (C363A, C621A, 
C993A, C6211993A, C363/993A, C363/6211993A, and NTS2-STOP) were processed 
as mentioned above. Receptor proteins were immunoprecipitated using anti-HA 
antibody (11400) and immunoblotting was then carried out with the NTS2 peptide 
antiserum (1110,000). 
7.3.5 Immunocytochemical Detection of NTSI and NTS2 
COS-7 cells transfected with HA-tagged NTSI alone or together with untagged-
NTS2 were plated on poly-L-1ysine-coated glass coverslips, fixed for 20 min with 4% 
paraformaldehyde (PF A; Polysciences, Warrington, PA) in PBS, pH 7.4 and 
preincubated for 30 min at room temperature (RT) with a blocking solution 
consisting of 5% Normal Goat Serum (NGS), 2% BSA, and 0.1 % Triton X-I00 
(BDH Inc., Toronto, Ontario, Canada) in PBS. Cells were incubated overnight at 4°C 
with mouse anti-HA (1/500), together with rabbit NTS2 peptide antiserum (1/15,000) 
in PBS containing 1 % NGS and 0.05% Triton X-l 00. Cells were then incubated for 
1 h at RT with a mixture of Alexa 594-conjugated goat anti-rabbit and Alexa 488-
conjugated goat anti-mouse antibodies (1/500; Molecular Probes, Eugene, OR). 
Results were analyzed using a Zeiss 510 laser scanning confocal microscope 
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equipped with Argon2 (488 nm) and HelNel (543 nm) lasers (Carl Zeiss Micro 
Imaging Inc., Thomwood, NY). Images were processed with the Zeiss 510 laser 
scanning microscope software and Adobe Photoshop 6.0. 
7.3.6 Receptor Binding and Internalization Experiments 
For cell surface binding experiments, COS-7 cells transiently expressing NTS 1 alone 
or together with NTS2 were transferred to 24-well plates 24 h following transfection. 
After equilibration for 10 min at 37°C in Earle's buffer (130 mM NaCl, 5 mM KCl, 
1.8 mM CaClz, 0.8 mM MgClz, HEPES 20 mM, pH 7.4) supplemented with 0.2% 
BSNO.l % glucose, saturation experiments were performed by incubating cells with 
increasing concentrations (0.1 to 4.5 nM) of [125I]_NT (2200 Ci/mmol; Perkin Elmer) 
isotopically diluted with unlabeled NT, in 250 III of binding buffer containing 0.8 
mM ortho-phenanthroline, and 10-5 M levocabastine (to prevent NT binding to 
NTS2). Nonspecific binding was determined in para11e1, by adding 10-5 M non-
radioactive NT to the incubation medium. After 30 min at 37°C, cells were washed 
twice with Earle's buffer and solubilized with 1 ml of 0.1 M NaOH. The 
radioactivity content was measured in a gamma counter. Dissociation constant (I<d) 
and maximal binding capacity (Bmax) were derived from Scatchard analysis of the 
data. 
For intemalization experiments, COS-7 cells transiently transfected with HA-
NTS 1 together with pTargeT (control) or NTS2 subc10ned into pTargeT were 
transferred into 24-well plates 24 h prior to assay. Cells were equilibrated for 10 min 
at 37°C in Earle's buffer supplemented with 0.2% BSNO.l% glucose. The 
equilibration medium was then replaced by 250 III of Earle' s buffer containing 0.2 
nM 125I_Iabe1ed NT in the presence of 0.8 mM ortho-phenanthroline and an excess of 
levocabastine (10-5 M) for 3-45 min at 37°C. At the indicate times, cells were 
washed twice with 500 III of binding buffer. To discriminate between surface-bound 
and sequestered 125I-Iabeled NT, cells were washed for 2 min with 500 III of a 
hypertonic acid buffer (Earle's buffer containing 0.2 M acetic acid and 0.5 M NaCI, 
pH 4) to strip off surface-bound radioactivity. Cells were then harvested in 1 ml of 
0.1 M NaOH and cell associated radioactivity was measured in a gamma counter. 
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Non-specifie binding was defined as binding in the presence of 10-5 M unlabeled NT, 
which represented less than 5% of total counts. 
To detennine the effect of prolonged NT exposure on NTSI cell surface 
binding, COS-7 cells transiently expressing NTS 1 alone or together with NTS2 were 
transferred to 24-well plates 24 h following transfection. Cells were incubated with 
or without 1 J.lM NT for up to 24 h in DMEM supplemented with 2.5% FBS. Cells 
were then washed once with hypertonic acid buffer, twice with Earle's buffer, and 
incubated with 0.4 nM [125I]_NT for 60 min on ice in 250 J.lI of Earle's buffer 
supplemented with 0.25% BSA, 0.1 % glucose and 0.8 mM ortho-phenanthroline, in 
the presence of unlabeled levocabastine. Cells were then processed for counting as 
described above. 
AH bindinglinternalization data were calculated and plotted using Prism 4.0 
(Graph Pad Software) and represent the mean ± standard deviation (S.D.) of n 
detenninations (as indicated in "Results"). Statistical comparisons between groups 
were performed using a two-tailed Student's t test. Differences were considered 
significant for p < 0.05. 
7.3.7 Measurement of MAP Kinase Activity 
COS-7 cells transiently expressing NTS 1 alone or together with NTS2 were split into 
6-well plates and incubated for 1-2 days in DMEM high glucose at 37°C. Cells were 
then serum-starved for 2 h and then incubated with 1 JlM NT at 37°C for up to 1 h. 
The reaction was stopped by the addition of ice-cold PBS containing 0.1 J.lM 
staurosporine and 1 mM sodium orthovanadate. After 30 min incubation on ice, cells 
were lysed in 50 mM HEPES, pH 7.8, containing 1 % Triton X-I00, 0.1 J.lM 
staurosporine, 1 mM sodium orthovanadate, and protease inhibitors. Celllysates were 
then centrifuged at 12,500 rpm for 10 min at 4°C and protein concentration was 
detennined using the Bio-Rad procedure with BSA as standard. Paralle1 experiments 
were done using untransfected cells to determine the specificity of the assay. 
Samples containing 30 J.lg of protein were denatured in Laemmli sample buffer and 
resolved on 10% Tris-glycine precast gels. Nitrocellulose membranes were then 
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incubated ovemight at 4°C with anti-phosphorylated ERKl/2 or anti-ERK1/2 rabbit 
antibodies (1/1,000; New England Biolabs, Beverly, MA) in PBS containing 1% 
ovalbumin and 1 % BSA, followed by a 1 h-incubation with HRP-conjugated anti-rabbit 
antibody (113,500). 
In order to quantify the effect of NT on ERK1I2 phosphorylation, the ratios of 
phosphorylated ERK1/2 over total ERK1I2 levels were determined by densitometry, 
using Scion hnage Software. Calculations and statistical analyses were carried out in 
Excel 2000 (Microsoft) and SigmaPlot for Windows version 7.0. The statistical 
significance of the activation of ERK1I2 between cells expressing NTS 1 alone or 
together with NTS2 was determined using a two-tailed Student's t test. Differences 
were considered significant for p < 0.05. 
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7.4 RESULTS 
7.4.1 NTS1 and NTS2 Receptor mRNAs are Co-expressed in Rat CNS 
In order to investigate the expression pattern ofNTSI and NTS2 mRNAs in rat brain 
and spinal cord, two sets of oligonuc1eotides designed to selectively recognize each 
NT receptor subtype were used for reverse-transcription PCR. As illustrated in Fig. 
7.1, PCR amplification of total rnRNA using NTS 1 primers gave rise to a single band 
migrating at 335 bp, as observed in earlier studies of rat whole brain extracts (Sarret 
et al., 2002). NTS 1 rnRNA was detected in aU brain regions examined, as well as in 
the spinal cord and pituitary (Fig. 7.1). PCR amplification of rnRNA using NTS2 
probes yielded two bands of 620 and 439 bp in size, corresponding to the full-Iength 
and transcrlptionally-spliced NTS2 receptor mRNAs, respective1y (Fig. 7.1). Both 
NTS2 transcripts were present throughout the brain and spinal cord but not in the 
pituitary (Fig. 7.1). No signal was detected when amplification was carried out with 
either one of the sense or antisense primers alone, demonstrating the specificity of the 
probes. Semi-quantitative analysis performed using GAPDH as an internaI 
correction standard indicated that the levels of NTS 1 and NTS2 rnRNAs were not 
statistically different between the various regions examined (not shown). Taken 
together, these data revealed that NTS 1 and NTS2 rnRNAs are co-expressed 
throughout the brain and spinal cord. 
7.4.2 Heterodimerization of NTS1 and NTS2 Receptors 
To assess whether NTSI and NTS2 formed hetero-oligomers, HA-tagged NTSI and 
untagged NTS2 cDNAs were co-expressed in COS-7 cells. These cells were then 
stimulated or not with 1 flM NT for 1 h at 37°C, lysed and the lysates subjected to 
immunoprecipitation using a HA antibody (Fig. 7.2; fanes 1 and 2). Western blotting 
analysis of these immunoprecipitates with the NTS2 peptide antiserum showed that 
they contained NTS2 monomers and homodimers (45 and 83 kDa, respective1y; 
arrowheads), which had been co-immunoprecipitated with the HA-tagged NTSI. 
Converse1y, co-immunoprecipitation experiments using the NTS2 peptide antiserum 
followed by immunoblotting with anti-HA revealed the presence of immunoreactive 
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bands at approximately 51 and 100 kDa, eorresponding to the size expeeted for 
monomerie and homodimerie forms of NTSI (Fig. 7.2; lanes 3-4, asterisks). No 
specifie bands were deteeted in cell lysates prepared from untransfeeted cells or in 
immunopreeipitates from cells expressing either HA-NTS1 or NTS2 alone, 
confirming the specificity of the interaction (not shown). Additionally, no co-
immunoprecipitation was observed when lysates derived from cells expressing each 
receptor individually were mixed together, suggesting that solubilization did not 
promote non-specific dimerization (not shown). However, NTS I/NTS2 
heterodimerization was not influenced by NT treatment (Fig. 7.2; lanes 2 and 4), 
indicating that NTS 1 and NTS2 form constitutive heterodimers in transfected COS-7 
cells. 
7.4.3 Structural Requirements for NTS1/NTS2 Heterodimerization 
To investigate whether the formation of disulfide bonds played a role in NTS1/NTS2 
heterodimerization, we tested the ability of a series of NTS2 cysteine mutants to 
heterodimerize with NTS 1. Each construct was expressed in COS-7 cells, together 
with HA-tagged NTS1, and celllysates were subjeeted to immunoprecipitation by 
using the HA antibody. As illustrated in Fig. 7.3, immunoblotting with the NTS2 
peptide antiserum revealed significant amounts of NTS2 monomers (45 kDa; 
asterisk) for all NTS2 cysteine mutants (C363A; lane 1, C621A; lane 2, C993A; lane 
3, C363/621A; lane 4, C363/993A; lane 5, and C363/6211993A; lane 6), implying 
that NTS2 had been effectively co-immunoprecipitated with NTS 1. These results 
thus suggest that disulfide bridging is not necessary for NTS1/NTS2 
heterodimerization. In addition, a second band was also visible around 83 kDa, 
indicating that NTS2 homodimers are not influenced by cysteine mutations 
(arrowhead). 
We also investigated the importance of the NTS2 C-terminal tail in NTS1/NTS2 
heterodimer formation, using a truncated receptor lacking the last 55 amino acids of 
NTS2. This construct was co-expressed with HA-tagged NTS1 and 
immunoprecipitation was carried out with the HA antibody, as described above. 
Western blotting of immunoprecipitates using the NTS2 peptide antiserum revealed 
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the presence of a translation product of approximately 35 kDa as well as a faint band 
around 70 kDa, corresponding respectively to the monomeric and dimeric forms of 
the truncated NTS2 receptor as deduced from its cDNA sequence (Fig. 7.3; lane 7, 
arrows). These results therefore suggest that the NTS2 C-terminal tail is not 
essential for NTS 1/NTS2 heterodimerization and that other domains of the receptors 
are taking part in the physical interaction. 
7.4.4 Co-expression of NTS2 Modifies NTSI Localization 
To determine whether the physical interaction of NTS2 with NTSI affected the 
binding properties of NTS 1, saturation binding studies were carried out on cells 
expressing NTS 1 alone or together with NTS2. As shown in Fig. 7.4A, incubation of 
either cell type with increasing doses of [1251]_NT in the presence of an excess of 
levocabastine to ensure selective labeling of NTSI (addition of levocabastine 
displaced >95% of e25I]-NT binding in cells expressing NTS2 alone; data not 
shown) revealed the presence of specific (i.e. NT-displaceable) and saturable [1251]_ 
NT binding. No significant difference in binding affinity was observed between cells 
expressing NTS 1 alone ("Ki = 0.28 ± 0.14 nM) or in combination with NTS2 ("Ki = 
0.25 ± 0.11 nM). However, Scatchard analysis of the data revealed that the density 
of surface e251]_NT binding sites was nearly 2-fold lower in cells co-expressing 
NTSI and NTS2 as compared to cells expressing NTSI alone (Bmax = 1538 ± 81 
finol/mg versus 2596 ± 89 finol/mg, Fig. 7.4B). Taken together, these results indicate 
that co-expression of NTS2 influences cell surface NTS 1 receptor densities, but not 
the affinity ofNTSl for [125I]_NT. 
7.4.5 Confocal Microscopie Localization of NTSI Receptors 
To confirm the influence ofNTS2 co-expression on the cell surface density ofNTSl, 
we examined the distribution of HA-tagged NTS 1 immunostaining in cells 
expressing NTS 1 alone or together with NTS2, using confocal microcopy. 
Immunocytochemistry revealed distinct distributional patterns for NTS 1 receptors in 
NTSI and NTSI/NTS2-transfected cells. In cells expressing HA-NTSI alone, 
immunoreactive receptors were predominantly located at the cell surface (Fig. 7.5A 
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and C; arrowheads). Only weak NTSI immunolabeling was evident intracellularly 
(Fig. 7.5A and C). By contrast, in cells co-expressing NTS 1 and NTS2, the bulk of 
NTS 1 immunoreactivity was detected intracellularly, within a juxtanuc1ear 
compartment (Fig. 7.5D-F; arrowheads). This NTSI intracellular immunolabeling 
was co-extensive with NTS2 immunoreactivity (Fig. 7.5E and F). Since previous 
studies have shown NTS2 to co-Iocalize with the trans-Golgi network (TGN) marker 
syntaxin 6 (Sarret et al., 2002; Perron et al., 2006), it may be surmised that in cells 
co-expressing NTSI and NTS2, the two receptors are concentrated within the TGN. 
Therefore, immunocytochemical data confirm that the cell surface density ofNTSl is 
decreased upon NTS2 expression in COS-7 cells. 
7.4.6 Effects ofNTSl/NTS2 Heterodimerization on NTSIlnternalization 
To determine whether co-expression ofNTS2 affected ligand-induced endocytosis of 
NTS 1 receptors, intemalization assays were carried out on COS-7 cells transiently 
expressing HA-tagged NTSI alone or in combination with NTS2. Association 
kinetics of[125I]_NT binding were determined on whole cells incubated for 3-45 min 
at 37°C in the presence of levocabastine and the proportion of sequestered 
radioactivity was assessed after hypertonic acid wash of surface-bound ligand. As 
shown in Fig. 7.6, [125I]_NT bound specifically to both NTSI (Fig. 7.6A) and 
NTSl/NTS2-expressing cells (Fig. 7.6B) in a time-dependent manner, reaching a 
plateau within 20 min of incubation. This labeling was specific since it was entirely 
competed for by an excess of unlabeled NT (not shown). In conformity with the 
results of saturating binding studies, the total amount of cell-associated radioactivity 
at plateau was markedly lower in cells co-expressing NTS 1 and NTS2 than in cells 
expressing NTS 1 alone (compare Figs. 7.6A and B), reflecting the lower density of 
cell surface receptors in the former. However, the proportion of intemalized 
radioactivity remained the same between the two cell types (87 ± 3.8% versus 86 ± 
2.9% after 20 min; Fig 7.6B and 7.6A, respectively), indicating that NTS2 expression 
had no effect on the efficiency ofNTS 1 receptor intemalization. 
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7.4.7 Functional Characterization of NTS1/NTS2 Interaction 
We next investigated the functional consequences ofNTSI/NTS2 heterodimerization 
by measuring receptor-mediated activation of the MAPK kinase pathway. In COS-7 
cells transiently expressing NTS 1 alone, stimulation with NT for up to 60 min 
induced a rapid « 5 min) phosphorylation ofERK.1/2 (Fig 7.7A, left panel; B). This 
effect was NTS I-mediated, since it was not observed in untransfected cells (not 
shown). Similar increases in MAPK kinase activity were observed after 5 min of 
stimulation with NT in cells co-expressing NTSI and NTS2 (7.5 ± 0.9 and 7.1 ± 0.4-
fold-increase, respectively; p > 0.95; Fig. 7 A, right panel; B), suggesting that co-
expression ofNTS2 did not significantly influence NTSI signaling. 
7.4.8 Effects of NTS2 Expression on NTSl Down-Regulation 
Previous studies have demonstrated that cell surface NTS 1 receptors are rapidly 
down-regulated following prolonged NT stimulation (Hermans and Maloteaux, 1998; 
Donato di Paola et al., 1993). By contrast, cell surface NTS2 receptors are 
maintained at the cell surface during persistent NT exposure (Perron et al., 2006). To 
investigate the effects of NTS2 expression on NTS 1 cell surface binding sites during 
prolonged NT exposure, COS-7 cells expressing NTS 1 alone or together with NTS2 
were pre-stimulated with 1 JlM NT for up to 24 h at 37°C and cell surface receptor 
binding was carried out at 4°C using 0.4 nM e25I]-NT in the presence of an excess of 
levocabastine. In COS-7 cells expressing NTS 1 alone, NT application induced a 
rapid decrease in cell surface NTS 1 binding, which was down to 66 ± 1 % of control 
values after 60 min and to 46 ± 3% of control values after 24 h of incubation with NT 
(Fig. 7.8). By contrast, in cells co-expressing NTS 1 and NTS2, cell surface NTS 1 
binding was only decreased to 72 ± 3% of control values after 60 min and to 75 ± 1 % 
of control values after 24 h of incubation with NT (Fig. 7.8). These values were 
significantly higher than those recorded at each of these two time points in cells 
transfected with NTS1 alone (p < 0.05 and p < 0.01, respectively). The present data 
therefore suggest that NTS 1/2 heterodimerization reduces the down-regulation of cell 
surface NTS 1 binding after persistent NT exposure. 
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7.5 DISCUSSION 
The present study demonstrates that NTS 1 and NTS2 form constitutive heterodimers 
in transiently transfected COS-7 cells. Although NTS I/NTS2 heterodimerization 
does not affect NTSI responsiveness to NT, our results indicate that it impedes NTSI 
trafficking both to and from the cell surface. 
It is now well established that many GPCRs exist as homodimers or 
heterodimers and that dimerization may alter their functional, pharmacological, and 
regulatory properties (Bouvier, 2001; Maggio et al., 2005). Previous 
immunohistochemical studies have revealed extensive overlap in the distribution of 
NTS 1 and NTS2 receptor pro teins in rat CNS, namely in the olfactory bulb, bed 
nucleus of the stria terminalis, anterodorsal thalamic nucleus, substantia nigra, ventral 
tegmental area, periaqueductal gray, and magnus paragigantocellular nucleus (Boudin 
et al., 1996b; Sarret et al., 2003a; Fassio et al., 2000). Accordingly, the present RT-
PCR data demonstrated that NTS 1 and NTS2 mRNAs were co-expressed in virtually 
all CNS regions examined inc1uding the spinal cord, suggesting that these two 
receptor subtypes are in a position to interact with one another in mediating NT's 
central effects. 
To determine whether NTS1 could form heterodimers with NTS2, co-
immunoprecipitation experiments were carried out in dually transfected COS-7 cells. 
Using two different combinations of antibodies, we were able to demonstrate that 
NTS 1 and NTS2 did heterodimerize and that the extent of their heterodimerization 
was unaltered by NT treatment, suggesting that NTS 1/ NTS2 heterodimers are 
constitutive. A similar agonist-independent mechanism was also reported for 
CXCR1/CXCR2 receptor heterodimerization, implying that GPCRs might exist as 
stable, preformed dimers (Wilson et al., 2005). Several studies have investigated the 
structural determinants involved in GPCR oligomerization (reviewed in Rios et al., 
2001). In particular, the C-terminal tail has often heen found to he critical for 
receptor-receptor interaction (e.g. GABABR1/GABABR2 heterodimerization; 
Margeta-Mitrovic et al., 2000). However, our findings suggest that the integrity of 
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NTS2's C-terminal tail is not crucial for NTSI/NTS2 heterodimerization. Likewise, 
C-truncation mutants of al-ARs were found to be ineffective in preventing either 
homo- or heterodimerization of this receptor subtype (Uberti et al., 2003). GPCR 
oligomerization may also be mediated by covalent interactions, as shown for 
metabotropic glutamate receptor 5 (Romano et al., 2001) and calcium-sensing 
receptor (Zhang et al., 2001). However, cysteine mutations in NTS2 extracellular 
loops were found here not to interfere with NTS I/NTS2 heterodimerization, 
indicating that disulfide-bonding arrangements are not required for this interaction 
and that other domains might be brought into play. 
We then sought to determine whether NTS2 co-expression induced changes in 
NTS 1 binding properties since heterodimerization, for instance between delta and 
kappa opio id receptors, had previously been shown to result in the generation of sites 
with novel ligand-binding properties (Jordan and Devi, 1999). For this purpose, 
radio ligand binding experiments were carried out in COS-7 cells transiently 
expressing NTS 1 alone or together with NTS2 by using [125I]_NT in the presence of 
an excess of levocabastine in order to selective1y inhibit [125I]_NT binding to NTS2. 
The results revealed a significant decrease in cell surface binding densities in cells 
co-expressing NTS 1 and NTS2 as compared to NTS 1 alone, although the affinity of 
NTSI for [125I]_NT was identical in both cell types. Immunocytochemical 
experiments confirmed that the cell surface NTS 1 immunoreactivity was 
considerably reduced in cells dually transfected as compared to cells expressing 
NTSI alone, suggesting that NTSI/NTS2 heterodimerization affected the membrane 
recruitment of NTS 1. Several studies have reported that receptor oligomerization 
could influence trafficking of GPCRs (reviewed in (Prinster et al., 2005». For 
example, expression of dominant-negative V2 vasopressin receptors led to a 
significant decrease in cell surface targeting of the wild-type V2 receptor (Zhu and 
Wess, 1998). In cells co-expressing NTS 1 and NTS2, intracellularly sequestered 
NTS 1 receptors were concentrated in the same juxtanuc1ear zone, previously 
identified as the TGN/Golgi complex, as NTS2 in cells expressing NTS2 alone 
(Perron et al., 2006; Sarret et al., 2003a). It is therefore likely that the decrease in the 
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membrane recruitment of NTS 1 is the consequence of its heterodimerization with 
NTS2 within the Golgi/TGN. However, why NTSI/NTS2 heterodimers, like NTS2 
receptors, should be retained in the TGN/Golgi remains unclear. Sorne GPCRs, 
including the GABABR, contain retention or export motifs that are thought to play a 
role in their cell surface expression (Pagano et al., 2001; Tan et al., 2004). Thus, 
heterodimerization might induce a conformational change that either unmasks a 
retention signal or masks an export signal in NTS 1, thereby conferring this receptor 
the trafficking properties ofNTS2. 
We then tested whereas NTSI/NTS2 heterodimerization affected the rate and/or 
efficiency of ligand-induced receptor endocytosis, as reported for other heterodimers 
(reviewed in Maggio et al., 2005). For instance, co-expression of ~lAR had been 
shown to inhibit agonist-promoted internalization of ~2AR in co-transfected HEK-
293 cells (Lavoie et al., 2002). However, our kinetic analysis revealed that NTS2 co-
expression did not influence e25I]-NT-induced NTSI internalization. This finding is 
coherent with the fact that when expressed alone, NTS 1 and NTS2 are equally 
efficiently intemalized via clathrin-coated pits upon NT binding (Vandenbulcke et 
al., 2000; Botto etaI., 1998). 
Recent studies have demonstrated that heterodimerization could also affect 
coupling and function of GPCRs. For instance, heterodimerization of NTS 1 with 
NTS3 has been found to modulate NTS I-dependent activation of the ERK1I2 
pathway (Martin et al., 2002a). In contrast, another report has indicated that 
heterodimerization of ~2AR with either delta- or kappa-opioid receptors did not alter 
its coupling properties (Jordan et al., 2001). To investigate whether NTSI and NTS2 
co-expression led to altered functional properties due to heterodimerization, MAPK 
kinase activation experiments were carried out in CÛS-7 cells expressing NTS 1 alone 
or together with NTS2. We found that co-expression of these two NT receptor 
subtypes did not affect NT-mediated ERK1I2 phosphorylation. This observation may 
seem at odds with the results of earlier studies which had shown that in CHû cells 
transfected with either receptor alone, NTS2 had a lower efficacy than NTS 1 in 
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activating the MAPK kinase pathway (Gendron et al., 2004; Poinot-Chazel et al., 
1996). However, it is unc1ear how many receptor molecules of either subtype 
undergo heterodimerization and it is therefore possible that the density of monomeric 
(or homodimeric) NTS 1 receptors at the cell surface of dually transfected cells might 
be sufficient for triggering an ERKl/2 phosphorylation response similar to that 
observed in cells expressing NTS 1 alone. 
Chronic exposure of GPCRs to their ligands commonly results in a time-
dependent dec1ine of their cell surface receptor density, referred to cell surface down-
regulation (Ferguson, 2001; Tsao and von Zastrow, 2000). Such is the case for 
NTS 1, which has been shown to rapidly enter the lysosomal degradation pathway 
instead of being recyc1ed to the cell surface after prolonged NT exposure 
(Vandenbulcke et al., 2000; Hermans et al., 1997). By contrast, NTS2 cell surface 
binding sites were found to be resistant to down-regulation upon sustained NT 
exposure (Perron et al., 2006). It was therefore of interest to determine whether co-
expression of NTSI with NTS2 would affect the regulation of NTSI cell surface 
density during persistent agoni st stimulation. Transiently transfected COS-7 cells 
expressing NTS 1 alone or together with NTS2 were stimulated for up to 24 h and cell 
surface receptors were labeled using 125I_ NT on ice. Whereas less than 50% of 
NTS 1 binding sites were maintained at the cell surface following prolonged NT 
exposure in cells expressing NTSI alone, more than 75% ofthem were still present at 
the surface after prolonged NT exposure in cells dually expressing NTS 1 and NTS2. 
This difference is likely attributable to NTSl/NTS2 heterodimerization, again 
suggesting that NTSl/NTS2 heterodimers have trafficking properties akin to those of 
NTS2 rather than NTS 1, and therefore that interaction between the two receptors 
reduces the capacity ofNTS 1 to desensitize upon ligand exposure. 
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In conclusion, our data provide clear evidence for a functional role of 
NTS I/NTS2 heterodimerization in NTS 1 receptor trafficking in co-transfected COS-
7 cells. These two receptor subtypes associate with each other via agoni st-
independent heterodimerization, which appears to involve primarily hydrophobie 
interactions. The coexistence ofNTS 1 and NTS2 in numerous CNS regions supports 
the view that heterodimerization of these two receptor subtypes may play a 
physiological role in the regulation of their cell surface density, and hence of their 
responsiveness to NT, in the mammalian CNS. 
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7.7 ABBREVIATIONS 
NT, neurotensin; GPCR(s), G protein-coupled receptor(s); TM, transmembrane 
domain; CHû cells, Chinese hamster ovary cells; CÛS-7 cells, green African monkey 
kidney cells; MAPK, mitogen-activated protein kinase; ERK1I2, extracellular signal-
regulated kinases 112; ER, endoplasmic reticulum; AR, adrenergic receptor; NGS, 
normal goat serum. 
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7.9 FIGURE LEGENDS 
Fig. 7.1: RT-PCR Analysis ofNTS1 and NTS2 rnRNAs in Rat CNS. PCRs were 
perfonned on mRNAs reverse-transcribed using specific primers for rat NTS 1 (upper 
panel) or NTS2 (lower panel). A 335-bp band corresponding to NTSI is visible in aIl 
brain regions sampled as weIl as in the spinal cord and pituitary gland. Two different 
isofonns ofNTS2 mRNAs, corresponding to the full-Iength and altematively spliced 
fonns of 620 and 439 bp, respectively, are evident in the same CNS regions, but not 
in the pituitary. Results are representative of three independent experiments. 
Fig.7.2: Co-immunoprecipitation ofNTS2 and HA-tagged NTS1 in Transfected 
Cells. COS-7 cells heterologously expressing a combination of HA -NTS 1 and NTS2 
were stimulated (lanes 2 and 4) or not (lanes 1 and 3) with 1 !-lM NT for 1 h, lysed, 
and subjected to immunoprecipitation with either HA antibody (lanes 1 and 2) or 
NTS2 peptide antiserum (lanes 3 and 4), as described under "Experimental 
Procedures". Immunoprecipitated receptors were revealed by Western blotting using 
NTS2 peptide antiserum (lanes 1 and 2) or HA antibody (lanes 3 and 4). Molecular 
mass markers are shown on the right. The illustrated blot is representative of three 
independent experiments. IPP, immunoprecipitation; lB, immunoblot. Arrowheads: 
bands corresponding to NTS2 monomers and dimers; asterisks: bands corresponding 
to NTS 1 monomers and dimers. 
Fig. 7.3: Effect of Cysteine Mutations or Truncation of NTS2 on NTS1/NTS2 
Dimerization. COS-7 cells heterologously expressing HA-NTSI with either NTS2 
cysteine mutants (C363A, C621A, C993A, C6211993A, and C363/6211993A; left 
panel) or C-tenninally truncated NTS2 receptors (right panel) were lysed and 
subjected to immunoprecipitation using the HA antibody. The co-
immunoprecipitates were then immunoblotted with the NTS2 peptide antiserum as 
described under "Experimental Procedures". Molecular mass markers are illustrated 
on the left. Each blot is representative of three independent experiments. Asterisk 
and arrowhead point to monomeric and dimeric fonns of NTS2 cysteine mutants, 
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respectively. Arrows point to monomeric and dimeric fonns of the C-tenninal tail 
deletion mutant NTS2-STOP. 
Fig. 7.4: Effect of Co-expression of NTSI and NTS2 on NTSI Binding 
Properties. COS-7 cells expressing NTS 1 alone (.) or together with NTS2 (.Â..) 
were incubated whole for 30 min at 37°C with increasing concentrations of [1251]_NT 
in the presence of an excess of levocabastine in order to prevent binding to NTS2. A, 
Saturation binding curves. [l25I]_NT binding to NTS1 is saturable in both cell types, 
although the Bmax is lower in cells co-expressing NTS 1 and NTS2 than in cells 
expressing NTS 1 alone. B, Scatchard analysis of the data indicates that in both cell 
types, e251]_NT binds to a single population of sites with ~ and Bmax values of 0.28 
± 0.14 nM and 2596 ± 89 fmol/mg versus 0.25 ± 0.11 nM and 1538 ± 81 fmol/mg in 
cells expressing NTS 1 alone or together with NTS2, respectively. The values 
correspond to the mean ± S.D. of two independent experiments, each performed in 
triplicates. 
Fig. 7.5: Co-expression of NTS2 Impairs Cell Surface Recruitment of NTSI 
Receptors. COS-7 cells co-expressing HA-tagged NTS 1 together with pTargeT 
(control; A-C) or NTS2 subcloned into pTargeT (D-F) were permeabilized and 
stained with a combination of HA and NTS2 antibodies. The subcellular distribution 
of immunoreactive receptors was then revealed by confocal microscopy. In cells 
expressing NTS 1 alone, immunostained receptors are most prominent peripherally, at 
the level of the plasma membrane (A and C). By contrast, in cells co-expressing 
NTS 1 and NTS2, NTS 1 immunoreactivity is concentrated in a juxtanuclear 
intracellular compartment (D-F). Arrowheads point to NTS 1 immunoreactivity. 
Fig. 7.6: Co-expression of NTS2 Does not Affect NT-induced NTSI 
Internalization. Kinetics (0-45 min) of [1251]_ NT binding to whole COS-7 cells 
transiently expressing NTS 1 alone (A) or together with NTS2 (B). Cells were 
incubated at 37°C, in the presence of an excess of levocabastine. Association curves 
before (cell surface + intracellular radioactivity; • ) and after (intracellular 
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radioactivity; ... ) hypertonic acid stripping of surface-bound ligand. The data are 
representative of one experiment performed twice in triplicate. 
Fig. 7.7: NT-activated MAPK Kinase Signaling is not Affected by Co-expression 
of NTS2. A, Time course of NT -induced MAPK activation in COS-7 cells 
transiently expressing NTS 1 alone or together with NTS2. Upper panels, 
phosphorylated ERKl/2; /ower pane/s, total ERKl/2. B, Densitometric analysis of 
the ratio of phosphorylated ERKl/2 over total ERKl/2 levels following incubation 
with 1 JlM of NT. COS-7 cells expressing NTSI (e) or co-expressing NTSI and 
NTS2 (0) were incubated at 37°C for the indicated times. Patterns of MAPK kinase 
activation are identical in both cell types. The results are representative of three 
independent experiments, each with duplicate determinations. 
Fig. 7.8: NTS2 Co-expression Reduces Down-regulation of Cell Surface NTSI 
Receptors Consequent to Persistent NT Exposure. COS-7 cells transiently 
transfected with NTSI alone (e), or together with NTS2 (0) were exposed to 1 JlM 
NT for or up to 24 h at 37°C, washed, and incubated on ice with 0.4 nM [125I]_NT in 
the presence of 100 JlM levocabastine for cell surface binding measurements. In 
cells expressing NTS 1 alone, prolonged NT stimulation results in a loss of 54% of 
surface [125I]_NT binding sites by 24h, whereas in cells co-expressing NTSI and 
NTS2, this loss is reduced to 25%. The results are representative of three individual 
experiments, each with triplicate determinations. Student's t tests were used to 
compare NT cell surface binding sites between NTS2 and NTS 1 expressing COS-7 
cells. Values are significantly different at all time points as follows: * p < 0.05; ** p 
< 0.01. 
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CBAPTER 8: GENERAL DISCUSSION 
The studies presented in this thesis were aimed at further understanding the molecular 
and cellular mechanisms underlying NTS2 receptor function and to shed light on the 
implication of this receptor subtype in mediating NT's effects in the rat CNS. A 
specific discussion for individual studies has already been provided in each chapter. 
Thus, the general discussion here shall present a concise overview of the new 
findings and concepts emerging from previous chapters and inc1ude them in the 
context emanating from the situation described earlier in the introduction. This 
discussion will also focus on topics that were not detailed in each of the individual 
manuscripts. Finally, 1 will suggest sorne possible molecular mechanisms that may 
underlie the NTS2 receptor' s behavior and propose new areas for further 
investigations. 
8.1 Localization of NTS2 Receptors in the Rat CNS 
Our knowledge of the distribution of NTS2 receptors in the mammalian brain was 
until now exc1usively derived from radioligand binding and in situ hybridization 
studies (Schotte et al., 1986; Kitabgi et al., 1987; Bétancur et al., 1998; Asselin et al., 
2001; Sarret et al., 1998). However, these techniques do not afford the cellular 
resolution to ascribe NTS2 to any specific neuronal element. With the aim of 
localizing NTS2 receptor proteins at both regional and cellular/subcellular levels in 
the rat CNS, we developed an antiserum directed towards a 15-amino acid synthetic 
peptide derived from the N-terminal domain of the rat NTS2 receptor, common to 
both long and short isoforms. We also developed a second antibody directed towards 
the C-terminal segment ofNTS2, allowing the selective recognition of the long NTS2 
isoform. It is important to note that these peptide sequences show no homology with 
other known NT receptor subtypes. This type of antipeptide antibody approach was 
previously applied to the immunohistochemical detection of other neuropeptide 
receptors in the rat CNS, such as the neurotensin receptor subtypes 1 (NTS 1) (Boudin 
et al., 1996b) and 3 (Sarret et al., 2003b) as well as the calcitonin gene-related 
peptide (Ma et al., 2003), Jl- (Arvidsson et al., 1995), ô-opioid (Cahill et al., 2001) 
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and substance P (Shigemoto et al., 1993; Liu et al., 1994; Horie et al., 2000) 
receptors, to name a few. 
The characterization of NTS2 peptide antisera revealed that the N-tenninal 
peptide NTS2 antiserum provided a better immunocytochemical NTS2-like signal in 
parafonnaldehyde-fixed material than the C-terminally directed antibody. 
Immunohistochemical studies were thus perfonned using the N-tenninal NTS2 
peptide antiserum, which recognizes both NTS2 receptor isofonns. Our studies 
provided the first mapping of NTS2 receptor proteins at the regional, cellular and 
subcellular levels and demonstrated that these receptors are widely, but selectively 
distributed within the mammalian CNS. By and large, our results demonstrated that 
the localization of NTS2-like immunoreactivity confonned for the most part to that 
previously depicted in previous rnRNA hybridization studies (Sarret et al., 1998; 
Walker et al., 1998; Lépée-Lorgeoux et al., 1999; see Table 2.6 for more details). 
Indeed, we found the highest NTS2-like immunolabeling levels in sensory areas 
including the olfactory, auditory and visual systems (see Chapter 3). Strong NTS2-
like immunoreactivity was also associated with relay nuclei of ascending 
somatosensory pathways including gracile and cuneate nuclei as well as spinal and 
principal sensory trigeminal nuclei. In addition, NTS2 receptor proteins were heavily 
expressed in structures involved in descending control of nociceptive inputs 
including the periacqueductal gray, gigantocellular nucleus pars alpha, lateral 
paragigantocellular nucleus as well as the dorsal and raphe magnus nuclei. However, 
our results also demonstrated that if widespread, the distribution of NTS2 receptor 
proteins was also more selective than the NTS2 rnRNA distributional patterns 
obtained by in situ hybridization techniques (Sarret et al., 1998; Walker et al., 1998). 
For instance, the hippocampus, known to express high levels of NTS2 mRNA 
throughout the dentate gyrus and all of Ammon's hom subfields, exhibited NTS2-
like immunoreactivity only in CAl and CA2 subfields (Sarret et al., 1998; Walker et 
al., 1998; Lépée-Lorgeoux et al., 1999). These discrepancies might reflect poor 
translation of NTS2 mRNA in certain subpopulations of neurons. Our 
immunohistochemical studies also revealed that the distribution of NTS2-like 
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immunoreactivity largely exceed that of NT tenninal fields (see Section 1.3.2). In 
fact, sorne of the highest concentration ofNTS2 receptors were found in areas devoid 
of NT inputs such as the cerebral cortex, hippocampus and cerebellum (see Chapter 
J), suggesting that NTS2 may also serve as receptor for endogenous ligands other 
than NT. Indeed, shortly after the publication of the manuscript re1ated to these 
results (Sarret et al., 2003 a), p-Lactotensin, an ileum-contracting peptide derived 
from bovine p-Lactoglobulin, was shown to selectively bind to NTS2 receptors 
(Yamauchi et al., 2003b). 
At the cellular leve1, NTS2 receptors were mostly concentrated within neurons, 
as reported for NTS 1 (Boudin et al., 1996b; Fassio et al., 2000). Of interest is the 
fact that NTS2 subcellular compartmentization varied strikingly throughout the 
rodent brain (see Chapter 3 for details). Indeed, immunolabeling was associated with 
axons and tenninals within sorne brain areas (e.g. diagonal band of Broca and the 
anterlor hypothalamus) whereas it was mainly associated with perikarya and 
dendrites within other areas, such as the hippocampus. As a rule, NTS2 
immunolabe1ing was mainly associated with dendritic neuronal elements. The 
immunohistochemical distribution of NTS2 receptors was further investigated 
throughout primary spinal nociceptive pathways using the same N-terminal peptide 
NTS2 antiserum in the course of a complement study, which is not included in the 
present thesis (Sarret et al., 2005). In this work, we established that NTS2 was 
associated with both cell bodies of primary afferent tibers in the dorsal root ganglia 
and their arborizations in the superficiallaminae of the spinal cord, providing the tirst 
evidence for an implication of this receptor subtype in NT-induced analgesia at the 
spinal level. However, our subsequent e1ectron microscopic studies revealed that 
within the spinal cord (see Chapter 6 for details), the bulk ofNTS2 immunoreactivity 
was associated with dendritic shafts, branches and branchlets, suggesting that the 
spinal NTS2-mediated nociceptive effects of NT may also be exerted 
postsynaptically. 
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It is worth noting that previous in situ hybridization studies had demonstrated 
that NTS2 mRNA expression is up-regulated in glial fibrillary acidic protein-
immunolabeled reactive astrocytes both in vitro and in vivo, suggesting that NTS2 
may be involved in neuronal regeneration and/or inflammatory reaction (Nouel et al., 
1999). However, none of the brain regions that displayed NTS2 immunoreactivity 
was immunopositive for the astroglial marker S 1 OO~, indicating that NTS2 receptor 
proteins are not expressed by astrocytes under basal conditions. It would be 
interesting therefore to determine whether astrocytes specifically express NTS2 in 
response to in jury. To do so, immunohistochemical detection of NTS2 receptors 
would have to be carried out at various time points in stab-wound animaIs in order to 
monitor NTS2 expression during an inflammatory reaction. Protein levels could be 
quantified in parallel though Westem blotting experiments. 
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8.2 Splicing of the NTS2 Receptor: Is the Isoform Functional? 
The heptahelical G protein-coupled receptors correspond to the largest superfamily in 
the human genome, inc1uding more than 600 genes (Venter, 2001; Sadee et al., 
2001). AIso, the chemical diversity among endogenous ligands is without equal. 
Indeed, GPCRs recognize signaIs as varied as biogenic amines, hormones, 
glycoproteins, neurotransmitters, nuc1eotides, ions, proteases, as well as several 
sensory messages (e.g. light, odors and gustative molecules) (reviewed in Gether, 
2000; Bockaert et al., 1999). Within the GPCR family, functional diversity is most 
often managed by the existence of multiple receptor subtypes, each encoded by a 
different gene. Alternative splicing of GPCR pre-rnRNA is also a mechanism 
observed in sorne receptor subtypes to further increase the number of receptor 
isoforms that can be synthesized from a single receptor gene (reviewed in Minneman, 
2001; Kilpatrick. et al., 1999). In the case of NTS2, such a mechanism has been 
reported in the mouse CNS, in which two NTS2 mRNA isoforms are derived from a 
single NTS2 gene, the short form resulting from alternative splicing of the primary 
NTS2 transcript (Sun et al., 2001). 
As shown for the mouse NTS2 receptor (Botto et al., 1997b), we have 
demonstrated that alternative splicing of the rat NTS2 gene generates a 5-
transmembrane domain variant isoform, lacking an internaI 181-bp sequence. Splice 
variants for several GPCRs have been shown to be differentially distributed 
(Minneman, 2001). These inc1ude isoforms of the calcitonin (Yamin et al., 1994), 
CRF (De Souza, 1995) and dopamine D3 (Sokoloff et al., 1992) receptors. However, 
this situation is not universal. For instance, in situ hybridization studies have shown 
that the 5-HT4 receptor splice variants are similarly distributed within the rat CNS 
(Claeysen et al., 1996). Such is the case for NTS2 receptor isoforms in that rnRNA 
levels and ratios did not varied significantly within the different regions examined 
(e.g. neocortex, thalamus, hypothalamus, medulla, cerebellum). However, other RT-
PCR studies have shown that while the two NTS2 isoforms were detected in whole 
brain extracts, only the full-Iength NTS2 isoform was detected in cultured astrocytes 
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(Nouel et al., 1999). At the protein level, our immunoblotting analyses revealed that 
the 45 kDa fonn (i.e. the monomeric full-Iength NTS2 receptor) was ubiquitously 
expressed in the CNS (e.g. brain, cerebellum and spinal cord), whereas the 32 kDa 
fonn (i.e. the monomeric vNTS2) was detected in none of the regions examined. 
However, a band twice the size of the variant NTS2 isofonn similar to that seen in 
transfected COS-7 cells was detected in the spinal cord, suggesting the truncated 
NTS2 receptor may selectively exist in its dimeric fonn within this region. In order 
to discriminate the cellular expression of these two NTS2 receptor proteins within the 
rat CNS, we developed an antibody directed towards the unique C-tenninal tail of the 
variant NTS2 receptor, allowing the specifie detection of the short NTS2 isofonn. 
Unfortunally, this antibody gave rise to a noisy signal that was not specific enough to 
draw conclusions in both immunocytochemical and Western blotting studies. As an 
alternative approach, immunolabeling could be carried out through a differential 
approach in which the signal detected with the NTS2 C-terminal peptide antiserum, 
which recognizes only the long isofonn, would be subtracted from that obtained with 
the N-terminal peptide antiserum. The resulting signal would thus correspond to that 
of the variant NTS2 isofonn. 
In contrast to the results of Botto et al. (1997b) who found that the mouse 
variant counterpart displayed no specific NT binding, we demonstrated that the rat 
vNTS2 specifically binds NT, although with a lower affinity than the full-Iength 
receptor (i.e. 1Cso of 10 /lM versus 2 nM, for the long NTS2 isofonn). Most of the 
GPCR spliced variants were shown to remain functional if their binding site was 
preserved. This was shown to be the case for both C-tenninally spliced endothelin B 
(Nambi et al., 2000) and somatostatin 2B (Vanetti et al., 1992) receptors. On the 
other hand, several transmembrane spliced receptors including the 5-TM domain 
D3nf dopamine receptor and the corticotropin-releasing factor receptor 2 (CRF2) 
were shown to display deficient functional activity due to the disappearance of 
critical segments (Schmauss et al., 1993; Miyata et al., 1999). We thus investigated 
whether the truncated NTS2 receptor retained the MAPK activation properties 
exhibited by the full-Iength receptor (see Chapter 4). We found that stimulation of 
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vNTS2-expressing CHO cells with NT induced a rapid and sustained 
phosphorylation of ERK1I2 as demonstrated for the long NTS2 isoform in a similar 
transfection system. To our knowledge, the rat variant NTS2 isoform is the first 
transmembrane spliced GPCR variant cloned so far that was shown to preserve its 
functional properties. However, vNTS2-mediated phosphorylation levels were lower 
than those obtained with the full-Iength isoform. Comparison of these two NTS2 
amino acid sequences revealed that only a few residues (i.e. 3 serines; refer to Fig. 
5.2) of the third intracellular domain of the full-Iength isoform are conserved in the 
corresponding part (i.e. C-terminal tail) of the variant isoform, suggesting that the 
third intracellular loop, although not essential, may play a complementary role in 
MAPK activation. 
Variations in G-protein coupling have been reported among several splice 
variants (reviewed in Minneman et al., 2001). In particular, the full-Iength and 
spliced-variants of both pituitary adenylate cyclase activating polypeptide (P ACAP) 
and prostanoid EP3 receptors were shown to modulate distinct second messenger 
systems (Spengler et al., 1993; Namba et al., 1993). It is important to note that the 
variant NTS2 isoform lacks the third intracellular loop of the full-length receptor and 
contains 37 unique C-terminal amino acids (see Chapter 5). These two regions are 
well known for their critical role in GPCR coupling specificity (Ferguson, 2001; 
Havlickova et al., 2002; Kang et al., 2005). Thus, we cannot rule out the possibility 
that vNTS2 might activate different signaIs than those observed in cells expressing 
the full-length isoform since we have only examined the ERK1I2 activation pathway. 
It would thus be important to investigate whether the stimulation of vNTS2 receptors 
elicits other biological responses using complementary second messenger 
measurements (e.g. cAMP, Ca2+, inositol phosphates). Results of subprograms 
executed by the NetPhos 2.0 server (Nikolaj Blom, Center for Biological Sequence 
Analysis, Technical University of Denmark, Denmark) predicted 21 and 12 potential 
phosphorylation sites within the full-Iength and variant NTS2 isoform sequences, 
respective1y (illustrated in Fig. 8.1). These consensus motifs may promote the 
binding of different GPCR interacting proteins, which specifically recognize a 
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phosphorylated domain and alter G protein specificity (reviewed in Ferguson, 2001; 
Bockaert et al., 2004; Sato et al., 2006). Whether NTS2 isoforms interact with 
different pro teins needs to be c1arified. 
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Figure 8.1: Schematic Diagram ofNTS2 (A) and vNTS2 (B) PhosphOlylation Sites. 
The phosphorylation sites (serine, threonine and tyrosine) were predicted by the 
neural network-based method of Nikolaj Blom according to the NetPhos 2.0 server. 
The position of the amino acid sequence is indicated be10w each diagram. 
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According to our immunoblotting studies in rat CNS, vNTS2 appeared to form 
multimeric complexes that might correspond to vNTS2 homodimers and putative 
heterodimers with NTS2. Several studies have shown GPCRs to behave structurally 
in a manner related to multiple-subunits receptors (reviewed in Bouvier, 2001; Bai, 
2004a; Prinster et al., 2005). Indeed, our co-immunoprecipitation studies in COS-7 
cells expressing both NTS2 receptors confirmed that the short NTS2 isoform 
interacts physically with its full-length counterpart. Previous studies have 
demonstrated that heterodimerization between GPCR splice variant isoforms (e.g. D3 
and D3nf dopamine receptor isoforms (Elmhurst et al., 2000)) may influence cell 
surface receptor expressIOn. Neverthe1ess, our immunoblotting and 
immunocytochemical studies in dually transfected cells revealed that co-expression 
of the full-Iength NTS2 isoform did not modify the cell. surface density of the 
truncated form over that seen in cells expressing vNTS2 alone, suggesting that NTS2 
does not act as a chaperone protein in vNTS2 trafficking. On the other hand, 
immunological studies have revealed that co-expression of the gonadotropin-
releasing hormone (GnRH) receptor with with its C-terminally truncated isoform 
resulted in impaired receptor insertion into the plasma membrane (Grosse et al., 
1997; Cheung et al., 2005). Whether the variant NTS2 influences the cell surface 
expression of the full-length isoform remains to be established. To do so, cell surface 
expression of NTS2 receptors would have to be monitored by confocal 
immunocytochemistry using the C-terminally directed NTS2 antiserum in cells 
expressing NTS2 alone or together with the variant isoform. Cell surface receptors 
could also be quantified in paralle1 immunolabe1ing experiments through Fluorescent 
Activated Cell Sorting (F ACS) analysis. 
Molecular association with different GPCR subtypes was also shown to result in 
dramatic effects on receptor signaling (reviewed in Prinster et al., 2005; Terrillon and 
Bouvier, 2004). However, the fact that ERKl/2 activation leve1s obtained in CHO 
cells expressing the full-length NTS2 (see Chapter 4 for details) alone were 
comparable to those observed in rat cerebellar granule cells, which are known to 
express both NTS2 isoforms (Sarret et al., 2002), suggests that the truncated NTS2 
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receptor does not modify signaling efficiency of the full-Iength NTS2 isoform. 
Further investigations will require the development of specific ligands for either the 
short or long isoforms in order to discriminate vNTS2- from NTS2-mediated 
signaling cascades, respectively. 
8.3 NTS2 Receptors and Long-term Neurotensin Exposure 
Upon prolonged agoni st exposure, nearly aIl GPCRs display a concomitant reduction 
of cell responsiveness to the stimulus, a process known as desensitization (reviewed 
in Gainetdinov et al., 2004; Claing and Laporte, 2005). Such is the case for NTS 1 
receptors, which were shown to desensitize after NT exposure (Vandenbulcke et al., 
2000; Hermans and Maloteaux, 1998). Indeed, confocal microscopic studies have 
shown that NTS 1 receptors were targeted to lysosomes for degradation rather than 
being recycled back to the plasma membrane, which may account in part for receptor 
desensitization after prolonged agoni st stimulation (Hermans et al., 1997; 
Vandenbulcke et al., 2000). Furthermore, there is evidence that de novo synthesis is 
required for the recovery of NTS 1 binding sites and function (Donato di Paola et al., 
1993: Hermans et al., 1997). On the other hand, little was known about the 
regulation of NTS2 receptors except that their stimulation triggers extended 
activation of ERK1I2 both in neurons in culture (Sarret et al., 2002) and in 
transfected CHO cells (as shown in Chapter 4 and Chapter 5 for the full-Iength NTS2 
and its short isoform, respectively). 
To determine whether persistent agoni st stimulation of NTS2 receptors gives 
rise to down-regulation, we investigated the effect of prolonged NT exposure on 
resultant cell surface [125I]_NT binding. We found that in contrast to cells transfected 
with NTS 1, NTS2-expressing cells retained the same surface receptor density despite 
efficient ligand-induced intemalization mechanisms. Since this maintenance of cell 
surface receptors was also observed when the incubation was carried out with the 
protease-resistant NT analogue JMV -431, we could not ascribe this mechanism to 
ligand degradation. Cell surface NTS2 binding sites preserved during persistent NT 
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exposure corresponded to functional receptors since NT -induced ERK1I2 
phosphorylation levels in cell exposed to NT for 24 h were equivalent to those 
previously reported in rat cerebellar granule cells (Sarret et al., 2002) and NTS2-
expressing CHO cells (refer to Chapter 4). 
Preservation of cell surface receptors in response to extended agoni st 
stimulation has been documented for a limited number of GPCRs so far (e.g. the ~l 
and ~3-adrenergic receptors (Liang et al., 2003; Thomas et al., 1992), the 
somatostatin receptor subtype 1 (Hokovic et al., 1999; Ramirez et al., 2005), the AT 2 
angiotensin receptor (Dudlez and Summerfelt, 1993), the GnRH receptor (Loumaye 
et al., 1982), and the long form of the dopamine 2 (D2L) receptor (Zhang et al., 1994; 
Starr et al., 1995; Filtz et al., 1994). The same phenomenon has also been shown for 
the single transmembrane domain NTS3 receptor upon sustained NT exposure 
(Navarro et al., 2001; Morinville et al., 2003). Unlike receptor down-regulation, the 
molecular mechanisms responsible for cell surface receptor maintenance, and hence 
for preventing functional desensitization, are poody understood. Depending on the 
type of receptor, mechanisms involved in surface receptor maintenance inc1ude 
transcriptional and post-translational induction of receptor synthesis, recyc1ing of 
intemalized receptors, impaired receptor degradation and/or targeting of reserve 
receptors to the cell surface (Thomas et al., 1992; Hukovic et al., 1999; Navarro et 
al., 2001; Liang et al., 2003; Liang and Fishman, 2004). In the case of NTS2, 
prolonged NT exposure did not influence the totallevels of immunodetected NTS2, 
indicating that receptor up/down-regulation is not involved in the resensitization 
mechanism. Neither did it require receptor neosynthesis since protein leve1s 
remained unchanged following NT exposure in the presence of the protein synthesis 
inhibitor cyc1oheximide. In addition, recyc1ing of intemalized receptors did not 
account significantIy for the reinstatement of the plasma membrane NTS2 receptor 
population since it was not affected by the recyc1ing inhibitor monensin nor by 
replacing the rat NTS2 receptor with its non-recyc1ing human counterpart. However, 
it appeared to involve translocation of spare receptors form intracellular stores since 
stimulation with NT was found to induce migration of NTS2 from Golgi/TGN to 
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endosome-like structures as evidenced by dual-Iabeling confocal microscopy (see 
Chapter 6 for details). To ascertain the functional re1evance of this resensitization 
mechanism, we monitored by electron microscopy the effect of intrathecal NT 
injection on the subcellular distribution ofNTS2 in neurons of the superficiallaminae 
of rat spinal cord. We found that agoni st stimulation induced an extensive 
re1ocalization of intracellular receptors to the plasma membrane of these cells (7-fold 
increase). Taken together, these results suggest that sustained activation of NTS2 
receptors promotes recruitment of intracellular receptors from the GolgirrGN 
complex to the cell surface, thereby preventing functional desensitization of NTS2-
expressing cells. 
Previous studies have shown that upon prolonged stimulation with 
fluorescently-labe1ed NT, intemalized ligand molecules were translocated from the 
cell surface to a juxtanuc1ear compartment corresponding to the TGN (Vandenbulcke 
et al., 2000; Sarret et al., 2002). It is therefore possible that intemalized NT might 
serve as a triggering signal for the translocation of resident NTS2 receptors from this 
compartment to the cell surface, implying a dynamic regulation of subcellular protein 
localization. For instance, the insulin-responsive glucose transporter GLUT4 was 
shown to be targeted from a post-endocytic compartment to the cell surface in 
response to extracellular stimuli such as insulin (Slot et al., 1991; Morris et al., 1996). 
In order to determine whether receptor endocytosis is a necessary prerequisite for the 
resensitization of NTS2 receptors, cell surface receptors will be further quantified 
throughout radio ligand binding studies following extended agoni st exposure in the 
presence of intemalization blockers (e.g. concanavalin A, sucrose, phenylarsine 
oxide). Similar experiments could also be carried out in COS-7 cells expressing 
NTS2 together with a dominant negative mutant of dynamin. It is also unc1ear 
whether NT regulates NTS2 surface receptor levels at a step prior to initial insertion 
in the plasma membrane rather than by altering their endosome trafficking following 
intemalization. Studies have reported that protein trafficking between TGN and the 
cell surface via endosomes is regulated by targeting signaIs, which have been 
identified in a variety of membrane proteins (reviewed in Tan et al, 2004). These 
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motifs referred to as "acidic c1usters" are usually ftanked by either tyrosine-based, or 
dileucine targeting signaIs and frequently contain consensus casein kinase (CK2) 
sites that also serve as TGN retrievai signaIs (Jones et al., 1995). For instance, 
efficient TGN localization of furin cannot occur unIess the serines of the acidic 
cIuster are phosphorylated by CK2 (Dittie et al., 1997). This phosphorylated acidic 
cIuster motif was shown to be linked to AP-l adaptor complexes via the cytosolic 
protein PACS-l, playing a role in the cIathrin-coated vesicIe formation on the TGN, 
as well as in their endosomal translocation (Crump et al., 2001). 
Such consensus CK2 phosphorylation sites are found in the third intracellular 
and C-terminai domains ofNTS2. Moreover, the third intracellular Ioop of the NTS2 
receptor contains an acidic c1uster motif that is surrounded by two dileucine signaIs, 
as shown in Fig. 8.2. However, a study using a truncated form of NTS2 receptor 
lacking the entire C-terminus (361-Stop; Fig. 8.2) showed that receptors are still 
maintained at the cell surface following sustained agoni st exposure, indicating that 
the C-terminal tail of NTS2 is not involved this resensitization process (Perron et al., 
unpublished data). In view of the presence of numerous TGN-targeting motifs and 
consensus CK2 phosphorylation sites in the third intracellular loop, it is tempting to 
speculate that NT-induced phosphorylation of NTS2 and/or conformationai change 
might be involved in the trafficking of the receptor. It would thus be important to 
investigate the effect of site-directed mutagenesis of these putative TGN motifs and 
CK2 posphorylation sites on the trafficking of NTS2 receptors following persistent 
NT exposure in order to determine whether the TGN to endosome transport of NTS2 
receptors is mediated via these targeting signaIs. 
Finally, GPCRs are also known to interact with numerous proteins that are 
implicated in cellular trafficking (Tan et al., 2004). In particular, a single 
transmembrane domain protein, called the receptor-activity-modifying protein 
(RAMP) 1, was shown to function as a chaperone in the transport of caIcitonin 
receptor-like (CRLR) receptors from the endoplasmic reticulum to the plasma 
membrane (McLatchie et al., 1998). In addition, other proteins have been shown to 
stabilize GPCRs at the cell surface. For instance, Homer-la was found to allow the 
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insertion of the metabotropic glutamate receptor 1 into the plasma membrane 
(Ciruela et al., 2000). Further characterization of cargo sorting proteins involved in 
the targeting of NTS2 from intracellular pools will therefore provide additional 
insight into the molecular mechanism leading to the maintenance of cell surface 
NTS2 binding sites after persistent exposure to NT. 
Figure 8.2: Two-Dimensional Model of the Rat NTS2 Receptor. Residues in the 
third intracellular and C-terminal domains of NTS2 are marked. Putative casein 
kinase 2 (CK2) phosphorylation sites, dileucine motifs, and tyrosine-based sequences 
are boxed. Dark circles highlight an acidic cluster. The C-terminal tail deletion 
mutant ofNTS2 was created by introducing a stop codon after position 361. 
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8.4 Heterodimerization of NTSI/NTS2 and Intracellular Trafficking of NTSI 
According to our immunohistochemical mapping studies (see Chapter 3 for details), 
there were a number of regions in which the distribution of NTS2 overlapped with 
that ofNTSl including the anterodorsal thalamic nucleus, olfactorybulb, bed nucleus 
of the stria terminalis, substantia nigra, and VT A. This observation might imply that 
certain neurons jointly express NTS 1 and NTS2 receptors, which might thus be in a 
position to interact with one another physiologically. 
Using two different combinations ofNTS2- and NTSI-selective antibodies, we 
were able to demonstrate that NTS2 and NTS 1 indeed interacted physically together. 
We also found that the extent of their heterodimerization was unaltered by NT 
treatment, suggesting that NTSI/NTS2 heterodimers are constitutive. Available 
structural data strongly suggest that many GPCRs can form oligomers in the absence 
of ligand stimulation (Bouvier et al., 2001; Terrillon and Bouvier, 2004). Indeed, 
crystallization of the extracellular N-terminal domain of the metabotropic glutamate 
receptor is consistent with such a model of constitutive dimerization (Kunishima et 
al., 2000). Our findings also suggest that neither the integrity ofNTS2's C-terminal 
tail nor disulphide bounding were critical for NTSI/NTS2 heterodimerization. The 
formation ofNTS1/NTS2 heterodimers might thus involve non-covalent interactions 
involving both extracellular and transmembrane domains. Such idea was indeed 
proposed and demonstrated for the P2-adrenergic (Hebert et al., 1996) and dopamine 
D2 (Ng et al., 1996) receptors. In order to unrave1 the molecular determinants that 
stabilize NTS I/NTS2 heterodimers, it would be interesting to carry out a series of 
experiments that would combine the use of synthetic peptides, site-directed 
mutagenesis and biophysical techniques. In addition, we should investigate whether 
the 5-TM variant NTS2 isoform is able to form heterodimers with the NTS 1 receptor 
as weIl. 
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Radioligand binding experiments in COS-7 cens expressing NTS 1 alone or 
together with NTS2 revealed that the presence of NTS2 did not affect the affinity of 
NTSI for [125I]_NT. However, our data suggested that NTS2 expression influenced 
cell surface NTS 1 receptor densities (Bmax). In parallel, confocal microscopic studies 
in dually transfected cells revealed that NTS I/NTS2 heterodimerization markedly 
affected the subcellular localization of NTS 1. Indeed, immunoreactive NTS 1 
receptors were principally located at the cell surface in cens expressing NTS 1 alone 
whereas the bulk of NTS 1 immunoreactivity was detected intracellularly within the 
perinuclear region in cens co-expressing NTSI and NTS2 (see Chapter 7 for details). 
A similar juxtanuclear location was previously reported for NTS2 in single-
transfected COS-7 cells (Perron et al., 2006) as well as in cerebellar granule cens, 
which do not express NTS 1 (Sarret et al., 2002). Our data thus suggest that NTS2 
acts as a negative dominant of the NTS 1 receptor by preventing its cell surface 
expression, presumably by retaining it in the Golgi/TGN through heterodimerization. 
Several studies have also shown that heterodimerization of GPCRs may also lead to 
intracellular retention of receptors (Terrillon and Bouvier, 2004; Prinster et al., 2005). 
This phenomenon may have pathophysiological consequences. For instance, a series 
of the frizzled (Fz) family of Wnt receptors was shown to be involved in the 
autosomal-dominant retinal degenerative disease by interfering with the maturation 
of the wild-type receptor (Kaykas et al., 2004). Surprisingly, our functional studies 
have revealed that NTS I-mediated ERK1I2 MAPK activity was not affected by 
NTS2 co-expression. However, it is possible that the density of monomeric (or 
homodimeric) NTSI receptors at the cell surface of dually transfected cells had been 
sufficient for triggering an ERK1I2 phosphorylation response similar to that observed 
in cells expressing NTS 1 alone. Despite the lack of effect on NTS 1 signaling, our 
findings suggest that NTS 1/NTS2 heterodimerization might have functional 
implications in receptor trafficking upon sustained agoni st exposure. Indeed, we 
found that NTS 1 cell surface binding sites were more resistant to NT -induced down-
regulation when the two NT receptor subtypes were expressed together than in cells 
expressing NTS 1 alone. 
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Sorne GPCRs contain retenti on or export motifs that are thought to play a role in 
their cell surface expression (reviewed in Duvernay et al., 2005). For instance, 
association of the GABABRI coiled-coil domain with that of GABABR2 serves to 
mask the GABABRI ER retention signal, allowing the trafficking of the heterodimer 
to the cell surface (Margeta-Mitrovic et al., 1999; Pagano et al., 2001). NTSI/NTS2 
heterodimerization might induce a conformational change as well, which either 
unmasks a retention signal or masks an export signal in the NTS 1 sequence, thereby 
conferring to this receptor the trafficking properties of NTS2 (as described in Chapter 
Q). 
One of the most striking features in NTS 1 and NTS2 amino acid sequences is 
the absence of glycosylation motifs in the N-terminal domain of NTS2, contrary to 
NTS 1, which presents three potential sites within its extracellular domains at position 
Asn4, Asn38 and Asn42 (Rostène et al., 1997). Glycosylation is a post-translational 
modification common in GPCRs and plays an important role in their structural 
maturation. Accordingly, reports have demonstrated that N-linked glycosylation of 
bradykinin B2 (Michineau et al., 2004) and AT} angiotensin II (Deslauriers et al., 
1999) receptors is essential for their proper trafficking from the ER to the plasma 
membrane. Heterodimerization between NTS 1 and NTS2 receptors may therefore 
impede NTS 1 glycosylation due to steric hindrance and its consequent cell surface 
expression. In order to confirm this hypothesis, NTS 1 putative glycosylation sites 
would be mutated into alanine by site-specific mutagenesis and subcellular 
localization of the receptor investigated by confocal microscopy in transiently 
transfected COS-7 cells. The subcellular distribution of NTS 1 could then be 
compared with that obtained in cells co-expressing NTS 1 and NTS2 receptors in 
order to determine whether glycosylation sites deletion gives rise to the same NTS 1 
localization pattern as when the receptor is co-expressed with NTS2. 
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CONCLUDING REMARKS 
The present study revealed that NTS2 receptors (i.e. the full-Iength and its spliced-
variant isofonn) are widely distributed in the rat CNS. It also indicated that these 
receptors are essentially neuronal in nonnal conditions and are mainly targeted to 
dendrites, as demonstrated in our electron microscopic studies. Most importantly, 
this study demonstrated that NTS2 receptors are associated with structures involved 
in the descending control of nociceptive inputs, in accordance with their postulated 
role in the mediation ofNT's supraspinal antinociceptive effects. We also confinned 
that NT acts as an agonist at both full-Iength and variant NTS2 receptor sites and 
demonstrated that these cell surface receptors are resistant to down-regulation 
following persistent agoni st exposure. Interestingly, NTS2 was shown to exert a 
dominant-negative effect on the intraceIluIar trafficking and down-regulation 
properties of the NTSI receptor through NTSI/NTS2 heterodimerization. The 
coexistence of NTS 1 and NTS2 in numerous CNS regions and their complementary 
role in the mediation of NT's analgesic effects support the view that 
heterodimerization of these two receptor subtypes may play a physiological role in 
the regulation of their cell surface density, and hence of their responsiveness to NT. 
Further studies will thus be required to determine how we can take advantage of the 
NTS2 behavior in the treatment of chronic pain without the disadvantages associated 
with opioid tolerance. 
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Immunohistochemical Distribution of 
NTS2 Neurotensin Receptors in the Rat 
Central Nervous System 
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ABSTRACT 
In the present study, we localized the levocabastine-sensîtîve neurotensîn receptor 
(NTS2) protein in adult rat braîn by usîng an N-tt!nnînally-directed antibody. NTS2-1ike 
immulloreactivîty was broadly disuibuted throughout the rd! brain. At the cellular level, the 
reaction product was exclusîvely associated with nellrons and predominantly, although not 
pxclusively, with their dendritic arbors. No NT82 signal was observpd over astrocytes, as 
confirmed by dual confoeal microscopie immunofiuorescence studies usîng the astrocytîc 
marker 810013. High densities of NTS2-like immunoreactive nerve cell bodies and/or pro-
cesses were detected in Olany regions documented to receive a dense neurotensinergic 
innervation, such as the olfactory bulb, bed nucleus of the stria terminalis, magnocellular 
preoptic nucleus, amygdaloid complex. anterodorsal thalamic nucleus, substantia nigra, 
ventral tegmental area, and several brainstem nuclei. Most conspicuous among the latter 
were struetUl'CB implicated in the descending control of nociceptive inputs (e.g., the periaq-
ueductal gray, dorsal raphe, gigantocellular reticular nucleus, pars alpha, lateral paragigan-
tocellular, and raphe magnus), in keepingwith the postulated l'ole ofNTS2 J'eceptors in the 
mediation of neuroten8in's supraspinal antinociceptive actions. However, the distribution of 
NTS2-like immunoreactivity largely exceeded that ofneurotensin tenninal fields, and SOlne 
of the hlghest concentrations of the receptor were found in areas devoid of neurotensinergic 
inputs Bueh as the cerebral cortex, the hippocampus, and the cerebellum, suggesting that 
neurotensin may not be the exclusive endogenous ligand for this receptor subtnle. J. Comp. 
Neurol. 46.1:520-538, 2003. .. 2003 Wil~y-.Liss, Ine. 
lndexlng terms: IIl1l1t mlcl'OfK'oPYj neuropeptide; proteln: receptor locallzaUonj brain 
The tridecapeptide neurott!nsiu (NT), originally isolated 
from bovine hypothalamus (Carraway and Leeman, 1973), 
was subsequently localized throughout the central ner-
vous system (CNS) of several manlmalian species (for 
review, see Uhl, 1982; Emson et al., 1985) and shown ta be 
involved in a variety of central functions. including ther-
moregulation, 110ciception, food consumption, regulation 
of dopaminergic and cholinergie neurotransrnissiou, aud 
neul'oendocline control (for reviews, see Kitabgî et al., 
1985; Kitabgî and Nemeroff, 1992; Rostène and Alex-
ander, 1997; Sarret and Beaudet, 2002). 
Neurotensin effects are exerted through a variety of 
receptar subtypes, two of whîch have been distinguished 
phal'macologically on the basis of their affinities for NT 
and sensitivity to the histamine antagonist levocahastine: 
an NT high-afflnity site, which does not bind levocnbas-
tine (N'fS1; Kd = 0.3 nM) and a NT low-afflnity site, 
which reeognizes levocabustine (NTS2; Kd = 2-4 nM; 
© 2003 WILEY-LISS, INC. 
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Mazella et al .. 1983; Schotle et aI., 1986; Kitabgi et al., 
1987). These two receptors have been molecularly identi-
fied in recent years and shown ta belong to the seven 
transmembl'ane domain G-proteill-coupled receptar fam-
Hy (GPCR, for l'eview, see Hermans and Maloteaux, 1998; 
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Vincent et al., 1999; Sarret and Beaudet, 2002). A third 
NT receptor (NTS3) Wall recently cloned fmm human 
brain (Mazel la et al., 1998), This receJltor is a type 1 
amino-acidreœptor with a single trallsmembrane-
spannillg regioll ('Orn>'sponding ta the Jlreviously cloned 
gp95/so.rtilin (Petersen et al., 1997), 
Autoradiographie ligand bindillg, in situ hybridizalion, 
and immunohistochemical studilèS have vielded abundant 
information on the distribution of the NTSI receJltors in 
mammalian brain. In brief. high concentrations of NTS1 
were found in association with selective neuronal popula-
tions throughout the hypothalamUil, basal forebrain, and 
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limbic syiltem (Sarrieau et al., 1985; Schotte et al., 1986; 
Moyse et al., 1987; Kitabgi et al., 1987; Palacios et al., 
1988; Dana et al., 1989; Elde et al., 1990; Sato et al., 1992; 
Nicot et al., 1994a,b, 1995; Boudin et al.. 1996; Alexander 
and I..eeman, 1998; Fassio et al., 2(00). They were mali\.-
edly enriche(l over dopaminergic mmrons of the ventral 
midbruin (Palacios and Kubar, 1981; Quirion et al., 1985; 
Hervé et al., 1986; Szigetby and. Beaudet, 1989, Scholte 
and I..eysen.1989; C'rllUlet et aL, 1999), cholinergieneurons 
of the basal forebrain tSzigethy and Beaudet, 1987; Szig-
elllY et al., 1988; Faure et al., 1995; Cape et al., 2(00), and 
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hypoUull.amus (Francois-Bellan et al., 1992). This distri-
bution is CQnsistent witb re.ported NTS1-mediated NT 
effects on locomotion and cognition, as well as on the 
sleep-wake cycle, memory, and regulation of hypo-
Ulalamopituitary fundions (Cape et aL, 2000; for review, 
see Rostène and Alexander, 1997; Binder et al., 2001; 
Sarret and Beaudet, 2002). 
Much less is known !.:oncerning the distribution, pllrtic-
ularly at Ule cellular lev!.'l, of the I!.'vocabastine-sensitive 
NTS2 receptors. Early autoradiographie binding slmties, 
based on th!.' displacement of spedfic 12.;I_labeled NT, 
[3H1NT, or [3H1SRI42948A binding by levocllbastine, re-
ported a widespr!.'ad distribution of levocabastine-
sensitive NTS2 receptor sites in adult rat brain (Sehotte et 
al., 1986,1988; Kitabgi et al., 1987; Sehotte and Laduron, 
1987; Betam:ur et al., 1998). Th.is widespre.ad distribution 
of NTS2 binding sites was wnlirmed recently by using 
direct autoradiographie localization of fHlIevocabastine 
(Asselin et al., 2001). Based on tbeir ubiquitous distribu-
tion, as weil as on their pattern of ontogenetic develop-
ment (Schotte and Laduron, 1987) and recovery after local 
destruction of neurons with kainic acid (Schotte et al., 
1988), low-affinity NT binding sites were originally Bur-
mised to be mainly associated with glial cells. Accordingly, 
NTS2 binding and/or mRNA were detected in association 
wiUt astrocytes both in vivo and in vitro (Nou.el et al., 
1997; Walker et al., 1998; Lépée-I..orgeoux et al., 1999) and 
NTS2 expression was found to be markedly up-regulated 
in reactive astrocytes surrounding a cortical stab wound 
(Nouel et al., 1999). However, in situ hybridization studies 
also dl'monslrated tIlat, in homeostatic conditions, NTS2 
was predominantlyexpressed by neurons within the CNS 
(Sarret et al., 1998). Fu.rOler evidel1œ for the pxpression of 
fllnctional NTS2 .receptors in neurons was provided re-
cently by studies in rat cerebellar granule cells in culture, 
wbich demonstrated cell surface NTS2 binding. ligand-
induced l"OCeptor int~malization, and NT-induced MAP 
kinase activation in these cells (Sarret et al., 2(02). 
The contribution ofNTS2 to tIle mediation of central NT 
functions is Ilot as clearly e.stablished. as Ulat of NTS 1. 
N onetheless, pharmacologie data based 011 the use of se-
lective NTS2 agonists (Labbé-Jullié I\t al., 1994) and an-
tisense oligonucIeot.ides (Dubuc et al., 1999a) have sug-
gested that NTS2 muy play a role in the mediation of NT 
antinociceptive effects. Further insight into the fum:tional 
role of NTS2 requires precise knowledge of the distribu-
tion of this receptor at boUl regional and cellular levels. To 
tbis aim, Wl' have investig-ated here the localization of 
NTS2 receptor pro teins in rat brain by immunohistochem-
iatry, using an antibody raised against the N-terminal 
segment of the c10ned rat NTS2 reœptor. 
MATERIALS AND }-lEmODS 
Ali animal-related procedUl'e.s were approved by the 
McGiII University Animal Care Committee and carried 
out according to tIle regulalions of tlte Calladiall Council 
on animal care. 
Primary antibody for NTS2 
inunullodetectioll 
Rabbil anti-NTS2 peptide antiserum was generated by 
using a synthe tic peptide (WPPRPSPSAGLSLEA}, corre-
P. SARRET ET AL. 
"pouding to Ule 7-21 predicted amino al'Îc} sequence in the 
N-terminal segment of the rat receptor (Chalon et aL, 
1996) and showing no homology with oUler known neuro-
tensill reœptor Bubtypes. The peptide was conjugated by 
melUlS of maleimide to ovalbumin. The conjugate was 
used. lo immunÎZe two rabbits (Affinity BioReagents, ABR, 
Golden, COl. The initial immunization was fullowed by 
five additional booster injections. Serum samples were 
analY7Rd separately for readivity by Western blotting and 
immullohistochemistry. One of Ule sera proved more seJl-
sitive tban Ute othe-f for immunohistochemistry and, 
tIlerefore, was used througbout the present study. 
Preparation of rat NTS2 construct 
The HA-tagged NTS2 eDNA was obtained tIl/"Ough reveJ'Se 
transcription of rat brnin mRNA isolated by (lolymerase 
chain reaction (PCR) by usingnucleotide ae'luencp.'135-61 bp 
(5'-ACAGAGATf'xGCATACCCATACGACGTCC,cAGACTA-
CGCTGAGACCAGCAGTCCGTC..(' .... 3') and 1268-1291 bp 
(5'-TCATACTTGTATTTCTCCCAGCxCT-3') of the open 
reading frame ofNTS2 mRNA (Chalon et al., 1996) as sense 
and 8I1tisense oligonucleotides, respectively. The l'CR prod-
uet Wa.\! purilied from a 1% low meJting temperature agarose 
gel and subcloned inm the pT ARGET expression vector (Pro-
mega, Madison, Wl). That the pr0JX'J" rat NTS2 sequence 
had been c10ned was confirmed by base psir sequellCÎng. 
Culture and transfectioll of COS-7 cells 
COS-7 cells were maintained in Dulbel'co's modiJied 
Eagle's medium with high glucose supplemented with 5% 
fetal bovine serum in th.e presence of lCXI U/ml penicillinl 
streptomycin (GibcoBRL, Ufe Technologies, Burlington, 
Ontario, Canada). Cella were grown at 37"C in a humidi-
lied almosphere with 59é CO" and plated in lOO-mm Petri 
dishp.q at a dellsity of 106 cellsldish. On the following day, 
semiconfluent l'ells were transieJltly t.rallsfected witll 
tIle rat HA-tagged NTS2 l'IJ(.'eptor cDNA by the 
diethylaminoethanol-dextranlchlomquine method, as de-
scribed previously (lnnamorllti et al.. 2001 J. Cells we.re 
collected 48-72 hours aftpr the beginnillg of the transfec-
tion and pl"OcessedfrJr immUllOl'redpüaüon or immunocy-
tocllemistry as described below. 
Preparation of brain membranes 
Adult Sprague-Dawley rats (200-2r:>O g; Charles River, 
St-CAlnstant, Quebec, Canada) were killed by decapita-
tion. Their braill8 wl're removed quickly and pla(''ed on ice. 
Cerebellum and brain were dissected, homogenized seps-
rately with a Polytron in buffer A containing 50 mM 
Tris-HCI (pH 7.0) and 4 mM etllylenediaminetetr-aacetic 
acicl ŒDTA) with protease inhibitors (Complete Proteuse 
lnhibitors tablets, Roche Molecular Biochemi.cals, Laval, 
Quebec, Canada), and cPJ1trifuged at 1,000 rpm for 10 
minutes at 4°C. The supernatant was eollected, and the 
pellet resuspended in buffer A and l'entrifuged again for 
10 minutes at 4°C. The supernatant from the second spin 
was combilled with that of the first for each sample and 
centrifuged at 4°C for 10 minutes at 46,000 lTJnl. The 
pellets were then reb"tlspeJlded in buffpf B, consisting of 50 
mM Tris-Hel (pH 7.0) and 0.2 mM EDTA with protease 
il1hibito['S, by vortexing and brief sonication. Prot~in con-
centration was determined by the Bio-Rad proced.ure with 
bovine serum albumin mSA) as st.andard Œr-adford, 
1976). 
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Immunoblotting analysis 
Membranes from rat brain and cerebellum were dena-
tured by using Laemmli sample buffer (Laemmli, 1970), 
resolvl'd by using 80/<. 'l'ris-glycine precast gels (InYitrogen, 
Burlingtoll, Ontario, Canada), and transferred to nitrocel-
lulose membranes (Bio-Rad Laboratories, !\tississauga, 
Ontario, Canada). Nonspeeific sites were blocked by 0.1 % 
Tween 20 and 1()~ milk powder (Carnation, Don !\tilla, 
Ontario, Canada in phosphate-buffered saline !pBS; pH 
7.4)) oYemight at 4°C. Nitrocellulose membranes were 
then incubated oyernlght at 4°C with the N-terminal spe-
cifie anti-NTS2 rabbit antibody 1111O,000) in PBS with 1% 
BSA and 1% oyalbumin. After washing with PBS-'l\veen, 
blots were ineubated for 1 hour at room temperature (RT) 
with an horseradish peroxidase (HRP) -conjugated goat 
anti-rabbit secondary antibody (114,000; Amersham Phar-
macia Bioteeh. Baie d1Jrfe, Quebec, Canada) in PBS with 
5% milk powder and proteins were Yisualizœ by using an 
enhanced chemiluminescent detection system (Perkin 
Elmer, Life Sciences, Boston, :MA). Specificity of anti-
serum was confirmed by preadsorption of the NTS2 anti-
body oyernight with an excess of immunizing peptide (2 
j.Lghnl of adsorbing peptide at a final antibody dilution of 
1110,000). 
Immunoprecipitation 
COS-7 cells were rinsed with PBS 72 hours after trans-
fection, detaehed from the dishes, and œntrifuged. The 
œil pellet was disrupted in RIPA buffer (150 mM N aCI, 50 
mM Tris-HCl, pH 7.5, 5 mM EDTA, 1%, IGE PAL, 0.5o/r 
deoxycholic aeid, O.lo/r sodium dodecyl sulfate) containing 
protease inhibitors and incubated for 30 minutes on iee. 
Lysatœ were then precleared with 25 j.Lg of protein 
A-Sepharose (Sigma, St. Louis, MOl for 45 minutes at 4·C 
and incubated oyetnight at 4°C with the NTS2 rabbit 
antibody (11800) or with a rat monoclonal antibody (clone 
3F10) directed toward the HA epitope (11400; Roche Mo-
lecular Biochemieals, Indianapolis, IN). The protein 
A-Sepharose was gently shllken in Iysis buffer containing 
1 % BSA for 30 minutes at room temperature before use. 
HA epitope-tagged NTS2 receptors were precipitated by 
incubation with 100 v.-g ofprotein A-8epharose for 2 hours 
at 4°C. After washing three times in Iysis buffer, com-
plexes were dissolved in Laemmli sanlple buffer and re-
soNed as described aboye. Nitrocellulose membranes were 
then incubated overnight at 4·C in PBS with a solution 
containing 1% BM and 1% ovalbumin and a 1/2,500 di-
lution of a mouse monoclonal antibody (clone 12CA5) di-
rected toward the HA epitope (samples precipitated with 
NTS2 antibodyl or with a 1/10,000 dilution of the NTS2 
antibody (smnples precipitated with anti-HA antibodyl. 
After washing with PBS-Tween, blots were incubatlld for 1 
hour at RT with HRP-conjllgated goal. anti-rabbit or anti-
mouse secondary antibodies in PBS with 5% milk powder 
(1/4,000; Amersham Pharmacia Biotech, Baie d'Urfe, Que-
bec, Canada) and proteins were visualized using an en-
hmlced chemiluminescent detection system. 
Immllnocytochemistry on COS.7 cells 
Transfected COS-7 l'ells, plated on poly-L-Iysine-coat~d 
glass coverslips, were fixed for 20 minutes with 4% para-
formaldehyde (PFA; Polysciences. Warington, PA) in 0.1 
M phosphate buffer (PB), pH 7.4, rinsed with 0.1 M 
Ttisma base-hllffered saline (TBS), pH 7.4, and preincu-
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bated for 30 minutes at RT with a blocking solution cou-
sisting of 5% normal goat serum (N GS), 2% nSA, and 0.1 % 
Triton X-loo (BDH, Ine., Toronto, Ontario, Canada) in 0.1 
M TBS. Double immllnostaining was performed byincu-
bating cella oVE'nlight at 4°C with tb!' anti-NTS2 peptide 
antiserum (1115,000) or with the anti-NTS2 pE'ptide anti-
serum preadsorbed with t.he antigenie peptide, togeLher 
with the Illouse monoclonal anLibody (clone 12CA5) di-
rocted loward the HA E'pitope, diluted 11500 in 0.1 M TBS. 
pH 7.4. containing 1% NGS and 0.05% Triton X-IOO. After 
washlng with TBS, cells WE're ineubated for 1 hour at RT 
witl! a mixture of A)PX8 488-conjugat.ed goat anti-mouse 
and Alexa 594-coIijugated goat anti-rabbit (11750; Molec-
ular Probes, Eugene, OR), washed t"tiee in TBS and 
mOUllted on glass slides with AquamoUllt. 
Double-labeled celis were analyzed by confocal micros-
copy by using a Zeiss 510 laser scanning microscope 
equipped with ft Zeiss inverted microscope and Argon2 
(488 nm) and HelNel (543 nm) lasers (Carl Zeiss Micro 
lnmging, Inc., Thotnwood, NY). Images were acquired 
simultaneously for both fluorophores (Alexa 488 and Al-
exa 594) by using the multitrack configuration mode and 
processed by using the Zeiss 510 laser scanning micro-
scope software. ldentical parameters were used to aequire 
the images for cells immunolabeled in the presence or 
absence ofNTS2 blocking peptide. 
Light microscopie immunoIabeling of rat 
brain sections 
Tissue jixatio". Adult male Sprague-Dawley rats 
(200-250 g; n = 10) were aneslhetized with sodium pt'll-
tobarbital {Somnotol; 1.2 ml1kgl and perfused transaortl-
caUy with a freshly prepared solution of 4% PFA in 0.1 M 
PB, pH 7.4. Brains were rapidly removed, cryoprotected 
overnight in 0.1 M PB eontaining 30% suerose at 4°C, and 
frozell for 1 minute in ÏSopentalle at -40°C. 
Single-labelmg immU1WhistocMmistry. Coronal sec-
tions (30 j.LIn thick) were cut on a freeting microtome along 
the whole rostrocaudal E'xtent of the brain from bregma 
6.70 to -14.60 and collected in 0.1 M PB. Immuno-
histochemistry was performed according to the avidin 
biotinylated-HRP eomplex (ABCl method by using a Elite 
ABC kit ('-octor Laboratories, Burlingame. CA). Briefly. 
free-fioating sections were washed twice with 0.1 M TBS. 
pH 7.4, pretreated for 30 minutes with 3% hydrogen per-
oxide in 0.1 M TBS to qUE'nch endogenous peroxidase. 
Seriai sections were then washed twice with TBS (2 x 10 
minutes), preincubated for 1 hour at RT ln a blocking 
solution containing 3% NGS and 0.2% Triton X-I00 in 
TBS, and incubnted ovemight at 4°C with the primary 
N'TS2 antibody (1110.000) diluted in TBS containiug 
0.05% 'l'fiton X-l00 and 0.5% NGS. After two rinses in 
TBS eontaining 1% NGS (2 x 10 minutes), sections were 
incubated for 1 hour nt RT in biotinylated goat anti-rabbit 
immunoglobulin diluted 1/400 in TUS (Vector laborato-
ries) and then 1 hour in }4~lite ABC solutjon (Vectur; pre-
pared according to the manufacturer's instructions). \ !su-
ali7.atiou of bollnd peroxidase was achieved by reaetion in 
a solution of 0.1 M Tris-HCI (TH; pH 7.4) con1ainingO.05'k 
:~-:!'-diaminobenzidine (DAH, Sigma-Alclrich), 0.()4!il; 
nickel chloJ"ide. and 0.001<)"(; H.O •. The DAH reat'tion was 
monitored under a micl"Oscopt' to determine the optimal 
duration of incubation (5 minut~s maximum) for yielding 
intl.>nse immunolabeling \Vith minimal badtground stain-
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ing. This reaction wail stoppai by several waslles with 0.1 
MTB. 
The same procedure was used for wntrol experimenl:s 
except that se(:tions were processed either WiUl antibodies 
preabsorbed ovemight with an exœss of immunizing pep-
tide (as for Westem blotting procedures) or in the absence 
of primary antibody. Sections were mounted on chrome 
alum/gelatin-coated slides, dehydrated in graded eth-
anols, defatted in xylene, and mounled with Permouut 
<Fisher Scientific, Montreal, Quebec, Canada). Labeled 
structures \Vere examined under brightfield illumination 
with a Leitz Aristoplan miscroscope (Leiea, DoUard Des-
ormeaux, Quebec, Canada), and labeling densities were 
assessed for eaeh region and visually SCOl'ed on a scale of 
-1+ to +++, aCt"Ording 10 both the number of labeled 
elements and the intensity of immunoreactive signal. 
Doable-Iabelinq immunohistoclu!mistrg. Frozen sec-
tions, prepared as above (n = 4 rats), were treated for 30 
minutes in 3% NOS in TBS and inculmted ovemight at 
4°C in a mixture of rabbit NTS2 antibody 0/10,000) and 
monoclonal monse anti-Sl00 j3-subunlt (11500; Sigma) di-
luted in TBS containing 0.05% Triton X-l00 and 0.5% 
NOS. The following day, sections were rinsed twice in TBS 
containing 1% NGS and inculmted for 1 hour in the same 
buffer containing a mixture of biotinylated goat anti-
rabbit immunoglobulin (1/400; ,"ector) and Alexa 488-
tagged goat a.nti-mouse (11500; Molecular Probesl. Sec-
tions were then rinsed in rus, incubated for 1 hour in 
ABC comple.'\{ solution, rinsed again in TB..'!, and incubati)d 
as above for 10 minutes in Il biolinylated tyramine solu-
tion (Adams, 1992; N~~N-Dupont, Wilmington, DE). After 
several buffer washes, sections were incubat.ed for l hour 
in a solution ofTexas-Red-conjugated slreptavidill (112r>ü; 
Jackson, West Grove, PA). Sections were then rinsed and 
mounted with Aquamount. The absence of cross-reactivity 
of the secondary antibodies was verified by omitting one or 
both primary antibodies during the ovemight incubation. 
Double-Iabeled sections were lmalYZed by confocal mi-
croscopy by using a Zeiss 510 laser scanning microscope 
equipped \Vith a Zeiss inverted microscope and Argon2 
(488 llm) and HeINe! (543 mu) lasers. Images were ac-
qllired simultaneollsly for both fiuorophores (Alexa-488 
and Texas Red) by using the multitrack configumtion 
mode and processed by using the Zeiss 510 laser scanning 
microscope softwaJ"e. 
Data analysis 
Light microscopie photomierographs and color images 
from double-Iabeling experiments were adjusted for COIl-
trast and brightness by using Adobe Photoshop 6.0 soft-
ware (Adobe, San ,Jose, CA). The final composites were 
processed by using Deneba's CanvaB 7.0 imaging software 
(Deneba Software, Miami, FL) on all Apple PowerBook 
G3. Brain structures wereidentified according to the no-
mp.uclature of Paxinos and Watson's atlas IPaxinos and 
Watson. 1986). 
RESULTS 
Characterization of NTS2 antisernm 
To demonstrate the specilicity of the NTS2 antiserum. 
Western blotting was performed QIl membranes prepared 
from rat brain and cerebellum Œig. lAt ln both struc-
tures, anti-NTS2 spet'ifically detet1:ed a lnmd. at 46 kDa, 
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reœpt<>r (N'fS2l antl .... nnn. A,B: Idt>.nliJlcution by W""t...rn Wotting (,e 
.ndogenouslyvs. heterologously ~ N'fS2 reœploni. A: Blot from 
whol. bruin (lalles 1,3) ,md œ .... J"'IInr (]anes 2, 4) m.ml"'·dIl<'S incubated 
w.th the N'fS2 antisorum. As n control, the anti""",m was prea<L.orbed 
w.th 2 ILIV'm1 of antigenic peptide (lan ... 3, 4>. Specifie immunoroactive 
bands are apparent at estimated molecular masses of 46, 80-85 and 
12·1 -206 kDa. Eadl lane repreeents the transfer of 60 l4f .1' membrane 
protPjn. Data are ""Prt'sentatiw offour imleJ ... ndent """"rimenta. B: Im-
munoprecipitntion with NTS2 anw..rum and bMting wîlh anti-HA an· 
IlI",,!y (h"re 2) or imnumoprecipitation with ""ti·HA antihody and Mol-
ting with anti-NTS2 antiserum (lane 4) ofhomogenates from COS-7 cells 
exp"""ing (lan •• 2, 4) or not (Ian. 1. 3; HA-N'fS2. Both approaches 
r ... a1 tr"mlaûoD produ<'Ù< of approximate!y 46. 83. and 12.'5-206 kDn in 
trnnsfectoo but not in untrnn.œctoo "';1Is. Data art' representntive of 
tlm'" illd.pend"nl t'XperilJl«nts. Miglatioll of molecular "'t>ight .narlte." 
is indicat<>d on the Ml. C-F: Dual immunoftuoœsœnœlabeJing ofC0S-7 
œll. transfected with cDNA ~.nc<lding flA-epitop<;-taggOO lIi"TS2 reœp-
tar. Lab<>Jing of the flA .pit""" (C) overlaps with .tnining produœd by 
the NTS2 antiserum (Dl. Pr.adsorption of NTS2 nnti..,rum with anti· 
gmic peptide ",rupletely nholisb"" NTS2-like immunostaining iF) in 
colis expressing the epitope-taggod r"""proT (E;. Tran .... uclear confocal 
mkroSl..."Opic ilWlb~ .rf:>I~lltative f,:Ji three fiW'panlt-e e~.-perinl€nt-ij, &ale 
bar = 5 I1m in F (applie. to G-jo'). 
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(',(lOsistent with the molecular weight of the monomeric 
form of the receptor as deduœd from its cDNA sequence 
(Fig. lA, lanes land 2), Specifie immunoreactive bands, 
which might reflet'! multimeric species ofNTS2 ret'eptors, 
were also detected al approximately 80-85 kDa and 124-
206 kDa in beth whole brain (Fig. lA, lane 1) and (''erebel-
laI' membranes (Fig. lA, lane 2), Ali of these bands were 
absent when the antibody was presaturated with the im-
Itlunizing peptide <Fig. lA, 1anes 3 and 4). 
To confirm that lhese Îlnmulloreactive bands corre-
sponded to the NTS2 receptor, crude membrane prepara-
tions from COS-7 cells p.xpressing HA-tagged rat NTS2 
recepwrs were immunoprecipitated with the NTS2 anti-
serum (Fig. lB, lane 2) or with the 3FlO antibody specifie 
for the HA-epitope tag <Fig. lB, lane 4), and, respectively, 
immu.noblotted. with the 12CA5 HA antibody (Fig. lB, 
lane 2) or with the NTS2 antiserum (Fig. lB, lane 4). 
These experiments revealed the preilenœ of 46- and 83-
kDa protein bands, as observed in rat brain and cerebel-
lum, in both immuuoprecipitates (Fig. lB. laues 2 and 4). 
In addition, immuuoreactive bands were dete<.1;ed at ap-
pnlximately 124-206 kDa in both preparations (Fig. lB, 
lane 2 and 4), whk.h presumably correspond to multimeric 
complpxl>8 of the receptor. No specific bands wpre d.etected 
in membranes prepared from nontransfu<,'ted cells <Fig. 
lB, lanes 1 and 3). 
Speciftcity of immwlolabeling 
To d.emonstrate the applicability ofthe NTS2 antiserum 
to immunohistochemical detection of the recppwr in P:FA-
fixed material, double immunolluorescent staining was 
carried out on COS-7 cells pxpressing the HA-taggPd 
NTS2 receptor. Confocal microscopy revealed that HA 
lFig. le) and NTS2 <Pig. 11» antibodips produced very 
similar pattems of immunostaining. No signal \Vas de-
tl.'Cted in unU'8.nsfected œlls or in the abspnœ ofprimary 
antibodies (data not shown). Preincuhation of the anti-
NTS2 antiserum with the N-terminal immunogenic pep-
tide completely abolished. NTS2-like (NTS2-Ii immunola-
beling lFig. 11"). However, the same œlls were still 
positively stained for the HA epiwpe, indicating that they 
did express Ule reœpwr (Fig. n: l. 
Immunolabeling of rat brain 8PCtions with a UlO,OOO 
dilution of NTS2 antiserum gave lise w selective immu-
nostaining patterns throughout Ule neuraxis (e.g., !<'igs. 
2A. 4-11). By contrast, sections incubated with antiserum 
p.readsorbed \Vith the immunogenic peptide were com-
pletely devoid of immunolabeling Œigs. 2B, Ge). 
Cellular distribution of NTS2-1 
immunoreactivity 
NTS2-1 imIllunoreactivity \Vas selectively couœntrated 
ovel' neu!'ofiS and most prominently within neuronal pro-
cesses (Table 1). Thus. in many regions such as the piri-
form cortex (Fig. 3A) and other cortical areas, NTS2-1 
immunolabeling was highly conœntrated uvee pyramidal 
œil demlritps, whereas the va,,'t. majority of the corre-
sponding perikarya were only modexately labeled. How-
pvel', in other regions. such as the centra) amygdaloid 
nucleus lFig. 3H), thp bed nucleus of the stria tenniualis 
lFig. 3D, 5A). or CAl of Ammon'Ii horn (Fig. 6A,m, both 
pelikarya amI dpndrites showed mode.rale to intense 
NTS2-limmunolabeling. NTS2-1 immunoreactivily wus 
also detected. in axons and axoll terminais Ulroughout Ule 
neuraxis, e.g., in the diagonal band of Broca <Fig. 3C) and 
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Fig, 2, Sped1icity of ItlVocabaflt.ine~f!E>ll8iti,,(l neurotensin ~ptor 
(NTS2J -!ike immunolabeling in rat brdin ..ctioru!. A: Section from the 
olfactory bulb, immuno.tained with anti-NTS2 serum diluted 
1:10,000. Ali wY" .... of the main oIfactory bulb nre .trongly imnmnopo-
sitlv". Most inwnsely stained are the exwrnal plexiform layer (Ep)) 
and the aec'Mory olfadory bulb CAOBJ. B: Section from lM ""me 
region incubated with primary antiBerum preadoorhed with 2 l-'{IIml of 
antlgp.B at the same fmol dilution as in A. Note the complete .uppres-
sion of the imn\uno1abeHng. For other abbreviation.~. sec I1st. Scale 
bar = 0.6 mnl in B (applies ta AB). 
in the anterior hypothalamus Œ'ig. 3G). Labeling of the 
ependyma was observed in sorne of our sections (e.g., Figs. 
5A. 8A,El, but this labeling was nonspecific, becausp it 
was still present in sections incubnted \Idth prendsorbed 
antiserum. 
No obvious NTS2-1 immunolabeling was evident over 
glial cells in our single-Iabeling e.xperiments. To formal1y 
exclude astrocl"tic involvement, dual immunolabeling ex-
pe.riments were performed bl" using our NTS2 antise.rum 
and the astrocytic marker Sl001'l in regions exhibiting 
either prominent somatie (Fig. 3D-F) or process labeling 
(Fig. 3G-1). ln the bed nucleus of the. stria termiualis, 
strongJy N'fS2-I-positive perilmrya as weil as small fluo-
rescent puncta resembling cross-se.ctioned processes were 
e~'ident by confocal microscopy (Fig. 3Dl. None of these 
structures exhibited 810013 îmmunolabeling within the 
same sections (Fig. 3E,F). In the anterior hypothalamus, 
N1'S2-1 immunoreactivity was localized ta punctate struc-
tures reminiscent of transected dendrites andlor glial cl-
ements (Fig. 30). Here again, none of these structures 
werp dually labeled with the SlOO13 antibody. which re-
vealed severa! astrocytic cell bodies as weIl as the cntire 
ependyma œig. 3H,n. 
Regional distribution of NTS2-1 
immunoreactivity 
TelenceplJalQn. Within the telencephalon, strong and 
selective NTS2-1 immunolubeling wa8 apparent in the 01-
factory bulb and tuberele, the basal forebrain, the basal 
ganglia, the amygdnloid complex, the hippocampal forma-
tion. and. thp cerebral l'()rtex (Table 1; for topographieal 
overview, sec Fig. 4). 
In the main olfacto.ry bulb, NTS2-1 immunoreactivity 
\Vas distributed throughout the granule l'ell, mitl'lll ce Il, 
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lTh(> iniA.n>'ii..Y ofimDluml>l'wli~ 1!r.~ qU;tIit.:dlvl>ly ;;('nr.x! ufo:iug tbç CA 1 î ..... ',m::l CA .. '! ~ ... )JOul:4i~J.l:01: ,:;1" AmDl(ln'lio horn '"j ro;:fim<nOO$.. IUI.(,nsily ç.f~~'1 IDlmun .... r.'.ttetivlly:. n(', 
latwlîng. + low shmal. ++ lIloo ... rak siwlul. + + + hiih sW:ll;ll, r"r"ITÎnM: \,; t:oùl.h IhooJinll into>mit.'f and the nUD1~1" Qflübi,kod C'Jenwnt:1!;, ~lSl,. JevN:aba~tinO-SI)nllHi ... ~ IlI?un't.mù>ln 
fi1'o;;f'p\o-r. 
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I."ig. 8. Cellular distribution of levocabastin(>-·sensitive neuroten .. 
sin rC?i'eptor-lilœ tNTS2-1) immunoreactivity in rat brnin sections. 
.A: ln many are.as I!ouch as the piriform cortex. NTS2-1 immunoreac~ 
tivity i. mainly apparent 'Net dend.rit..... ln regioru. such as the 
centraI amygdaloid nucleus (B) or the bed nudeU8 of the stria termi .. 
na1is (Dj. 1\-,.s241 inununQrt'-activity J8 pr.f..>{Jomimmt]y as.soeiat..ed with 
ru>t'Ve cell bodie.<;. C: NTh'"2-immun01WlctÎVe OXôns and .axonal varicos-
itiE's (arrowhead81 are v1!1îhle in sevt"..rn.l rPgion..~ Imch as hE'N> in the 
diagonal band of Broca. D-I: Dual Îmmunoftuorescouoo Jabeling of 
external plexifonn, and glomerular layers (Fig. 2A; Table 
1). ImmunoposHive perikarya were most intensely labeled 
in the mitral cell layer (Table n. Mod!'rately labeled mi-
tral cell dendrites also extended t1u'Qugh the extemal 
ple_!(iJhrm layer into the glomerular layer. III tbe glomer-
ular layer, a moderate ml'shwork ofNTS2-I-posiüve neu-
ronal processes surrounded the g1omel'llli. Perigloll1erular 
t'ells were occasionally labeled (Table n Labelingin the 
granule œil layer was abundant, although quite diffuse, 
makingit difficult to identify illdividual immunoreadive 
cells. The accessory olfactory bulb displayed very strong 
immunotabeling of neuronal pmeessei! (Fig. 2A; Table 1). 
527 
J'Io'TS2 and of the astrocyle antigen SlOOp. D: In the bed nucleus of the 
stria term.inal.is. NTS2-1 immunorea('ti~"Îty is apparent over sonwa 
and small proœsses, E$: None of these structures are immunoreae: .. 
live for th. SlOOp antigen within the same .... dion. G: In th" antenor 
hypothalamus. NTS2·1 Jabeling is detected in th. forru of .mall pundu 
pervading the neuropil~ pn!(lominnntly in it..'9 dorsomedjal llSJX>C.'1 •• 
Il,): lieN ngnin, nonEt of thé NTS2·]-inununoreactivl? su'Ucturê& co-
locali7.e S 10Qp , ... ithin th, """'" section. For Ilhbr.mation. •• see li.t. ScaJe 
bar in C = 60 lJ.IIl lu A.B, 40 lJ.IIl in C, 25 ILnI in D-F, 200 ILm in ('_1. 
In the olfactory cortex, only the olfactory tubercle 
displayed substantial numbers of immunolabeled nerve 
cell bodies. A few NTS2-I-positive perikaJ-ya were al80 
J)J'esent in the ta!'nia tecta, the islallds of Call1'ja, the 
piriform and prepiriform cortex \Fig. 3AI, and the lat-
eral olfactory nucleus (Table 1). Ali ofthl'8e structures, 
as well as the anterior olfactory nucleus (Fig. 4) and the 
dorsal and ventral endopiriform nuclei displayed at 
least low leve!.;; of fibeJ' labeling. In contrast. the piri-
f01'l1l and prepirifol'lll cortex stood out by exhibiting a 
dfmse network of strongly immunostained dendrites 
(Fig.3A). 
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In tlle basal forebrain. NTS2-I-immlilloreactive neuro· 
nal cell bodies were observed in the ventral pallidum, the 
subsu·iata.l area, fue medial and lateral septum (Fig. 4A), 
the diagonal. band of Broca (Fig. 4A), the magnocellular 
preoptic nucleus, and most prominently fue bed nucleus of 
the stria terminaIis Œ'ig. 5A). With the exception of the 
latter two nuclei, labeling of processes and terminaIs in ail 
offuese smlctures was more prominent than fuat ofneu· 
ronaI perikarya (Fig. 3C; Table 1). In addition, immuno-
reactive processes and terminaIs were encountered in fue 
septohippocampal nucleus and tite substantia innominata 
(Table 1). 
With the exception of the caudate putamen, which dis· 
played low to moderate numbers of relatively sman, 
NTS2.I-positive neurons (Fig. SC; Table 1), the basaI gan· 
glia exhibited only low numbers ofimmunolabeled nen'e 
cells or none at ail (Table 1). The nucleus accumbens (core 
and shell), the caudate pulalllen, and the flllldus striati 
also contained sparse NTS2.I-imlllunoreactive processes 
and terminaIs. By contras!" the globus pallidus (Fig. 5B) 
and the entopeduncular nucleus exhibit:ed a dense net· 
work of inlmllllolabeled libers (Table 1). 
The centraI amygdaloid nucleus (Fig. 3B) and the sui>-
nuclei of the colticalamygdala (cf. posteromedial amyg· 
daloid nucleus in Fig. 4B) bofu exhibited a Illoderate num· 
ber of strongly NTS2-1-immunoreactive multipolaf 
neurons (Table 1). In addition, sparse immunolabeled cells 
were found in the mediaI nucleus of the amygdala. AlI of 
these nuc1ei, as well as the basomedial nucleus, exhibited 
low to moderate dl.'llsities oflabeled processes and termi· 
naIs (Table 1). 
The hippocampal formation was among the most 
heav.ily Iabeled regions of the brain (Fig. 48; Table 1). The 
most striking pattl.'rn of staining W8S found in fue GA 
fields offue hippocampus p.roper. CAl exhibited extremely 
strong immunostaining of pyramidal cell bodies and apical 
dendrites (Figs. 4, 6A,BJ. These processes coursed furough 
Fig. 4. Topographie distribution of levocabastine--sensitive n~UJ"Oo­
temün reeeptor-like H\'"TS2·l) immunoreactivity. A ;;chemntic midsag-
ittal seetiQn through the rat brain provides an overview of the distri-
bution of NTS2-1 immunoreaL'Ûrity throughout the n<>Urwùs and 
indicates the rostrocnudaI levels or the coronal sedioJltl illustrated 
below. Symbols iu schf:>mut.lc iU'lgittal seet:ion~ dots, NTS2-1-positive 
neuronal perikar}'B.; twisted lînel!, labeled neuronal processes. A: At 
anlerior l~els~ the neorortex (lDost notably layer V and sUllragranu-
lar layera), pîriform col."text olfnctory tubercle, And late-ral septum all 
C]isplay modt>rate 10 Etrong immuno"..activîty. The nwd.iodor,tuù aspect 
of the caudate putauu>n is a180 moderately labolOO. B: Forth •• cau· 
"lal1y, v~ry strong: immul'lolaht>ling la ~ide.nt. in CAl and CM hi~ 
pocampal subftelds, Moderaw to dense lmmUn08taining is ... gain evi-
dent in Cf!n>brnl cntil.".Jt. The posterolu.edial (:Ortic11] amygdaloid 
nucleus a1so displays intense NTS2-1 immunoreactivity. Finnlly~ mod-
lP'-1'ale immunolalwling L'i ev.ident in the pru71fn.~cu]ar nucleus of the 
thalamus mld lhroughout th. hypothalamus, C: At caudal me.enœ-
phalic and rostral pontine l,pyels, the strongee,t immunoreactive slgJUJ:J 
is observed ln the, interpeduncular nudeus, the caudal linear raphe, 
and th. ""rinqueductnl gray. Th. """"rio. colJieulus al •• di"Play. 
moderate immlmolaœling, dî.ffe.re-ntîally distributed among"its layE"fS. 
The pontine nudei are strongly labeled. D: In the caudru ponst the 
superior Qlivary complu and tilt' nudeus ur the trapezoid body are 
ClJn@pic:uously labeled. In the same section.. rostral mt>dullary nuclei 
such aB thf;> prindpnl sen.,<;ory and spinal trigeminal nudel, tIIE' medial 
v€'.stibuJar nuclew;,+ and the c(lchlear nuclei display medium to strong 
immunon>aetlvity, In the Ct".rebellum. both the deep nudei and the 
cerelx\.l1ar corte'!C display high lev.els of !'iïS2~1 inlmunoreadivity. li'or 
abbrwirttions. 0"" H.t. Sc'ale bar = 2,5 mm in D (appli~s t<> A-D), 
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Fig. 5. Distribution of levocabo.tine· ... nsîtive neurot"nsin 
rf.'(.'eptor-like (NTS2-11 inunuru> ... ru:tivit~· in the '-al forebrain (Al 
and basal gnnglia (B.C). A: In the bed nucleus afthe stria terminalis. 
numet'O\lS ceU bodi~ are strongly immunoreactive. In addititm .. tbere 
lB a moderate staining of the neuropil 8urrounding the somata. 
B: Within tb. globus palIidus. NTS2-1 immunoreacth'ity is """""iated 
Ule stratum radialum and ramilll'd inlo thl' stratum lacu· 
nosum moleculare, forming a mesh oftranse<ted dendritic 
prollles <Fig. 6A,m. ln CA2, the labeling diminished in 
intensity \Fig. 6A; Table 11 and in CA3, no labeling was 
apparent at low lllagnification except for a light staining of 
the stratum lacunosum moleculare <Fig. 6A). At high lllllg· 
nification, however, it became obvions that Ole apical den· 
d.rit.es of CA3 pyrami!lal t'ells were in faet labeled, al-
UlOugh less intensely so Ulan in CA1 or CA2. CA3 nerve 
eell bodies wp.re not labeled (Table 1). In Ule dentale 
gyrus. graJlule cells wpre immullonegative (Fig. 6A; Table 
1) but a few failltly labeled cell bodies, as weil ru; sparse 
fibers. in the hilliS showed NTS2-1 immunolabl'ling (Table 
1). No immllnolabeling was apparent in the hippocampus 
in se<,tions in!.'ubated Witil antisentm preadsorbed with 2 
",glml antigenic peptide (Fig. 6C). The entorhinal cortex, 
as weil as the pre- and parasubiculnm. exhibited moder-
ately to intenseJy labeled uerve cell bodies in layer II (Fig. 
6D,El. Th.!' entorhinal co.rtex also exhibit.ed moderate 
staining of neuronal processes (Fig. GE; Table 1). 
ln ail neoc'Ortical areas, apical dendrites of layer V py-
ramidal nenrons were the most 8trongly immuuoreactive 
st.ructul'es fFig. 7A; Table 1). These L'Ould be traced ail the 
way to tayer 1 in which they rami1lpd (Fig. 7 A). Allocorti!.'al 
areas, represenled by theretrosplenial L'OrteX, also dis-
played strongly Illbeled pyramidal cells (Fig. 7B. inserl). 
Modemte nllmbers of NTS2-I-positive neuronal somata 
were observed in the frontal, parietal fFig. 7A, inserl), 
occipital, temporal, l'etrosplenial, and iusular cortex. Cino 
529 
with neuronal prœ._. roursing in betw.~n {aocid"" of myelînated 
"-'lOns. C; In th~ eaudate putamen, smaU .piny type JI·lme immunopo-
sihve n~uronal perikarya are visible bet",.en th. liber bundles of the 
interna! capsule. A light staining of the nHtropil i. evident a. wen. 
t'or abbr""iation., see list. Scale bar in B = 75 J.Lm in A. 160 pm in B, 
40 pm in C. 
gulate and perirhinal cortice.s exhibited only low llumbers 
of immunoreactive somata (Table 1). 
Diellcephalo1l. In the thalamus, Ule paraventricular 
(Fig, 8A), anterioJ" dorsal and lmterior ve.ntrul (Fig. SB), 
venu'Omedial, mediodorsal. lateral and medial geniculate 
(Fig. SC, Ïllt'ert) nuc1ei d.isplayed low to modemtll numbers 
of NTS2-I-immuuoreactive somata (Table 1), Most of 
these nllc1ei also exhibited intensely labeled neuronal pro-
cesses exeept for the anterior ventral and medial genicu-
late nuclei or tht> dorsal lier of the lateral geniculate body, 
which we/'(l cOIllpletely devoid of NTS2-1-positive pro-
cesses (Table 1). The reuniens, reticular, cl.'Jltral medial, 
rhomboid, parafascicular (Fig. 4BJ, and subparafascicular 
nuclei ail exhibited moderate 10 dense netwooo of NTS2-
l-positive .fille!'" but no immullopositive nerve œil bodies 
(Tablt> 1). 
Within Ule hypothalamus, low ta moderate numbers of 
immunoreal'live nerve ceU bodies were eviclent in the su-
pl'aoptic, arcuate !Fig. 8E,F), and ventrolllediai nucleus 
(Fig, 4), ru; weil as in the retrochiasmatic area (Fig. 4), the 
lateral hypothalamic a/'(lll, and Ule lateral malllmillaJ'Y 
nucleus <Fig. 8FJ. Ali of these Iluclei also d.isplayed mod-
erate to high levels of immunolabeled neuronal processes 
(Table 1 J. As in the thalamus, light tQ moderate labeling of 
processes was detected in sever al additional nuc\ei, 
namely the antl.'rÏor hypothalamus <Fig. 3G), sllprachias-
matie nucleus, para- (Fig. SD> and ppriventricula!' nuclei 
(Fig. 3G), tuber cinereum <Fig. 3Gl, medial mammiUary 
nucleus (Fig::;, 4, 8F), and lateral and medial preoptic arl.'a 
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}i"ig. 6. Di6tribution <tf levocabastine-·sensitive nf.'urotensin 
r"""pror-Jiu (NTS2-11 imnmnoreactivity in the hillpocampru forma-
tion, A: ln Ammon's harn, inten8e NTS2-] immunolnheling i~ e"ident 
iu. stratum P)TaDlidal4:\, radiatum, and lacunosum moleculare of CAl 
and CA2. C,\3 displays only moderate, diffuse lnbeling, exe.pt in the 
st.rat·um lacunosunl molf.'n.1lnre~ wht>ce the Inbeling Ü~ m.ore p.ru .. 
nouneed. The dentate gyrus is Iikewise moderately but diffusely la-
beled except for the granule cel1 layer, wbich is total),.. devoid of 
ilUlDunostaining. B: At high magnillcation. virtually ail CAl pycami-
dal cells ace M>E'D to be ÏmmWl.opositive. Theîc apical dendrites prusa 
(Fig. 4; Table n The outer zone of Uie median eminence 
(Fig. BEl as weil as the supramammillary nucleus (Fig. 
8F) exhibited 8trong NTS2-l fiber labeling (Table 1). 
In Ule zona incerta, "'parse, lightly slained nerve cell 
bodies wl're detected amidst intensely Inbelec} nemunal 
processes (Fig. SC; Table I J. The subthalamic nucleus 
exhibited modl'rate leveIs of NTS2-I-positive processes, 
but no immunoreacHve nerve Cl'U bodies (Table l J. 
Both subdivisions of the habl'uula displayed sparse, 
lightly labeled nerve cel! bodies (fig. BA; Table Il. The 
P. SARRET ET AL. 
througb the stratum mwatum and ramify in the stratum lacrmosum 
molecu)are. C: P...,,,dsorption orthe antisenlnl with 2 j1gIml of all.tigeu 
re-sults ln a complete l~ of NTSz..J immunQreactivity. D: The ento--
r)\Ïna1 cortex &>;J w~jl ru; the pre- and parMubic:u]um aU diF:play nu-
m.rous, atrongly hlbel.d neITe 0011 bodies in lnyer II. E: At high 
magnification, lalX"llng over neunlD~ Jn the ent..,rhiual cortex 11:\ seen 
to spare the nucleus and to extend for a short distance \Vithin proxi-
nla) dendrite •. For abbreviationo, ...., list, SCIlle bar in .0 = 400 l'>m in 
A,C. 80 JUIl in B, 150 ILm in n, 60 Ilm in E. 
lateral habenula also exhibited a lIloderately dense plexus 
of NTS2·I-positive processes (Fig. BA; Table 1). The sub-
fomical organ, while devoid ofimmunopositive cell bodies, 
harbore<.! a moderalely dense network of immunoreactive 
proce.sse.s (Tabl!.' 1). 
MesellcephaJoll. In Ule midbrain, t.he oculomotor 
(Figs. 4, 9Al and magnocellular part. of the red nucleus 
(Fig. ge) contained medium numbers ofintensely sllün('(} 
NTS2-positive nerve t'l'Il bodies. Lightly labeled and/or 
less numerous neurons were also observed in the substau-
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Fig. 7. Distrjbution of levocabastin.e-sensith·e neurotf:'Dsln 
receptor-lib (NT$2.1) immunoreactivity in the cerebral cortex. A: In 
neocort!eaJ f~\..<; such .as the prtriet:.d cortex jJJustmted ~, ft sub-
population of layer V pyramidal rolls (insertl ""hibit intonse immu-
nolaheling of tJu.ir ceU bodÎ<>s and apical dendrit .. s. Th" latt ... may Il<> 
followoo up to the &uperficiallayers, in whi.h they.ami(y. B: Ailocor-
tital aresa. representOO ht're by the retrospleninl rortex, display a 
similar pattern ur labeling. Scal. bar in B = 150 f1J'l in A (60 ",m in 
in""rt), 75 ",m in B (.15 p.m in i"""rtl. 
tia nigra, pars reticulata (Fig. 9D,E), ventral tegmental 
area <Figs. 4, 9Dl, interprouncular (Figs. 4, 9Dl and in-
terfascicular nuclpi, Pf.'.riaqueductal gray (Figs. 4, 9A,Bl, 
dorsal raphe nucleus (Figs. 4, 9A), and superior and infe-
riQr collicuH (Fig. 4; Table 1 J. In most of Utese structurp$, 
and most prominently in the Pf.'riaqueductal gray, dorsal 
raphe nucleus, and substantia nigra pars reticulata. these 
labele.d perikarya were embedded in a dP1\8(' meshwolk of 
immunolabeled proeesses <Figs. 4, 9). In the superior L'OI-
liculus, labeled Pf.'.rikarya were exclusively obsprved in the 
innp,r gray laye.r, immed.iately adjacent lo the optic nerve 
layer, and in the deep gray, where Yleywere con.centrated 
laterally. The substanüa nigra, pars compacta (Fig. 9m, 
peripeduncular nucleus, deep mesenœphalic nucleus (Fig. 
9D), and precommissural nucleus were devoid of immu-
Ilopœitive perikarya but diblllayed low t.o moderate label-
ing of neuronal proeesses (Table 1). The l'audal linear 
raphe nucleus (Fig. 4C), while devoid ofperikaryal immu-
nolabeling, displayed inten~ely labeled processf.'S (Table 
1), 
Paru;;. Th.e pontine nuclei (Fig. 4C) and nucleus of Ule 
trapezoid body (Figs. 4D, 9H) displayed a Inoderate num-
ber of &1.rongly immunostainpd neuronal perikarya. Less 
numerous and/or more lightly stailled cell bodips were also 
evidpnt in the superior olivary complex and 8uperior para-
olivary nucleus (Figs. 4D, 9Fl as well as in Ute principal 
seusory (Fig. 40) and motor trigeminal nuclei (Table 1). 
Except for Ule nucleus ofthp trapezoid body, these struc-
tures were aIse pervaded by Illoderately abundant imlllu-
noreactive neunmal pl'OCt'llses (Fig. 9F,G; Table n The 
pal'mnedian raphe nucleus displayed no NTS2-I-pœitive 
nerve cl'll bodies but a moderately dense network of Ïm-
munolabeled processes (Fig. 9G; Table 1). 
Jfedulla oblongala. In the medulla oblongata, yari-
able numbprs of moderately ro inteJl8('ly hlbeled NTS2-1-
immunoreactive cell bodies and processes wt're observed 
in ail Sl.'usllry and most of Yle motor cranialnerve nuclei 
(Table 1), including the vestibular complex !Fig. 10A,m, 
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the cochlear nuclei (Figs. 4D, lOA), the subnudei of the 
spinal trigeminal nucleus (Fig. lOA-C l, Ule nucleus of the 
solitary tract (Figs. 4D, lOB,Cl, as weil as thp lrochlear, 
abducens (Fig. lODl, fadaI (Fig. 10A), vagal (Fig. lOB), 
and hypoglossal (Fig. IOB,C) nuelpj, In addition, Yle iufe-
riol' olive (Fig. 10B,Cl, the gigantocellular reticular nu-
cleus, pars alpha (rostroventral medial medulla; Fig. 
lOA,Fl. the lateral paragignntocellular \Fig. lOA) and lnt-
l'l'al .reticular nuclei, the parvocellular reticular nucleus 
<Fig. lOA,B,Gl, the ext~l'lHll Clllleate and CUlleate nuclei 
(Fig. lOB,C, El, the linear nucleus orthe raphe (Fig. lOB), 
and the nuclei raphe magnus and pallidus (Fig. lOA,F) 
displayed low to moderate perikaryal NTS2-1 immunola-
beling as wpll as moderate to dense lllbpling of neurorull 
processes (Table 1). Structurcsin which immunolalwled 
processes but no œIl bodies were observe.d iuclude the 
gigruttoœl1ulnr and intermediate reticular nuclei (Fig. 
IOA,B), the medullary rpticular field (Fig. IOC), the 
paratrigeminal (Fig. 10Hl and gracile (Fig. IOC) nuclei, 
nucleus X (Fig. lOB), and the nucleus raphe obscuru>! (Fig. 
lOB; Table 1). 
Cerebellllm. The deep cerebellar nuclei displayed a 
moderate numbel' of strongly immunoreactive nerve cell 
bodies intersPf.'rsed among a plexus of immunopositive 
processes (Fig. UA; Table 1). The lateraI nucleus was 
slil,rhUy more intensely staine.d than intermediate and 
medial nuclei (Figs. 4D, HA). In the cerebellar cortex, 
NTS2-1 immunoreactivity was present in ail three layers. 
Purkinje cell Pf.'rikarya and dendritic processes ascending 
in the molecular layer were the most strongly labeled 
elements (Fig. llB,C; Table 1). Labeling in the granule 
cell layer was less pronounced and esseutially accounted 
for by the immunolabeling of a subpopulation of granule 
cells (Fig. llD; Table 1). In the molecular layer, sparse. 
strongly labeled nemonal perikarya (not shown) were ev-
ident among the Pf.'rvasive Purkinje cell dendrites (Fig. 
Ue,Dl. 
DISCUSSION 
The present stl.ldy provides the tirst description of the 
distribution of NTS2 receptor proteins in mammalian 
brain. The NTS2 antiserum usedhere was raised against 
a sequence from the N -terminus of the rat receptor unique 
among Imown NT receptor sequences. 'l'hl! specificity of 
the antiserum was initially establiShed by Western blot-
ting of membranes prepared from whole brain and cere-
IwHum (which previously had been shown to express 
among thp higbest levels ofNTS2 mRNA and bindingsites 
in rodent brain; cf. Sarret et al., 1998, 2002; Walker et al., 
1998). The NTS2 antiserulll specifically recognized a band 
at 46 kDa, which corresponds to the molecular weight of 
the monomeric reeeptor deduced from its cDNA sequence. 
ln addition, other specifie bands were deteeted at molec-
ular weights co.rresponding to multiples ofth.e monomeric 
recepror's sizp, thus possibly retrresenüng multimeric 
complexes of NTS2. None of thp_~e bands were present 
when the blots were incubated WiUI antiserum pread-
sorbed with th!.' antigenic peptide, imlicating that the 
NTS2 antiserum selectively recognizf.'d the native recep-
tor protein. 1'0 further support. Ute notion that the immu-
norp.adive bands detected in brain homogf.'n3tes indeed 
corresponded ro the NTS2 reœpto.r, immunoprecipitation 
p.xperiments were carried out ou mpmbranes from COS-7 
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Fig. 8, Distribution of wvocaba.tine·sensitive neurotensÎn 
recept{JT-like (NTS2·1; immunonoac:tivity in the diencephalon. A: HA.-
benular complex. The l .. t«raI h.'lbenula "xlùbits moderate to dense 
liber staining, wherea" the medial hnbenula ;5 only Iightly and ,lif· 
fusely stained. The ventromedially adjoining para""Dtrirular lha· 
lamie nnde". di''PIIlYS strong immunolaheIing, B: The :mterior dorsal 
thalnmic nucléus displnys intense pcrikaryal and neuropil immuno-. 
e-taînîng. wh~rt'as thft npjghhoring antenor ventral nucleus Îs Qnly 
lightly renctive-. C: Intense immunoreactivity is apparent ove-r the 
dor"al laterlll and ventral tÎ<'rs or the Iat.ral genicnlate nlleIe'l' "" 
weU ~ in thE? adj()ining zona incerta. AB seen in thp insed." n106.i: "fthis 
P. SARRET ET AL. 
immunostaining is aeeounted for by dendrîtic processeB. D: Within the 
partlVfi"nt·rk'UJa.r nUdE.>\L':l, NTS2·1 immunQ~act.ivity î.s selectively de-
tect.d within .mill punctate pro .. """", E: The arcuate nucleus (Are) 
djsplays both immu1'loreuctive nerve œil bodies (arrowheruJs. ln.'iet1J 
and a dense netwodt of strongly îmmunoreadive processes. Diffuse 
imnwnolaheling is also evident ov~r the extem..'l.l ZODf> of the median 
eminence. F: At the level of th" mammillary bodies, th. I"ternl mltm-
millary (LM) and supmmnmmilIary (SuMl nuel.i .lmw modera! .. t<> 
Mmng neuropil immunolabeJing, t'or otheT abbreviations, """ list. 
Scale bar in F = 130 ",ru in "'B.D. [,00 .. m in C (4û "'fil in in ... rt). 80 
Jl.Ill in E (50 Jl.Ill in in ... t); 200 Jl.Ill iu F. 
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Fig. 9. Distributüm of le-vocahastine·SRDsitivE> neurotensin 
receptor-Iike (NTS2~]) immuuore-activity jn D.wsf?nce-phnlon (A-E) 
and pons rF-H). A: The ventral p"naqu.ductalgl'ay<PAGl anddonal 
raphe nucleus both êxhibit a df'DSe network of immunopositive pro-
cesses. IntE'll$ely immunoreactive nerv-e cell bodies are rusa evident 
within the o(.'Ulomotor nudft\us. B: In thf:\ dONal part of th-e PAG. 
labeled neuronal perikarya (arrowheads) are apparent amidst a less 
intensely stnlned plexus of immuuoreactive processe~. C: Inten.twly 
immunostained nen'(> Cl"ll bodi-cs are dek-cted in the ventral. magn1>" 
cellular porli.on of the red nudemL 0: The bo"Ubstantia nigr~!. pars 
compacta (SNe) and r~ticulata (SNr) exhibit a d.ns~ notwork oHm-
munopositive pr()('ess~. ln the vootrlll tt'!lg:m.entnl nr()a~ thé lnl'H'lling j,g 
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Jess întp.n.se and concerns n.erve œll bodies as weIl as processes. E: At 
high magnimation, NTS2-I-po.itîve norvo 0011 bodi@s \arrowheam.) 
can be id.entifled llDlOngllt the dense plexus ofprnces..'\es pE>I'VRding the 
SN'!"_ F: In the rOi(ual pons. the 8upenor olivary complex exhibits fi 
mix of la'beled somata and processes, G: The paramedian raphe nu· 
deus dbJplays a high density of immunolalwled pl'OCeSS6iJ, wherPti 
the median raphe nucleus îs completely devoid of NTS2 immunore-
activity, 11: In th.e nucleus of the trH[~zojd body. NTS2·) immunore· 
arlivity is predominantJy associated wit'h small neuronal per~. 
For other abhrf:'vintions~ Sfi'e list. Sc--d1e har in II = 280.,un in A, 6.';.,un 
in B, 120 !Lm in C, 350 !Lm in D. 50 j1Jll in E. 240 "'ID in F, 150 "'ID in 
G,R 
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Fig. 10. Distribution of lev.ocabaatine·sensitive neurotenll"in 
rt'<..'-eptur-like (NTS2-U ÎIu.lnU.nart>-activity in the medulla oblongata 
A-C: Low·magnili<at.îon photonùcrograph. iIIustrating labding of 
c.raninl nerve ~I\$i)rv nucl(>j, Some of thest>'. such as the mediaJ vas· 
tibular 'A.Bl and d<>~ cochlear nuel_i (AI are more or 1_ uniformly 
and very strongly e.taint>d. Others, such a..'i the aUfJt>ntH' (A) and spinal 
,"atibular (B) Dudei and ventral <ochlear nudeus ,AI. exhibit lighter 
st.aining of nie neu.ropil and !\i'"IS2·I.>Of!:itjve neJ"'\~e ct>n txxlit>.s ure vis· 
iblp. even at low mngnification. D: The abtlu(:(!ns nucleus dîsplays 
nump...roU:8 intensely stained neurons 3S weIl as a strong Jaheling of the 
neuropil. E: The extt"rual CWlea.te nuc!(>us exhibitl30 a mooerate num· 
cells transfe<,ted or not WiUl cDNA encodîng the 
N-tprmînally lIA-t.<lgged NTS2 r!'ceptor. Both immuno-
precipitation with an anti-HA epitope antibody and detec-
P. SARRET ET AL. 
ber of NTS2·I-positive perikarya in it. Iat .. mJ aspect. The neuropil is 
st.rongly .tain.d and pervaded by a den •• network of immuuQIabeI.d 
processes. F: Th .. gigantoc.Uular reticular nucleus. pars alpha, exhib-
ils nomorou. labeled perikarya Ils _II as proc<>"""". Medially, th" 
nucleus rnphe magnus i. int~llBely st"ined. and the raphe pallidu. 
displays nl.ooernte immWloJ."eru.'tivity. G: Intenst>ly NTS2-1 immunQ-
rendive neurol15 in the (h"U"VO:Cellular reticular nucleus are sur· 
rounded by a modt>rat~ly dt>n.":It> pJeXtl50 of jmmunopositive fibprs, 
H: The paratrigeminal nucleus is pervaded by il den ... plexus of 
intensely atained procE"Me8. For abbrt?Vh\tinn.s~ see tist, Sçale bar in 
H = 700 j1.Ill inA-C, 60 /LIU in D,E.H. 170 /Lm ill F. 75 j1.Ill in G. 
tion with anti-NTS2 and the reverse experiment gave rise 
to the ;lame major bands pattent as d.etected in rat bmin 
and cerebellum homogenates. TIIeS!! findil1gs col1firm that 
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li'ig. Il. Di&tcibution of leYacahastine~s('>llSitive neurow.nsÎn 
l'<'('(>plur-Iilœ (NTS2·1) immunoreaetivity in th<' œrebellmll, A: ln· 
t ... """ly label~d nerve cen bodies are detect-ed among A network of 
immUJlOreactivIP proœ.-S~ within the lateml and interJlwdiate ,,'en-
bellar Duel"i To the leU of the mc,tior œ..,bellar pedunele. light to 
moderate inununoreaci..i.vity L."l uhsel ..... ed in the laieral v~tibu lar nu .. 
deus, B: Sagitl<'ll ""olion thceugh the parallocculu8, ilIustrnting th<' 
pres .. nce of NT'52·1 îmmunolabeling in ail three laye ... of œre""lIar 
our antiserum selectively CI'\Jl!s-reacts with the rat NTS2 
recepwl'. 
To establish the applicability of Ule antiserum w the 
immunohisl.ochemical detection of NTS2 receptors, 
double-Iabeling studies were perfofIDpd on COS·7 œlls 
traJ1/li!'11tly expl'l'.ssing the N-tel'minally HA-tagged NTS2 
recl'ptor, TIll' NTS2 anti.serum pxclusively labeled cells 
Ulat also exhibited HA Înununoreactivity, indicat.ing that 
il sl'll'ctively rl'COgnized cells expressing the NTS2 recep-
tOI'. Preadsorption of Ule NTS2 antiserum WiUl immUllQ-
genic peptide l'Ompletely abolished immulloslaiuing, con-
firming that it was attributable to the NTS2 antibody. 
Similarly, sections of rat brain incubated with pread-
sorbed anUsenun were virtuallv devoid of immuuostain-
illg, suggesting tha! as in tranÙected cells, the alltibody 
selectively recognized the NTS2 receptor. 
WiU!in the brain, NTS2-1 immunoreaetivity was exclu-
sively fouud in neurons, However, its subeellular comlh'ut-
mentalil.ation varied markedly between brainregions. 
Thus, whereas in SCJlue al'eas, Bueh as the hippocampus, 
the immunolabeling was associated with boUt perikarya 
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cortex, C: At hîgher magnification, labeling of Purlùnje cells and of 
their "pk .. 1 dendrites trllyersing th<' moleoulm laye" i8 ""ident D: At 
high magnification, individual immunopositive granule œU" <an he 
identifled (black arrowhead.l, In additioD, the plexus ofPurkinje cell 
dendtit •• ;,. ",.olv.-d in the molecular layer (white arrowheads). For 
abbreviation~. see 11st .. Seule bar in D = 400 lJdD in ~ 500 p.m in B. 1.'30 
jIJIl in C, 30 jIJIl in D, 
and rlendrites, in others, sueh as tht1 cerebral cortex or the 
globus pallidus, it c1early predominat.ed over dendrites, In 
yet olliers, Bueh as tht1 diagonal band of Broca and the 
anterior llY(X1U!alamus, it waB maillly associated with ax-
ons and axon terminaIs, These data suggest that, unlike 
NTSl receptors, which are reportedly more or less uni-
formly distributed OWf perikarya, dendrites, and axons of 
neurons in which lliey are expressed (Boudin et al., 1996; 
Fassio I!t aL, 2000), NTS2 reeept.of8 may he selectively 
targeted to specifie neuronal elements. and rnost promi-
nently to dendritic proce~8es. 
Previous in situ hybridization studies have rl'ported the 
presence of NTS2 mRNA expres:',ion in glial and epelldy-
mal cells in intact adult rat brain (Walkel' et al., 1998; 
Lépée-Lorgeoux l't aL, 1999), Furthermore, double-
labeling experimellts have demol1strated NTS2 mRNA ex-
pression in glial fibriUary ncidi.c protein-immunolabeled 
rooctive astrocytes, both in vitro and in vivo (Nouel et aL, 
1999). No glial and/or ependymal labeling \Vas rl'adily 
apparent heJ'e in NTS2-Îmmunoreacted .sections. To COll-
firm tlle lack of association of NTS2-1 immuuoreactivity 
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with astrocytes, we performed dual-Iabeling experiments 
using lhe astroglial marlœr SlOO~. In none of the regions 
examined ditt Sl~ immunoreactivity colocalize with 
NTS2-1 immullostaining, suggesting that under basal con-
ditions, NTS2 receptJ.J'f protejns are not present in satro-
cytes. This i8 not to say, however, ihai they would not be 
detel,"table under conditions of reactive gliosis. 
The topol,rraphic distribution ofNTS2-1 immunoreactivity 
was extensive, as expected from earlier subtractive auto-
radiographie binding studies based on the displaeement of 
specifie 1211I_labeled NT, [3HINT. or ["HISR142948A bind-
ing by levocabastine (Kitabgi et al., 1987; Schotte et al., 
1986, 1988; Schotte and Laduron, 1987; Betancur et al., 
1998) or on direct binding of [3Hllevocabastine (Asselin et 
al., 2001). TllUS. NTS2-1 immunolabeling was detected in 
ail regions previously reported to exhibit higll levels of 
NTS2 binding sites, including olfactory bulb, all olfactory 
relay nuclei, septum, bed nucleus of the stria terminali.s, 
amygdaloid nuc\ei, CAl of the hippocampus, pre- and 
parasubiculum, cerebral cortex, several thalamic nuclei. 
arcuate nucleus, mammillary bodies, interpeduncular nu-
cleus, superior colliculus, periaquedul.tal gray, dorsal ra-
phe nucleus, red nucleus, substantia nigra, ventral teg-
mental area, nucleus raphe magnus, vestibular eomplex. 
and cerebellum. However, the present study also demon-
strated that, if widespread. the distribution of NTS2 re-
ceptor proteins was also more selective than previously 
sunnised from the diffuse diBtributional patterns yielded 
by autoradiographie binding studies (Kitabgi et al., 1987; 
Schotte et al., 1986, 1988; Schotte and Laduron, 1987; 
Betancur et al., 1998; Asselin et al., 2001). 
The distribution of NTS2-I-immunoreactive nerve cell 
bodies was also in good agreement with that of NTS2-
expres.sing cells as determined by in situ hybridization in 
both rat (Walker et al., 1998; Lépée-Lorgeoux et al., 1999) 
and mouse (Sarret et al., 1998) brain. By and large, all 
regions reported ta exhibit medium to strong NTS2 mRNA 
levels, sucb as the olfactory bulb, cerebral cort.ex, hip-
pocampal formation, periaqueductal gray, and cerebellar 
cortex. to name but a few. were immunolabeled here. 
There' were several regions, however. in which NTS2~1 
immunolabeling appeared more restricted than pxpeeted 
from in situ hybridization data. For instance, the medial 
habenula, which was reported, to contain high levels of 
NTS2 mRNA (Sarret et al., 1998; Lépée-Lorgeoux et al., 
1999), was barely immunoreactive in the present study. 
Similarly, the hippocampus, whicll was shown to express 
very high levels ofNTS2 mRNA tbrougbout ail subfields of 
Ammon's hom and the dentat-e gyms (Sarret et al., 1998; 
Walker et al., 1998; Lépêe-Lorgeoux et al.. 1999), exhib-
ited NTS2-immunoreactive cell bodies only in CAl and 
CA2 sub-flelds. These discrepancies could reflect poor 
translation of the NTS2 message in certain subpopula-
tions of neurons or could be due to selective targeting of 
NTS2 proteins to neuronal processes. Thus, NTS2 mRNA-
positivelNTS2-immunonegative neurons in the medial ha-
benula could account for the terminal immunolabeling 
observed in their projection field within the interpeduncu-
lar nucleus Œutcher. 1995). Alternatively, the lack of ap-
parent cpllular immunoreactivity in areas containing high 
levels of NTS2 mRNA could reflect selective targeting of 
NTS2 receptor pro teins to plasma membranes. Indeed, the 
diffuse NTS2-1 immunolabeling observed here over the 
CA3 subfield and dentale gyrus wasreminiscent of the 
pattem of labeling described for the 8S~ somatostatin 
P. SARRET ET AL. 
receptor in brain areas in which this receptJ.lr was found 
by ele<,"tron microscopy to be selel'tively addressed to 
plasma membranes (Dournaud et aL, 1996). 
Inconuml to NTSl mRNAŒlde et al., 1990; Sato etaI., 
1992; Nicot et al.. 1994a,b; Alexander and Leeman, 1998) 
or immunoreactivity (Boudin at al., 1996; Fassio et al., 
2(00), which are more or less restricted to regions inner-
vated by neurotell5ine.rgic axons, NTS2·1 immunoreactiv-
ity I..onsiderably exceeded. t11at of NT terminal fields. Thus, 
sorne orthe most heavily labeledregions in the brain, sucb 
Ils the hippocampus, the cerebral and cerebellar cortices, 
and medullary crarualnerve nuc1ei have been described as 
being innervated only sparsely if at ail by NT flben; 
(Jennes et al., 1982, Emson et al., 1985). These findings 
p/'Ovide furlher support to the hypothesis Hml NT may not 
he the exclusive endogenous ligand for this receptor sub-
type (San-et ei al., 1998). There were, however, regions in 
which NTS2-1 immunoreaetivity showed considerable 
ovel'lap WiUl NT terminal fields, including the olfactory 
bulb, bed nucleus of the stria terminali.s, magnocellular 
preoptic nucleus, anlerior dorsal thalamic nucleuB, sub-
stantia nigra, ventral tegmental area, periaqueductal 
gray, nucleus raphe dorsalis and magnus, and lateral 
paragigantucellular nucleus (Jennes et al., 1982; Emson et 
al., 1985). AH of these regioDs (except for ol1c1ei raphe 
magnus and lateral paragignntocellular nucleus), as weil 
as several others in which NT axons are less p/'OlIlillent, 
such as the entorhilllù, frontal, and retrosplenial cortices, 
the pre- and parasubiculum, tbe cortical amygdala, the 
pontine nuc\ei, and various medul1ary nuc1ei, also display 
high levels of NTSl 1B0udin et al., 1996; Fassio et al., 
2(00), indicating lhat, in many brain structures, NTS2 i/l 
in a position to il1teract with NTS1 in mediating NT's 
ceJltral effects. 
The distribution of NTS2-1 immunoreaL'tivity also over-
lapped ext!'llI!ively WiUl thal of the single-transmembrune 
domain receptor NTS3/sortilin (exœpt in the granule 0011 
layer of the cerebellar cortex and medullary reticu1ar forma-
tion, which were eHricbed in NTS2- but nol in NTS3-
immuno.re8Ctive neurons; (Sarrel et al., 2003). This wide-
spread codistribution ofNTS2 with. NTS3Isortilin mises the 
possibility of interactiolll! between these two receptors fur 
the mediation of th!> NT signal, particulallY inligllt ofrecent 
sludies showing that NTS.'l cau internet with NTSl to en-
hanee the NT-indw.,'Cd phosphorylation of mil:ogt>ll-activated 
protein kill!l8Cl'l and turnover of phosphoinositides in the 
IIT29 human cancer cellline <Martin et al., 20(2). 
A striking f!>atnre of NTS2 distr.ibution. was ils associ-
ation with eve.ry single sensory system in the brain. Thus, 
ail olfactory l'elay nucl~j, including the olfactory bulb, 
e.xhibited NTS2-l immulloreaetivity. The audit ory system 
was also labeled from th!' cochlear nuclei, through the 
superior olivp, the inferior collkulus, and the medial 
geniculate nucleus, all the way to the tem poral cortex. 
Lilœwise, th!> visual system exhibiled NTS2-1 immunola-
heling throughout the lat~ral geniculate body, sU[lracbi-
asmatic nucleus, I>uperior collkulus, and occipital L'OrteX. 
The nucleus of the solitary tract, Il major relay for vist'eral 
and gustatory input, exhibited moderato immunolabeling. 
Finally, NTS2-1 immunorpactivity was a8socialed with re-
lay nuclei of ascending somatoSeJlSory information, ill-
cluding the gracile and cuneate nuc\ei, spinal and princi-
pal sensory trigeminalnucll'.Î, and parietal <-'OlteX. 
Of particular interest from a functional perspective wa'! 
Hle intense labeling of brainstem structures involved in 
pain control. Indeed, recent pharmacologie studies have 
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demonstrat~d that the NT antagonist SR142948A, which 
does not distinguish belween NTS1 and NTS2, blocks 
NT-induced antinocieeption (Guily et al., 1997), whereas 
the NTS1-speci.fic antagonist SR48692 does not (Guily et 
al.. 1993; Dubue et al., 1994; Labbé ... Jullié, 1994). Further-
more, the NTS2-selective Iig'and, levocabastine (Tyler et 
al., 1998; Dubue et al., 1999bl and N1'S2 antisense oligo-
nucleotides (Dubue et al., 1999a) both inhibit the antino-
dceptive etTects ofintracerebnlVentricularly admillist~red 
NT, whl.'.reas knockillg down the NTS1 gene in miel.' i8 
without etTect (Remaury et al., 2002; but also sel.' Petti-
bonI.' et al., 2(02). Microinjection sludies have long iden-
tified regiolls involved in the desconding control of noci-
cept.ive inputs as sitt'S of NT-inducl'd antinociception 
CK.:divas et al., 1982; Mayer and Priee, 1989; McHaffie et 
al., 1989). The strong NTS2-1 immunolabeling found here 
in regions Bueh as the periaqueductal gray, dorsal raphe 
nucleus, raphe magnus and pallidus, gigantocellular nu-
cleus, plUS alpha, and lateral paragigantocellular nucll.'us 
suggests thut NTS2 roceptors are id.I'a11y poisl'd to regu-
lat~ N'Ft! supraspinal antinociceptive actions. 
Strong NTS2-1 immunoreactivity was associated with 
cerebellum-related brainstem nuclei sueh as the eJ.1:ernal 
cunMte nucleus, pontine nuc1ei, inferior olive, and vestib-
ular complex, 8uggesting that NTS2 is associated with 
both mossy and. climbing fiber a1Terent cerebellar systems. 
NTS2 immunolabeling was also observed over Purkinje 
cells, del.'p cerebellar nudei, vestibular complex, and red 
nucleus, suggesting thut NTS2 receplors are equally in-
volved in the regulation of the cerebellar output. In cere-
bellarcorœx, NTS2-1 immunoreactivitywas evidentover a 
subpopulation of granule cells, in conformity with the 
recent demonstration offunctionally coupled NTS2 recerr 
tors in Ulese cells in primary culture (Sarret et al., 2002). 
Taken togeUler, the pres l'nt result;; suggest a prominent 
i/lvolvement of NTS2 in the regulation of eerebellar rune-
Hon. HowevH, bl'cause thl' cerebellum is essentially de-
void of NT innervation, the stimulus responsible for NTS2 
activation in this structure remains to be eslablished. 
In conclusion, the prP.sent study demonstrates thut 
NTS2 receptors are widely distributed in the rat CNS. Il 
also indicates thut this reeeptor is essentially neuronal 
and Ulal it is prl.'dominantly, IIlthough not exclusively, 
target~(l to dendritt'8. High levels of NTS2 reœptor pro-
teins were detected in regions documented toreœive a 
dense neurott'nsinergic innervation (namt>ly tht> hypothal-
amus, the ba.~al forebrain and ventral midbrain, and BeV-
erallimbic and brainstem structur!'sJ, in keeping with the 
poslulated. role of this l-eceptor in transducing NT's ac-
tions. and Illost 8pecifically its antinociceptive etTects. 
However, the distribution of NTS2 largely exceeded that 
of NT'1l terminal fields, suggesting that il may also serve 
as receptor for other endogenous Iigand(s). 
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ABSTRACT 
The rote and slgnali1g properties of the Iow-affinity neurotensin 
receplor (NTS2) are still controversial. In particuIar, il is unclear 
whether neurotensil acts as an agonist, Inverse agonist, or antag-
onlst al thls site. ln vIew of the growIng evIdenoe for a role of NTS2 
in antinoclceptbn, the ekJcidation of the phannacological and 
coupfing propertles of thls recepfor Is partIcuIarIy crltlcaL ln the 
present study, we demonstrate that in Chinese hamster ovary 
(CHO) ceUs expressi1g the rat NTS2 receptor, rKUOtensln (NT), 
Ievocabastlne, neuromedln N, and the high-affinity NT recepfor 
antagonist SR48692 [2-{[l-(-7-chloroqulnolin-4-yl)-5-(2,6-
dlmethoxyphenyl)-lH-pyrazole-3~ino}adamantane-2-
carboxyllc acid) ail bild to and actlvate the NTS2 reœptor. This 
activation is followed by ligand-induced internaJization of recep-
tor-ligand complexes, as evidenced by confocal mlcroscopy us-
Ing a fluorescent NT analog. AlI compounds tesled produced a 
Neurotensin (NT) is a tridecapept.ide t1lll.t eXl'rts nl'uro-
modulatory functÎ.ons in the œntrnl nervous system and has 
endocrinelparacrine actions in the periphery (Vincent, 1995; 
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rapld and sustained activation of exlracellular signaI-reglAated 
kinases 1/2 (ERK112) but wera wiIhout specifie effect on ca" 
mobUization. 1he agonlst-induced activation of ERK1J2 was com-
pletely aboIlshed by preincubation of the œUs with the endocyto-
sis inhi>itOfS phenylarsine oxida and rnonodansylcadaverine as 
weil as overexpression of a dominant-negatlve mutant of dynamin 
1 (DynK44A), indlcatlng that raceptor Intemallzatbn was raqulrad 
for ERKll2 activation. NTS2-1nduced activation of ERK112 was 
not species-specifie, because the same agonlstlc effects of NT 
and analogs were observed in CHO œlls lransfected with the 
human NTS2 recepfor. In corJCIusion, thls study demonstrates 
thet NTS2 Is a bona fIde NT recepfor and that actlvatbn of thls 
reœptor by NT or NT analogs results in an intemalization-
dependent activation of the ERK1J2 slgnallng cascade. 
RosÛ'ru> and Alexander, 1997). NT hns been shown to mod-
ulate dopaminergic transmission in the nigrostriatal and 
mesocorticolimbic pathways \Nemerolf, 1986; Kitabgî et al., 
19891, thereby implicating this neuropeptide in the paLho-
physiology of severnl central nervous system disorders, In-
c1uding Parkinson's disease and schizophrenia (for l'eview, 
!le(! Kitabgî et al., 1989; Binder et al., 2001: Kinkead and 
Nemerolf, 2(02). In addition, NT injection in the brain or 
ventricular system produces hypothermia (Martin et al., 
1980), changes in blood pressure <Rioux et u1., 1981), and 
nOll-opioid-dependent analgesia lKalivas et al., 1982). 
NT mediates its central and peripheral efTects through 
inu,raction with three receptor subtypes, refetTed to as 
NTSl, NTS2, and NTS3. NTS1 and NTS2 belong 10 thl' sevell 
ABBREV1ATIONS: NT, neurotensin; ERK112, extracellularsignal-regulated kinases 112; SR48692, 2-{[1-(-7-chloroquinolin-4·yl)-5-(2,lkllmethoxy-
phenyO-1H-pyrazole-3-carbonylJamino}adamanlane-2-carboxylic acld; Levo, levocabastine; CHO, CIlinese hamster ovary; COS, Cercopitheœs 
aethiops; NN, neuromedln N; DMEM, Dulbecco's mod~ied Eagle's medium; FBS, fetal bovine serum; G-418, geneticin; MDC, monodansylca-
daverine; PAO, phenylarslne oxide; PTX, pertussls taxin; PVDF, poIyvinylidene dlfluoride; Ruo-NT, Na-BOOIPY-neurolensin-(2-13); PeR, poIy-
merase chain reactlon; BSA, bovine serum albumin; bp, base palr(s); PSS, phosphale-buffered saline; OMSO, dimethyl sulfoxlde; /WOVA, analysls 
of variance; RT-PeR, reverse transcriptiOll-po!ymerase chain readion; EGFP, enltanœd green fluorescent protein. 
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tr:msmembmne domainiG protein-couplE'd reœplor tillnily 
(Tanaka et al., 191JO; Vita et. al., 1993. 1998; Chalon et al., 
1996; Mazella et al., 1996). whereas NTS3 is a single kans-
membrane domain sorting reœptor prE'dominanUy associ· 
ate<! with vesiculal' organelles Ilnd the Golgi apparatus (PI'. 
tm'sen et al., 1997; MazeUa et al., 1998). Pharmacological and 
biochemical studles have indlcated that the hlgh-afflnity 
(subnanomolal' range) NT l'eceptol' NTSl is cou pIed t.o cGMp, 
cAMP, and inositol phosphatee signaling l,agcades (for review, 
see Hermans and Maloteaux, 1998; \ïncent et al., 1999). 
Stimulation of NTSl also induces the activation of extracel-
lular signal.rHgulated kinases 112 tERKll2) through coupling 
with both pertussis to.xin-scnsitive and -insensitive G pro-
teins. This activation leads in turn to the expression of pro-
lifemtive genes such as c-fos, Krox.24, and elk·1 iPoinot-
Chazel et al., 1996; f:hlers et al., 1998, 2000; Portier et al., 
1998; Martin et al., 2OO2a). These etrects are selectively 
blocked by the nonpeptide NT antagonist SR48692, which 
displays a nanomolar afflnity for NTSl (Gully et al., 1993). 
The low.afflnity (nanomolar rdnge) NT reœptor NTS2 (lif-
fers from the NTS1 site not only by its l()"fold lowel' afflnity 
for NT, but alsa by its selective recognition oflevocabastine, 
a nonpeptlde hIstamine Hl recl'plor ant.agonist that sclec. 
tively inhibits NTbinding t~ NTS2 without atrecting its 
binding to NTSl (SchoUee et al., 1986; Kitabgi et al., 1987). 
NTS2 als.o displays a much lower aftinity (lC50 = 300 nMl 
than NTS1 (lC"" = 5.6nMl for the SR48692 compound (Gully 
et al., 1993); howL'ver, the phanllacolagical and signaling 
properties ofNTS2 are still extremely controversiaL In par-
heular, doubts havI.' bean cast regarding the agonistic prop-
erties of NT at this site and, hence, about whetheror not this 
protein may be regardpd as a trul' NT receptor. lndeed, in 
CliO cells stably tl'ansfected willl human NTS2, SR48692, 
but neither NT nor levocabastine, was found to activate 
classic second messenger syst€rns, such as phosphoinositide 
hydrolysis, CaH mobilization, or ERKl12 phosphorylation 
(Vita et al., 19981. Furthermore, in tran.'!fectE'd CHO and 
COS.. 7 cells, this SR48692-inducOO. activation of the hlillmn 
NTS2 was blocked by NT, suggesting that the endogenous 
pE'ptide was acting as a competitive antagonist at the.~e sites 
(Vita et al., 1998; Richard et al., 2001). 
By contrast, in Xenoplls lael'Îs oocytes express'ing the 
Illouse NTS2 receptor, NT, neuromedin N (NN), and levoca-
bnstine were ail round to activate Cn2+ -dependent ehloride 
currents (r.lazella et al.. 1996). In addition, application of NT 
or levocnbastine on rat cerebellar granule ceUs, which endo-
genously express thp NTS2 but not the NTSI recpptor, in-
ducOO a sustained activation ofthe ERKtJ'2 signaling cascade 
(Sarret. et nI., 2002). Congruent with an agonist role of NT at 
this sit€, rodent NTS2 receptors were round to effldently 
intemalize via c\athrin-coat..'<l pits upon NT binding both in 
stably transfected human embryonic kidney 293 cells (Botto 
et aL, 1998) nnd in mt ceretwllar granule cell cultures ISarret 
et al., 20021. 
It is unclear whether the reported agonisticlantagonistic 
elferts of NT on the human versus rodl'nt NTS2 receptor arl' 
caused by speCÎl',s ditrerences between the two reœptors or by 
variations in receptor coupling as a result of the cell type in 
which the receplor is expressed. In view of tlll' growing l'vi-
denœ for a role ofNTS2 (Dubue et al., 1999a,b; Remnury et 
nI., 200'2; Yamauchi et al., 2003), in addition to thnt ofNTSl 
(Tyler et al., 1999; PettJbone et al., 2002), in antinocicelJtioll, 
and therefore of the possibility Ihat NTS2 might represent a 
new target for the development of nonopioid analgesic drugs, 
the need for precise knowledge of the pharmacolo!,olcal and 
signnling properties of this rLoceptor seems particularly clit-
ieal. Thus, the aim of the prffif'nt study WaS to chamcterize 
the pharmacological and signnUng properties of the rat NTS2 
reœptor expressed in stably transfeeted CHO cells and to 
compare these properties with thuse of the human NTS2 
receptor expressed in the srune œll line as weil as with our 
own earlier data on tlle properties of the mt N'l'S2 receptor 
endogellously pxpressed in rat cerebellar grauule cells. 
Materlals and Methocls 
Materlals. Th" chemicals use<! in the Jl.I'I!SI!ot study w(>n> oblained 
from the following sources: Dulbecco'. modified Eagle'. medium 
(DMEM) and F·12 medium, fetal bovine serum <FBS), glutamine. 
('~·n 8, gentamicin, and LipofuctAMINE w .. re from Invitrogen 
(Carlsbad, CA); NT, monodansylcadaverin<> (MDCl, php.nylarsine "". 
ide <PAO), sodium orthovanadate (Na. VO.\ pertu","i. OO:<in <P'fXJ, 
and sUlUrosporine weI" from Sigma-Aldrich (St. Louis, MO); anti· 
phosphorylatedgRKV2 and anti·ERK1I2 antibodips were from New 
r:ngland Biolab. ilIeverly, MAl; horseradi"h peroxidase-œl\iugated 
anti·rabbit antibodie. and the enhanced ch .. milominellC<!llce detee· 
tion system were from Ame1'6ham Bi_ien .... Ine. (Pisœtaway, NJ): 
ComJ.l.te JJrotea ... inhibioor and polyvinylidene difluodde (PVDF) 
m .. mbrnnes were from Roche (Montreal, QC, Canadai; NN wa. from 
Sachem Califomia <Torran.e, CA). Lovocabastine and SR48692 were 
kindly provided br Janssen Pharmaceutiœls (Antwerp, Belgium! 
and Banofi S}llthelabo (Toulouse, l'rance), J'eSJx>ctively. Ali other 
chemiœls wpre of grade A purity. 
Traruofection of CRO Cells.. CHOIKI cells were cultured in 
DMEMIF·12 medium mixture O:11supplemented wiih 104 FBS and 
50 mgll genlamicin at 37"C in 75-cm' Falcon flasks in a humidilied 
atmospher. of 95% air and 5% CO •. For transfection, CHO!Kl .",ns 
wcro grown to subconfluence (70-80%) in 2·1-well Petri dish". and 
incuboted for -1 h al 37'C in transfection mLodium [mixturn of pTAH· 
GET·rNTS211 fLIiImll (Sarret et al., 2(03) or pTAHm;T·hNTS2 and 
40 "glml I.ipofectA.'1UNE in serum·free DME1.1]. 'l'ransfectinn me-
dium was thon roplaced with DMEM/F-12 medium, and th" cells 
were tr.ln.forred 36 h later to a 75<m' l1ask containing fresh me· 
dium .0JlJllemented with G-418 al a concentration of 800 "gfml. 
Alter 2 weaks of""l ... tion with G-418, a tot.al of2.3 and 12 individu .. l 
clones wero isolated for CHOfr?lo'TS'J and CHOIhNTS2, respectively. 
Each clone WB. oeparntely grown and te.;t<.>d for ils capacity to 
internalize Na·BODrPY·neurotensin·(2·13) Œ1w>-NT) as de.cri""d 
below. CHO/rNTS2 clone no. 16 and CHOlhNTS2 clone no. 1 wero 
used for aU experiments. 
Rev"....., 'l'nmscription-Polymerase Chain Reaction Analysls. 
Total RNAs i2 jJgi weI'<' <>:<trncted fmm CHCVrNTS2 and CHOIKI ""JI. 
using QJAGEN RN""sy Mini Spin eoJumns (QIAGl;;N, Mississauga. 
ON. Canada) and submitted tu N'Vers<! Irnnscription (reverse transcrip-
(j,m system kit; Promega, Madison, \\1) for 1 h at 42"C. Fin;t,.st ... md 
cDNAs W".Te then subjeett>d 00 35 cydes of PCR in a final rMCtion 
volume of 50 p.l of the maction buffer \50 mM KCl. 10 mM Tris. pH 9.0, 
1.5 mM MgCI", 0.1% Triton X-100, OJl2"f BSA, 200 ,..\1 dNTPs, and 0.5 
nnits of Taq DNA pol)'me."..,) oontaining 100 ng of either one of th" 
foUowing th ..... pairs of ""IlE<' and antisense prîm~rs as descrihed p"'" 
viously (Bar..,t QI al.. 20Q2l. TIl" 6rsl pair (5' ·ACACCCATTGTGGACA· 
CAGCC-3' and 6' -TICATCCGAGATATAC,cAGAA-3') prm-idod for the 
l'Ullplification of a fragment of rN1'8l receplot· cDNA with a p""lict..>d 
sizP of :3.15 bp. The """,",d !,~ir 15' -GAATGTGL"llX.ITGTCCTTCGC .. 3' 
and 0' -AC'ITGT·A TI'l'GTCCCAGt.:1CTG .. ;l'i provided for thp amplifica· 
tion ofa fragment ofrN1'82re ... eptorcDNA with Il predicted.ize of620 
bp. TIle third pair IS'·TGCC'(}AGAACTCTGGAAAGGT-3' IInd 5'-
CACA(h\GGCGAAGAGGAA.~C('~a') provided for the amplification of 
a ftaglru'nt of rNTSa ft'CPptor cDNA with a predicted .ize of 426 "p. 
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Amplification WIIS carried out with !lm lirst <'Ycle at 95 OC for 3 nÙD, M'C 
for 2 min, 72"(: ·fur 45 8, followed by 34 crd .... at 950C for 40 5, 54'C for 
:l5 <, 72'(: for 45 S, and a final exmnsion .mp at 72'C for 5 min. l'CR 
products were tlwn nnalyzed on Il 1.5% agnrœe I!"l. 
Blndinr of "'l-NT to CHOIrNTS2 Cells. For binding experi-
nlent., ""Il. were _n on 24-well plates and ineubak>d at 37"C in 
DMEM/F-12 nwdium 48 h beforo the ""say. Cell • .... ..,re equilibraW 
for 10 min at 37'C in Earle'. buffer (130 mM NaCI. 5 mM KCI, 1.8 
mM CaCI .. 0.8 mM Mb.cl •• and 20 mM HEP~~S, pH 7.4\ .Ul'ple-
mented ",ilh 0.2';< DSA and 0.1% glucose. Cells were then incubaW 
with 2.5 nM 126I_lIi'T (JOO Cilmmoll for 30 min at 37"C in 250,,1 of 
Eark>'s buffer containing 0.8 mM ortho-phenanthl'Olillê in thé pres-
Qnce of increusing conl'Qntrntions (from 10-11_10-5 A.i} of tlonradio-
activ~ NT, levoeabastine. NN, "r SR48692. CeU. were then wa.bed 
twie ..... -ithEarl •• bufferand harvest .. d in 1 ml orO.1 M NaOH. and 
1-hp radioactivity content \\"aS DleaBUrPd in a 'Y counwr. lC50 values 
wero determined from eompetition curves as the concentration of 
unlabeled ligand ne<:L'6Sary to inhibit 50% of =I-t.'T,spedfic binding. 
lntracellnlar Calcium Measurem~nl5. .'or intrllcellular cal-
cium (lCa'+1;) measurem .. nts, the CHOIrNTS2 and ClIO/KI cells 
were culturod on 22-mm glas. coverslips and incubated in ... rum-
fre. DMEM supplemented .. ith .. jtl\I Fluo-4iacetoxymethyl o.ter 
(Molecular Probes, EUl!"ne, OR) nt 37'C for 30 min. C.U. wsre then 
wnshed three times with 0.5% BSA and further inrubated in PBS-
HEP~~ (1.40 mM NaCI, 5.4 mM KCI, 2 mM CaCl" 1 mM MgC12 • 
6U.O, and 10 mM HEP~;S, pH 7.35) at 37"C for 30 min to allow the 
aœtoxymethyl esmr rorm to be hydrolyzed. Tbe coverslips were then 
mounted on ihe stage of a Nikon Eclipse TE300 inverted mÎcl'O!!cope 
(Nikon, Meh-iIJe, NYI, and th. ceUs wl're IDaintnined at 3TC 
tbroughout the experim~nts with a heating Peltier .Iement. 
NT, NN, Ù'voeabastine, or SR486'9'l, diluW in fresh PBS-HEP~~S 
containing. for th. solubili7.ation of the latter two drtllfS. 0.01% 
dimethylsulfoxide iDMSOî, wero added to the ceUs nt Il final concen-
tratiQll of 1 J,LM. and images of fluorescence were aequin."il every 5 5 
using Il CoolSnap,. eharge-roupled device <",mem Œoper Scientific, 
Trenton, NJ) cooled nt -30·C. Additional experiments were ""rried 
out uslng 0.01 'l DMSO in pB..<;'lmp~~s IIlone to t:ei<t for possible 
nons"""if", effects of the solubililjng agent. Band-pa." filt .. "" were 
used for ~xcitation and "mission (450-190 and 520-560 nm, res"",,-
tivelyt Average fluomsc0ncê intensity for e..'\ch œll was: mfo3suroo. 
using MetaFluor software package (Universal Imaging Corporation, 
Downmgto\\TI, PA). Jo~ach Ca2+ CUTV9 ln J..l.g 2 r~prp.tll8nts th~ Ilvf?rage 
response of n cell •. 
Western Rlotting Analyses of ERK1I2 Activity, CHOlrNTS2, 
CHOIhlli'TS2, and CHOJK1 œlls were grown for 3 days in DMEMf 
F-12 mL>dium containlng 10% FBS, slan'ed in ""rum-th!" DMEM for 
1 h, and then stimulated ror various time intervals 11-00 min) with 
NT 000 nMi, levocab".tine ,100 nM or 1 p.\fI, NN noo nM), or 
SR4869'l noo nM) at ;17·C in ... n.m-free medium. In sorne experi-
ments, ""lis were preineubated 'l\'ÎtlI PAO or MDC (two endocytosi. 
inhibitors) for 30 minor ... 'ith PTX IG, protei" inhibitor) for 18 h (100 
ng/mll before stimulation with NT or JIi'T analogs. Tbe roaction was 
"toppell by ""piration (ff tbe medium and the addition of ire-eold 
Hanko' balance<! salt solution containing 0.1 jLl.\lstaurœporine and 1 
mM sodium orthovanadam. Cells wero Ih.n left for 30 min at 4'C 
and Iysed in 50 mM HEPES, pH 7.8, oontaining 1 % Triton X-1 00. 0.1 
,.M staurosporine. 1 mM sodium orihovanadate. and Complete pro-
teas. inhibitor. TI.e <eUI)"Sate. were œnlrirul!"d at 8000g for 15 min 
nt 4"C, and thl? supernatants were stored at -2Q<'C untH use. 
For each Iysam, equal amount. ofpromins (25 ",g) were separaW 
on 10% SDS-polyaclYlamide gels and ell'Ctrotransferred on PVDF 
membrMws as described previously iGendron et al., 2003). PVDF 
membranes coutaÎnillg pro teins were in('ubated for 2 h at room 
t'l'mperature I\'ith anti-Ilhospborylated E'RKlf2 \ 1:10{)()) or nnti-
ERK1I2 \1:1000) rabbit antibodies, followed by fhree waslles with 
Tris-buffered saline/Tw<,en 20. Detection of inrmunoreactive proteins 
was AecomplishPd using ho-rserlldiJJh ~roxidasê-oorùugat{-d and-rab-
bit (1:2000} and an enhanced ('h.emilumin(>sC(~nœ detêttion system. 
To quantify the effect of NT and lIi'T arudogs on ERKlfl phosphor-
ylatiOll. the ratios of phosphorylated ERK1I2 owr total ERKlfl 
leYAI. we .... determined by densitometlY, using Scion Image (Scion 
Corporation, .~'rederick. MDI. The stati.tienl signilicance of the aeti-
vation ofERKlJ2 in st.imulaW versus nonstimulated œlls was ver-
ified usin!; ANOV A, and the p valu •• we.., obtained from Dunnett's 
tables. 
Dindinr of Fluo-NT to CUOIrNTS2 C .. IIa. CHOIrl'.'Tb'2 ... Us 
were grown for 2 clays on 12-mm polY-I-lysine-coa.ted gla .. coven;lips 
in DMEMIF-12 modium containing 10% FBS and stimulated for 30 
min at 37"C 'l\'Îth 50 nM Fluo-NT in serum-free DMEM containing 
0.8 mM ortlw-l'henanthroline alone or in the presenc{' of levocabas-
tin .. (10 ",Ml or phenylarsine oxide lenda<ytosis inhibitorl (10 ,.Ml. 
At the end of th .. incubation, relis wor. washed twice with ice-cold 
PBS, air-dried, mounted on glass slides 'l\'Îth Aquamount (Poly-
sciences, Warrington, PA) and examined using the Zeiss LSM510 
confocallnser-scannÎng microsrope (Carl Zeiss Canada Ltd .• Toronto, 
ON, Cannda) equipl'ed wilh a Zeiss lnv"rted microscope and Il heU-
mn/noon las!?r {543 mn1. 
ImmunoOuoretlCence studies. CHO/rJli'Tf:;'2 cells were grown on 
12-mm glass coverslips for 3 da)"S in DMEMlF-12 medium eontaining 
10% FBS and then starv .. d in serum-froo DMEM for 1 h. CeUs 
pretreated or not wilh PAO (10 p.'f, 10 min at 37"C l were then 
tr"ated or not witb SR48692 1100 nMi for 5 min at 37°C in serum-
free DMEM. The reaction wa. stopped by aspiration of th. medium 
and the addition ofice-cold Hanu' balanced .alt solution oontaining 
0.1 jLl.'d staurosporine, and 1 mM sodium orthovanadate. Aner 10 
min of incubation on ie •. œil. wer!' fJXed for 20 min with methanol at 
-20OC and rehydrated with Hank.' balanced salt solution for 30 min 
at MOm temperatur ... phosphOlylaUld ERK1I2 were laheled "vt'r-
night at 4"C using anti-phosphorylamd .ERK1I2 rabbi! antibod;"s 
Il:100i and revealed uoing goal anti-rnbbit AlexIl488- or Alexa594-
L'Onjugated soconclary antibodi". (Moloc'lÙar Probes; diluted 1:500 in 
Hanks' balanœd salt .olutionl for 80 min at room tempernture. Alter 
w8s1ûng, c()vE>n:lli]>s W{)rE" mounted on gJass slitfus u..,ing Aqullmount 
and examined using the Zeiss LSM510 cenfocallaser-scanning mi-
crosrope equipped with a Zeiss inverted microscope, an argon la""r 
\488 1lIl1), and" helium/nron laser \543 nm). Images wern 1111 taken 
using th!? sume aCQuit;itioIl setting,;. 
Th determine whether Iigand-indue,",l r_ptor intemaliy.ation 
WIIS necessary for NTS'l-induced ERK1I2 phosphorylation, the above 
Înlmunofluo:MScQnœ as.'\:ay was l'P.P'!atM on CHOfrNTS2 oolls prein-
cubated for 10 min with PAO (10 "MI as weil as on CHOIrNTS2 .,,11. 
cotransfeck>d with pcDNA1-DynK44A (kindly pro\'kied b,v Dr. Ste-
pben S. l'erguson, Carleton Uni~ersity, Ontario, QC, Canmla) and 
pEGFp-Nl !BD Bioscienres, Mississauga, ON, Canada). For this 
purpose. pcDNAI-DynK44A 11 P4Vml) and pECWP-Nl ((I.i ",glmn 
plasmids wero mixed with 40 ",glml LipofedA.\UNE, and the mix-
ture was kept at l'oom temperature for 30 min b.>fo", beillg added to 
the culture medium. CHO/rNTS2 ... lIs gr"",n to 25 to 30% suhcon-
fluence on 12-mm poly-L-lysine~""ted glass coverslips wpre then 
tran.rected for 4 h at 37"(; with thi. DNA-Iipiil eomplex. At the end 
of the incubation, tronsfec,tion medium wa. roplaeed with fresh 
medium, and ceU. were proœssed 36 h later for immunolllbeling of 
the phosphorylnmd ERK1I2 ns described above. 
Results 
Expression and Blnding Properties or rNTS2 ln 
Transfeeted CHO Cells. Reverse transcription-polymerase 
chain reaction (RT-PCRl Ilnalysis of rat NTS1, NTS2, and 
NTS3 l'xpression \Vas perfol'med on Ilolltransfected CHO 
cells (CHOlKl) and on CHO œil. tl'ansft'Lwd with rat NTS2 
receptor cDNA (CHOIrNTS2). As shown in Fig. 1,\. a 620-bp 
band corrosponding to the size ofthe NTS2 rl.'ceptor fragment 
WIlS observed in CnOlrNTS2 cells but Ilot in CIIO/K1 cells. 
In contrast. a 425-bp product corresponding tu the NTS3 
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Amplifi<'Iltion was cmri~-.d out with the first L"yCIe at 95 'C for 3 min, M·C 
for 2 min, 72"C 'fur 45 5, followed by 34 c.l'd", at 95·C for 40 s, 54'C for 
as ,~~ 7~C lor 45 Si, and a final êxtension step nt ï2~C for 5 min. l'CR 
products wpre wn analyzoo on Il 1.5% agllJ'(lee gel. 
Bindinlr of "'I-NT to CHOIrNTS2 CelJs. For binding ""peri-
nll.q}ts, c~lls wero gt:own on 24 .. well plates and incubated at 37~C in 
DMEM/F-12 medium 48 h beIote the as""y. Cen. "',,.,, equilibrawil 
for 10 min at 37'C in Earle·. huff,,!' (130 ml\I NaCl, fi mM KCI, 1.8 
mM CaCI .. 0.8 mM MgCI •• and 20 mM HEpgS, pH 7.41 .upple-
mented with 0.2% DSA and 0.1% glucose. Colis weN then incubat.-d 
with 2.5 nM "'''I-NT (JOO Cilmmoll for 30 min at 37"C in 250/LI of 
Earle'. buffer containing 0.8 mM ortho-phenanthroline in the pres-
ence ofincreusÎng concentrations (from 10-1J_10-5 M} ofnonradio-
activ" NT, lev0<:3bastine. NN, or SH48692. Cell. ",ere then washed 
twiœ witb Earle'. buffer and harv".ti>d in 1 ml of 0.1 M NaOH, and 
t.he radioactivity content \Vas measured in a y counter. ICo<> values 
wero dIltermined from competition curv.,. as the concentration of 
unlaooled ligand necessary ta inhibit 5lfk of '''''I·r.;'T ,gpecifie binding. 
lntracellular Calcium MeasuremenÙJ. l"ôr intraL'ellular cal· 
cium tl(;8'+1;) measuremE'nt.s, the CHOIrNTS2 and CH0IK1 cells 
were cultured on 22-mm glass eove • ."lips and illcubat.OO in serum-
free Dl\1EM supplemellted ",ith 4 ,.hl Flu0-4/a«,toxynwthyl •• ter 
(Molecular Probes, Eugene. OR) at 3Te for 30 min. Cells were tben 
w"shed tb"", times with 0.5% BSA and furtber incuba~-.d in pBS-
HgPI<;S tl40 mM NaGI, 5.4 mM KGI, 2 mM CaCI" 1 mM MgCl2 • 
6n.O, and 1Q mM HEP.~;S, pH 7.35) at :l7"C for 3Q min to allow the 
a""to.ymethyl ester form to he h.l'drolyzed. The coverslips w"r. then 
mounted on the stage of a Nikon Eclipse TE300 inverted microscope 
(Nikon. Melville, NYl, and the cells wero maintained at 37'C 
throughout the experiment.s with a beating Peltier element. 
NT, NN, levocabastine, or SIt486'92, dilut.OO in fmsh l'BS-HgpgS 
containing, for the solubili1.atlon of the lat.ter two dnlgS, 0.01% 
dimethylsulfoxide rDMSOl, \Vero added to the cells at a final concen-
tration of 1 pM, and images of fluorescence were acquired evelY 5 s 
using a CoolSnap,. charge-coupled device camera !Roper SeÎl>nti6c, 
Trenton, NJ) cooled lit -35·C. Additional experiments were carried 
out using 0.01% DMSO in PBS-HEl'gS alone to test for p,,,_ible 
nonspeeific effect.. of the solubiliûng agent. Band-pass filtero wp", 
"sed for excitation and .,mission (450-190 and .5~60 nm, rl?spee-
tively), Average fluorescence intensity for each ceU was measuroo 
using MetaFluor software paclœll'" (Universal Imaging Corporation. 
DowninbTf:own, .pA). gllch CIl'+ c'UrYe in Fig 2 te)lrN'<,nts tb .. aVHage 
respons. of n cell., 
Western mottinlr Analyse. of ERKII2 Actlvity. CHOIrNTS2, 
CHOIhJl<'TS2, and CHOJK1 œil. we", grown for 3 day. in DMEMf 
F-12 medium c'Ontaining 10% FBS. stan'ed in serum-free DMEM for 
1 h, and then stimulated for various time intelVal. 11-00 mini with 
NT (100 n1.1I, levocabastine (100 nM or l ",,\ll. NN <100 nMJ, or 
SR48692 (100 nM) at 37"C in serum-free medium. In sorne experi-
ment., cells were preincubat.OO "ith PAO or MDC Itwo endocytosi. 
inbibitors) for 30 miuor\\ith PI'X (G; prowin inhibitor; for 18 h (100 
ng/mll befo ... stimulation with NT or r..'T analng •. Th" reaction wa. 
st>pped by aspiration uf tlle medium and the addition of ice-cold 
Hank.' balanced salt solution containing 0.1 ,..\f staur06perine and 1 
mM sodium orthovanadate. C.,lh were th.n left for 30 min nt 4'0 
and lysed in 50 mM HEPES, pH 7.S, containing 1 % Triton X-I 00, 0.1 
",M staurosporine. 1 mM sodium orthovanadate, and Complete pro-
tea.., inhibiter. Th" «,lIlysates wer. centrifuge<! at 8000g for 15 min 
at 4"C, and the supernatant.s were stored at -2Q·C unlil use. 
For "/leh Iysate, equal amount.. ofproteins (25 /Lg) \Vere separ/lt.-d 
on 10% SDS-polyaclYlamide gel. and electrolrllnsferred on PVDF 
lllBmhmnes "s described previously (Gendron et al.. 2(03). PVDF 
lUêmbranes oontaining proteins were incubnted for :2 h al room 
t»mperaturo with 3nti-phosphorylated ERKll2 !1:IOOO) or antÎ-
ERK1I2 \1:1000) rabbit antibodies, followoo by three washes with 
Tris-buffured .alinell'woon2O. Detection ofimmunoreactive proteins 
WBS accomplished tlsing horseradish peroxidase-conjugate<l anti-rab-
bit (1:2000' ,md an enhanced chemiluminesct'nœ detection syst<'lll. 
To quantify the .ff""t of NT and JI<'T an"logs on ERKlf2 phospbor-
ylation, the ratios of pho.phorylat.OO ERK1I2 0\"" total ERKlfl 
leyel. were det<>rmined by d"nsitomi>try. usinll Scion Image (Scion 
Corporation, .Frederick. MIll. The stoti.t""') .lgnifimnce of the acti-
vation of ERK1I2 in stimulated versus nonstimulawd cell. was vor-
ili.d tlsing ANOVA, ami th. p valu". were obtained from Dunnett's 
tables. 
llinding of Fluo-NT to CIIOlrNTS2 Cfol!a. CHO/rNTS2 <ells 
we .... grown for 2 days on 12-mm pelY-L-lysine-œated gla •• eoverslips 
in DMEMIF-12 medium contoining 10% FBS and stimulated ror 30 
min at 37"G with 50 nM F1uo-NT in serum-fr"" DMEM coniaining 
0.8 mM t>rtlw-phenanthroline a10ne or in tb. presence of levocabas-
tin .. \l0 ,..Ml or phenylarsine oxide lendocytosi. inhibitor! (10 ,.M). 
At tbe end of the incubation, cel). ",or" wa.hed twi"" with ice-cold 
PBS, air-dried, mounted on glass .!ides with Aquamount (Poly-
sciences, Warrington, PAl and examined using the Zeiss 18],1510 
eonfocallaser-!lCanning microscope ,Carl Zeiss Canada Ud., Toronto, 
ON, Canada) equippoo wiih Il Zeiss inverted microscope and a heli-
um/nron las",r 1M3 mn). 
Immunofiuore8Cf.".JWc 8tudies. CHO/rNTS2 œlls we .... groWll on 
12-mm glass coverslips for 3 day. in DMEMIF-12 medium containing 
10% FBS and tben starred in serum-free Dl\.ŒM for 1 h. cen. 
pret ....... t.-d or not with PAO (10 ""\{, 10 min at 37"C 1 wen! then 
tr .. awd or not with SR48692 1100 nM) for 5 min at 3TC in serum-
fre<> DMEM. The reaction was stoppe<! by aspiration of th. medium 
and the addition of iN'-COld Hanks' balance<! salt solution containing 
0.1 /Li\{ staurosporine, and 1 mM sodium orthovanadate. AfWr 10 
min ofincubation on iee, cells were fIxed for 20 min with methanolat 
- 2O"G and rehydrat.-d with Hanko' balanced salt solution for 30 min 
at room tempera!ur ... Phosphorylated ERK1I2 w .. re laheloo over-
nigbt at 4"C u.mg anti-phosphorylated ERKl/2 rabbi! antibodies 
/l:l00j and rovealed u.ing goal anti-rabbit Alexa488- or Alexa.594-
c'Onjugated socondary antibodies (Molpt,ulur Probes; diluwd 1:500 in 
Hanks' balanœd Mit solution) for 60 min at room temperature. After 
washing, cov .. rsIips WeN U\ount.OO on glass slides ""ing AquaU\ount 
and examined using the Zeiss LSM510 confoeallaser-scanning mi-
croscope (>quipped \Vith a Zei .. inverted microscope, an argon laser 
(488 nm), and Il b~lium!n<>on laser (543 nm). Images w@re ail tabn 
".ing the same acquisition ""tUngo. 
Tu dewrmine whether Jigand-inducf?d feœptor Întt:.>ma)jzation 
was necessary for NTS2-induced ~;RK1I2 phosphorylation, the above 
immunot1uomscenœ assay "'as repeat.OO on CHOtrNTS2 œil. prein-
cubat.OO for 10 min with PAO (10 /LM) as weil as on CHOIrNTS2 cell8 
cotransfected with pcDNAl-DynK44A (kindly provided b:; Dr, Ste-
phen S, Fergw;on, Carleton Unh'ersity, Ontario, QG, Canada) and 
pEGFP-Nl ,BD Bioscience., Mississauga, ON, Canada!. For thi. 
purpose. pcDNAI-DynK44A Il p..gIml) and pFJWp-Nl (0.1 p..gIml) 
plasmids were mixed y,ith 40 /Lg/ml LipofectAMINE, and tho mix-
ture wag kept al room temperaturo for 30 min before bein.g addro ta 
tbe culture medium. CHOlrNTS2 œil. groom to 25 to 30% subean-
fluence on 12-mm poly-L-Iysin .. ~oated glass coverslips were then 
transfect.OO for 4 h at 3T'C \Vith this DNA-Iipid complex. At the end 
of tho incubation. transfection medium wa. roplaœd with rr .. sh 
medium, and cell. wc, ... proressed 36 h later for immunolabeling of 
th" phosphorylate<l ERK1I2 "0 d""eribed "bov •. 
Results 
ExpressIon and Blndlng PropE'rties or rNTS2 in 
Transfected CHO CeUs. Reven:e transcription-polymerase 
chain renction (RT-PCRl analysis of rat NTS1, NTS2, and 
NTS3 expression was perlol'lned on Ilolltransfected CHO 
cells ICHOlKl) imd on CHO ceUs trans[ecU.'tI with rat NTS2 
receptor eDNA (CHOhNTS2). As ShO\li1l in Fig, lA, a 620-bp 
band corrosponding to the size of the NTS2 receptor fragment 
was observed in CHOlrNTS2 cells but Ilot in CHOII<1 ce11s, 
ln contrast, a 425-bp pruduct corresponding to the NTS.3 
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p!asm in the fonn of slIIaI!, endosome-like fluorescent dus-
U'l'S (Fig. 6Al. By contrast, Fluo·NT labeling was confined to 
the cell surface after pretrl'atml!nt wilh the mldocytosis in-
hibitor PAO (10 JL1t!, 1.0 min) (Fig. 6B). Fluo-NT internaliza-
tion was NTS2-spl'Cific, because nontransfected CHO/IU 
ceUs (not shown) and cells coincubated with Fluo-NT and an 
excess of levocabastine (Fig. 6C) were enlirely fluorescent-
nl!gative. 
To detennine whether Iigand-induced N'l'S2 receptor int .. r-
nalization \Vas necessary for ERKlt2 activation, CHO/rNTS2 
cells were pretreated or not with PAO (10 /LM) or IIfDC (400 
/LM) and stimulated for 5 min with 100 nM NT. levocabas-
tine, or SR48692. PAO and MDC both completely inhibited 
the effect of stimulation by either ligand on ERKlt.l phos-
phorylation, lU' measured by Westl!m blotting <Fig. 7A). 
The l'fled. of stimulation with SR48692 011 ERK1J'2 activa-
tion was also verified by immunofluore.cence in CHO/rNTS2 
cells, using antibodies against phosphorylated ERKII2. In 
contradistinetion wilh nonstimulated c.,lls, which were im· 
munonegative (Figs. 6, D and G, and 7B), cells stimulated for 
5 min with SR4869'2 (100 nM) exhibiled intense phosphory-
lated ERK1I2 immunoreactivity, mainly within their nucleus 
(Fig. 7B, arrowheads). Tllis induction of phosphorylated 
ERKlt2 Îmmunoreactivity was totally prevented hy prnincu-
bating the cells with PAO (Fig. 7Bl. 
To fUlther confrrm that lhe NTS2-induL'ed EHK1J'2 activa-
tion was dep.'ndent on Iigand-induced intoernalization, CHOI 
rNTS2 cells were transiently transfect.ed \'tith a dominant-
A B 
10 
n = 32cetls 10 
8 ~ S i:' i:' ï!! "ie 
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.. 1: j 4 ;: 4 
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Ilegative mutant of dyl1amin 1, DynK44A, tugether with the 
fluorescent protein EGFP (with a ratio orlO:1), to distingllish 
DynK44A-expressing from -nonl!xpl'{'ssing ce Ils. Stimulation 
of these dually transfected cfi'JIs with 100 nM SR48692 in-
creased phosphoryJat.ed ERK1f..! immunofluoreseence in ap-
proximate!y 40% orthe cells (Fig. 6, E and HJ, whereas 1000/,; 
of the cells expressing only the rNTS2 receptor wern acti-
vated alter siimulation with SR486'<12 (Fig. 7B). This d,,-
cresse wa. caused by the overexpression of the dynamin 1 
dominant-negative mutant, because none of the cells COD-
CU'med to OVerel<l'TeSS DynK44A, by virtue of their coexpres-
sion of EGFP, showed phosphorylat.ed ERK1I2 inununoflull-
reSCE'nce (Fig. 6. F and J, arrows). 
Discussion 
The presl'nt stlldy demoll8trlttoe" that Murowll8in acti-
vate. the mitogen-activated prowin kinase cascade through 
its interaction with either rat or human NTS2 receptors in 
transfucted C no cells. It also indiClites that ligand-induced 
internalization of this receptor ie required for NTS2-medi-
ated signaling. 
We previously demonstrated that stimulation of rat cere-
hellnr granule cells. which endogenously r,xpress the NTS2 
receptor, with either NT or levocabastlne resulted in ERKll2 
activation (Sarret et al., 2002). Theseresults differed from 
those obtained by other groups that had n'ported antagonis-
tic or inverse agonistlc effects of these two drugs on the 
n=22ceUs 
r 
~
Fig. 2. lnirncellular Ca'" mobiliza· 
tion in F1uo-4-load.d CHû <ells. A-C, 
application of l "M SH48692 t<> CUOI 
r~"r82 œlk jndut~ an ÎnC1"f:f1St>. fol~ 
ll)wed by a plateau, in iutl-aœUular 
Ca2 +. By oont.rast, no inerf!ase in ln-
trat'eDular C.~2'" is obse-nred after ] 
l'.M NT. 1 "M Levu. or l "M NN. nor 
are any of these drugs. able to prevent 
th*" Ca2• mooilization efTPtt of 
SR48692. D, """,e type of SR48692· 
mduced t'eli\pOllSe ~.rved in 
CHOIKI '-"t'Ils (nontrnnd@d;@d cens,_ 
The curvl'!S N'present the Dleans of n 
responding ceUs and five experiments. 
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human NTS2 receptor heterologously expressed in COS 
(Richard et al.. 2001) and CHO (".eUs fVita et al., 1998), 
respectiveIy. A fin,"1; objective of the present study was there-
foro to dctermine whelher these discl'epanCÎes wcre caused 
by species differences or by endogenous versus heterologous 
exprl'ssion of the NTS2 roceptor. 
For th.is put'pose, \Ve firat establisbed a stable œU line of 
cno cells expressing the rat NTS2 receptor (CHO/rNTS2 
eells). RT-PCR analysis confirmed that these ceIls did ex-
press the NTS2 receptor, to the exclusion of the NTS1. 
125I_NT \Vas accordingly round ta bind to these cells with a 
pharmacology characteristic ofthllt ofNTS2, both in terms of 
affinity for NT and of relative affinity for the NT analogs 
levocabastine, NN, and SR48692 (Chalon et al., 1996; Ma-
zella et al., 1996; Botto et al., 1998; Vita et al., 1998; Sarret 
et al., 2(02). 
We then t.ested the effects of NT and ofvarious NT analogs 
on the mobiIization of [Ca2 +1; in tlle8e transfe<."ted cells. As 
previously reported for cortical cerebellar neurollS endog-
enously expressing the rat NTS2 recep10r (SatTet et al., 
2002), or for transfected CHO cells expressing the human 
NTS2 recep10r (YIIa et al., 1998), neither NT, levocabastinl', 
nor NN affected Ca2+ mobilization in CHûlrNTS2 cells. By 
contrnst, incubation with the NTSl antngonist SR48692 
caused a marked elevation of intraœl1ular calcium in the 
same cells. This increase confurmed t{) oorlier reports of 
SR48692-induced Ca2 + mobilization in CHû cells trans-
fected with either human (Vila et al., 1998) or rat (Yamada et 
al., 1998) NTS2 receptol"s. However, whereas in these previ-
ous studies the effects of SR48692 were antagonized by con-
comitant administration of an excess of NT, NN, or levoca-
bnstine and could not he elicited in nontransfected cells, in 
the present siudy, the effects ofSR48692 were not blocked by 
NT, NN, or levocabastine and were equally strong in non-
A 
o 1 3 5 10 15 30 60 nùn 
~I-------I== 
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1142-
transfected ce Ils, suggesting that they were not medialed by 
NTS2. Likewise, in rat cerebellar granule cells, SR48692 
induced a rabus! !Ca2 +1, increase that was unaffected by 
concomitant applkation of NT 01" levocabastille and was 
therefore interpreted as being NTS2-independent (San'et et 
al.,2002). 
We then 500ght to determine whether NT activated 
EHKl12 in trnnsfected CHO/rNTS2 relis as in rat cerebellar 
granule cells (Barret et al., 20(2). Application of 100 nM NT 
to CHO/rNTS2 cells induced a robust, dose-dependent in-
crease in ERK1I2 phosphol-ylation, This activation was rapid 
and sustained over 60 min. Il aIso was mediated by NTS2, 
because it could not be elicited in IlOntrausfected cells. TIll' 
similarity ofthese findings with thOSB obtained in nf.>urons in 
culture iSarret et al., 2002) suggests that the observed acti-
vation is physiologiesl and not caused by artifactitious cou-
pling of the reœpt{)r subsequent ta its aberrant expression in 
CHO l'elis. 
Levl'ls of ERK1I2 activation comparable with those ob-
tainpd aller stimulation with NT were achieved by incubat-
ing CHO/rNTS2 cells with either NN or levocabastine. That 
tbese two drugs would display effects comparable with tbose 
of NT is congruent with rP.~ult.~ in X. loevis oocyte~. which 
showed that N'l', NN, and levocaba.qtine ail stimulated 10 the 
same extent an NTS2-mediated Ca2 + -activated inward CI-
current (Mazella et al., 1996; Botto et al., 1997; Dubue et al., 
1999b). However, the present results differ from those ofVita 
pt IÙ. U998J, who found no l'ffect of NT, NN, or levocabastine 
on ERKtI'2 activation in CHO cells transfected with the hu-
man NTS2 receptor. Ta dl.'termine whether this discrepancy 
was related to species diffenmces. we repeated tbe expori-
m.mts in cno cells trausfected with hNTS2 in lieu ofJ"NTS2. 
Our J'P •• ults showed the same NTS2-mediated activation of 
ERKll'2 phosphorylation in cells trarufeded with the humau 
B 
D 
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Duratloa of stlmulatloa (mla) 
o 10"910'" 1O.1 1o<'M 
"" 'Pp44""" ~ - - __ Of' pp 2-
~ 61·= .... '~:: 
l''IJ. 3. Neurotenain activation of ERK1J2 in rNTS2·transf""ted CHO c.U", CHOIrNTS2 (A. B, and Dl and GHOIKI (C 1 cells we ... 8timumted with 
various conc-entrations of NT (Dl for 0 ta GO min (A--<~), and ERKll2 phosphory1ation leve]s werê det-lIrmlned as df:>f:lCJibed under l.\la.t.erials and 
Methot/s. A, G. and [J. t.>P. phosphorylat<>d ERKltl; bottom, total ERKltl, A. .timulati"n of GHOIrNTh'2 «,JI. with 100 nM NT indue""" rapid and 
trus\ai.ned adivatiou ofERKlf2, B. densitometric me-asurements of ERKl.tl activation (phœphorylat.(;!:d ERK1J2 over totnl ERKltl) expreüed as -fQ]d 
ine"","" owrcontrol ± KE.M. ,e. CHOIKl,1l = 3;_. CHO/rNTS2.1l = 4j,k'llO\'A and Dumwtfol. .,p < 0.05; ".p < 0,02; and ..... p < 0.01 compared 
wlth control. untreated cell •. C. stimulation of wild·type, nontransf.et.>d CHO c.U. ",ith 100 nM NT ha. no effect on ERK1J2 phospborylation. D, 
dose-depe-.-ndeot activation of l'JRKl12 aftE'r application of 10-9 to 10-6 M NT for 5 min (repl'f.'sent-ative of two independrnt experiments). 
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plasmid as in ceUs transfected with the l'NTS2, sUj,'gesting 
thllt the differences between the pl'l'1!cnt and earlier results 
are not. the reslIlt of di fferences between rat and hllman 
NTS2 but rather of variations in the sensitiviiy of the meth-
ods employed for the detection ofERKlt2 phosphorylation. 
Stimulation with the NTlSl ,mtagonist SR48692 also re-
sultoo in a marked increase in ERK1t2 activation in both 
A 
B 
c ~~ ~ ~ n,." ~ci',~ @ ~~" sct ~ cP V~ ~~ 
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Fig. 4. Eff..,t of neur.tensin, l~ocabastin., neuromedin N, and SR48692 
on ERK1t2 phosphorylalion in CHOIrNTS2. CHOIrNTS2 tA and Hl and 
CHOlKl ICl cen. were mat",) or not for 5 min with a batt.>ry of NTS2 
agonistr and harvestp.d for the drurminatinn of ERKlf2 phosphorylaUQn 
levcl. as described under MaÜrio/sulld Melhods. NT (100 nM), Levo ,100 
nMi, NN 000 nM,_ nnd SR48692 ,100 nM) an indure ERKl!.! phosphor· 
ylation in CIIO/rNTS2 œIL. (A) but not in CHO/KI relIs (Cl. Not.> that 
ERKlfJ pho-.~ph(Jrylation le\"els are mru:kffily higher in œlL<; mnmlatf:'d 
with SR48692 than with other druli", an .ff.ct that i. not modified by 
ooincubation with NT (100 nM), B. deœitometrÎe measurenlenta of 
t:RK.lf~ activation (phosphoryIated l':RK1l2 over t"ta] ":KKl!.!' expre.sed 
as -folt! mereaM: (i\"fT ccntrol ::t S.E.!\:!. (/1 = 3. CANOVA and DUlUlett's} 
", p < 0.1 Nld "., P < 0.05 compa.red with contrQl, unt:ri:?'aied œlls. 
CHO/rNTS2 and CHOlhNTS2 cells. Unlike the effects of 
SR48b'92 on C1l2 + mobilization, these etTeets were mediated 
by NTS2. because they were not. obsp.rved in nont.ransfected 
CHO cells. Prevlous studies have reported on the agonistic 
propertie.s of SR4869'2 on both rodent (Botto et al., 1997; 
Yamada et al., 1998) and human (Vita et al., 1998) NTS2. 
Surprising ber" was the fact that, although SR48692 dis-
played a mu ch lower affinity than NT. NN, or levocabastine 
for the NTS2 receptor (present study; Gully et al., 1993; 
Mazella et al., 1996; Botto et al., 1998; 'ïta et al., 1998; 
Yamada et al., 1998; Nouel et al.. 1999; Richard et al., 2001; 
SaI1'et et al .. 20(2), it induL-ed ERKlt2 phosphorylation much 
more efficlently (-7 -fold more efficient tlUl.ll NT in ceUs 
transfected with the rat reœptor), To determlne whether thlJi 
discrepancy could be explained by th!' binding ofSR4869'2 to 
a site distinct from the target of NT or ils analogs, we re-
peat..>d t.he SR4869'1 stimulation experiments in the pre.ence 
of 100 nM NT. Despite it.s higher affinity for the receptor, NT 
had no competitive inhibiting effect on the SR48692-inducpd 
gRKll2 activation, suggesting that the two drugs interact 
with different binding pockels as they do on the NTS1 recep-
tor (Labbé-Jullié et al., 1995; BalToso pt al., 2000). 
Immunofluorescent studies confirmed that stimulation of 
CHO/rNTS2 ceIls with SR48692 produced a robust increaso 
in phosphorylated ERK1J'2 lovels. Furthermore, they dOffion-
strated t11at thle increase mainly occurred in the nucleus, 
suggesting that sollle of the targets of activatoo ERK1J2 may 
be transcription fuCt4rs sueh as Elk-l, Ets, Stat1J3. or c-Mycl 
N·Mye and, by extension, that th.~ activation of the NTS2 
reœptor results in the modulation of gene expression. 
It \Vas recently shown that in COs.. 7 cells transfected with 
the human NTS2 receptor, the reœptor was constitutively 
aL1;ive and that NT and levocabastine hehave as a Ileutral 
alltagonist and inverse agonist. respecl;iveIy, on thp. produc-
tion of inositol phosphate (Richard et al., 2(01). Hy contrast, 
the present NT- or levocabastine-induced effects on ERK1I2 
phosphorylation are unlikely to he caused by neutral antag-
oni.tic Of inverse agonistic propel'ties of the drugs, because 
th.~re wa. no evidence of constitutive NTS2 receptor activity 
in our system. Imleed. no ditTerence was observed belween 
the basal phosphorylation level of ERKlt2 in CHOlrNTS2 
and in nontransfected CHO cells. }'urthermol'e, had NT or 
levocabastine ad:ed as inverse agonists, they should IlOt, as 
they did, have increased phosphorylation of ERKlt2 to leve]s 
higher thon those measured ln nontransfected cplls. 
As previously demonstrated for lIlowe and human NTS2 
receptors in transfected cells (Hotto et al., 1998; Martin et al., 
2002bi and for fat NTS2 receptors in t'Crebellar grlUlUle cells 
(Sarret et al., 20(2). stimulation of rat· NTS2 receptors het-
erologously p.xpressed in ClIO cells reJ!ulted in a ligand-
induced internalization of receptor-Iigand complexes. Ulis 
effoc't WIlS inhibited by the endocytosis inhibitor phenylarsine 
oxide, sllggeslÎng that il was mediated by c1athrill, as docu-
mentp.d for most G protein-coupled receptors iKrallenburg et 
al., 1999; Pierœ et al., 2000; MiUer and Lefltowitz. 2001; 
Claing et al., 20021. That a fluorescpnt analog of NT was able 
to induce NTS2 internalization further Ilrgups in favor ofits 
agonistic role at the NTS2 n'ceptor. 
It iB now weil docllmpJJ.ted that. seven tmnsmembra.ne do-
mainiG protein,collpled receptors may activatp ERKI12 via G 
protein-independent mechanisms. involving interaction of 
the receptor with endoq'tic proteins Bueh as dynalllin 
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(Kranenburg et al., 1999; Pierce et al., 20(0) and ~arre8tins 
(Miller and Lelkowitz. 2001; Claing et al.. 2002). In the 
present study, we found that blocking recepler intenulliza. 
tion wilh phenylarsine oxide or monodansy1cadaverine com· 
pletely impaired the ability of NT, as weil as of aIl olher 
NTS2 agonists tested, to activate ERKI12 in CHOIrNTS2 
cens. Furthermore, oyerexpression ofDynK44A, a dominant.. 
negative mutant form of dynamin 1, was found to selectJvely 
inhibit SR48692-induced EUKlf..! activation in cells dually 
expressing th", NTS2 and the dominant..negative mutant. 
These result.. strongly "uggest that the NTS2-mediated acti-
vation of the mitogen-activated prolein kinase pathway i. 
predicatro on the intemaUzation of receptor.ligand com-
plexes via a dynamin-dependent and G, protein-independent 
mechanism. 
In conclusion. the present results reyeal that NT, as weil as 
mlUly orthe known NTS2 receptor ligands, aet as agonists at 
this site, at least as pertains to the promotion of ERK1I2 
A c 
B 
114 lr 
2;2 
.f! 1 
o 
phosphorylation. This finding is important in that il lends 
further support to the premise tbat NT i8 au endogenous 
ligand at this re{."eptor. Il. also suggests that NTS2.acting NT 
analog/! may constitute a promising new class of nonopioid 
analgesic drugs, provided that these drugs do not, as does 
SR48692, exert other actions (e.g., NTSl antagonism and 
NTS2-independent induction of Ca .... mobilization). [nde~d, 
recent studies have demonstrated that NT, but not SR48692 
(Dubue et al., 1994), induœs antinociceptiye effects in the 
mouse through interat"tion with NTS2 as weil as with NTS1 
receptors (Dubue et al., 1999a,b; Tylpr et al., 1999; p .. ,ttibone 
et al., 2002; Yamauchi et al., 2003). An intriguing observa· 
tion ia that the suslained, NTS2·mediated activation of 
ERKlf2 documented he.ro seems to he exerted to the exclu· 
sion of otller signaling systems. Thus, stimulation of NTS2 
does not seem to induce Ca2 + mobili7..ation (present study; 
Sarret et 'ù., 20(2) or cAMP or cGMP production (Chalon et 
al., 1996; Botto et al., 1998). }'urther studies will obviously he 
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Fig. 5. Effort of neurotensin. l"".""brultine, and SR48692 
on ERKll2 ph""phorylation in GHlMtNTS2 celbo. CHOI 
bNTS2 œUs weru tl"eated or ""t ror 0 to SO min witb 100 
nMNTiAl "rror 5 min witb" bath>.ryofllo'TS2 agoni ..... Œl 
and harv •• ted ror the d ... rmination of ERKl/'l pb."phor· 
ylation levels as described und"r Mct~riaJ'Jt and Mdhod., 
C, densitometric mCMurements oC ERKl/'"l activation ex .. 
pt"eBh-ro 3S .. fu)d inerea..% over control ± S..~,M. (u = 5-7) 
(A.'<OVA and Dunnett's). *, p < OJlOl tompared with con· 
trol, unm.ai.ed œUs. NT (100 nMI. Levo (1 pM), and 
SR48692 (100 nM) alI indu"" ERK1I2 pbosphorylation in 
CHOlhNTS2 œn •. 
Fig. 6. RoI. of NTS2 reœptor internalizatian in ligand· 
induced ERKII2 activation. A-G. CIIO/iNTS2 œil. incu-
bated witb 60 nM Fluo--rrr for 3H luin at 37;)(; and P..x.am-
ined b.y cuufo<:a1 microooopy. A, punctate Flu.,.~"T labeling 
i.s evident througbout the cytoplasm of CIIOIrNTS2 cons; 
B, Fluo-NT laJx.ling i. confined ta th. penphery oithe c.Us 
in CHOIrNTS2 œlls pNincubaœd wiîb the endocytoljls in-
hibitor PAO 00 "Ml; C, FlW)o~"T la""ling i. specifie and 
l'(>(..'eptor-mediated. becauf*! the Iabeling ~ oompletelyabol-
ish.d by an e""""" of levocabastine (10 P.\{l. Images w ..... 
acquired using the same parrunet.ers and ",present threE' 
dill" .... nt ",:periment... D-I. CHO/rNTS2 ceu.. transrected 
",ltb a IU,l mlio of dynamin 1 (DynK44A) and pEGFP and 
pn>ee':\..'\ed {or irnmunofiU1)l'eacenœ deteclinn of phosphory-
lated ERKlJ2. Beeause of the tran8f~l-t..ion ratio. most of the 
EGFP-positive «Ils (green) can he assumed to express 
DynK44A. D and G. brumllevel of phospborylated ERKl/'l 
in,munOl"t'acti~ity in nonm.at~d .. lis. F~H, phosph.ry. 
lat~d ERKltl-inunuDorPactiw signal Ïi! evident witbin thp 
nucleus of a subp<>pulatian of NTS2-expressing l'elis afrer 
5-min exposure ta 100 nM SR4S692. F and !, in merged 
image. of phospborylat~d ERK 112- and EGFP·label.d 
fields, aU EGt'P-pesitive (o.g., DynK44A-exp" .... ing) col18 
(wbite ar""".) art' ph .. phurylated t;RKl/2-immunonega· 
tive~ indirotjng that interualizatlon hlnckadt> prevents 
ERKIJ2 activation (representative orthree different exper· 
iments). 
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needed to determine how diverse NTS2-mediated signaIs 
truly are and whether sorne aecount, in contrast to those 
reported here, for short-term NT signaling. 
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The present study demonstrated that alternative 
splicinJr of the rat ,,1.2 reeeptor ~ene ~enerates a 
5-tronsmemhrane domain variant isoform (vNTS2) that 
i8 co-expressed with the full-Ien~h NTS2 receptor 
throu~out the brain and spinal cord, as evidenced by 
reVerse transcription-PCR. The vNTS2 polypeptide is 
281 amino acids in len~h, which is 135 amino acid. 
shorter than the full-Iength il8Oform. Immunohistochem-
ical and radiolill'and bindin~ studies re,,-ealed that the 
HA-taued recombinant vNTS2 receptor is poorly tar-
~eted to plasma membranes in transfected COS-7 ceUs. 
Bindinll' studies also showed that the truncated reeeptor 
displayed a 5000-fold lower nffinity for neurotensin (NT) 
than its full·len~h counterpnrt (le"" of 10 #LM and 2 DM, 
respeetively). Yet NI' bindinll' induced efficient internal-
ization of recepto .... ligand complexes in vNTS2-trans-
fected .,.,11s. Furthermore, it produced a rapid «5 min) 
activation of the mit~en·activated protein kinases 
(ERKll2) pathway, indicating functional coupling of the 
variant reeeptor. This activation is sust&Ïned (>1 h) and 
is aiso produced by the NTS2 altonÎst levoeabastine. 
Western blottinlt exp .. riments sult~ .. sted that vNTS2 i" 
not expressed in monomeric form in the rat central 
nervous system. However" it does appear to form a vari-
ety ofmultimeric complexes, includinll' homodimers and 
heterodimers, with the full-Ien~ NI'S2. Indeed. eo-im-
munopreeipitation studies in dually transfected cells 
demonstrated that the two receptor isoforms can form 
stable associations. Taken to~ether. the pres .. nt results 
indicated that the rat vNI'S2 is a lunctional receptor 
that may play a role in NI' sienalintr in mammalian cen-
tral nervous system. 
The tridecapeptide neurotensin (NT)! produces Il wide array 
oC biological responses wheu udministered peripherally or in 
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In.titutes for H""lth Re •• arch. Th. cost. of publication of thi.; article 
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FS.C. Section 1734 ""Ioly to indioate this fuet. 
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kal Inrututi:>, [)ept, cl N~rology ami Neuro:surgery. Hm. 896, 3&)1 
I.'niv<'T>lity St.. Mont"I\I, Qu.bff n3.A2B4, Canada. Tel.: 514-398-1913: 
Fax: 514-398-5871; E·mail: alain.h""udel@mcgiU.ca. 
1 The abhré,,-iatJ.ons u~ed arp: ~--r > npurotensin; G-PCR(s}~ G prot.ein-
c(Jupled TeCl!ptm'(~); TM, transmembrnnt' dt'majn~ CHO c(>ll~. ChinE'?E" 
the central n .. l'VOUS system (CNS). NT .. ff,,<:ts indude anlllgesia 
(J, 2). hypothermia (3), antipsycho.is 1.4\ catalepsy (5), and 
change in blood pressure (6). NT i. also known for its reguJa-
tory role on midbrain dopaminergÎc and basa! forebrain cholin· 
ergie neurons (7, SI, and cumulative evide...,e has implicated 
the NT system in the pathophysiology of schizophrenia (9). 
NT signaling is mediated by interaction of the peptide with 
either one of t1lree different receptor subtypes. referre<! to as 
l'.rl'Sl, NTS2, and !Io'TS3. NTSl and NTS2 belong tothe familyof 
seven transmembrane-spanning, G protein-coupled reœptors 
(GPCRa) and exhibit high and low affiuity for t>i"T, respedively 
(lO, 11). The NTS3 reœptor i" a single lranllmemhrane domain 
50rling reœptor \Vith lOO'if, homology te gp951sorlilin (12, 13). 
NTSI is predominantly coupled to Gqll1 04. 15) and activa1es 
phospholipru;e C il6, 17). Phannacological and biocht>.miclù stud-
ie!' ha".., indicated that NTSl is al.., involveil in the modulation 
of intraœllular l .. v .. l. of cGMP (18), cAMP (19, 20), i nosit{}1 phos-
phates (21), and extraœllular signal-regulated kinases ŒRKlf.ll 
(22). MlK,h less is known about the signaling p"thways ofNTS2. 
Stimulation of NTS2 was fuund to incluee Ca2 + ·clepend .. nt chIo-
ride cUlTents in XJ,·tuipll,< oocytes expressing th" monse receptor 
(2.'31. More recent studies have shown mat stimulation of NTS2 
wim either lIo"T or me selective 1I<'TS2 Iig-.md. levocabastine. acti-
vates the ERK1I'2 cascade both in CHO œIl. stably transfected 
with cDNA encoding mt or hnman NTS2 (24) or in cultured rat 
cerebellar granule œlls (25). 
The cDNA sequence of me mou ... NTS2 receptor is composed 
of four eJ<OD.!! separated by th:ree introns (26 •• The fir.t <'_'ton 
encodes the region containing T1\I domains 1-4, whereas exons 
2-4 encode the region containing TM 5-6, TM 6, and TM 7. 
l'espectively. The exi.tence of a deletion-type NTS2 mRNA 
encoding a C-tel'minally truncated fonn oC the receptor, which 
lacks an inteIilal 181-bp sequt>nœ, has been reported in the 
mouse (27). Both mouse NTS2 m&"'A isoforms ru.., derh'oo 
from a single nts2 gene, the short fonn resulting from alterna-
tive splicing of the primary NTS2 transcript at inlron 23 (26). 
The con'CSponding truncated NTS2 mRNA encodes a 282-
amino acid protein (27). 
Othe .. GPCRs en~<Kling .equenOOf! have b" .. n "h"wu t<> .imi-
larly genernte truncated reeeptor isoforms through alternative 
splicing, exon skipping. or intron retention (28). Many of the ... 
"pliœ variants, 8uch as me truncated forms of me prostalloid 
h.":lm.ste.r Qvary cellil; C08-7 ('ells, grE'en African Ulonkey kidnfi>y cen~; 
M.APK, mitogen-nctivated protein kill~~ ERKI/2, fi'xtraceHular sig-
ual-regul:!ted kinase:.i 1/2; DMEM, Dulbecco's mOlhfied "~agle\:; me-
dium; 1t."jA. bovine serum albumi1\~ HRP. h.ol"seradi~b pero..,idase, 
HA, hemagglutinin; RT~ room u>mllerature~ CNS, ('{!entral nervous 
system; PRe:;. phol:lpbate-huffered :.ialin,,~ GAPDH. gly(·taralch.hydA-3-
pho.phate d.hydrog.n"".; MEK. MAPKIERK kiu",,~; fluo·l\ï. 
N,,·BODI!'Y-neurnt<>nsm·(2-13 .. 
This paper is ... ail ... on line .1 http://ww\\'.jbc.org 10219 
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reœptor EP. and endothelin B reœptor (29. 30), dilfer l'rom 
their full.length count .. rparls in th .. ir intraœllular C·temlinal 
tai!. Others show a disparityin the third intraœllular loop (e.g. 
the D. dopamine !'eCpptor variant (:JO) or in the transmem· 
bran ... (TM) domains (c.g. the D. dopamine reœptor i80form 
(32»). Yet oth""'E dilfer From the iull·leJlgth reœp!or in their 
extracellular N·terminal loop as exemplified by the truncated 
fonn of the angÎotensin II receptor (33). 
Spliœ variation" may hav .. little or no .. fFect on ligand hind· 
ing properties (34I. However, sorne deletions, particularly in 
TM domains, wel'e shown to bave significant impad on ligand 
recognition. For example, a short variant of the 5-hy· 
droxytryptamine 2C l-eeeptor lacking TM domains 6 and 7 was 
1'e!>Orted to be totally devoid of serotonerg:Îc binding activity 
(35). Similarly, the 5-TM domain jsofoTms of the D. and endo· 
thelin A recept<lTS exhibit no ligand binding 1,32, 36). Shorlened 
l'creptor isojj)rms may also display aberrant or impaire<! cou· 
pling, even in the face of nonnalligand binding. For illlltance, 
the four a1ternatively spliced Îsoforms of the EP. recept,or, 
which vary only in their C·œnninal mils, couple to difFerenl G 
proteinE and activate diverse second messenger systems (29). 
The generation of alternatively spliced GPCRs may also af· 
fect the function (If their full·length ~,)Unterj)"rt$. Thus, co-
expression of the full·length gon.'\dotropin.releasing hormone 
receptor together with tbat of its C-terminally truncated Îso, 
form, which is incapable of ligand binding and signal transduc· 
tion, was round to impair targeting oftbe full·lengtb receptor to 
the plasma membrane (37). Finally, alternative splicîng of 
GPCRs has been associated with a number of gen~tic disomers 
(38), For instance, "plice variants of the growib hormone-r,,· 
I .. asing honnone reœptors have been documentro in primary 
human prostate carcinomas and diverse human cancer cell 
lines (39). 
This study was initiated to determine whether Ùle spliœ 
variant form of the NTS2 receptor origlnally identified in 
mouse brain extn.cts was also expressed in rat brain and to 
investigate the binding, internalization. and $ignaling ploper-
tics of tms reœptor isoform, as comp.'\l'ed with those of the 
full·lellgth JIi'TS2 reœptor, in mammalian cdls. Our I,,"ults 
demonstrate the existence ofa f'unctionaI5·TM domain variant 
form of lIo'TS2 (vNTS21 in rat brain and suggl"St that this 
truncated œ<.'eptor may play a role in the modulation of 1I;'T 
efFects in the CNS. 
EXPERIMENTAL PROCEDURES 
ExprcSflùm. of Rat n'TS2 mRNi\.-ln ar.du ta asse5...:; the expression 
of vNTS2 mJù'fA in rat CNS and op.inal oonl, a,lult male Sl'ragu.,. 
Dawl~y rats (200-21'.>0 g, CharI ... River Br •• ding Lnboratori •• , St· 
Constant. Quebec. Canada) wen! kiU~d by de<apitation. 'The brain and 
i-pinal rom we-re rapidly n>-llloved. and the areas of înteN>St were di&-
_t.d on iœ. SampI •• won! Bolubilized in 1)"';'0 buITer! 4 M guanidinium 
thiocyanate, 0.01 M Tri.·HCI, p.H 7.5, 0.97'it II-mereaptoethnnoll, and 
total rü\'A Wall ."tractM usiDg tbe SV RNA Isolation System kit IPro-
m()ga, Madison, \1;"1), ft(;(-Ording w the manufadu.rer's instrul1;ÎonS. 
These totalmRNAs (2 p.g) WBre the" rev • ...."tmn.<cribed at 42 'C for 
1 h usiug the lWvers~ Tron~'Tiption Sy~:ttem kit ! Promega, Madison, 
Wn. First strand cDNAs w ..... 3ubjected 10 35 cydes of PCR in a final 
reaction volume of 50 ILl of ",action ImITer (50 nt.\! KCL 10 nUI Tri .. HCI, 
pH 9.0,1.5 nUI'MgCI", 0.1% Triton X·1OO, O.Q2ek bovine ""l'Um albumin 
(BSAi. 200 p.M dNTP., 0.5 unit of TaqDNA polym"rnse·! ""ing a ""t of 
primers ,5'·GAATGTGG"T(]{:TGTCCTTCGC·3' and 5'·ACTTGTATT· 
TCTCCGAGÜCTG·:I') deri,ed rrom b"" •• 667-1287 in th. sequence 
reported previausly (11, for the rat ~"1"S2 recepti.'T, The oligonudeotides 
u~rl :u(> Ranking tbê reglon whe<..n> th~ deletiou 0(,'1,'111"$ in the mou,se 
vNTS2 receptor (27; ,md a1JQW th" amplification of fragmml. of pre-
dict.d _izes of 620 and 4S9 bp. as demonstrakd previously (25) in rat 
cereoollar granule con cultUrE!S_ As internaI standard for semi-quanti-
lative annl}~is, the houseko-eping gNli" glyœraldt<-hyde-3-phosphate 
debydrogennse (CAPDU) '\Vas concurl"enUy runplif:ted uoSlng primers 
5'·CAAGA'ITGTCAGCAATGCAT-3' (il~.nse, nudrotid •• 511-5301 and 
5'-CTTGATGTCATCATACTTGGC-3' (anti.~.n ••. nucleotid.,. 856 tu 
836), which targot a 346·bp ""quene. in the rat GAPDH gene. The 
ratios of NTS2 over GAPDH mJù"lAs and betwoon th. NTS2 reœptor 
isoforms \Vere detE'nnined by dp.nsitometry, using NIH Scion loulge 
Softwan>. Calculations and statistical analyses wece perfonned using 
t:xceI 2000 (Microsoft.' and Priam 3'()2 (Grnph Pad Software). Stati.tiMl 
analyses w.re performed u.ing a on.·way analy'" ,Jfvari"Jlœ (Bolü.r· 
roni'. mukipl. comparison testl. Total Jù"lA sampI ... wer. suhj.eled t<> 
!m'ene transcription in the absence of the enzyme 10 ""nlrol ror intrin· 
sic contamination by genomic DNA, and the reaction was pt,.>-rformed 
without Jù"A to control for contamination doring the experiment. 
Gen. Con.lruc/,....,The HA·tagged cDNA .nooding the rat variant 
NTS2 recoptoc was obtained thr.ugh reverse transaiption of v'NTS2 
mRNA isolat<!d from mt hr"ù, by PCR u.ing nucleotid." (ir ·ACAGAG· 
ATGGCATACCCATACGACGTCCCAGACTACGCTGAGACCAGCAG· 
TCCGTGG·3'1 and t5'·TCATACTTGTATTTCTCCCAGGCT·3·) .s 
8eMe and antlsense prime-rs, N'speet1vE'ly. The formfi!r eontains th(> HA 
tag sequence r.llowed by the 44-61·bp sequence of the rat NTS2 ""C· 
~ptor mRNA (11). whereai!. the latter eorre8ponds to the sequence 
1268-1291 bp of the open ",ading frame of the rat ",.2 recept<lr gene. 
'ri." p .... ,bet.d .iz .. or th. amplified (ragmenlii WE're 1.6 kb for the 
fulJ..l.-ngth NTS2 and 1..4 kb ror th. spliced variant t(,rm of the ""'.ptm. 
Fidelity of FeR amplification wa •• onfirm.d by DNA se'lu • .n, ... analy.'" 
usingthe ABIPRISM® 8100 Genetic Analy""r in th. MOBIX laboratory 
(Mc:Mru.ter University. Hamilton. Ontario, Canada). The FeR produet 
corresponding to vNTS2 was purif .. d l'rom ft 1'\·low melting agaro .. gel 
and sulx!lQned into the pTargeT expression vecror f,Promega: ~AIadi80n. 
WIl. 
CcII Culture and TI,(Ulbfl'!<,ti(J~~'ôr MA]=1{ kitl.lliW activity and rn~ 
dioligand bin<ling ~xperim~nt.l, CHO and cos. 7 cell.! were .tably tralU!-
fl?ct:ed with the HA-vNT82 -COlliltruct. Brlefly. cpJ1s were maint.ained nt 
87 'C in a 5% CO. atroo.phere in Dulbecco'. m<><lified Eagle'. medium 
fDMEM) F·12 sad DMEM lI.ith Iùgh glucose, ",spectiwly, supple-
mented \\ith 5<:"i. €etai bovine Hrum in the presenCE' oC 100 uniWml 
penicillinlatreptomyein Onvitrogen). ~lÙJ were grown in 100-mm 
diMe. to 70-80"", oonl1u~nce and tra""f.ct.d with 4 ILl! of the HA· 
vNTS2-pTargf:.'lT plasmid br using th(l Lipofectamine'l'll transfet1;Ïon 
rE>agt>nt (Invitrogen) l\OOI,.)rding to the mnnufa<.1.urffrs ÏMtru.ctioIlS. Aner 
72 h at 87 '·C, positive .. ll~ ""' .... seleded with a FACSVant1lge c.U 
sorter (BD Biosdenc~s. following sequentia] laœling with a mouse 
monodOIUlI antibody (clone 12C,\5) directed toward the HA epitope 
(11500; Roche Applied Science) and Alexa 4S8-<-onjugated goat anti· 
mou,,", antihody (V1000: Molecular Probes, Eugen., OR). Stable CHû 
(for M.o\PK kinase aotivity) and CQS.7 {for mdi.ligand binding e:<per· 
im.nlBi tran&f.ct.~ntJ; were ""Iecwd in th. presenœ of 500 ,.gIml G418. 
Ft)r West-en\ hlotting and immunot>ytochemi51ry experiments~ COS~7 
CE'lls WeJ'e trAn..~p..J)tly tron~1:ed with 7 in1 of a Illixturt.'" of 100 p..\t 
ehloroquine and 0.2.<; mg/ml DEAE·dextran ronuining 4 ILg of plasmid 
DNA IHA·vNTS2, HA·NTS2 (40" untagged NTS2, or a mixture of 
HA-vNTS2 and untagged NTS21 in DMEllf high glu..,. •. Aftt>r Il h at 
37 ec. the solution was rE<IDovecl and the cells w(I<re trented for l min 
with 10% dimeth.vlsulfoxid. in phosphaw·buITered saline <PHS), rinsed 
twice with PHS, and N'turned to the H7 "C inc-ubator in growth medium 
I:mJlplenumt-ed ,,·ith 5% feta) hovin(> S\'lUJD. 
Immrm;:~.;ytocJu~mislry ou COS-7 C'ells-Tô a.AAeSS the SuhcfoHular 
di..tribuii<m ofvNTS2, COS·7 c.n. trnnsfeeted wiU. HA-vNTh'2 cDNA 
we", plated on poIY-L-lysine-eooted glau _ ... lip... fixed for 20 min 
with 4~} paraformaldehyde IPol}'sciences, Warringt<ln, PA) in PHS, pH 
7.4. and preincubated for 30 min nt room temperature (RT) with a 
blockîng solution consii>ting of 5q normal goat Berum. n BSAJ lmd 
0.10;; Triton X·1oo IBDH. Toronto, Ontario. Canada! in PUS. CeUs were 
incubated ovp..might at '" "e \Vith il pu)yclonaJ antilxxl.y dir.ected !nward 
thé 7-21-aminQ acid sequence in the N~terminal segment of the rat 
NT82 receptoc (1I25,000; matiil? on demand by Affinity Bil3Reagpnts. 
AUR. Golden, COI, whleh reccgtÙz"s both short and long isoforms of the 
"",eptar (40). together ",ith a mou.., monoclonal aniibody,clone 12C'\5. 
115(0) directed toward the HA epitol'" in PBS oontaining 1'\· normal 
g()Qt serum and O.O.Ii% Triton X-JOO. Cells wue then incubatE-d fol' l 11. 
nt RT with a mixture of Alexa 59.f..cOl\iugated goat anti·rnbbit and 
Al.P.xa 48S-eonJugati'tt gout lUlti-mOUSii! Ilntihodie.tl (1n50~ M"oleeu1nr 
Probes. EugeJliio>. ORt For .&lledficîty l'Qntro~. cells W6re jnçubaw.cl with 
I.mti-!\i,-s2 Jwpt.J.de :lntüwTum J1t'eadsorbpd with tht> anti~nic peptidf:>, 
For œll.urface immunolabeling experime ... ts. COS· 7 cells exp,..,..,;"g 
the HA-tagge-d vNTS2 reeeptor were ~dained using th~ Alexa 48S-
oonjugated monoclonal anti·HA IgG 111500; Mol.cular Probe" Euge .... , 
OR) ln serum-deplete-d medium for 1 h at 37 t'C. Ce-lls were !ben washed 
with PUS, fixe<! with 1ifi· pamfonunldehyde ror 30 min al RT, and 
ww.he~l llgain wltb PR.~ prîor to f.-xnmÎnatiou. 
For dual .Îmmun,,)ocalizntion of vNTS2 and NTS2. COS-7 cel1s co-
335 
Appendix C: Reprint of J. Biol. Chem. (2005) 280:10219-27 
NTS2 Receptor Splice Variant 10221 
expres.ing HA-tJlgg~ vNTS2 and the untagg~ NTS2 were incubaW 
ovemight al 4 .;le with mous.? mQnochmal anti·HA antibody in concert 
"ith rabbit NTS2 peptide antiserum (IJ10.00m in PBS containing 1% 
NGS and 0.05% Triton X·100. Thi. serond NTS2 anti..erum i. directed 
toward a syntbetie peptide (YSJo'RLWGSPRNPSLG) ccrr" ... ponding to 
th. :197-412 prodict:.>d amino add ""'Iu • .n ... in th<> C·terminal tail of [ru. 
rut NT82 re«>ptar \<ustom·raised by Affinity SioR.agenls, ARR, 
G"ld.n. CO) that .pecifically rtl<'l'>gnize. th. full·lengtb receptor. Cells 
WIi".J"e thf!n im.-'ubaW for 1. h at RT witb a mixture of Al~..xa ~ 
"'onjugated glli"lt aJl.tl ... mnuse and Ale..~a 594 .. (.'()njugated goat allti~rnlA>jt 
antibodies (\/750; Moleeular Probes, Eugene, OR). 
Cells were -e-xamined \\.;th a Zeiss 510 roseJ'-scruming ronfoe.."Ù micro--
orope equipped with argon2 i488mnJ and He/Né! (543 nm) la •• ,.. (Carl 
leu'!! Micro lmaging Ine ..• Thornwood. NY). Images were proœsSf'd 
using the 7~iss 510 laaer-S<'anning microscope software and Adobe 
Photosb0IJ 6.0. 
Immum>pNcipittIlÎon anc11mmunoblotting AnaJysi$-.For immuno-
llrecipitation studies, COS-7 cens lP..xp~ing e-ither the HA epitolle-
t.agg.d v)l;'1'S2 or the unlagge<l fuIl·length NTS2 wer. ly .. <1 in RIPA 
buffet (150 DM NaCI, 50 mM Tris.HCI, pH 7 ii,.5 mM EDTA, 1% IGEPAL, 
0.5% decn.."Ycholic acid. 0.1% SDS) containing protease- inhibitoJ"S iCom-
piete'" inbibit:or tablets; Roche APpli~ Science} and 1ncubated for 30 
min on tee. Lysatee: were then predeared \Vith 5 mg of prQtein A· 
Sepharœe (Sigma) for 4" min at 4 'C and incubated overuigbt at 4 'C 
with " rat monodonal antîb<>dy 'don. 3F10) direcW toward th" HA 
epitop. \11400; Ro<l", Applied Science). The prolein A-&pha......., was 
gently sb.ken in Iyr,is buffe. t'Outaining 1% B!'lA for 30 min nt RTbofore 
u ... Re.,.,ptor prorei"" were im1uunopredpitaW with 3 mg of pr<>tein 
A~8ephar(:w:w for 2 h ai -1 '--C, COJDplexE"f< w~re djstWlved in Laemmli 
.ample buffer (411 and , .... olved by uoing 10% Tru...glycin. precast gel. 
!Inviirogen)_ Non"l"'cific site. were blocke<! by 0.1"< Tween 20 ŒMD 
Chemical. lne., Gibbotown, NJ) and 10% milk powder (Carnation, Don 
lI·Jill., Ontario, Canada) in PBS ovemight at -4 'C. Nitrocellulose m.m· 
bran~. were tben incubated wilh rabbit N-t.erminally dh...,ted NTS2 
antibady (1/10,000) overnigbt At·l oC, followed by borscrndisb peroxi· 
ru..... (I{RPk.lIiuga~d goat anli·rabbit antibody for 1 h at RT (114000; 
Amersha.m Eiosciences). SIWcificity of nntÎ.St!rum ",.n.s confIrllled by 
l'rearlBorption of th .. NTS2 antibady ovemight \Vith an ex .... ofimmu· 
nizing peptido l211l!iml of ad.orbing peptide flt a final antibody dilutioD 
of 1/10,0(0). 
For tell surface labeling experlmenis, Cos. 7 cella .:xpr ... ing HA-
vNTS2 o. to·exp .. ssing HA·vl,'TS2 and untagged fuU·length NTS2 
were washed with '''''''''<lld PBS and incubated wltb th. N·terminally 
direct.d NTS2 peptide antlserum (1110,000) in PBS contnining 0.5% 
BSA for 2 b nt RT. Cells were tben wasbed th ... hm •• witb PlIS and 
transe.ned into l.5-ml Epp<>ndorftubes. They w ..... trealad with 100,.1 
of RIPA buffer for 1 b at 4 "Co lysed, and œntrifuged at 12,5(KI rpm at 
4 <Je fur ao min. The sUpl:'rnaœ.uts were incubated witlt protein A~ 
Sepb"._ for 2 h at 4 'c to 1mn\Unoprecipitate aotibady-bound oeil 
surfac~ receptors. Immunf;precipitat.es wew. pnx'(>8&'() a..'i described 
above. Membl'llnt:>il were prQbed with l"flbhit N4erminal1y dîrectRtl 
NTS2 antibady (lt20001, followed bya 1-h incubation wilb HRP·con,iu· 
gated goal anti-rabbit antihody (1140()(); Amenmam Bi03cie.nces). 
For heterodimenzation experimenb. CQS..7 00& expressing the HA 
epitape-taggeil vN'1'S2 tagetber witb th. wltngg.d full.l.ngth NTS2 
were trented as de6Cl"ibed above. RP.CE'ptOT proteins wpre immunopre--
cipitnted using th. rat anti-llA antibady (clone 3~'10; 1/400>, and im· 
munohloUing was tlwn t>arned out with thE:' N-t-enninolly or C-termî-
naUy dire<t.d NTS2 anti."".ra \1IIO,OO()). 
To de~rru.ine which. mO.]K\llar forJ1lt!. t'[ th~ vNTS2 protIP-in are ex-
J1~s.."ted in mt CNS. Westt'".rn bJotting t'xperimlPnÛ! Wf>..re p~rfonned on 
membranes from rat .spinal if..'Ord~ as fuis e.tructuce- had been shO\'\'u 
prevlQusly '.27) to exp ..... among th. highestlev.I. .fvNTS2 mRN'A in 
the mou~. Rat spinal oom membrane preparations were oblained as 
deocribed pr,,.,-iously (40). Approximntely 70 ilS" of pratoin Clom .ach 
sample were loaded ont-o 8~ Tri.<j~glycinp. gels and t.rnu..sferred to nitro-
œllulose memb.rnncs for immunobJotting. Membranps were incubntpd 
with the "ffinity·purifi~ N-~rmin.nl.pecific anti-NTS2 rabbit anlibody 
(1I121iO) uvemight nt 4 oC iu PBS containing JI,} o.albumin and 1% 
B8A. fQllowed by HRP..,.,n,iugat .. d anti·rahbit secontlary antibody in 
PHS Wilh 5'/(- mUt J)Qwder, Specificity of antlserum WI\,."; l'{)ufirmed by 
pread.<"rptilln \ViU, the ant;g..nic p.pti<l~. 
Reœptor Binding Expel'imenls-For radioactive ligand binding ex· 
perimenls. COS.7 cen. ~:xpressing HA-vNTS2 were grown on 2.(·well 
platas and incuhaW at 37 oC in DMEM higlt gluco .. medium for 72 b 
befofe the assay. Ce.Us were equîlibratM for 10 min at 37 oC in Enrle's 
buff .. i 130 mM NaCI, 5 mM KCI, 1,8 mM C"CI.> OB mM MgCI., HEPES 
20 mM. pli ï.4' .upplemented ",itb 0.2%' BSA and 0.1'':;. glucose and 
ineubaW with 0.·1 nM ''"l-laboled NT \1670 Ci/mmol) for 30 min at 
37 'c in 250 IÙ of Earl.'. buffer containing 0.8 mM orlJw.pbenanU,.o-
Jin.e. in the pfi1SeD<:e ofincreasing ooncentrations (from 10 ... 10 to 10--3 AH 
of nonradiooctiv(J NT. The cell'l were thi'n washed twice with Earle's 
bulTer and barvested in 1 ml of 0.1 loi N"On. and th. radioactivity 
oontent was mêflSured ln a gamma countf...r, le.so valu~s were dmt· 
mined from competition. C\ln'eB as the concentration ofunla.lx>l~ ligflnd 
nece.sury ta inbjhit 5O'if. of ""'I·labeled NT-.pe<ifu: binding. NQJ"'peciik 
binding "'ao d.rmed as binding in the presence of. 10,oo()"foid exce ... of 
unlnheled ligand. which represent-Ed less man 1 ~+ of total counts. 
For fluorescent ligand labellng, Cos. 7 œUs .xpr .... ing th. HA 
epitop ... tagged vNTS2 were grown on poIY-L-Iysin.·treated gl .... cover-
slips nnd inrubaW at 37 'C in DMEM high gille""" m.dium ro. 24 h. 
They were th,m equilibrnted for 10 min nt 37 "C in Ende\; buffet' 
eontainjng 0.2% B.."3....t\ and 0.1% glucose in the presence or in thE ab:se-nce 
of 1.0 fJ.M phenylariiin~ oxide, an endocytosis inhibltoTt and incubnted for 
30 min in th~ .an'" buiTer with 50 DM of Na-BODIPY-NT-(2-13l (F1uo-
NT) in the presen<."(> or absence of l mM nonfluor~nt NT. Cens were 
air--dried. mount.ed an glass I!!lides with Aquamount (Polyrsciencej$, \Vnc~ 
ringWll, PAl, and exam.in.d by oonfoeal micrcscopy na described above. 
Measurement of MAP Kùwse Acti.vity-CHO cells stahly expressing 
HA·togged vNTS2 wore Bplit into 6-well plates and incubaW ror 1-2 
day. in DMEJ',lC} .... 12 at 37 'Co C.Il. were then serum·5tarwd ovemight, 
pretroated or not with MEK inbibitors PD98059 (50 ,.101) (New England 
Biolabs, Bt'V<!rly. MA) or UOl26 (10 ,..U IProlllE'ga, Madison, \VI) Cor 30 
min. and inculmted with .!\i'T (0.1-10 ,..\1) or l"vocal_tin. (1 ,..,,) at 
37 "C (gr the indieated times, The ri'.aetion was b1.1.1p}wd by Mpinlti01\ of 
the medium an<l th. additioD o-fiœ-cold PBS containing 0.1jJ.lA staUTO-
spanne and 1 nûl :mdituu orthQvanndate. Aftp.J' 30 min of ioeubatiQft on 
jeo, colis wer .. ly •• d in 50 lIlll HEPES. pH 7.8. oontajning 1% Trit"" 
X·lOO, 0.1 ,.M stnurosporine, 1 mM sodium orlbovanadat., and prot .. ""e 
inhibjtor •. Celllyo,ate. were then centrifuged at 12,500 rpm for 10 min 
nt 4 'C, and th. sup.matant. were store<! at - 20 'C unhl use. Parallel 
experimenls were doue using untransCect"d ceU. to determine th<> spec· 
ificity of the aosay. Frotein conœntration was dete"mined by the Blo-
Rad pro<edur. with B8A "" standard. Sample. contnining 40 ,.g of 
prot~-ln wer-e denatured in Laemmli Mln\pl~ bu ffer (41), resolved usùlg 
1.0% Tris-glycino pJ'\'Cast g.Js. and tran.r.rred to nitrocellulô_. mem· 
branes {Bio-Rnd), Nitrocellulose membl'unel:\ W(l"re Încuhated overnight 
at 4 'C with anti'fJh"'liliorylaled ERKltl or anti·ERKll2 mbbit ,mti-
bodies (111000; New EnI/land Biolaba) ln PBS contlllning 1% ovalbumin 
and 1% BSA. Detection ofimmunoreactiv. protoins ",as accomplieh.ed 
by using HRP-conjugat.ed anti-rabbit and an pnhaneed chemilumÎnes-
cent dat.ction system œ .. rkinEImer Lile Sci.nce.~ To quantify tb. 
olT.ct of NT on ERKM! phoephorylation, lru. ratio. or phosphorylated 
ERKltl over total f.:RKl/2 lt>Vels weri' determined by denk,'itomrtry, 
usùtg NIB Scion Image 6Oft.ware. Cakulatlf.mB ami stati.trtical Wla1ySi'tO 
wp.r. peJi'nrm~ using Exaol 2000 tllticrt...,ft") and Pri.ru 3.02 iGraph 
Pad Soft"ar .. ). Th • .tatistical signillcanc:e of th. activation of ERKII2 
between transfeci-ed and nQntrnnsfècted celIs wu '\·eriti~d using the 
paired t test~ and p values were obtained from Dunneû's tables. 
RESULTS 
Expression of NTS2 Rcceptor mRNAs in the eNS-In order 
to asses" "'lpression patternt- of /Ii'TS2 mRNAs in rat brain and 
spinal COI-<I, " set of oligonucleotide primers desiglled w ""Iee-
tively rewgnize the regian flnnking the deletion yielding 
vNTS2 in the mouse (27) Will' used fol' reverse transcription· 
peR. As soown ill Fig. 1, PCR amplification of total mR.i~As 
yielded two bands of 620 and 4.19 bp, col1'espond ing to the 
expectOO size. ofNTS2 and v!li'TS2 reœptor fragmpnts, fi'6pcc. 
tively, in ail regions examine<!. No signal was dctectOO when 
trall~cribed lIroducts from homogenates were amplified with 
"ither one of the sense or antigense primers alone (Ilot shown). 
Semi·quantitatÎve analyses performe<! u.ing GAPDH as an 
intemal correction standard indicatOO that mImA lev"l. for 
either of the two isofurms, and henee the ratio of vNTS2 over 
NTS2, Were Ilot statistically difr .. rent betweell the various re-
gions examined (Table 1). 
Isolation ulld Mole('Ular Charadcrizatù", of the Rat NTS2 
Receptor Varia"t Iso/Orm-Rat vN'l'S2 re"'-'ptor cDNA wa. Î,..,. 
late<! from brain tissue b,)' reverse transcription-peR, using a 
pair of sense and antisellst" primers correspondillg to the open 
reading frame of the full·length NTS2 receptor. The s]J<lCificity 
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Fln. L Reverae transerl.ptlon-PCR ana.lyslB of NTS2 mRNAs. 
Ampüfication of /Ii"J'S2 and v NTS2 mRNAs WQl! !Tom vario... brain 
:re.gîons. PL~ WE're performed on mR.:~A'1 revelse:+trumcribed using 
prime ... l1anking th. truncated portion of NTS2. The expeeted sizes of 
th. reverse transcription·PCR producte were 620 and 439 bp for the 
full-Iength and SplicN faTm of NTS2. respectiv.ly. n", ho"""k.."ing 
gt''''' GAPDH w,," "Iso amplified and ... 00 "" an mtemal <ontrol for 
semi·quantitativE' analyses, 
TABLE 1 
Dcnsilomelrü: (IuaJysis of the t'f"-f(ù>nal e:XJJ11!.."l..",ûm of L'NTS2 
and 1\782 mRNAs ill t"~ rot eNS 
Values rep:rosent means ~ S.E. of four independent experiments. No 
regional differenee in the expression of either isoforDls Is detectable 
(p > 0.05, one-wuy iUUl])1liS of varinnce, BOlû.t>rrnnj'g multiple COIDpal'-
ison te3t). 
Structure 
NeocortE"..x 
Spinaloord 
Medulla 
Olfaeb>l'Y bulb 
Hipp<><ampus 
HypothalllnlU' 
C.r.h.llum 
Thalamus 
. Rc-reptor tQ GAPllH ratio 
,,-NT82 NTS2 
mMtnU'}' IUlils 
0.91 ~ 0.15 0.99 ± 0.07 
0.93 ~ 0,10 1.06 ± 0.01 
0.93 ± 0.10 1.03 ~ 0.05 
0.98 ± 0.10 115 ~ 0.08 
0.91 ± 0.12 1.21 ~ 0.13 
1.09 ± 0.14 1.28 ~ 0.17 
0.13 ± 0.12 0.87 ~ 0.05 
0.90 ± 0.09 1.17 ~ 0.12 
vNTSiiNT82 
0.92 ~ 0.15 
0.88 ~ 0.11 
0.91 ± 0.13 
0.88 ± 0.14 
0.78 ± 0.16 
0.89 ± 0.14 
0.83 ± 0.15 
0.81 ± 0.14 
of the amplification was verified by ag3TOse g",1 electrophoresis. 
which revealed two bands of the .. xpected Bize (full-Iength = 
1251 bpi variant isoform = 1070 bpl (not sbown). Th .. nuclei" 
acid sequence ofvNTS2 was identical to that of the full-length 
]1;"82 with the exception of ft 181-nllcleotide del .. tion COITe-
"ponding to NTS2 balle pairs 760-940. It i. worth noting Ùlat 
the nucleotide sequenœ orthe 5' -part of th .. truncated receptar 
shares high homolog.,v with the con".,nsus sequenœ of verte-
brato spliœ donor-acceptar sites (42). The del",tion causes a 
framt'sbift in the open reading frame, leading to a premature 
stop codon. The short rorm of the rat NTS2 contains 281 anùno 
acids, Înstead of 416 for the long forro (Fig. 2A), It shows a 
global arnino acid sequence homology of79.9 and 77.4% with its 
full-l .. ngth count .. rpart and the mou.. .. splic ... l NTS2 iAo/arm. 
respectively. Hydrophobicity analysis, perronned according ta 
the m .. thod of KYù' and DoolitHe (Bio~:'lit version s.o.m, indi-
cated thut vNTS2 is a 5-transmembralle domain receptor with 
an inlra~-ellular C-terminal tail. The resulting prot"in ia devoid 
of th .. last two trallSmembran .. domains ofthe full-It'ngth 1\;"I'S2 
reœpwr and contains 37 unique C-terminal amino acids Œ'ig. 
28). The C-ternùnal domain of the variant isororro is rieh in 
<y.teine and methionine residuI>s. 
Expression of .>NTS2 in COS-7 Cells-In order to investigate 
Ù", Ilhannucological and functional properties of rat vNTS2. we 
est.ablished a COS-7 cclI line stabl.v expres.sÎng an HA epitope-
tagged v]l;"S2 rect'ptor, using cDNA transfPCtion. Immunohis-
tochemical analysis rev .. aled that withÎn these cells, th .. bulk of 
immunoreactive receptors. visualÎzed using eith",r HA (Fig. !.l, 
A. and C) or NTS2 N-temlÎnally dire<.'ted antibodies rFig. 3B), 
was intraœllular and conc('ntrnted in a Golgi-like structure 
surrounding the nucleus. No immunol1uorescence signal was 
del.ected in nonlransfecled ce lis or in œil" incubated in the 
A 
llatII'I32 : l'LIllIII'RNPS!.GEll;;II : 
RatvJlflJ2 : ~ ••••••.... ___ , •. 
B NTS2 vNTS2 
.'"" 2. Comparlson oC rat fUli-lelljfth and vnrlantNTS'.o! lsoform 
sequences. A, alignment of rat l\i'TS2 isofonn sequences. Identim! 
sequencee- found in ~,-.s2 rP~r'tor 1l!tÛoTm.,fij are ûl(J<h~d~ and the puta~ 
live transm.emhranfi' f.E'gmftnœ are box«l. Gaps !()r aHgnnumt are inm-
catecl by (lot". Th~ .short fonn ofNTS2 rout-atns 281. nminQ add.J, iU:'ltE>ad 
of 416 for the long Corm. The resuLting protein lB devoid orthe IMt two 
transmembrane oomaiOB and contnÎns 37 unique C4erminal amino 
acide. B. schematic representntion of the secondary structure of~'"fS2 
J"()('Et{.t.o.rs. Common nmino ru.1ch!. f1l"Et s"hown in It!a('k, Ir nique amino ncid 
residut"..-S in fuEl sequence of NTS2 and v~'"J'S2 are rép.reSEtnted in 
hatcl,,!d and gray, respectiv.ly. 
absence of primary antibodi"" (data not .hownl. Preill~ ... bation 
of the ",,82 antiserum with its 3ntigenic peptide completely 
aholished NTS2 immunolabeling (Hg. 3/J) WiÙlOut affecling 
the HA epÎt.ope staining (Fig. 3C). Surface labeling studies on 
nonpenn..abilized cells indicateo:l that vNTS2 was poorly ex-
presse<! on the œl! sUJface (data not shown 1. 
Ta con/irm that the immllnoreactive protein expres6ed in 
transfecled cells corresponded to the variant receptor, lysates 
from COS-7 cell", expre~"ing the lL.\ epitope-tagg .. d v'NTS2 
reœptor were immunoprecipitated with the anti-HA antibody. 
Immunoblotting using the NTS2 l'''ptide antiserum rev .. aled 
the presenœ oftwo distinct translation produds as fol!ows: one 
of -32 kDa. corresponding to the monomeric form ofthe rec"p-
tar as deduced from its cDNA sequence, and another of -60 
kDa, i.e. of the size of putative vNTS2 homodimers (~'ig. aB, 
Inne 1). By contrast. in L'Olltrol COS-7 cells expressing the 
full-length receptor. immunoreactive bands w .. re detl'Cted at 46 
kDa, as weIl a. around 80-85 kDa. oorresponding to the size o[ 
monomeric and dimeric lill'ms of the full-Iength receptar, re-
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Anti-HA 
E 
32 _.,J:~, ; ... 
2 3 
Anti-NTS2 
Ctllsumc. 
kOa n 
~-I 
• 42-
FiG. 3. Expression of vNTS2 recoptor prototn ln transfeeted 
COS.7 c"U •• A-D, dual immunolabeling ofCOS·7 ""IL. transr.d:ed with 
cDNA eneoding th. HA epitope-taggod vNTS2 receptor. Staining for th .. 
HA epitope (Al co·loCHliz"" wjth lIi"1'82 immullnlnb.lillg (8). <'Onl'irmillg 
recognition of tbe vNTS2 by the 1'<"1'82 antise,um. Preadoorl'tion of 
NTS2 antiserum with its Rlltigenic peptide corupletely abolülles NTS2 
immmwlnbeling (0) in ceUs exp""ssing the epitope-tBglI"d ,..,..,pt", (Cl. 
Scaü bG1; 10 p.m in A and B; 5 p.m in C and D. E, Weetern blotting 
analysie; ofNTS2 receptor isofnrms. Immunoprooipitation \Vith HA an· 
tihody and bl.tting with N-terminaUy direct"d Nrs2 antiserum of 
homogenate .. from transfeetOO CQS..7 cells ilane 1, C08-7/HA-vNTS2: 
lalle 2, CQS..71HA·NTS2; tane 3. untransfeeted œUs). In cells trans· 
fected with vNlS'l, specifie 1mmWlol'eru.1Jve bands are evident nt 32 
and 60 kDa, eOITE.>spondiug to the lDolecular weight:; Qf mouomerlc and 
dimeri< r.,ms ohNTS2, The sam. bands were deteeted in ""Il.urinee 
lal.:w!ling experiment.s \L.'Jing the N-tenniunlly directed N182 antiserunl 
liane 4). ln œlLs uansfectOO with the full·longth 1'<"1'82, immunoreartive 
bands are visibl. at 46 and S3 kD", eorre.ponding to the molecular 
weight~ of ruoDomenc and dimi'rie forms of NTS2. ,..-1rr()U' and armw· 
hrod repr ... nt the monomerie "",forIll of v r."TS2 and NTS2, r •• pee-
tively. No specifie band la evident in nonu"ansfected œIls ([ane .1), 
speclivl'ly (40) /Fig. 3E, {aile 2l. No specifie bands were l'vident 
in homogenates prepared from nontransfeded cpll" (Fig. 3E, 
[aile 3J. 
To determine whether any particular Illolecular fonn of the 
reœptnr was targpted tu the œil .urfnce, COS-7 c .. lls express-
ing the HA epitope-tagged vNTS2 were incubated ror 2 h with 
the N-tel'minally directed N'r82 peptid .. antiserum, and anti-
body-bound cell surface reœptors were separated from un-
bouml cytoplasmic reœptors by using protein A-Sepharose 
beads. rmmunoblottingwas then perfornlro by usingthe ~~rs2 
antiserum, As seen in Fig. SE, lane 4, the ('..,Il swface fraction 
contained tbe same two forros (82 and 60 kDa) as fractions From 
wholeeells, 
Bindinj[ and I"tema[izmim! Propl!rtii'" of "NTS2-To deter-
mine ihe binding properties of the short N'I'S2 i80for111, COS·7 
œlls stahly expressing vN'I'S2 were incubnted with 0.4 l1.M 
I2SI·laJx.Jed NT for 30 min at 37·C with increasing concentra-
tions ofnonradionctive 1\'1'. As shown in Fig. 41\., unlabeled NT 
inhibit..,.1 specifie 1241·1abeled NT hinding with an IC50 value of 
10 ,.M œig. 4t\), No specifie 1251-labeled 1\1 binding wa" ob-
.er'led in nontransfected œlls (data not shown), 
In ol'd .. .r to visunlize NT bindillg lU,,1 internBlization, C08-7 
cells expr"""ing vN'rS2 were incuooted fur various periods of 
tÎnte with 50 nM Fluo-ili'1' at 37·C and were examined by 
confùcal micl'oscopy (Fig. 4, B-D). FolIowing:.JO min of incuba-
tion with the fluorescent ligand, pnnctate fluorescent labeling 
wns evident throughout the cytoplasm of transfected cells, 
sparing tJu.. nucleus <Pig. 4, Band ('J. No lluOreBœnt labeling 
was 'lisible in nontransfected œlIs (not shownj or in transfected 
cells incubated with an e.xœsi! of 110"'1' Wig. 4DJ, When the 
incubation was carried out in the presence of tJu.. end.ocytos.is 
inhibitor phenylarsine oxide, bound fluorescent molecules re-
mained c1ustered on the œil surface (data IlOt shown), 
Signaling Propertœs 01' dVTS2-We then investigated 
whether the truncated form of the rat N'I'S2 reœptor retained 
the l\IAPK activation (ERKll2 pathwnyJ pt'Operties exhihited 
by the long form of the reœptor (24\. Stimulation with NT of 
ClIO cells stahly expnlSf!Îng the rat vNTS2 inducN! the phos-
phorylation of ERK1I2 (p42144'n<,m) starting at concentrations 
of 1 ,.1>1 (Fig, 5A). 'rime course studies in which the oeil. were 
stimulated fhr 1-60 min with l"M NT showed thi" effu<.t tu he 
rapid «5 min) and 8ustained (over 1 h) (Fig, 5B), Dl'nsitomet-
rie analysis of the ratio of phosphorylated ERKll2 over total 
ERKll2 I .. "els indicated that the NT-induced increase in 
MAPK phosphorylation was 1.4 :!: O.l-fold and reached a pla· 
teau alter 15 mill of stimulatioll (Fig. 5C, e). This .. ffet.1; was 
vNT82-mediated, as it was not observed in nontransff.'cted œlls 
(Fig. 5C, 0), A similar activation was observed following 10 min 
of stimulation with the N'l'S2 agonist levocahastine il ,.M; Fig. 
5D). Pretreatment with selective MAP kina.e kinase (MEKl 
inhibitors (PD98059 or UOl26) significantly inhibited NT-me-
diate<! RRKlf2 pho"phorylation in these cell. (Fig. 5E). 
Heferodimerization of NTS2 Receptors-In rat spinal cord 
meJl1brnne preparation. Îmmunoblotted with the N-terminally 
directed NTS2 antiserum (which recognizes both N'fS2 iso-
forIlls; Fig. M), ft prominent band was e\'ideni at 46 Wa, 
('orresponding to the molecular weight of the monomeric fonn 
of the full-length NTS2 reœptor detecied in tran..fected COS.7 
cells (compare Fig. M with Fig. 3E, !ant! 2), Surprisingly, no 
band was visible at 32 kDa, i,e, at the size e .. 'pected for th" 
Illonomeric form of the truncated receptor kg. Fig. 3E, lalle 1). 
However, as in COS-7 transfet.ted with the HA-vNT82 œig. 3/0:, 
lalle 1), an immunoreactivl' band was detected al 60 kDa, 
corresponding to the size of putative 'lNTS2 homodimers (Fig, 
6..4). An additional l»md was 'ÙS() ob""rv",,! at 75-8i'j kDa œig. 
M, asterl~,k), whieh might correspond to vNTS2INTS2 het-
erodimel'S, AlI of these bands were absent when the antibody 
was pre-saturated with the immunizing peptide {not shownl. 
To investigate whether the species of NTS2 recepturs de-
tectN! at the 75-85·kDa molecular weight mark rouIt! ('orr,,· 
spond ta "NTS2I!-;1S2 heterodimers, w(' CQ-('xpressed HA· 
taggro vNTS2 together with untagged N'fS2 reœptors in 
GOS-7 cells and subje<.'1:ed cell lysates tu Westen1 hlotting anal-
ysis. As shown in Fig. 6B, both ll1onomeric and putative ho-
modimeric forms of variant \32 and -60 kDa, arrows) and 
fllll-!enQ'th (46 and -85Idh. orrt)l/'heads) ~"'I'S2 reœptors were 
detected using the N.tenninally directe<! 1'<"'I'82 peptide anti-
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FlG,4. B1ndlnlt Md Internallzlltlon 
of NT ln COS-7 cells expresslng 
vNTS2. A, competition inhiliition of "0[. 
labeled NT binding to whole CQS.7 cells 
.t.ably el<[>re,,~ing v NTS2, ('",n. w .. ,... in· 
cuhated with 0.4 nM 12l<1·Jabeled NT for 30 
min at 37 'C with incre....mg <onœntra· 
tions of nonradinacti\", NT. Binding IC .. 
= 10 l'M. The resultll< are ~presentative of 
thr"" ind.pendent experimenb>. B and C. 
(''fmfocal miclOS('.()pie imaging of fluo-NT 
inl:ern.alizatinn in COs. 7 cells •. xpNSSing 
v~LS2. Cells were iDcubat.ed {or 30 min 
at 37 'C with 50 DM fluo-NT and air·dried. 
InteJnalized fluore8Cent lîgand Dl<Ikcules 
are det.fot.>ted in thE" ft)l'fil oi f!>IDflU endo--
some-like partiel ... distributed tlu'Ough· 
out th. cytoplasm. D. fluo-NT labeling is 
pn'vented when the incubation 19 per-
formed in the presence of an exeess of 
nonfluoresœnt NT, &ale bar. 10 /1lll in B; 
5 "'ln in C and D, 
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FIG. 5. MAPK kinase slpallnlt ln CliO ee..Us heteroJo&ously p.xpressln& vNTS2. A. dose·depend.nt elTect of1l<'T on MAPK ŒRKI12J 
pho.pharylation. c.n. wcrc trcated for 5 min with the indicated concentra tians of NT. Ph08phorylation leyels of l\fAPK wc.e detocted by 
immunoblotting as described under "'Experimental Procedures," Upper panels of A. D, D, and E, phoaphorylaW ERKll2; lou-er panels, total 
ERK1I2. B 1 time course ofNT·stimulated MAPK phoe.phorylatioD in CHO œ)]s stahly e-xpressing vNTS2. C, densitometrie analysis orthe rntîo 
ofphosphorylated ERK1t2 over t"Jtal ERKJJ2 )ev~)s foUl,wing incuhnt.J<nl with t fl.:M of NT, lTnt.ransf~rted (0) and vNT.32·expl"essing (.) CHO 
ceUs w""re .incubated at 37 -;OC fQr the indicatf:>d times. Values rppre~t the means ~ S,E. oft1vE:" indppen-dent el.."}>f:>rinlftuts. Tranafected Cfi'U 
values are signiflcantly different from nontransfected ("ElU values at aU tUn@ poînts as follow.s~ ~.p !SI 0.05: '~"*, p s: 0.01; and i$'~, p :s; 0.001. 
D, ERKlfl phosphorylation le'\mls in vNTS2·expressing CHO cells stimulated with )pvocabastine for 10 min nt 37 "C. E~ MEK inhibitors 
prevent ERKlt.2 activation by NT in CHO ceUs exprt"ssing vNTS2. Cells were pNtreated with PD9S059 (50 I..&.M) or U0126 (10 I..&.M' and treat.ed 
'with NT 111..&.M) far 5-15 min at 37 t·C. The results are represenL"\tive of three inilividual experiments. each with duplicate determinatiQns. 
serum. An immunorenctive band was also obse.rved at the 
-75-kDa mark (asterisk), consistent with the theoretical mo· 
lecular ",eighi of a vNTS2fNTS2 heterndimer. 
Cell ]yoates wl."re then subjected io immunoprecipitation 
with the rai anti-HA antibudy. Immunoblotting of the.e imffiu-
noprecipitat". with the N·tenninally directed NTS2 antiserum 
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A B C D 
l' ! ~ll' 1 . • kDal 1,1 /;1 kDa :;24.4 
'CI <kW' ~-83-1_ 83- .c ,. • • > >,t~ 
ut .. .. ~ .lJ;' c- .c ,. 32-. 32- .. ... • 
IPP HA HA 
lB It-Iemt It-Iemt It-Iemt c.t.mt 
t'm. 6. Ch ...... cterbatlon ol vN'l'S2INTS2 heterodimers by co-
lmmuDoprecipitatloD5 lmmunoblotting {lB} analysis Qf NTS2 rtlœp-
tors in spÎnal cord membrane preparations (A) and in cos.. 7 eeUs 
oo-expressing 10;"1'82 nnd HA·vNTS2 (B) using a N-termiMlly dite<ted 
NTS2 antibody. C and D~ ro-.immunoprecipitation (ZPP) studies on 
COS-7 colis heterologously .,'pr .... ing NTS2 '.la""" 21, HA-vNTS2 
(lalt!!11 3 J. or a oombinntion of both Uan~s 1). Ce-l1s were lysed and 
8Ubjec:ted to immuDoprecipitation wlth rat nnti·HA antibody, Thfil co. 
immunopncipitat.P$ were thfm immun-oblQtted uaÎng" N-ternlinaDy fG) 
or C-tenninally !Di directed NTS2 peptide antisera as described under 
"'Ex:pe-r.iml2.ntal Prooodur~." Molecular mass mnrkers are shown to the 
left of A mu! B. Mol.,.,dar lUasses fur B n1s. apply for C and D. ~:a(h 
illustrated blot is l'epresentative of three independent expenmtlnts. 
.4.rrow:s and arroll'hl!ad~ represent i&oforms of vNTS2 and l'i'"TS2. re--
spectively. A.t"isk. reprP.Ilf'ltt th. putative vNTS2INTS2 hetercdim ... 
showed that they contained HA-tagged v]l;'TS2 as weil as un-
tagged NTS2 :reœpwrs, suggesting that long and short forms of 
NTS2 receptors phY8ieally interaet œig. OC, laJœ 1l. Indeed, 
immunoreactive b .. 'lnda we .... d .. t.octed at huth 3'2 and 46 k.Da, 
i.e. al. the molecular weights of the lIlonomeric Corros of the 
variant and full-length recept.ors, as w .. n a. at. -60 kDa, cor-
l"eSponding W the presulIlptive homodimerie isoform of vtli'TS2 
(Fig. 6C, lone 1). Higher mole<."Ular weight bands (-75 and 
-110 kDa) were also evident, which may represent heteromul-
timeric furms ofNTS2 receptor •. lmmunoreactive bands COITt'-
sponding to monomeric and putative homodimeric forma of 
v?li"TS2 132 and 65 kDa, respectively) were also detected in 
COS-7 rell. transf.ecte<! with the HA-vNTS2 cDNA alone !Fig. 
6C, lalll! 3). However, no specifie bands were ohs .. rved in cells 
expressing the full-length r-."TS2 alone (Fig. 6C, lem" 2). 
Immunoprecipitates ",pre also subjected to W .... tern blotting 
analy.is using the C-œnnÎ naUy directe<! NTS2 antiserum, 
which selecüvely rocognizes the full-length lIi'TS2, l'hi.s anti-
body ravealed the presence of the full-length isoforlll in co-
transfed.,.} cells subjeded to immunopl"e<.~pitation with the HA 
antibody, ronfirming that NTS2 illterads physically with 
vNTS2 (Fig. SV. fane Il. No bands were det.ected with the 
C-terminally directed NTS2 peptide antiserum in immunopre-
cipitates from COS-7 cens exprt'ssing .. ither NTS2 (Fig. GD, 
lane 2) or HA-vlli'TS2 \Fig. GD, lalli! .1) alone, confinning the 
specificity of the interaction. 
Ta investigate whether vNTS2INTS2 heterodimel~zation in-
fluenœd trafficking of the truncated receptnr to the œil sur-
face. COS-7 œlls ro-expressing the HA epiwpe-tagged vtli'TS2 
and the untagged full-l.mgth NTS2 were i ncubated fur 2 h \Vith 
the N-terminally di.t'Cted NTS2 peptide anti""rum. and anti-
body-bouml cel! surfhce reCf'l'wrs Wf>re .separated from un-
hound q-t<lp)asm ie reeeplors hy using protein A-&pharose 
heads. Immunohlotting Wal! then performed using Ùle mouse 
TABLI! Il 
DemûlonlRfr;e analy~;.,,' of the efJw::1 of NTS2 j!xprtUlSion on ('dl 8ur{at:-l! 
f"XPression of J{A~l'NTS2 
The ~]atÎ\-'(> inœn.....:;.ity QfHA-vNTS2 is p..xprt';i;St"d B:l percent oft{)tal 
surface recepwr {monomer + dime-r + multimer~ immunoreactivjty, 
VnJues repnsent the- mean.s ± RE. orrour independ~nt ~xperiment8i. 
HA-v!'w:"'TS2 i:~fi)l'1ru, 
ni ... r Muhinll!r 
... 
HA-vNTS2 21 ±2 28± -1 511:6 
IIA-vNTh"2 + NTS2 2'.I:!: 2 
anti-HA antil""ly. As ""'-'n in l'able II, the density of bath low 
(monomers) and high (dimers and muitilllers! molecular weight 
forms deta'ted in the œil surface !radion (22 :!: 2, 26 :!: 3. and 
52 :!: 4%, respectively) was the same us in the cell fraetion from 
œlls trnnsfected with vlli'TS2 alone (21 :!: 2, 28 ± 4, and 51 :!: 
6%, correspondingly). Confocal microscopy confirme<! tbat as in 
COS-7 œil. tran.fected with vNTS2 alone (Fig. 3), the bulk of 
vNTS2 immunoreactivity in COS-7 co-expressing NTS2 and 
HA-vNTS2 was intracellular (Fig. 7B). Predictably, vNTS2 and 
NTS2 immunorpactive intracellular .tores c10sely overlapped. 
in kl.'eping with their demonsirated heterodimerizat.Îon (Fig. 7, 
A-C). 
DISCUSSION 
In this study, we have delllonstratt.'(1 the presence of an 
altematively spliœd form of th" NTS2 reœptor Illfu~A in rat 
brain, comparahle with the one praviously identifie<! in the 
mOllSe (2'lj. Most importantly, we have shown tbat this 5-trans-
mmnbrane domain truncated reœptDr protein is functional, in 
that il. specificallv hinds and intemalizes !'<ï and is couple<! ta 
the activation of the ERKlfl pathwllY. 
Alternative splicing is a frf>ljuent occurrence in mammalian 
gf>ne e:tpl"$Sion, eonh'ibuting both ta protrome div"Mty and to 
functional complexity of lI<,nom"1i by lIen .. rating stI"Ucturally 
distinct isoforms from a single gene (43 J. N ucleic acid st'<juence 
analy.is demoll$trated that tlle vNTS2 isoform "",ults !rom ft 
181-bl' deletion in the full-Iength cDNA that lends to a frame • 
• hift in the reading frame, introducing Il premature stop codon. 
The st'<juence of the cDNA fragment isolated showed partial 
sequence overlap with th .. previously publishpd rat full-Iength 
NTS2 sequence {lll, indicating that vNTS2 was indeed gener-
ated by alternative splicing from a donor-accepwr splice site a8 
suggested by Sun Ilt al. (26). This type of proce>Ising does not 
appear to he regionally seleeiive hecause mRNA levels and 
ratio.. ofthetwo isoforms did not vary significantly hetween the 
di.ffuren t regions .. xamine<!. 
Western hlotting analysis of COS-7 cell. I:ronsfeeted with 
cDNA encoding an HA-tagged rat vNTS2 reveal",l the presenœ 
of distinct translation pl"Odu<'ts of -3'2 and 60 kOa. The former 
correspond. ta the molecular weight of the m<momeric furm of 
vNTS2 a. de<!uced from its eDNA sequence, whereas the latter 
likely represents a homodimeric form of the reœptor, Immnno-
cytoehemistry revealed that the bulk ofthese vNTS2 proteins 
were intracellular. This observation is in agreement ,,~th the 
results of suhprograms executed by the PSOR'f II server 
(Kenta Nakai, Human Genome Center, Institute for M<--dical 
Science, University of Tokyo, .Japanj. which prediet the su bœl-
lular localization ofvNTS2 from its amino acid sequence in the 
.. ndoplaslllie retieulum (44.4" .. l, intraœl1 ular vacuoles (22.2%), 
Golgi apparatus (lI.l 'k), plasma membrane (l L 1%· l, and mi-
tochondrial compart.ments (11.1%). Buth immunoblotting and 
immllnocyl<lCbemical experilllents .aggest ù"tt the vN1'S2 re-
ceptor is IXK)rlv target.,.} t;o Illasma membranes. Howe""r, thi. 
restricted targeting does not appear to he linked to the molec-
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Fln. 7, Double immunolnbeling of COS.7 cellA co-e"'pretllllnll' NTS2 Imd IIA-vNTS2. Stnining with th. C-l.erminally rurected NTS2 
antiserum ~J, which e-xclusively reeognizes the long 180form. CC)oolocalizea with immunoreactivity for the HA epitope (B) in eo-transfected cells. as 
.vident in th. overlay (C). 
ular sJll!'CÎes .recruited te the membrane because both low (mo-
nomerie) and high {putative dimeriel molecular weight forms 
were detect.ed at the cell surface. 
Despite its short tronsmembrane span, the rat vNTS2 still 
specifically binds 12ll1-labeled l\;"'I" albeit with a considerably 
lower affinity thau the full-length recepter (ICao of 10 l'M per-
sus 2 nM, for the full.length isoform). This result differs from 
thase of Botto et al. (27), who found no specifie binding of 
'21lJ·labeled NT te mouse vNTS2 transicntly expresse<! in 
COS· 7 cells. Thi. discrepancy may be explained by species 
differences, by variations in the sensitivity of the methods 
employed. or by the nature of the .. xpression system. IndCt"d. 
stable transfectants might express higher levels and/or recruit 
more effieiently vNTS2 to the membrane than transiently 
transfected cells. Previous studies have shown that NT binding 
to rat NTSl and human NTS2 reœpters involved residues 
located in TM 6 and in the tbird intracellular loop (44, 45). 
These l'Csidue~ are lost in the variant isoform, due u> the 
splicing of the last two TM domain5 of NTS2, which may 
e.xplain the lower afIinity ofvNTS2 for NT as compared with 
the full-Iellgth receptor. 
Coruocal microscopie expcn:ments demonstrated specifie, l'C-
cepter.mediated internalization of fluorescent l'i"T. The internal-
iZM lill"nd was conœntrated within small endosome·like or-
ganelles, a pattern con.sistent with earlier reports (24, 46) on 
internalization via the full·lengtb NTS2 l'eceptor. This flnding 
suggested to us that the NTS2 variant isofonn was functionally 
responsive te NT, as conflrmed by MAPK activation exporimpnts. 
Stimulation with NT induced Il rapid and sustain"d in-
crease.in ERK1I2 phospborylation in CHO cclls transfected 
with vNTS2, indicating functional coupling of the truncated 
receptor to the MAPK signaling pathway. Stimulation of 
thesc cells with the NTS2·spccific agonist levocabastine alsu 
resulted in ERKll'2 activation. The time course of ERK1I2 
activation rorresponded to that observed following stimula· 
tion of the full.length receptor in a similar transfection s.vs-
rem (24). Activation of ERK1l2 was already apparent at con-
centrations ofl'li"T lower than the lCM (1 l'M), in keeping with 
the detection of ligand-induced internalimtion at concentra· 
tions of fluo-NT of 50 n~!. However. phosphorylation I .. vels 
obtained following stimulation with 1 l'M NT were lower in 
cells transfected with the vNTS2 than with the full.length 
rf'Ceptor (lA l'ersus 2.9·fold increase o,""r control (24)). They 
were also lower than those produced in cultured rat c .. rebel-
lar granule cells, which endogenously express the two NTS2 
isoforms (25). The.e results suggest that the third intracel· 
lular loop and the C·terminal tail ofthe full-Iength NTS2 are 
not essential for but Illay play an accessOI'Y role in MAPK 
aetivation. To our knowledge, the vNTS2 is the firai TM-
spliced GPCR variant cloned to date that wa .. found to main-
tain signaling propertÎes. Indeed. other TM spliee variants of 
GPCRs, such a. the cOl'ticotrophin-releasing factor receptor 
2, havp been reporte<1 to relain their agoni.t binding proper-
ties but io totally lose Ù1eir fundiollal coupling (47). 
Western blotting stndies lIsing an N-terminally directed 
NTS2 peptide antiserllm t"evealed that the 32-kDa monomeric 
fonn of vNTS2 i8 not expressed in the spinal cord, whereag a 
band twiœ the size of vNTS2 is prest".nt, suggesting that the 
NTS2 ,""ce.ptar variant may exist in homodimeric form in the 
rat CNS. By contrast, a spocific band was det .. cted at 46 kDa, 
i.e. at the molecular weight of the full·leugtb ;"oform of the 
reœpter, indieating that in contrast to its variant isoform, the 
full-Iength receptor exists in monomeric form in rat CNS. 
These results are similar te those previously reported far mem-
branes prepared !rom rat hrain and cerebellum (40). In addi-
tion, specifie bands were delected at molecular weight marks 
highe:r tban th .. put:ati\'P vNTS2 <limera. One of thes .. wail 
nppro.ÛI11ntely twice the Bize of the monomeric fornl of the 
full-Iength receptar ft nd was the:relbre inlt"rprered as a putathe 
NTS2 homodimer. Another migratt"d slighÙ,v lower. tI.. would 
be expocted from a vNTS2INTS2 heterodimer. Ind.,...l, reœnt 
biochemical, biopbysical, and functional studies (48, 491 have 
shown tbat GPCR caIl assemble as hetenl- as weil as ho-
modimerie complexes. To test whether the vNTS2 could actu· 
ally associate with its full·length counlt"rpart, we carried out 
immunopreeÎpitation experiments on COS-7 œlls ro-express-
ing HA.tagged vNTS2 and nntive NTS2. These expe.rilllenls 
demonstrated tbat the two NTS2 isoforms did Ilssociate when 
co-expressed in COS-7 relis, because bath receptors were pulled 
down usiDg an HA antibody. Furthermore, the presence in 
th",se d Ilally transfected cells of a band at the theoreticru mo-
lecular weight ofvNTS2INTS2 helt"rodimers indicated that the 
band delected at. the sam" level in sl>inal rord m .. mbraIWS 
might indCt"d have colTesponded to a vNTS2-NTS2 het-
"rodim"r. This vNTS2/NTS2 helerodimer was stable during 
eelllysis and reducing Tris·glycine gel elect:rophoresis, suggest-
ing that the interaction involves a nonrovalent hydrophobie 
interface between the reœptor proteins. 
To investigaœ whether heœrodinrerization of NTS2 and 
vNTS2 receptors affected targetÎng of the truncated receptor te 
the plasma membrane, we examine<! by Western blot the ex· 
pre;;sion of vN'l'S2 on the œil surfilce of si ngly translècte«1 
verslLç dually transfected œlls, and we compared the immuno-
eytochemical distribution ofNTS2 and vNTS2 in dually trans-
fected œlls. By usiug either technique, we found tbat co-expres· 
sion of tbe full-Iength ?Ii"l'S2 did Ilot noticeably incrense the cell 
sumee density of the truncated form over that seen in eells 
expres"ing HA-vN'l'S2 alon ... suggesting thot the fllll-iength 
NTS2 dOCll not aet as a chaperonc prat,ein for its shorter iso-
fOTm. However, intracellular vNTS2 stores closely overlapped 
with those of NTS2. supporting the notion that the two recep-
tors heterodimerize. 
In summary, our results indicate that the rat vNTS2 tS 11 
functional receptor that i. expressed in ronjunction with the 
full-Iength l'Ii"l'S2 recepter throughout the CNS. Our datn also 
indicate that tbis truncatt"d 5-TM rereptor does not exist in 
monomeric form in the rat CNS. Rather, it ,,"sociates both with 
its"lf and with the fllll-iength 7·TM reeeptor to form large 
molecular weight homo- and heterodimer speeie •. Thf'refore, it 
is likely that these associations provide for subtl~ regulation of 
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the NT signal. as demonstxated previously (50) for the splice 
variant isoform of tlle growth horlllone-relensing hormone 
reœptor. 
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APPENDIXD 
GenBank Report (Accession Number A Y946024) 
LOCUS AY946024 846 bp mRNA linear ROD 
22-MAR-2005 
DEFINITION Rattus norvegicus variant neurotensin receptor 2 (Ntsr2) 
MRNA, complete cds. 
ACCESSION AY946024 
VERSION AY946024.1 GI:61613030 
KEYWORDS 
SOURCE 
ORGAN l SM 
REFERENCE 
AUTHORS 
TITLE 
JOURNAL 
PUBMED 
REFERENCE 
Rattus norvegicus (Norway rat) 
Rattus norvegicus 
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; 
Euteleostomi; 
Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; 
Sciurognathi; Muroidea; Muridae; Murinae; Rattus. 
1 (bases 1 to 846) 
Perron,A., Sarret,P., Gendron,L., Stroh,T. and 
Beaudet,A. 
Identification and Functional Characterization of a 5-
Transmembrane Domain Variant Isoform of the NTS2 
Neurotensin Receptor in Rat Central Nervous System 
J. Biol. Chem. 280 (11), 10219-10227 (2005) 
15637074 
2 (bases 1 to 846) 
AUTHORS Perron,A., Sarret,P. and Beaudet,A. 
TITLE Direct Submission 
JOURNAL Submitted (28-FEB-2005) Montreal Neurological Institute, 
McGi11 University, 3801 University, Room 896, Montreal, 
Québec, H3A 2B4, Canada 
FEATURES Location/Qualifiers 
source 1 .. 846 
/organism="Rattus norvegicus" 
/mol_type="mRNA" 
/strain="Sprague-Dawley" 
/db_xref="taxon:10116" 
gene 1 .. 846 
/gene="Ntsr2" 
CDS 1 .. 846 
/gene="Ntsr2" 
/note="vNTS2; GPCR" 
/codon start=l 
/product="variant neurotensin receptor 2" 
/protein_id="AAX47307.1" 
/db xref="GI:61613031" 
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Itranslation="METSSPWPPRPSPSAGLSLEARLGVDTRLWAKVLFTALYSLIFA 
FGTAGNALSVHVVLKARAGRPGRLRYHVLSLALSALLLLLVSMPMELYNFVWSHYPWV 
FGDLGCRGYYFVRELCAYATVLSVASLSAERCLAVCQPLRARRLLTPRRTRRLLSLVW 
VASLGLALPMAVIMGQKHEVESADGEPEPASRVCTVLVSRATLQVFIQVNVLVSFALP 
LALTAFLNGITVNHLMALYSQEPSWLCMSSAGCRTMPADSCTATSPMMDGLMSSM ISI 
TISTW" 
ORIGIN 
1 atggagacca gcagtccgtg gcctccgagg cccagcccca gcgcagggct 
gagcctggag 
61 gcgcggctgg gcgtggacac tcgcctctgg gccaaggtgc tgttcaccgc 
gctctactcg 
121 ctcatcttcg catttggcac agcgggcaat gcgctgtccg tgcacgtggt 
gctgaaggcg 
181 cgggccggtc gccccgggcg cctgcgctac cacgtgctca gcctggcgct 
ctcagccctg 
241 ctgctactgc tggtcagcat gcccatggag ctctacaact tcgtgtggtc 
ccactaccca 
301 tgggtcttcg gcgatctggg ctgccgtggc tattacttcg tgcgcgagct 
gtgcgcctac 
361 gccacagtgc tgagcgttgc cagcctaagc gcagagcgct gcctggccgt 
gtgccagccg 
421 ctgcgcgccc gccgccttct caccccgcgc cgcacccgcc gcctgctgtc 
actggtctgg 
481 gtcgcctctc tgggccttgc cctgcccatg gcggttatca tgggacagaa 
gcacgaagtg 
541 gaaagcgcgg acggggagcc tgagcctgcc tcgcgtgtgt gcacggtgct 
ggtgagccgc 
601 gccacacttc aggtcttcat ccaggtgaat gtgctggtgt ccttcgctct 
ccccttggca 
661 ctcactgctt tcctgaatgg catcactgtc aaccacctga tggccctcta 
ctcccaggag 
721 ccatcgtggc tgtgtatgtc atctgctggc tgccgtacca tgcccgccga 
ctcatgtact 
781 gctacatccc cgatgatgga tggactaatg agctctatga tttctatcac 
tatttctaca 
841 tggtga 
Il 
Disclaimer 1 Write to the Help Desk 
NeBI 1 NLM 1 NIH 
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APPENDIXE 
Available online at www.sciencedirect.com 
eC.BNc.@D .... OT' BBRC 
ELSEVIER Biodlemical and Bioji1y!!ÎCal Research Communicaûol1ll 343 (2006) 799··~ 
www.eJsevier.com/local.elybbn: 
Sustained neurotensin exposure promotes œil surface recruitment 
of NTS2 receptors 
Amélie Perron a. Nadder Sharif a, Louis Gendron a, Mariette Lavallée a, Thomas Stroh a, 
Jean MazeUa b. Alain Beaudet a, • 
• !t{ontn'iJl N""''''''git:al htstltute. McGüI University. Montreal. Que .• CaMda HJA JIU 
b Ins.itu. de l'Iwrnl,,,,,,lcgi~ !t{o/ùul<iire <1 CeJhJllir~. CNRS •. "i<>phi<l AIt.IpoIJ>. IXiJôO V"Jbo,vw. Front:< 
Reœived 1 March 2006 
Available online 20 Mardi 2006 
ln this sIndy. we investigat<ld whether persistent agonisl stimulalion of NTS2 receptors gives cise to dow'll-regulation, in light of 
reports that Iheir activation induced 1000g-lasting c/kcIS. To address Ihis issne, we incubaled COs.. 7 ceUs expressing the rat NTS2 with 
neurOI<!n!IÎn (NT) for up 10 24 h and _asur<ld resultant ecU ''IIrface [12'I}-NT binding. We round that NTS2-expres!IÎng ceUs retained the 
same surface receptor den!IÎty despile ellicient inlemalizationmechanisms.This preservation was neither due 10 NTS2 neosynthesis nor 
rœyc1ing since it W"dS nol blocked by cycloheximide or monensin. However. it appeared 10 involve tmns1ocatlon of spare receplors from 
internaI stores, as NT induced NTS2 migration (rom trans-Golgi network 10 endosorne-like struçtures. This stîmulation-induced regu-
lation of œil surfilee NTS2 receplors was even more striking in rat spinal euro neurOIIS. Taken together, Ihese results sugges! lhat sus-
tained NTS2 activation promotes fIX,'fUitment of intracellular receptors \0 the ceR surfaçe, thereby preventing functional desensitization. 
© 2006 Elsevier lne. A 11 rights reserved. 
ky1t'ordr: Neuroœll8În; GPCRs; Lonll-term <lÎtnulation: Down-r,,!!ulation; Inlraœllular stores: lù<.,'CÜ",; Internalimtion 
NeuTotensin (NT) is a tridecapeptide that was sno\\-n to 
be involvcd in a varicly of central and periphcral ncuro-
modula tory effccts inc\udi n~ naloxone-independent analge-
sia, hypothermia. and neuroleptic-like modulation of 
doparninergic patnways [1]. Most of thes.: effects result 
from the speciflC interaction of the peptide witb two ceU 
surface G prolein->:oupled receptors (GPCRs) referred to 
as NTSI and NTS2. The former binds NT with high affin-
ity (~= 0.2 nM). whereas the latter binds NT with lower 
affinity (J(d = 2 nM) and is reçognized by the antihistamine 
drug levocabastine [2,3]. Biochemical sludies have indicat-
cd that NTSI is implicatcd in the modulation of intraeellu-
lar levels of inositol phosphates [4], cAMP [5], and 
extracellular signal-regulatcd kinases [6], whercas NTS2 
induces Ca2+-dcpI.'Ildent chloride currents in Xl.'flOpUS 
oocyll!.~ [7] and activates the ERKI/2 cascade, both in 
• Corresponding author. Fax: +1 514398 5871. 
C."",i! uJ4r ..... : abeaudet@;frsq.gouv.qc.ca (A. Beaudct). 
0006-191X1S - ... front matter © 2006 Elsevier Inc. Ail rights res<!t'\-ed. 
doi:IO.IOI6lj.bbrc.2006.03.047 
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translècted CHO ceUs (8] and in cerebellar gr.lOule cells 
in culture [9]. 
Most GPCRs are subjected to regulatory processes in 
order 10 control their re~'POnsiveness to persistent agonist 
e.'q)Osure [10,11). Agonist-induced reguJation of GPCRs 
usually involves receptor desensitization, due to uncou-
p1ing from G proteins. followed by receplor internalization 
and down-regulalion. The latter is charm:terizcd by a 
dccrcase in the tolal number of receptors and lypicaUy 
involves incrcased turnover or reduced S]ntbCl>is of recep-
lors. In the case of the NTSJ receplor, slIch dcsensitization 
processes have been reporte<! in NIE-J 15 cells as weil as in 
raI culturcd neurons after prolonged incubation in the 
presence of NT [I2,13J. The disappearanee ofNT-binding 
sites was sunnised to result from degradation of intemal-
ized receptors after fusion with lysosomes, &inee il was par-
tially inhibited by the lysosomotropic drugs chloroquine 
and methyJamine [13.14~ Moreover. destabili7Jùion of 
NTSI mRNA was reported in NtE-IIS and HT29 celJs 
Appendix E: Reprint of Biochem. Biophys. Res. Commun. (2006) 343: 799-808 
800 A. Perrou ,1 al. 1 Bi"d"7uirol {uld Bit1physical Reseanh Cmnm,mii:o,i",s 343 (](1()6) 799-808 
after long-tcnn agonist exposure, suggesting that post-tran-
scriptional events may be directly implicated in the down-
regulation process [15]. Finally, it has been established Ihat 
de novo synthesis is required for the recovery of NTSI 
receptor-binding sites and function [12,1 3 ~ 
Little is lmown about the regulation of NTS2, except 
that ilS stimulation with NT induces Jong-tenn rnetabolic 
etfects due to prolonged and sustained activation of 
ERKI/2, either in transfected CHO eells [8] or in neurons 
in culture [9]. Therefore, the present study was iniliated 
in order to detennine whether extended stimulation of 
NTS2 leads to a down-regulation of ccII surface receptor 
density and/or of intraeellular receptor protein levcls. 
Our fCSulls demonstrate that ccli surface NTSl receplors 
are maintained following persistent exposure 10 NT 
through a recyding-independent mechanism that involves 
recruitrnent of receptors from intraeellular stores. 
Materials and method.<i 
Gt'nr rons/rlKls The cDNA encoding the rat and human NTS2 
NœpIOIS (rNTS2 and hNTS2, n:spectively) were obtained through ~ 
transcription of brain mRNA and subcloned into the mammaJian 
expression vector pTargeT (Promega, Madison. WI) as described in [16J 
and [8~ The subcloning of HA·tagged NTSI inlO peDNA3 WM describcd 
previously [17]. 
QII nJ~ and trans/erllons. COS-7 ceUs wen: mainlained in Dul-
becco', modified Eagle's medium (DMEM) supplemenled with 5'Y. fe1al 
bovine serum (PHS) in the pre!!etlœ of peniciUinlstreplOmycin (100 U/m1; 
Invilroll>'" Burlinston, ON, Canada). ('.eUs were lransiently transfected by 
the DEAE-<lex\r<lnlchloroquine melhod w;th 41'8 af rNTS1, hNTS2, or 
HA·tagged NTSI pasmid. 
Rucplar bindlnt experimmts. COS-7 cdls expressing rNTS2, hNTS2 
or HA-NTSI were incubaled with or without 1 !lM NT for 1-24 h in 
DMEM with 2.5%, FBS or Earle'. butTer (HOmM NaO, SmM K.O. 
1.8 mM CaCl, • 0.8 mM MgC12. and 20 mM Hepes. pH 7.4) for long (1-
24 hl and short (0···60 min) lem> experiments. respective/y. CeUs wen: 
..... hed onœ with hypertonie ucid bulrer (Earl.', containing 0.2 and 0.5 M 
NaCI. pH 4), twice ,,;th Earle' •• and incubaled ""th 0.4 nM ml_labeled 
NT (1670 G/mmol; Perkin-Elrner) for 60 min on iœ in Earle's supple-
menled with 0.25"10 BSA, 0.1% JluCOSIl. and 0.8 mM o,th.'·phenanthroline. 
Cells were lben wnsbcd twiœ wilh ice-i:Old Eade'., harvested in 0.1 M 
NaOH, lInd radioactivity conlenl was ,.,.,..ured in a gamma counler. 
Non-specil\c binding was defined as binding in the presence of a 10,000-
fold excess of unlabeled ligand, which corn:sponded to Jess tlum 1 % of 
total counts. StatÎSlÎcul compsrÎsons berween groups were perfonned 
.lSing ft Student's 1 test. Dill:ren:<:s "'''''' considen:d significunt for 
p<0.05. 
For ""periments with recyclinginhibitars, trlUlllfected COS-7 cell, wen: 
equilibrated for 10 min at 37"C in Earle's supplemented ""th 0.25% BSA 
and 0.1 % ghl<:ose. Cells were then pn:stimulated for 30 min with 25 )lM 
monensin (Sigma) in EarIe'. at 37 oC and incubaled with or without 1 )lM 
NT in the continuous presence of monerurin for 60 min Ilt 37 "C. CeU. \Vere 
then wnshed once with h)'JM"1onic .cid bulr.... lWiœ with Eark, s and 
binding with radioligand was perfanned as descrihed abave. 
IIIII1IUltohlottillg <lIIoIy.!"s. COS-7 cells exprellSing rNTS2 were .Iimu-
Iated or nol with 1 IIM NT ""th or ",ithout 70 !lM o;ycloheximide for 1 or 
24 h al 3PC and resuspended in i=1d bulfer containing 10 mM 
Tris-HCI, pli 11.0. and 1 mM EDTA with protease inhibilOts (Complete 
Protease Inhibitar table\$, Roche MoIeçular Biochemicals. Lava~ QC. 
Canada). CeUs were tben disrupted by sonication and pelleted by 
œntrifuging Rt 12,000g for 30 min al 4 "C. ParaDel •• periments were done 
ming untranslècted cells as ft r>egative control. Prolein concentration was 
detennined using the Bio·Rad methnd (Bio-Rad Laboratories. 
Missisaauga. ON. Canada). Sample& containing :n IIg of crude memlrane 
protcins wcre denatured ln Laemmli $Impie butTer, r_lved an 10% Tris-
glycine precast gels (Jnvitrogen), and lransferred ta nitrocellulose mem-
branes (Bio·Rad). Membranes wen: then incuboled with the NTSl peptide 
antiserum (1/10,000: previously characterized in [16]) ovemight at 4 "C in 
PBS containing 1% ova/bumin (Sigma. St-Louis, MO) and BSA. followed 
by HRP-conjugaled anti-rabbit secondory antibody (1/3500: Amenham 
Pharmacia Bioteçh, Baie d'Urfé, QC, Canada) in PBS with 5% evaporated 
milk (Carnation. Don MiUs, ON, Canada) for 1 h al room letnperature 
IR 1). Immunoreactive proteirul wen: de\ected using an enhanced chemi-
luminescent system (Pnkin-Elmer Life Science, BœIOn, MA). The e/fect8 
of Iong-tenn NT expoiu", on rNTS2 prolon Ieveb were quantified by 
densilOmetry using Scion Image. CaJculation and statistical analyses "....., 
carried out in Excel 2000 (MlCfO$oft). 
J"""...,.."odremlstry t»I COS·7 cells. COS-7 œlls expressing rNTS2 
"",e stimulat"" or nol with 1 )lM NT for 1 h at 37 "C, lÎ>Ied for 20 min 
",th 4% paraformaldehyde (PFA) (Polysciences. WlIrrington, PA), pre-
incuboted for 30 min with a blocking solution (S'Y. nonnal goat teTUm 
(NGS). 2% BM, and 0.1% TrilOn (Sigma», and illQlhaled ovemight at 
4"C witb the NTS2 antÎllerum ( 1/25,000) alone, or in concert witb cither Il 
monoclonal antibody against syntaxin 6 (1/1000; Transductioo Uibom-
IOries, Lexinglon, KY) or guinea pis anti·PIST anlibody (1/1000; gift of 
Dr. Hans-JIlrgen Krcienkamp, 1n.~litule far Human GenelÎi:S, Hambllf!. 
('rermany). Cellg wue tben incubll.ted for 1 h at RT with ft mixture af 
Alexa 488-<:anjugated goal anti ... abbil with eitber Alexa 596-<:oojusaled 
goat anti-mouse or anti-guinea pig aDtibodies (1/750; Molecular Probes. 
Eugene, OR). Cells wo-e examined with a Zeiss 510 m- scamting cruI· 
focal microscope equipped with Argon2 (488 nm) and HelNel (543 nm) 
lase" (Carl :leÏ$. Micro Imaging lne .. Thomwood, NY). Images wen: 
processed using the Zeiss 510 Iaser-s<;anning microsÇOpe software and 
Adabe l'hotO$hop 6.0. 
Ta quantity perip/leral (lIS an index of cclI surface) versus internai 
NTS2 immunolabeting in penneabilized ceUs, a IOtal of 12-1 S ceUs per 
condition (i.e., untreated or stimulated far 60 min ",th NT) from four 
independent experiments were randamly seIected and analyzed using the 
ItnageJ software (Nationallœtitules afHealth. Belhesda, MD). For thi. 
purpose. peripheral and inttacellutar compartments "'en: detineated and 
intesraled fluorescenœ densities as$OCÎaled "'Ih eilher of the$e Iwo corn-
partments were measured. Values an: ""pressed as a percenlage of the 
IOlal tluorcsœno:e density (peripheral +intraœDular) for each condition. 
Statistical rom parisons hetween condi tions were performed using a Sm-
dent', 1 test. 
MI!tlIlJJ'lJltltnI of MAP kllwsè tll'Iivity. COS-7 œlls expressing rNTS2 
were incubaled at 37"C in DMEM. 2.5% FBS ";th or withoui 1 )lM 
NT for 14 h. serum~arved for 2 II, and tben incubated \\ith 1 )lM NT 
for O. 5, 15. 30 or 60 min al 37 "C. The reactÎon Wll$ stopped by 
addition of iccH:old PBS contaîni"tl 0.1 jlM staurosporiœ (Sigma) and 
1 mM lIOdium arthovanadate. CeIIs wen: tben lyse<! in 50 mM Hepes, 
pH 7.8, contaÎtÙt18 1% Tritan, lU )lM staurosporine. 1 mM sodium 
arthovanadate, and prOlease inhibilors. (,.ell Iysates were centrifuged at 
Il,000g for 10 min at 4 oC and protein ~ ration was determined 
by the Bio-Rild procedure as described abQI.-e, Samples conuùning 30 "g 
of protcin "....., denatured in Laemmti buffer and resolved by using )()"!o 
Tr~yci"" precast gels. Nitrocellulose membranes were incubaled 
a\-emight at 4"C with anti-phosphorylaled ERKI/2 or anti·ERKI/2 
mbbit antibodies (1/1000; New England Biolabs, Beverly, MA), fol-
lowed by HRP-<:anjugated goat anti-rabbit antibody for 1 h at RT (II 
4000; Am .... ham Pharmad8 Biot<-ch). To quantify the elfect of NT on 
ERKl/2 phosphorylation, the ratio. af pho.phorylated ERKI/2 o\'er 
total ERKI/2 ""-eIs wen: deœrmined by densilOmetry using Scioo 
Image softwure. Calculations and statistical analyses were perfonned 
using ExceI 1000 and SigmaPlot 2001. Statistical significance af the 
IWtivalÎon af ERKJ/1 hetween untrealed and NT-prestimulated cell, 
was determîned using a Student'. 1 test. 
... 752 Jnmnmogo/J luMmg. Adult male Spraglle-Dawley rats (200-
150 8; Charles Ri"'r, St·Constant. QC, Canada) were anesthetized with 
hak'thane and intratheçaUy injected or not with NT (12(10 pmol). After 
20 min. rats wen: transaortically perfused under pentobarbital anesthesiu 
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witha mixture of3.7S%acroltln and 2"/0 PFA. Lllmbar spinal oords Wete 
remaved, fixed in 2% PFA and cut (SOlon) uslng a vibrating microtome. 
Sec:tions wcre incuboted in 1% sodium borohydride and cryoprotcctant 
solution (25"/0 $ucrose and 3% glyccrol) prinr to $nap freezing in isopcn-
llIne (-70 "C). transfer to Iiquid nitrolll'l',llnd tha\l<ing. Sa:tions were then 
incublled for 48 h at 4 oC with NTS2 IlntiserUln /1/1800), follnwed by 2 h 
at RT with colloidal gold-co'liugllted goat ami·rabbit antibody (1/50; 
Cedarlane Laboratories, Homby, ON, C.anada). Sections were fixed with 
2% glUlaraldehyde and immunogold deposits 'Nere enhanced using the 
IntenSE kit (Amersham Pharmacia Biotedl). Sections wetethen po$I.fixed 
with osmium tetroxide, dehydrated in ethanoJ. tlat-emhedded in Epan, 
counterstained \\'Îth Iead citrate and uranyl aœtate. and examined ""th a 
JEOL JOOCX transmission ele<.1ron microl<a>pe. Negati_ were digitized 
on a scanner and proces$ed using Adohe Photoshop. Quantitati", llnalysiS 
â the ultrastructurdl w.tribution â NTS2 immllnorea<tivity was per-
fonned on th."., to four grids per experimental condition from thœe 
independenl experiments (n = 3 rau~ A total â 38 and 31 randomly 
;teIected labeJed dendritic profiles within the supetiiciaI layers (Jaminae 1 
and JI) of the spinal cord from respecti\-eIy non·treated and NT-inj«ted 
rau were 81ll11yzed using the Neurolucida morphometry sâtware. Fmt, 
deusity of immlUloreacti", NTS2 receptor gold partiel.,. associated with 
seJeçted dendrites was caJculated per surface area and expressed as 
immunogold/silver partieles per fUD'. Serorul, gold parlicles weredassilied 
as heing intrm:dlular or membnute-aS$OCÎated. The proportion of mem-
brane-associated NTS2 receptors was expresse<! as a percentage of the 
lotal number of gok! particles. Statistical COOIpIlIisons hetween groupa 
were perfonned u.~ng a Student's t test. Difkrences were oonsidered sig-
ni&ant for p < 0.05. 
Results 
Celi slirface NTS2 receplors are resistant 10 ,lowlt-reguJation 
To invesligale the effects of prolonged incubation with 
NT on NTS2 ccli surfaœ density, rNTS2-expressing 
COS-7 cells were presIimulated with 1 IlM NT for up 10 
24 h al 37 oC and ccII surface receptor binding was carried 
out using 0.4 nM e2SIFNT on ice. As shown in Fig. lA, 
NT stimula tion resulted in an immediate decrcase in the 
density of cell surfaœ NTS2 binding sites (50 ± 4% of base-
line values arter 5 min). A similar but weaker response was 
obtained in NTSI-expressing œlls (73 ± 2% ofbaseline val-
ues at 5 min; Fig. lA). UIXlD sust .. üned NT exposure, NTS2 
binding progteSsively retumed 10 baseline values (100 ± 
4% of baseline aCter 24 h) whereas NTSI binding kepl on 
decreasing (46 ± 1% of baseline after 24 h; Fig. lB). 
NTS2 binding sites were a1so maintained at bascline Ievels 
aller a 24 h stimulation with the metabolically stable NT 
analog JMV-431 (106 ± 6%), suggesting that maintenance 
of NTS2 œil surface hinding sites was not due to peptide 
degradation (not shown). Taken together, these data show 
Ihat contrary to NTSI, œil surface NTS2 binding siles are 
maintaincd Collowing persistent agoni st stimulation despite 
efficient intemalization mechanisms. 
E.Dèct of prolongl'd NT exposurl' 011 NTS2 rl'ceptor prO/l'in 
Iet-els 
ln order to detcrmine whether prolongcd exposure to 
NT affectcd lOtal NTS2 protcin levels. rNTS2-cxpressing 
COS-7 cells were stimulated with 1 !lM NT for different 
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Fig. 1. Persistent agonist·induced reguJalion of œil surface NT rcceplors. 
CQS·1cellse:xpressing rNTS2(e) or NTSI (0) wereexposed to 1 J1M NT 
for ()..(,() min (A) and up to 24 h (B) at 37 "C, acid-washed, and incubated 
",ith [mI}-NT on ice for monitoring cell surf""" m:eptors. The resuhs are 
representatiwof three individuaI experiments± SEM, each with tripticate 
determinations. Studenl's • tesu were used CO compare NT œil surface 
bindingsites hetween rNTS2 and NTSI expressing COS-7œlls. VaIueaare 
signilicnntly dilllrent at all time points with .p < 0.05 and •• p < 0.01. 
periods of time and crude membrane preparations were 
anulyzed by Western blotting using a NTS2 peptide anlise-
rom. As sœn in Fig. 2. Ihe totallcvels of immunodetected-
NTS2 (45 kDa) were not signülcantly different after than 
before NT stimulation (103 ± 15'Y. of control values after 
24 h), suggesting that NTS2 is neither up- nor down-regu-
lated follo""ing prolonged agonist exposure. To confinn 
that prolonged NT stimulation did not induœ NTS2 neo-
synthesis. COS-7 cells were incubated with NT in presence 
of the protein synthesis inhibitor cycloheximidc for up to 
24 h. ImmunobloUing of crudc membrane preparations 
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Fig. 2. Effee! of NT stimulation on NfS2 receptor protein Jeo..-eIs in COS-7 
ceIls. COS-7 œil. transiently trallSl"ected with cDNA encoding the rNfS2 
reœptor were stimuJated WÎth 1 11M NT for ditl:rent periods or time al 
37 oc and membnmes wen: isolated as descn'bed under "Materials and 
methods~. Similar experiments were done with UIItransfected (UT) tells as 
a negalive conlrol. Western bIoltÎng analysis was performed using lhe 
NTS2 peptide antiserum after a 10% Tris--glycine gel electrophoresis under 
reducing conditions and NTS2 reœptor protein 1e\'CIs wmo quantlfled by 
d<ru!itometric analyoi.. The data "1'f"""Ilt meaJUI ± SEM or th...., 
individual eJ<periments. 
using the NTS2 peptide antiscrum revealed that treatment 
with cydoheximide did not affect receptor protein levels 
(not shown). 
,'lIaÎl1tenont·c of cell sl/rfacc NTS2 reœptors is a rec:l'clÎng-
illdepemlenr process 
To invesligale whether receptor recycling accounled for 
the preservation of ccII surface NTS2 receptors following 
prolonged NT exposure, rNTS2-expressing COS-7 cells 
were lirst preincubated with monensin for 30 min and incu-
bated with 1 IlM NT togelher with monensin for 1 h at 
37 oc. Monensin is known 10 hinder laIe receptor recycling 
steps heyond the acidification of endocytic vesicles [18]. As 
shown in Fig. 3A monensin had Iittle if any clreet on the 
preservation of [\2SI}-NT binding levels follo'Wing NT 
exposure. Indeed. cell surface levels of NTS2 receptors rep-
resented 92 ± 8% of pre-stimulation values, whieh were 
comparable 10 those measured in the absence of monensin 
followillg the same stimulation ptriod with NT (90 ± 4'Yù). 
Previous site-dire~:ted mutagenesis studies have revealed 
lhat Tyr 237 is a critical residue in the rccycling process of 
NTS2 receptors [19]. Indeet.l, the human NTS2 in which a 
cysteine residue naturally replaces the (}Tosine in position 
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Fig. 3. Recycling;' DOt in\'olved in the maintenance 0( œil surface NfS2 
binding sites. (A) COS-1 œlls exprcssing rNTS2 \Vere preincubolted \Vith 
25 "M monensin for 30 min and stimulatcd witb NT with the recycling 
inhibitor for 1 h at 37 "C. The peptide \Vas removed by acid wasb aod ..,11s 
were incubatcd with [t"IJ-NT 00 ice to detennine the arnoml of cdl 
surface reœptors. Bach point is the mean ± SEM from triplicate deter-
minations of nt least !wo different experiments. (Bl COs.. 7 œlls expressing 
the non-recycling lruman NTS2 reœptor were exposed to l "M NT for up 
[0 24 h at 37 oC, acid-lVashed, and incuooted wi1h [""I}-NT ()II ire for 
monitoring œil surface reœptors. The results are "'P"""",mtive 0( two 
individual aperimenl$ ± SEM. each with triplicnte determinations. 
237 dues not undergo recyeling following Iigand-înduœd 
internalization [In ln order ln study further the potential 
impliC'<Ition of rt..'Ceplor recycling in the mainlenance œil 
surface NTS2 reœptors. hNTS2-expressing COS-7 cells 
were prestimulaled with 1 IlM NT for up 10 24 h at 37 oC 
and œil surfaœ rcceptor binding was carried out by using 
0.4 nM C2sI}-NT on ice. As shown in Fig. 38, NT stimula-
tion resulted in rapid deerease in the density of ccII surfaœ 
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human NTS2 binding sites (36 ± 8% of bascline values 
after 5 minI, suggesting efficientligand-induced intemaliza-
tion. However, human NTS2 reeeplors al50 progressively 
.resurfa ... "Cd upon extended agonist exposure (82 ± 5% of 
baseline after 24 h) despite their inability to undergo recy-
c1ing [19). Taken together. these results suggest that recep-
tor recycling does not aeeount by itself for the maintenance 
of cell surface NTS2 receptors. but that other mechanisms 
must he brought into play. 
Effect of [ang-term NT stimula/ian on NTS2 rt!(,l'plor 
tr,ifjickùtg and fllllct;on 
In order to visualize the cffect of NT stimulation on 
NTS2 intracellular trafficking, u",!nsfected COS-7 cells were 
incubated in the presence or absence of 1 ~M NT for 
60 min at 37 oC and the distribution of immunolaheled 
receptors was examined by confocal microscopy. hrununo-
staining or non-stimulated, permeabilized cells revealed a 
prominent juxtanuclear pool of NTS2 receptors as weil as 
5mall peripheml, preb1Jmably membrane-associated. recep-
tor c1usters (Fig. 4A). To ensure that the localization of the 
receptors was not due to an idiosyncratic feature of COS-7 
cells, wc repeated the experimenis using CHO ceUs stably 
expressing rNTS2. As in COS-7 cells, NTS2 cxhibited a 
predominantly intracellular distribution (not shown). Fol-
lowing 60 min stimulation with NT at 37 oC, intrdcellular 
immunoreactive receptors were no longer conœntrated 
ncxt to the nucleus. but heeame seattered throughout the 
cytoplasm in the form of small vesicle-like clusters 
(Fig. 4A). However, there was no apparent change in the 
density of cell surface receptor clusters (Fig. 4A. arrow-
heads). Indeed, quantitative image analysis confirmed that 
there was no difference in the relative density of periphcral 
itnmunolabeling hefore and after NT stimulation 
(15.3 ± 1.8'V. versus 15.9 ± 3.6%, respectively: p > 0.95; 
Fig. 4B). These data suggest ihat receptor activation results 
in a redistribution of i ntracellula r receptor stores without 
any apparent loss of cell surface receptors. 
To ascertaill whether NTS2 receptors present at the cell 
surface following prolonged NT exposure were runctional, 
rNTS2-cxpressing COS-7 cells were preincubated or not 
with 1 ~M NT for 24 h at 37 oC and serum-starved for 
2 h without the agonis!. ERK 1/2 phosphorylation was then 
measured in response to subsequent pulse stimulations with 
NT. As shown in Fig. 5, NT induced a rapid «5 min) and 
sustained phosphorylation (over 1 h) ofERKl/2, irrespec-
tive of whcther eeUs .had heen preincubated or not with NT 
for 24 h. Moreover. densitometric analysis of the .ratio of 
phosphorylated ERKI/2 over total ERKI/21cvels indicat· 
cd that NT pretreatment did not significantly influence the 
agonist-induced ERK 1/2 activation (5.2 ± 1.6 versus 
4.6 ± O.6-fold increase in ERKI/2 phosphorylation levels 
at 5 min in cells pretrcatcd or not with NT. respectivcly; 
p :> 0.95). This cffeet was NTS2-mcdiated since it was not 
observed in untransrected cells (no! shown). Thus. these 
data inùicate that NTS2 receptors maintained at the cell 
B 
100 
o ..L...L--1r 
o 60 
Nturotensin (min) 
Fig. 4. NT -induœd inlra(:cllular redistribution of NfS2 teœplors in COs. 
7 œUs. lA) rNfS2-expressîng COS·7 ceI1s were stimulated or nOi witb 
1 !lM NT for 60 min ut 37 "C. Immunolabeling was !ben perfonned on 
~meabilized œlls by \l$Ïng the NfS2 peptide antiserum. ScaIe 
bar·" SIIIll. (B) Quantitative anal)'Sis of NTS2·lilœ inununoreacti'e 
stainÎng densitieo in Cos.7 cell. stimulaled or nol with NT. Data are 
expressed as a perœnlage ± SEM of inlegr.Ued density V'dlues associated 
""lh peripheral lincluding ceI1 surface) versus intraœlluJar compartment. 
"''Of total fluo"""""",,, Irepresentative of four independent experimen!S). 
surface foJlowing sustained ligand exposure are truly 
funclional. 
Golgi lIppllrazus and TGN liS putazive sources of lIewly 
recnlÎted NTS2 reœptors 
To investigate putative intracellular sources for the 
membrane recruitment of NTS2 receptors. we co-Iocalized 
NTS2 with the molecular markers syntaxin 6 or PIST. 
using dual labeling immunOL)'tochemistry in rNTS2-
expressing C0s-7 cells. Previous studies have shown that 
syntaxin 6 is present mainly in the trans-Golgi network 
(TON) and participates in vesicular trafficking between 
the TON and endosomes [20), whereas PIST (PDZ domain 
protein interacting specifieally with TCIO) is known io he 
associated with the Golgi apparatus (21). In unstimulated 
œUs (Figs. 6A-F), NTS2 immunoreactivity (Figs. 6A and 
D) was largely intracellular and concentratcd in a compact 
juxtanuclear structure that was .immunopositive fOT endog-
enous syntaxin 6 (Fig. 6B) and PlST (Fig. 6E). as shown in 
ovcrlays (Figs. 6C and F). These data strongly suggest that 
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Fig. 5. Effect of persistent stimulation with NT on ERKI12 phosphorylation in COS-7 œlls heterologously ""pressing rNTS2. Cells were pretreaœd (0) or 
not(e) with 1 !lM NT for 24 h at 31"(; and subsequently incubated ""th l "M NT for the indicated periods oftime{O-ro min} ERKI/2 activity "". 
determined by the ratio of th~ densitometric analysig eX {itosphorylated ERK 1/2 over total ERKI/2 Jevels expre8O&ld as fold incre8Sll O\"et control. Data 
represent the means ± SEM of Iwo individual experiments, ", .. ch with triplicate detenninations. 
NTS2 localizes primarily 10 the TGN/Golgi complex. This 
observaiion was conlirmed by the ract that disassembly of 
the Golgi complex by Brefeldin A induced a total disper-
sion of NTS2 through the cytoplasm (data not shown). 
Following a 1 h-incubation with 1 pM NT (Figs. 6G-L), 
NTS2 immunolabeling was still noticeable in the TGN/ 
Golgi where it remained co-localized with syntaxin 6 
(Fig. 6H) and PIST (Fig. 6K). However. NTS2 was also 
apparent in vesic1e-like structures distributed throughout 
the cytoplasm of the cells. These fluorescent c1usters were 
partially immunoposilive for syntaxin 6. bUI not ror PIST, 
as shown in overlays (Figs. 61 and L). Similar experiments 
using the anti-Iampl antibody as a molecular marker 
revealed that NT exposure did not induce the Irafficking 
of NTS2 receptors to lysosomes for degradation (not 
shown). Taken together, these data suggest that NTS2 
receptoTS targeted to the plasma membrane subsequent to 
NT stimulation could originate rrom the TGN/Golgi. 
Effect of NT stimu/olion (JI! cell si/rfoce ATS2 recepror 
density in rat spinal cord lIeurOllS 
To detcrmine whether the preservation of ccII surface 
NTS2 receptors observed follo\\<ing suslained stimulation 
of transfected ceUs in vitro also occurred in neuronal cells 
in vivo, we examined by immunoclecuon microscopy the 
fate of NT·slimulaled NTS2 reccptors in neurons of the 
superlicial layers of the rat spinal cord, which had previ-
ously been reportcd to contain high concentrations of 
NTS2 receptor immunoreactivity [22]. Jn both slimulated 
and unstimulated conditions. the bulk of NTS2 immunore-
activity was asSO\.-iated with dendrilic shafts. branches. and 
branchlets (Figs. 7A and Bl. In saline-injected rats, NTS2 
immunolabeling within these dendrites was associated 
mostly with intracellular vesicles and organelles 
(Fig. 7A). Only a small fraction of immunogold particles 
was found on the plasma membrane (4.7 ± 2.6% of total; 
Fig. 7q. Following 20 min exposurc to intrathecal NT, 
there was a considerable increase in the proportion of 
immunogold-receptor complexes associated with the plas-
ma membrane (35.1 ± 8.5% of total; Figs. 78 and C). By 
contras\. the density of immunoreactive receptors 
(immunogold partides/pni) was not statistically signifi-
cantly differcnt betwcen NT- (4.6 ± 2.3 partides/pmz) 
and saline-injected (8.2 ± 4.7 partides/pm2) animais 
(p > 0.95; Studenfs t test). indicating that the NT-induced 
change in plasma membrane receplor density was a 
trafficking event. 
Discussion 
In the present study, we have demonstrated a preserva-
tion of cell surface NTS2 reccptor densities following pro-
longed cxposure to NT. This preservation did not depend 
on receptor neosynthesis or recycling, but appeared to 
involve rccruitment of spare receptors from intraceUular 
stores to the plasma membrane. 
Sustained activation of most GPCRs triggers a lime-
depelldent dccline of cell surface receptors. This proccss, 
which reverses upon agonist removal, is of dircct clinical 
rele"1\nce as il accounts in part for cellular desensitization 
to a varicty of GPCR.acting drugs [23]. As conflrmed in 
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FiS. 6. Dual immunolabelinS of NIS2 and trans-Goigi network markers in C0S-7 ccUs. Confocal microscopie images of œlls transiendy ""pressinS 
rNTSl prein<:ubated (G-L) or not IA··F) with 1 !lM NT for 1 h al 37"C. In unstimulated œlls, Nn21abe6ng ,,;Ih the Nnl p"ptide antiscrum IA.D) <"0-
Iocalizell ,,;th immunorelll.lÎvily for the TGN/GoI~ marketS syntaxin 6 (B) and PIST (El in lœ perinuclear zone as nident in the overlays (C,F). 
Following incuœlÏOll with NT, NTS2 immunoSllIining i. pIIn<,'late and dispersed thraughout the œil. Part ofNTS2-pooitive veaiclesallO "'-"ibit .yntaxin 6 
!H) bul not PIST (K) immUlloreaclivily a,< shown in the merl!"d images (I,L). Ali images were acquired noing the same pntlllll\ltel'8 and represenl Ihree 
ditTerenl experiments. 
the present study. agonist stimulation of NTSI Iikewise 
resuIted in a loss of ecU surface reccptors that is known 
to occur through internalization and Iysosomal degrada-
(ion (reviewed in [15]). In the case of NTS2, stimulation 
with NT was found herc to first induee a rapid decrC'<lSc 
in ccII surface receptor density (Le., 50'10 by :; min). This 
decrease was previously shown by us {9] and others (24) 
10 he duc 10 Iigand-induccd receptor intcmalization and, 
ao;ordingly, to he cntirely abolished in the presence of 
sucrose or phenylarsinc oxidc, which inhibits internaliza-
lion. Howevcr, this decrease was short-lived and, in spitc 
of persistent ligand exposure, NTS2 receplors rapidly 
resurfaced. Indccd. binding activity recovercd to 80% of 
pre-stimulation Icvels by 1 h and to 100% after 24 h of 
stimulation with NT. This reinstatement of ccli surface 
receplors cannot he ascribed 10 ligand degradation as the 
same phenomCl1on was obseNcd when Ihe incubation 
was carried out with the prolease-resistanl NT analog 
JMV.431, instead of NT. The œil surface billding siles 
maintained during persistent NT exposure corresponded 
to functional NTS2 receptors, sincc NT-induced ERKI/2 
phosphorylation Icvels in ceUs cxposed 10 NT lor 24 h were 
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Fig. 7. Electron microscopie detection QfNTS2 immunoreacrnre .--ptoTS 
in superficiallaminae of the rat lumbar 3Pinal con!. (A) ln the absence of 
the agonis\. gold pan ides (Le., NTSl immunalaheling) UIe mainly 
intracdluJar and poorly associated wid> dendritic (Den) plllSma metn-
brane$. (8) In the presence of NT, numeroll$ immunogold paniclC$ ale 
aSllOcialed wit.h Œ.'I1dritic plasma m ... mbrnne$ (arrowheads). (C) Efkcts of 
NT exp"'''''''' on membraœ-associated/total NTS2. The ast..-isk indienlC$ 
a &Îgnificant dillerence (p < O.lIS) from control. 
comparable to those measured in control eeUs and were 
simiIar 10 (hose previously reported in mt cerehellar 
granule œlls [9) and transfected CHO eeUs [8]. 
Maintenance of cell su/face reœptors in rcsponse 10 
sustained activation has been documented for a limited 
number of OPCRs induding the P3-adrenergic receptor 
[25J. somatostatin reeeptor subtype 1 (26). and AT2 angio-
tensin Il receptors [27). It has also been shown for the sin-
gle transmembrane domain receptor NTS3, following 
prolonged stimulation with NT [28,29). Cell surface recep-
tor densities are known toresult from the equilibrium 
between receptor internalization, recycHng, and recroit-
ment from intraccllular stores [30). In the case of NTS2, 
recycling ofintemalized receptors, demonstrated under dif-
rerent experimental conditions (24,311 did not appear to 
account significantly for the reinslatement of the plasma 
membrane receptor population after prolonged NT expo-
sure. Indeed, cell surface receptor recovery was not alfected 
by blockade of receptor recycling with monensin nor by 
replacing rat NTS2 with the non-recycling human NTS2 
[19]. Neither did the maintenance of ccII surface NTS2 
receptor densi tics appear to require receptor neosynthesis 
sincc NTS2 protein leve1s, as measurcd by Western blot-
ting, remained unchanged following NT exposure with or 
without the protein synthesis inhibitor cycloheximide. 
Immunocytochcmistry revealed that under baseline 
conditions, the bulk of NTS2 prolei_ns were intraeellular 
(i.e .. 84.7 ± 1.8% of total receptors in basal conditions). 
This observation is in agreement wiih the results of sul>-
programs executed by the PSORT II server (Kenta Nakai, 
Ph.D., Institute for Medical &.'Ïence, University of Tokyo, 
Japan), which predicted the subce1lular localization of 
NTS2 from its amino aad sequence to be poorly localizcd 
to the plasma membrane (22.2%) and possibly confined to 
intracellular stores sucb as the endoplasmic reticulum 
(33.3%), Golgi apparatus (11.1%). intraœllular vlll.'Uoles 
(22.2%), and mitochondrial compartments (11.1%). How-
ever, confocal microscopie experiments on permeabilizcd 
ce1ls dcmonstrated that NT induced an extensive redistri-
bution of NTS2 receptors from the TON/Golgi complex 
(synt.uin 6 and PIST-positive) to vesicle-Iike structures, 
suggesting that the maintenance of surfaœ NTS2 recep-
tors involved mobili2111ion of spare receptors from inter-
naI stores. Although syntaxin 6 was mainly conccntrated 
in the TGN, it was also detected in the NTS2-containing 
vesicles that formed as a result of NT exposure. This 
co-Iocalization is consistent \\-lth previous results showing 
that syntaxin 6 co-Iocalizes broadly with the early cndo-
somal autoantigen EF.AI in BHK-21 cells and may there-
fore he implicated in TGN to endosomes tr'àfficking [32]. 
Interesiingly. an earlier study in NTS2-cxpressing cerebel-
lar granule cells had demonstrated tbat following pro-
longed NT stimulation, internalized fluorescently labeled 
NT was largeted 10 a syntaxin 6-positive juxtnnuclear 
compartment. corresponding to the TGN (9). It is thert> 
fore possible that internalized NT is tnrgeteù to the 
TGN and serves as a triggering signal for the transloca-
tion of residcnt NTS2 receptors from this compartment 
to the œil surface, implying adynamie regulation of sul>-
ceBular protein localiza(jon. 
The physiological and pharmacological relevanœ of the 
present results was L'Onfirmed by immullogold e1ectron 
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microscopie studies of the supcrficial laminac of the rat 
spinal cord. Intrathecal injection of NT rcsulied in a seven-
fold increase in Ihe proportion of immunoreactive NTS2 
rcceptors associated with dendritic plasma membranes as 
compared with saline·injected controis. This increase in 
the dcnsity of plasma membrane-associated NTS2 was 
not aceompanied by a statistically signifieant increase in 
the overall rcceplor population, suggesting that, as in our 
in vitro studies. the NT-induced inerease of NTS2 recep-
tors al the plasma membrane of dorsal born neurons was 
a trafficking event Thcse results arcreminiscent of the 
enhaneed recruitment of ô-opioid receptors (DOR) 10 the 
plasma membrane of dendrites in the same superficial lam-
inae of the dorsal horn foUowing either prolonged mor-
phine treatment (33) or chronie inflammation [34). 
However, whcreas tbis enhanced DOR targeting was he ter-
ologously mediated through stimula lion of Il-opioid reccp-
tors [351 the present inercase in NTS2 externalization likely 
results from stimulation ofNTS2 receptors themsel\'es. The 
present rcsults may, therdore. explain the highly potent, 
long-lasting antinociceptive elfects of the NTS2-specific 
agonis! JMV-431 in tests of spinal analgesia [22]. 
In conclusion. we have demonstmted Ihat eell surface 
NTS2 receplors arc rcsislant to down-regulation follo\!ring 
persistent exposure to NT. By Inference from the patterns 
of intracellular distribution of NTS2 receptors observed 
using confocal and electron microscopy, we propose that 
the maintenance of ceU surface NTS2 receptors is due in 
part 10 the recruitment of spare receplOrs from internai 
stores. This stimulation-induced regulation of ccli surface 
NTS2 rcceptors was even more slriking in rat spinal cord 
neurons in vivo (sevenfold increase in ccli surface receptor 
density) than in transfected COS-7 colIs in vitro (return 10 
baseline). Such maintenance of NTS2 bioavailability upon 
prolonged agonist treatmenl might prove of great impor-
lance for the use of NTS2-selective agonists for the lreat-
ment (lf chronic pain. 
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